

Search Results

Table of Contents

Search History	page 7
1. [Influence of boric acid on strains of the genus <i>Candida</i>].	page 8
2. Boric acid treatment of vulvovaginal candidiasis.	page 8
3. Diaper dermatitis: current concepts.	page 8
4. Treatment of vulvovaginal candidiasis with boric acid powder.	page 9
5. Current therapy of vulvovaginitis.	page 9
6. <i>Torulopsis glabrata</i> vaginitis: clinical aspects and susceptibility to antifungal agents.	page 10
7. Management of persistent vulvo vaginal candidosis due to azole-resistant <i>Candida glabrata</i>	page 10
8. Boric acid vaginal suppositories.	page 11
9. Biotypes of oral <i>Candida albicans</i> isolates in human immunodeficiency virus-infected patients from diverse geographic locations.	page 11
10. Oral <i>Candida albicans</i> biotypes in Chinese patients with and without oral candidosis.	page 12
11. Chronic fungal vaginitis: the value of cultures.	page 12
12. Treatment of <i>Torulopsis glabrata</i> vaginitis: retrospective review of boric acid therapy.	page 13
13. Successful use of boric acid to control azole-refractory <i>Candida</i> vaginitis in a woman with AIDS.	page 13
14. Susceptibility of <i>Candida</i> species isolated from female prostitutes with vulvovaginitis to antifungal agents and boric acid.	page 14
15. Terconazole cream for non- <i>Candida albicans</i> fungal vaginitis: results of a retrospective analysis.	page 14
16. Phenotypic characterisation of <i>Candida albicans</i> isolated from chronic hyperplastic candidosis.	page 15
17. Biotypes of oral <i>Candida albicans</i> isolated from AIDS patients and HIV-free subjects in Thailand.	page 16
18. <i>Candida albicans</i> strain differentiation in complete denture wearers.	page 16
19. <i>Candida lusitanae</i> as an unusual cause of recurrent vaginitis and its successful treatment with intravaginal boric acid.	page 17
20. Boric acid susceptibility testing of non- <i>C. albicans</i> <i>Candida</i> and <i>Saccharomyces cerevisiae</i> : comparison of three methods.	page 17
21. Vulvovaginal trichosporonosis.	page 18
22. Phenotypic diversity of oral <i>C. albicans</i> isolated on single and sequential visits in an HIV-infected Chinese cohort.	page 19
23. Common complementary and alternative therapies for yeast vaginitis and bacterial vaginosis: a systematic review.	page 19
24. Treatment of vaginitis caused by <i>Candida glabrata</i> : use of topical boric acid and flucytosine.	page 20
25. Biotypes and randomly amplified polymorphic DNA (RAPD) profiles of subgingival <i>Candida albicans</i> isolates in HIV infection.	page 21
26. Biotypes and randomly amplified polymorphic DNA (RAPD) profiles of subgingival <i>Candida albicans</i> isolates in HIV infection.	page 22
27. In vitro activity of bergamot natural essence and furocoumarin-free and distilled extracts, and their associations with boric acid, against clinical yeast isolates.	page 23
28. In vitro activity of bergamot natural essence and furocoumarin-free and distilled extracts, and their associations with boric acid, against clinical yeast isolates.	page 24
29. Vaginal <i>Candida parapsilosis</i> : pathogen or bystander?	page 24
30. Vaginal <i>Candida parapsilosis</i> : Pathogen or bystander?	page 25

31. Recurrent vulvovaginal candidiasis	page 26
32. Recurrent vulvovaginal candidiasis.	page 27
33. Entrapment of lipase in polymer of polyvinyl alcohol-boric acid for esterification in organic media	page 27
34. Boric acid for refractory candida glabrata vaginitis	page 28
35. Boric acid for refractory Candida glabrata vaginitis.	page 29
36. Candidiasis (vulvovaginal).	page 29
37. Candidiasis (vulvovaginal)	page 30
38. Prevalence of Candida glabrata and its response to boric acid vaginal suppositories in comparison with oral fluconazole in patients with diabetes and vulvovaginal candidiasis	page 31
39. Prevalence of Candida glabrata and its response to boric acid vaginal suppositories in comparison with oral fluconazole in patients with diabetes and vulvovaginal candidiasis.	page 32
40. Study on physicochemical properties and pharmacodynamic action of recombinant uricase	page 33
41. Phospholipase, proteinase and haemolytic activities of Candida albicans isolated from oral cavities of patients with type 2 diabetes mellitus	page 34
42. Prolonged (3-month) mycological cure rate after boric acid suppositories in diabetic women with vulvovaginal candidiasis.	page 35
43. Prolonged (3-month) mycological cure rate after boric acid suppositories in diabetic women with vulvovaginal candidiasis	page 36
44. Local treatment of vulvovaginal candidosis: General and practical considerations	page 37
45. Recalcitrant Trichomonas Vaginalis Infections Successfully Treated With Vaginal Acidification	page 40
46. Recalcitrant Trichomonas vaginalis infections successfully treated with vaginal acidification	page 41
47. Recalcitrant Trichomonas vaginalis infections successfully treated with vaginal acidification.	page 42
48. Biotypes, genotypes and ketoconazole susceptibility of Candida albicans isolates from a group of Thai AIDS patients	page 43
49. Vulvovaginal candidiasis	page 44
50. Boric acid addition to suppressive antimicrobial therapy for recurrent bacterial vaginosis	page 45
51. Antifungal mechanisms supporting boric acid therapy of Candida vaginitis	page 46
52. Evaluation of biotyping of medically important Candida spp [Czech] Hodnoceni biotypizace lekarsky vyznamny ch kandid	page 47
53. Antifungal mechanisms supporting boric acid therapy of Candida vaginitis.	page 48
54. Recurrent vaginal infections. Candidosis, bacterial vaginosis [German] Rezidivierende vaginalinfektionen : Candidose, bakterielle vaginose	page 49
55. Azole resistant Candida glabrata vulvovaginitis treated with boric acid	page 50
56. Boric acid addition to suppressive antimicrobial therapy for recurrent bacterial vaginosis.	page 50
57. Azole resistant Candida glabrata vulvovaginitis treated with boric acid.	page 51
58. Candidiasis (vulvovaginal).	page 52
59. Management of recurrent vulvo-vaginal candidosis as a chronic illness.	page 52
60. Candidiasis (vulvovaginal)	page 53
61. Antifungal activity of chemical agents against Candida albicans	page 54
62. Management of recurrent vulvo-vaginal candidosis as a chronic illness	page 55
63. Candida glabrata complicating in vitro pregnancy: Successful management of subsequent pregnancy	page 57
64. Candida glabrata complicating in vitro pregnancy: successful management of subsequent pregnancy.	page 59
65. Boric acid for recurrent vulvovaginal candidiasis: The clinical evidence	page 59

66. Boric acid for recurrent vulvovaginal candidiasis: the clinical evidence.	page 60
67. Boric acid for recurrent vulvovaginal candidiasis: The clinical evidence	page 61
68. Impact of platinum on the soil invertebrate <i>Folsomia candida</i>	page 63
69. Symptomatic <i>Trichomonas vaginalis</i> infection in the setting of severe nitroimidazole allergy: Successful treatment with boric acid	page 64
70. Yeast vaginitis during pregnancy: Susceptibility testing of 13 antifungal drugs and boric acid and the detection of four virulence factors	page 65
71. Boric acid as reference substance: Pros, cons and standardization	page 66
72. Rapid separations of Nile blue stained microorganisms as cationic charged species by chip-CE with LIF	page 67
73. Chronically recurrent vulvovaginal candidosis-problems and chances	page 69
74. Guideline vulvovaginal candidosis (2010) of the German Society for Gynecology and Obstetrics, the Working Group for Infections and Infectimmunology in Gynecology and Obstetrics, the German Society of Dermatology, the Board of German Dermatologists and the German Speaking Mycological Society.	page 70
75. Guideline vulvovaginal candidosis (2010) of the German Society for Gynecology and Obstetrics, the Working Group for Infections and Infectimmunology in Gynecology and Obstetrics, the German Society of Dermatology, the Board of German Dermatologists and the German Speaking Mycological Society	page 71
76. Yeast vaginitis during pregnancy: susceptibility testing of 13 antifungal drugs and boric acid and the detection of four virulence factors.	page 74
77. Yeast vaginitis during pregnancy: Susceptibility testing of 13 antifungal drugs and boric acid and the detection of four virulence factors	page 75
78. Genotyping Reveals no Link Between <i>Candida albicans</i> Genotype and Vaginitis Severity in Turkish Women	page 76
79. Genotyping reveals no link between <i>Candida albicans</i> genotype and vaginitis severity in Turkish women.	page 77
80. FLUCONAZOLE AND BORIC ACID FOR TREATMENT OF VAGINAL CANDIDIASIS--NEW WORDS ABOUT OLD ISSUE.	page 78
81. FLUCONAZOLE AND BORIC ACID FOR TREATMENT OF VAGINAL CANDIDIASIS--NEW WORDS ABOUT OLD ISSUE	page 79
82. <i>Candida</i> vaginitis in non-pregnant patients: A study of antifungal susceptibility testing and virulence factors	page 79
83. <i>Candida</i> vaginitis in non-pregnant patients: a study of antifungal susceptibility testing and virulence factors.	page 81
84. 2nd National Congress on Medicinal Plants	page 81
85. <i>Candida</i> vaginitis during contraceptive use: the influence of methods, antifungal susceptibility and virulence patterns.	page 118
86. <i>Candida</i> vaginitis during contraceptive use: The influence of methods, antifungal susceptibility and virulence patterns	page 119
87. The antimicrobial effect of boric acid on <i>Trichomonas vaginalis</i>	page 120
88. Recurrent vulvo-vaginal <i>Candida</i> infection	page 121
89. Management of persistent vaginitis.	page 123
90. The antimicrobial effect of boric acid on <i>Trichomonas vaginalis</i>	page 124
91. Management of persistent vaginitis	page 124
92. BASIC study: is intravaginal boric acid non-inferior to metronidazole in symptomatic bacterial vaginosis? Study protocol for a randomized controlled trial.	page 125
93. Glucose tetrasaccharide (Glc4) instability in urine, resolved by use of a special collection tube	page 126

94. Guideline: vulvovaginal candidosis (AWMF 015/072), S2k (excluding chronic mucocutaneous candidosis).	page 128
95. Guideline: vulvovaginal candidosis (AWMF 015/072), S2k (excluding chronic mucocutaneous candidosis)	page 129
96. Guideline: Vulvovaginal candidosis (AWMF 015/072), S2k (excluding chronic mucocutaneous candidosis)	page 130
97. Boric acid destabilizes the hyphal cytoskeleton and inhibits invasive growth of <i>Candida albicans</i>	page 133
98. BASIC study: Is intravaginal boric acid non-inferior to metronidazole in symptomatic bacterial vaginosis? Study protocol for a randomized controlled trial	page 134
99. An Alternative Approach to Assess the Habitat Selection of <i>Folsomia candida</i> in Contaminated Soils	page 135
100. Non-albicans <i>Candida</i> Vulvovaginitis: Treatment Experience at a Tertiary Care Vaginitis Center	page 136
101. Influence of boric acid on strains of the genus <i>Candida</i> [Polyglot] Vliv kyseliny borite na druhy rodu <i>Candida</i>	page 137
102. Diaper dermatitis: Current concepts	page 137
103. The boric acid powder treatment of vulvovaginal candidiasis	page 138
104. Treatment of vulvovaginal candidiasis with boric acid powder	page 138
105. Current therapy of vulvovaginitis	page 139
106. The boric acid powder treatment of vulvovaginal candidiasis.	page 140
107. Enhanced differentiation of isolates of <i>Candida albicans</i> using a modified resistogram method	page 140
108. Nystatin versus boric acid powder in vulvovaginal candidiasis	page 140
109. Nystatin versus boric acid powder in vulvovaginal candidiasis.	page 141
110. Bacterial and chemical analysis of otitis externa during immersion in saturated solutions. Double blind test on the usefulness of prophylactic and therapeutic preparations [Italian] RILIEVI BATTERIOLOGICI E CLINICI SULL'OTITE ESTERNA IN SATURAZIONE. STUDIO A DOPPIO CIECO SULL'EFFICACIA DI PREPARATI PROFILATTICI E TERAPEUTICI	page 141
111. [Bacteriological and clinical notes on otitis externa in saturation. Double-blind study on the efficacy of prophylactic and therapeutic preparations].	page 142
112. A new simple method for biotyping <i>Candida albicans</i>	page 143
113. A new simple method for biotyping <i>Candida albicans</i>	page 144
114. Clinical evaluation of a salicylic acid/boric acid/ammonium alum combination as coadjuvants in the treatment of <i>Trichomonas vaginalis</i> and <i>Candida albicans</i> vulvovaginitis [Portuguese] AVALIACAO CLINICA DE UMA ASSOCIACAO ACIDO SALICILICO/ACIDO BORICO/ALUMEN AMONIACAL COMO COADJUVANTE NO TRATAMENTO DE VULVOVAGINITES POR TRICHOMONAS VAGINALIS E CANDIDA ALBICANS	page 144
115. Growth inhibition of <i>Candida albicans</i> and other medically important yeasts by vaginal contraceptive products.	page 145
116. <i>Torulopsis glabrata</i> vaginitis: Clinical aspects and susceptibility to antifungal agents	page 145
117. Growth inhibition of <i>Candida albicans</i> and other medically important yeasts by vaginal contraceptive products	page 147
118. Antifungal agents vs. boric acid for treating chronic mycotic vulvovaginitis	page 147
119. Antifungal agents vs. boric acid for treating chronic mycotic vulvovaginitis.	page 148
120. Boric acid vaginal suppositories	page 149
121. Management of persistent vulvo vaginal candidosis due to azole-resistant <i>Candida glabrata</i>	page 149
122. Current treatment of vulvovaginal candidosis [Serbian] DANASNJE LIJECENJE VULVOVAGINALNE KANDIDOZE	page 151

123. Current treatment of vulvovaginal candidosis [Serbian] DANASNJE LIJECENJE VULVOVAGINALNE KANDIDOZE	page 152
124. Physiological traits associated with success of <i>Candida albicans</i> strains as commensal colonizers and pathogens	page 153
125. Discrimination of strains of <i>Candida albicans</i> isolated from deep and superficial sites by resistotyping.	page 154
126. Discrimination of strains of <i>Candida albicans</i> isolated from deep and superficial sites by resistotyping	page 154
127. Chronic fungal vaginitis: The value of cultures	page 155
128. Physiological traits associated with success of <i>Candida albicans</i> strains as commensal colonizers and pathogens.	page 156
129. Biotypes of oral <i>Candida albicans</i> isolates in a Tanzanian child population	page 156
130. Biotypes of oral <i>Candida albicans</i> isolates in a Tanzanian child population.	page 157
131. Successful use of boric acid to control azole-refractory <i>Candida</i> vaginitis in a woman with AIDS	page 158
132. Treatment of <i>Torulopsis glabrata</i> vaginitis: Retrospective review of boric acid therapy	page 158
133. Over-the-counter and alternative medicines in the treatment of chronic vaginal symptoms	page 159
134. Over-the-counter and alternative medicines in the treatment of chronic vaginal symptoms.	page 160
135. Boric acid vaginal suppositories: A brief review	page 161
136. Boric acid vaginal suppositories: a brief review.	page 162
137. Resistogram typing of oral <i>Candida albicans</i> isolates from normal subjects in three successive trials.	page 162
138. Susceptibility of <i>Candida</i> species isolated from female prostitutes with vulvovaginitis to antifungal agents and boric acid	page 163
139. Terconazole cream for non- <i>Candida albicans</i> fungal vaginitis: Results of a retrospective analysis	page 164
140. Boric acid pessaries: Efficacy and toxicity in treatment of chronic vulvo vaginal candidiasis	page 165
141. Phenotypic characterisation of <i>Candida albicans</i> isolated from chronic hyperplastic candidosis	page 165
142. Biotypes of oral <i>Candida albicans</i> isolated from AIDS patients and HIV-free subjects in Thailand	page 166
143. <i>Candida albicans</i> strain differentiation in complete denture wearers	page 167
144. Phenotypes and randomly amplified polymorphic DNA profiles of <i>Candida albicans</i> isolates from root canal infections in a Finnish population	page 168
145. <i>Candida lusitanae</i> as an unusual cause of recurrent vaginitis and its successful treatment with intravaginal boric acid	page 169
146. Efficacy of maintenance therapy with topical boric acid in comparison with oral itraconazole in the treatment of recurrent vulvovaginal candidiasis	page 170
147. Efficacy of maintenance therapy with topical boric acid in comparison with oral itraconazole in the treatment of recurrent vulvovaginal candidiasis.	page 171
148. Phenotypes and randomly amplified polymorphic DNA profiles of <i>Candida albicans</i> isolates from root canal infections in a Finnish population.	page 171
149. Treatment of chronic recurrent vulvovaginal candidiasis by oral fluconazole and prophylactic local boric acid [Hungarian] Chronicus recidivalo vulvovaginalis candidosis kezelese per os fluconazolal es prophylaxisa lokalis borsavval	page 172
150. Boric acid susceptibility testing of non- <i>C. albicans</i> <i>Candida</i> and <i>Saccharomyces cerevisiae</i> : Comparison of three methods	page 173
151. Vaginitis due to <i>Candida krusei</i> : epidemiology, clinical aspects, and therapy.	page 174
152. Vaginitis due to <i>Candida krusei</i> : Epidemiology, clinical aspects, and therapy	page 174
153. Otomycosis in Turkey: predisposing factors, aetiology and therapy.	page 176

154. Vulvovaginal trichosporonosis	page 176
155. Otomycosis in Turkey: Predisposing factors, aetiology and therapy	page 178
156. Phenotypic diversity of oral <i>C. albicans</i> isolated on single and sequential visits in an HIV-infected Chinese cohort	page 179
157. Common complementary and alternative therapies for yeast vaginitis and bacterial vaginosis: A systematic review	page 180
158. Treatment of vaginitis caused by <i>Candida glabrata</i> : Use of topical boric acid and flucytosine	page 181
159. [Up to date in sexually transmitted infections: epidemiology, diagnostic approaches and treatments].	page 182
160. Up to date in sexually transmitted infections: Epidemiology, diagnostic approaches and treatments [Spanish] Actualizacion en infecciones de transmision sexual: Epidemiologia, diagnostico y tratamiento	page 183
161. Phospholipase, proteinase and haemolytic activities of <i>Candida albicans</i> isolated from oral cavities of patients with type 2 diabetes mellitus.	page 185
162. Local treatment of vulvovaginal candidosis : general and practical considerations.	page 185
163. Biotypes, genotypes and ketoconazole susceptibility of <i>Candida albicans</i> isolates from a group of Thai AIDS patients.	page 186
164. [Evaluation of biotyping of medically important <i>Candida</i> spp].	page 187
165. Impact of platinum on the soil invertebrate <i>Folsomia candida</i>	page 188
166. Boric acid as reference substance: pros, cons and standardization.	page 188
167. Rapid separations of Nile blue stained microorganisms as cationic charged species by chip-CE with LIF.	page 189
168. Symptomatic <i>Trichomonas vaginalis</i> infection in the setting of severe nitroimidazole allergy: successful treatment with boric acid.	page 190
169. [Genotyping of Vaginal <i>Candida glabrata</i> Isolates Using Microsatellite Marker Analysis and DNA Sequencing to Identify Mutations Associated with Antifungal Resistance].	page 190
170. Boric acid destabilizes the hyphal cytoskeleton and inhibits invasive growth of <i>Candida albicans</i>	page 191
171. An Alternative Approach to Assess the Habitat Selection of <i>Folsomia candida</i> in Contaminated Soils.	page 192
172. Non- <i>albicans</i> <i>Candida</i> Vulvovaginitis: Treatment Experience at a Tertiary Care Vaginitis Center.	page 192
173. Boric acid-dependent decrease in regulatory histone H3 acetylation is not mutagenic in yeast.	page 193

Search History

1. EMBASE, Medline; (BORIC AND ACID).ti,ab; 3855 results.
2. EMBASE, Medline; TRICHOMONADS.ti,ab; 1261 results.
3. EMBASE, Medline; TRICHOMONIASIS.ti,ab; 5530 results.
4. EMBASE, Medline; (TRICHOMONAS AND VAGINALIS).ti,ab; 8574 results.
5. EMBASE, Medline; CANDIDA.ti,ab; 109539 results.
6. EMBASE, Medline; (BACTERIAL AND VAGINOSIS).ti,ab; 7150 results.
7. EMBASE, Medline; (VAGINAL AND INFECTIONS).ti,ab; 11701 results.
8. EMBASE, Medline; (SEXUALLY AND TRANSMITTED AND INFECTIONS).ti,ab; 22239 results.
9. EMBASE, Medline; CANDIDIASIS.ti,ab; 28057 results.
10. EMBASE, Medline; (VAGINAL AND SUPPOSITORIES).ti,ab; 1033 results.
11. EMBASE, Medline; 2 OR 3 OR 4 OR 5 OR 6 OR 7 OR 8 OR 9 OR 10; 169242 results.
12. EMBASE, Medline; 1 AND 11; 173 results.
13. EMBASE, Medline; Duplicate filtered: [1 AND 11]; 173 results.

1. [Influence of boric acid on strains of the genus Candida].

Citation: Ceskoslovenská gynekologie, Jan 1949, vol. 14, no. 2, p. 97-100, 0374-6852 (1949)
Author(s): KOCKOVA-KRATOCHVILOVA, A
Subject Headings: Boron Compounds
 Candidiasis
 Leadership
 Boric Acids
 Candida
 Old Medline
Source: Medline

2. Boric acid treatment of vulvovaginal candidiasis.

Citation: Obstetrics and gynecology, Jun 1974, vol. 43, no. 6, p. 893-895, 0029-7844 (June 1974)
Author(s): Swate, T E; Weed, J C
Subject Headings: Capsules
 Candida albicans
 Vaginal Smears
 Candidiasis Vulvovaginal
 Humans
 Index Medicus
 Recurrence
 Female
 Boric Acids
 In Vitro Techniques
 Abridged Index Medicus
 Ointments
Source: Medline

3. Diaper dermatitis: current concepts.

Citation: Pediatrics, Oct 1980, vol. 66, no. 4, p. 532-536, 0031-4005 (October 1980)
Author(s): Weston, W L; Lane, A T; Weston, J A
Abstract: Diaper dermatitis may result from prolonged skin contact with wetness and bacteria. Ammonia plays no apparent role in the generation of diaper dermatitis. Candida albicans frequently contaminates a diaper dermatitis and should be considered present in any diaper dermatitis and should be considered present in any diaper dermatitis known to be present for longer than three days. Topical fluorinated glucocorticoids, boric acid, and mercury-containing preparations should be avoided in the diaper area because of their toxicity.
Subject Headings: Blister
 Infant
 Diaper Rash
 Humans
 Candidiasis
 Diagnosis Differential
 Water
 Bacterial Infections
 Erythema
 Infant Newborn
 Abridged Index Medicus
 Index Medicus
 Ammonia
Source: Medline

4. Treatment of vulvovaginal candidiasis with boric acid powder.

- Citation:** American journal of obstetrics and gynecology, Sep 1981, vol. 141, no. 2, p. 145-148, 0002-9378 (September 15, 1981)
- Author(s):** Van Slyke, K K; Michel, V P; Rein, M F
- Abstract:** A double-blind comparison was made of the use of 14 daily intravaginal gelatin capsules containing 600 mg of boric acid powder versus the use of identical capsules containing 100,000 U nystatin diluted to volume with cornstarch for the treatment of vulvovaginal candidiasis albicans. Cure rates for boric acid were 92% at 7 to 10 days after treatment and 72% at 30 days, whereas the nystatin cure rates were 64% at 7 to 10 days and 50% at 30 days. The speed of alleviation of signs and symptoms was similar for the two drugs. There were no untoward side effects, and cervical cytologic features were not affected. In vitro studies found boric acid to be fungistatic and its effectiveness to be unrelated to pH. Blood boron analyses indicated little absorption from the vagina and a half-life of less than 12 hours. Acceptance by the patients was better than for "messy" vaginal creams, and self-made capsules containing boric acid powder are inexpensive (31 cents for fourteen) compared with the costly medication commonly prescribed.
- Subject Headings:** [Capsules](#)
[Candidiasis Vulvovaginal](#)
[Humans](#)
[Powders](#)
[Index Medicus](#)
[Nystatin](#)
[Adult](#)
[Female](#)
[Boron](#)
[Boric Acids](#)
[Suppositories](#)
[Double-Blind Method](#)
[Random Allocation](#)
[Abridged Index Medicus](#)
- Source:** Medline

5. Current therapy of vulvovaginitis.

- Citation:** Sexually transmitted diseases, Oct 1981, vol. 8, no. 4 suppl, p. 316-320, 0148-5717 (1981 Oct-Dec)
- Author(s):** Rein, M F
- Abstract:** Trichomoniasis is reliably treated with a single 2-g dose of metronidazole; however, with this regimen simultaneous treatment of sexual partners is particularly important. Trichomoniasis in pregnant women, who should not receive metronidazole, might be treated initially with clotrimazole vaginal suppositories, which appear to cure about 50% of cases. Topical antifungal agents of the imidazole class are superior to polyenes in treating vulvovaginal candidiasis. Boric acid powder applied intravaginally in gelatin capsules for 14 days appears as effective as imidazoles. Nonspecific vaginitis is now recognized as involving infection with anaerobic bacteria of the vaginal flora as well as Gardnerella vaginalis. The condition is most successfully treated with a seven-day course of metronidazole, which probably acts by eradicating the anaerobes. In addition, metabolites of metronidazole may act directly on G. vaginalis. Sulfanilamide-aminacrine-allantoin preparations are much less effective than specific therapies and have no role in the treatment of vulvovaginitis.
- Subject Headings:** [Vaginitis](#)
[Male](#)
[Clotrimazole](#)
[Humans](#)
[Antifungal Agents](#)
[Candidiasis](#)

Vulvovaginitis
 Index Medicus
 Metronidazole
 Bacterial Infections
 Female
 Boric Acids
 Imidazoles
 Trichomonas Vaginitis
 Pregnancy

Source: Medline

6. *Torulopsis glabrata* vaginitis: clinical aspects and susceptibility to antifungal agents.

Citation: Obstetrics and gynecology, Oct 1990, vol. 76, no. 4, p. 651-655, 0029-7844 (October 1990)

Author(s): Redondo-Lopez, V; Lynch, M; Schmitt, C; Cook, R; Sobel, J D

Abstract: *Torulopsis glabrata* is second only to *Candida albicans* in frequency of isolation from the vagina in both asymptomatic women and patients with yeast vaginitis. We retrospectively studied 33 patients from whom vaginal isolates of *T glabrata* were obtained. *Torulopsis glabrata* caused symptomatic vaginitis in 42% of the patients but was unassociated with symptoms in 30%; in 27% of patients, its importance was uncertain because of concomitant pathology. Antifungal susceptibility testing was performed on 39 *T glabrata* strains isolated from 39 patients. The minimal inhibitory concentrations (MICs) of the majority of *T glabrata* isolates fell within the sensitive range of the antimycotic drugs tested; however, no correlation was found between in vitro antifungal MICs and the response to azole drug therapy. Clinical success was achieved in 67% of the patients although mycologic cure occurred in only 33%. A small number of patients developed recurrent and often chronic *Torulopsis* vaginitis unresponsive to conventional therapy. Limited experience suggests that vaginal boric acid therapy may be of value in these recalcitrant cases.

Subject Headings: Antifungal Agents
 Candidiasis Vulvovaginal
 Humans
 Index Medicus
 Recurrence
 Adult
 Female
 Middle Aged
 Candida
 Abridged Index Medicus
 Microbial Sensitivity Tests

Source: Medline

7. Management of persistent vulvo vaginal candidosis due to azole-resistant *Candida glabrata*.

Citation: Genitourinary medicine, Apr 1993, vol. 69, no. 2, p. 112-114, 0266-4348 (April 1993)

Author(s): White, D J; Johnson, E M; Warnock, D W

Abstract: CASE REPORT--SUBJECTS--Three cases are described of long-standing vaginal candidosis due to *Candida glabrata*. These had failed to respond to local and systemic antifungals. In each case the infecting strain appeared resistant to a range of azole drugs in vitro. CLINICAL COURSE--Case one--This patient recovered following prolonged treatment with oral itraconazole in combination with oral and vaginal nystatin. Case two. Yeasts were eradicated from this patient following cyclical treatment with oral dydrogesterone; prolonged vaginal treatment with nystatin may have helped. Case three. This patient did not respond to a prolonged course of oral itraconazole in combination with vaginal and oral nystatin, oral medroxyprogesterone or intravaginal boric acid. Eradication of *C glabrata* was finally achieved by local application of 1% gentian violet.

Shortly after eradication of the *C glabrata* infection, both Case two and Case three developed infections with other *Candida* species responsive to azole antifungals.

Subject Headings: [Medroxyprogesterone Acetate](#)
[Itraconazole](#)
[Ketoconazole](#)
[Humans](#)
[Administration Oral](#)
[Candidiasis Vulvovaginal](#)
[Antifungal Agents](#)
[Administration Topical](#)
[Nystatin](#)
[Gentian Violet](#)
[Adult](#)
[Female](#)
[Fluconazole](#)
[Drug Resistance Microbial](#)
[Index Medicus](#)
[Microbial Sensitivity Tests](#)
[Econazole](#)

Source: Medline

Full Text: Available from *National Library of Medicine* in [Genitourinary Medicine](#)

8. Boric acid vaginal suppositories.

Citation: The Annals of pharmacotherapy, Nov 1993, vol. 27, no. 11, p. 1355-1357, 1060-0280 (November 1993)

Author(s): Thai, L; Hart, L L

Subject Headings: [Candidiasis Vulvovaginal](#)
[Humans](#)
[Pessaries](#)
[Clinical Trials as Topic](#)
[Adult](#)
[Female](#)
[Boric Acids](#)
[Index Medicus](#)

Source: Medline

9. Biotypes of oral *Candida albicans* isolates in human immunodeficiency virus-infected patients from diverse geographic locations.

Citation: Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology, Jan 1995, vol. 24, no. 1, p. 32-36, 0904-2512 (January 1995)

Author(s): Tsang, P C; Samaranayake, L P; Philipsen, H P; McCullough, M; Reichart, P A; Schmidt-Westhausen, A; Scully, C; Porter, S R

Abstract: Oral *Candida albicans* isolates from HIV-infected individuals in Hong Kong, Australia, Germany and England were characterised using a biotyping system based on enzyme profiles, carbohydrate assimilation patterns and boric acid resistance of the yeasts. A total of 44 biotypes were found amongst the 117 oral *C. albicans* isolates examined. The major biotype A1R accounted for 17.9% of all isolates while the second commonest biotype was A1S (11.1% of isolates). Whereas these two biotypes were isolated from all the regions studied, there were a number of other biotypes unique to individual countries. The data indicate that there are many different sub-strains of oral *C. albicans* in HIV-infected patients, some of which are globally prevalent. However, further work is required to ascertain the diversity of oral *C. albicans* biotypes, if any, in health and disease.

Subject Headings: [Australia](#)
[England](#)

"AIDS/HIV"
 Candida albicans
 Candidiasis Oral
 Humans
 Index Medicus
 Germany
 Dentistry
 Mycological Typing Techniques
 Population
 Hong Kong
 AIDS-Related Opportunistic Infections

Source: Medline

10. Oral Candida albicans biotypes in Chinese patients with and without oral candidosis.

Citation: Archives of oral biology, Jun 1995, vol. 40, no. 6, p. 577-579, 0003-9969 (June 1995)

Author(s): Xu, Y Y; Samaranayake, L P

Abstract: A total of 53 oral Candida albicans isolates from Chinese patients with clinically diagnosed oral candidosis (27 patients) or without overt signs and mycological manifestations of infection (26) were biotyped using two commercially available API micromethod kits and a boric acid-resistance test. There were no significant differences in the biotypes in health and disease, although the biotype AIR was present only in diseased individuals. The biotype AIS accounted for 21% of the total isolates, as in a number of other previous studies from the West. However, 14 of the 27 biotypes characterized were new biotypes that have not been described before. These preliminary data indicate that biotypic profile of C. albicans may bear no relation to the virulence of the isolates, and that diverse subtypes of the fungus are globally prevalent.

Subject Headings: Candida albicans
 Virulence
 Candidiasis Oral
 Humans
 Colony Count Microbial
 Index Medicus
 China
 Dentistry
 Boric Acids
 Drug Resistance Microbial
 Mycological Typing Techniques
 Mouth
 Tongue
 Carrier State

Source: Medline

11. Chronic fungal vaginitis: the value of cultures.

Citation: American journal of obstetrics and gynecology, Sep 1995, vol. 173, no. 3 Pt 1, p. 820-823, 0002-9378 (September 1995)

Author(s): Nyirjesy, P; Seeney, S M; Grody, M H; Jordan, C A; Buckley, H R

Abstract: Our purpose was to examine the importance of fungal cultures in evaluating patients with symptoms of chronic vaginitis by assessing the relative contribution of various yeast species and by comparing infections caused by Candida albicans with those caused by other species. A prospective observational study of patients referred with chronic vaginal symptoms was undertaken. In addition to a standard evaluation of symptoms, cultures for yeast were performed on modified Sabouraud agar plates. Seventy-seven isolates were obtained from 74 patients. A total of 68% were Candida albicans; 32% were other species. The clinical syndromes caused by non-Candida albicans isolates were indistinguishable from Candida albicans infections. Fluconazole gave a short-term mycologic cure in all Candida albicans but only 25% of non-Candida albicans cases ($p <$

0.001). In non-*Candida albicans* infections, boric acid suppositories achieved the best mycologic cure rate (85%). Because non-*Candida albicans* species are responsible for a significant number of chronic fungal vaginal infections and are more resistant to therapy with fluconazole, fungal cultures are a valuable aid in confirming the diagnosis and selecting appropriate therapy.

Subject Headings: [Prospective Studies](#)
[Candida albicans](#)
[Candidiasis Vulvovaginal](#)
[Humans](#)
[Index Medicus](#)
[Recurrence](#)
[Female](#)
[Fluconazole](#)
[Candida](#)
[Abridged Index Medicus](#)
[Saccharomyces cerevisiae](#)
[Chronic Disease](#)

Source: Medline

12. Treatment of *Torulopsis glabrata* vaginitis: retrospective review of boric acid therapy.

Citation: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, Apr 1997, vol. 24, no. 4, p. 649-652, 1058-4838 (April 1997)

Author(s): Sobel, J D; Chaim, W

Abstract: The charts of all patients who were seen at a vaginitis clinic between January 1989 and December 1994 were retrospectively reviewed; 80 patients whose vaginal cultures yielded *Torulopsis glabrata* were identified. Sixty of these patients experienced 75 symptomatic episodes of vaginitis attributed to *T. glabrata*, and these patients are the subject of this review. Of the 60 symptomatic patients, 40 had uncomplicated *T. glabrata* infection, and 20 had mixed infection, most commonly in association with bacterial vaginosis. Evaluation of treatment of *T. glabrata* vaginitis with vaginal boric acid (600 mg/d for 14 days) revealed clinical improvement or cure in 21 (81%) of 26 episodes and mycological eradication in 20 (77%) of 26 episodes. One-third of the patients received maintenance therapy with boric acid. The clinical response and mycological eradication rates associated with therapy with topical and systemic azoles were <50%. The rate of therapeutic response to boric acid administered to patients with mixed *T. glabrata* infection remained high. In conclusion, in this series of patients with *T. glabrata* vaginitis, for whom repeated courses of antimycotic therapy with azoles had previously failed, boric acid emerged as a promising modality of therapy.

Subject Headings: [Vaginitis](#)
[Humans](#)
[Antifungal Agents](#)
[Candidiasis](#)
[Retrospective Studies](#)
[Female](#)
[Treatment Outcome](#)
[Boric Acids](#)
[Candida](#)
[Index Medicus](#)
[Follow-Up Studies](#)

Source: Medline

Full Text: Available from *UHB Online* in [Clinical Infectious Diseases](#); Note: ; Notes: Click on 'Sign in via OpenAthens' and enter login credentials

13. Successful use of boric acid to control azole-refractory *Candida* vaginitis in a woman with AIDS.

Citation: Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association, Nov 1997, vol. 16, no. 3, p. 219-220, 1077-9450 (November 1, 1997)

Author(s): Shinohara, Y T; Tasker, S A

Subject Headings: "AIDS/HIV"
Administration Intravaginal
Humans
Candidiasis Vulvovaginal
Antifungal Agents
Index Medicus
Adult
Female
Fluconazole
Boric Acids
Drug Resistance Microbial
Suppositories
Acquired Immunodeficiency Syndrome

Source: Medline

14. Susceptibility of Candida species isolated from female prostitutes with vulvovaginitis to antifungal agents and boric acid.

Citation: European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, Jan 1999, vol. 18, no. 1, p. 59-61, 0934-9723 (January 1999)

Author(s): Otero, L; Fleites, A; Méndez, F J; Palacio, V; Vázquez, F

Abstract: The aim of this study was to determine the antifungal susceptibility of 108 Candida albicans and 23 Candida glabrata isolates obtained from female prostitutes with vulvovaginitis, a population for which available data is limited. Amphotericin B, flucytosine, and fluconazole were tested by broth microdilution, and boric acid was tested by the agar dilution method. The susceptibility patterns found in this population were the same as those in the general population. Candida glabrata required greater concentrations of boric acid for inhibition in vitro than did Candida albicans.

Subject Headings: Humans
Candidiasis Vulvovaginal
Antifungal Agents
Prostitution
Index Medicus
Female
Drug Resistance Microbial
Boric Acids
Candida
Microbial Sensitivity Tests

Source: Medline

Full Text: Available from *UHB Online* in *European Journal of Clinical Microbiology and Infectious Diseases*
Available from *ProQuest* in *European Journal of Clinical Microbiology and Infectious Diseases*

15. Terconazole cream for non-Candida albicans fungal vaginitis: results of a retrospective analysis.

Citation: Infectious diseases in obstetrics and gynecology, Jan 2000, vol. 8, no. 5-6, p. 240-243, 1064-7449 (2000)

Author(s): Sood, G; Nyirjesy, P; Weitz, M V; Chatwani, A

Abstract: Although it is FDA-approved for use in vulvovaginal candidiasis caused by non-Candida albicans species, terconazole cream has not been studied in patients with these

infections. We sought to assess the clinical and mycological efficacy of terconazole cream in women with non-*C. albicans* vaginitis. The records of patients who had received a 7-day course of terconazole cream for culture-proved non-*C. albicans* vaginitis were reviewed. Data with regard to patient demographics, clinical and mycologic response to therapy within 1 month of treatment, and outcome with other antifungal therapies were analyzed. Twenty-eight patients received terconazole cream for non-*C. albicans* infections. Three patients did not return for follow-up. The median age was 45 years. Seven (28%) patients were nulliparous. The median duration of symptoms was 3 years. Nine patients (36%) had received terconazole within the 6 months prior to referral. Overall, there were 20 *C. glabrata* cases, 3 *C. parapsilosis*, and 2 *C. lusitanae*. Fourteen (56%) patients achieved a mycologic cure; 11 (44%) noted a resolution of their symptoms. Prior terconazole use was not associated with treatment failure ($P = 0.09$). Ten failures received boric acid suppositories as subsequent treatment; a cure was effected in 4 (40%). Two of three patients (67%) were eventually cured with flucytosine cream. Five (20%) patients remained uncured. Terconazole cream may be an appropriate first-line treatment for non-*C. albicans* vaginitis, even in patients who have previously received the drug.

Subject Headings: [Antifungal Agents](#)
[Humans](#)
[Candidiasis Vulvovaginal](#)
[Flucytosine](#)
[Vaginal Creams Foams and Jellies](#)
[Index Medicus](#)
[Female](#)
[Middle Aged](#)
[Boric Acids](#)
[Treatment Outcome](#)
[Triazoles](#)
[Retrospective Studies](#)

Source: Medline

Full Text: Available from *National Library of Medicine* in [Infectious Diseases in Obstetrics and Gynecology](#)

16. Phenotypic characterisation of *Candida albicans* isolated from chronic hyperplastic candidosis.

Citation: Journal of medical microbiology, Feb 2000, vol. 49, no. 2, p. 199-202, 0022-2615 (February 2000)

Author(s): Williams, D W; Wilson, M J; Potts, A J; Lewis, M A

Abstract: The phenotypes of 35 *Candida albicans* isolates from 19 patients with chronic hyperplastic candidosis (CHC) and 35 isolates from 30 patients with non-CHC infections were compared. Typing was based on carbohydrate assimilation, chemical sensitivity and serology. Eight carbohydrate assimilation profiles were evident with the API-20C system and a single profile predominated for isolates from CHC (17 of 19 patients; 89%) and non-CHC (18 of 30 patients; 63%). Chemical sensitivity tests revealed four profiles with no significant difference between CHC and non-CHC isolates. Serotype A predominated for isolates from both CHC (15 of 19 patients; 79%) and non-CHC (25 of 30 patients; 83%) infections. Boric acid resistance was more prevalent in CHC isolates, although a significant difference was not apparent. In summary, there was no overall difference in the phenotypes of isolates from CHC and non-CHC patients, and clonal restriction of CHC isolates was not demonstrated.

Subject Headings: [Hyperplasia](#)
[Candida albicans](#)
[Candidiasis Oral](#)
[Humans](#)
[Index Medicus](#)
[Serotyping](#)
[Mouth](#)
[Phenotype](#)

[Mycological Typing Techniques](#)
[Chronic Disease](#)

Source: Medline

17. Biotypes of oral *Candida albicans* isolated from AIDS patients and HIV-free subjects in Thailand.

Citation: Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology, May 2000, vol. 29, no. 5, p. 193-199, 0904-2512 (May 2000)

Author(s): Teanpaisan, R; Nittayananta, W; Chongsuvivatwong, V

Abstract: This study was conducted to examine biotypes and antifungal susceptibility patterns of oral *Candida albicans* isolated from HIV-infected patients, HIV-free patients with candidiasis and healthy subjects. All isolates were biotyped using a typing system based on enzyme profiles, carbohydrate assimilation patterns and boric acid resistance. Thirty-eight biotypes were found amongst 218 oral *C. albicans* isolates. The major biotype found was A1S, which accounted for 32.6% of all isolates, and this biotype was the most common in all groups. There was a greater variety of biotypes of *C. albicans* in the HIV-infected group than in the other groups; however, there was no statistically significant difference between the groups. The minimum inhibitory concentrations (MICs) of a total of 118 isolates were determined for amphotericin B and for ketoconazole using the National Committee for Clinical Laboratory Standards (NCCLS) broth macrodilution method and the E-test. When the antifungal susceptibility patterns among the groups were compared, a statistically significant difference was found only with amphotericin B. The median MIC of amphotericin B in the HIV-infected group was higher than in the healthy group (P=0.013, NCCLS method; P=0.002, E-test). However, this difference in sensitivity was not restricted to any sub-type investigated. Our results showed that the biotype patterns of *C. albicans* isolates that colonize HIV-infected patients are similar to those of HIV-free subjects, and there is no relationship between antifungal susceptibility patterns and the biotypes.

Subject Headings: [HIV Seronegativity](#)
[Dentistry](#)
["AIDS/HIV"](#)
[Candida albicans](#)
[Saliva](#)
[Candidiasis Oral](#)
[Humans](#)
[Index Medicus](#)
[Ketoconazole](#)
[Dose-Response Relationship Drug](#)
[Mycological Typing Techniques](#)
[Amphotericin B](#)
[Microbial Sensitivity Tests](#)
[AIDS-Related Opportunistic Infections](#)

Source: Medline

18. *Candida albicans* strain differentiation in complete denture wearers.

Citation: The new microbiologica, Jul 2000, vol. 23, no. 3, p. 329-337, 1121-7138 (July 2000)

Author(s): Abu-Elteen, K H

Abstract: Strain differentiation of 66 clinical isolates of *Candida albicans* obtained from healthy dentate and complete denture wearers was performed. Resistogram method based on differences in the resistance of *C. albicans* isolates to sodium selenite, boric acid, cetrimide, sodium periodate and silver nitrate was used for strain differentiation. Of the 32 potential strains that can be distinguished, 14 different resistogram strains of *C. albicans* were found among the 66 isolates tested. Strain-C--was the most predominant (24.3% of total isolates), while strain A-CDE was the least predominant (1.5%). The results showed no particular association of certain strains with *Candida* infections in complete denture wearers. Sensitivity to antifungal agents showed that isolates from

different strains were most sensitive to amphotericin B and nystatin and least sensitive to miconazole.

Subject Headings: [Miconazole](#)
[Periodic Acid](#)
[Silver Nitrate](#)
[Candida albicans](#)
[Humans](#)
[Candidiasis Oral](#)
[Antifungal Agents](#)
[Index Medicus](#)
[Nystatin](#)
[Cetrimonium Compounds](#)
[Denture Complete](#)
[Amphotericin B](#)
[Boric Acids](#)
[Drug Resistance Microbial](#)
[Microbial Sensitivity Tests](#)
[Stomatitis Denture](#)
[Sodium Selenite](#)

Source: Medline

19. Candida lusitanae as an unusual cause of recurrent vaginitis and its successful treatment with intravaginal boric acid.

Citation: Infectious diseases in obstetrics and gynecology, Jan 2001, vol. 9, no. 4, p. 245-247, 1064-7449 (2001)

Author(s): Silverman, N S; Morgan, M; Nichols, W S

Abstract: Increasing use of short-course antifungal therapies in patients with recurrent vulvovaginitis may enable the emergence of less-common, more resistant yeast strains as vaginal pathogens. We report the case of a patient with chronically symptomatic and repeatedly treated vaginal candidiasis whose infection was attributable to *Candida lusitanae*, a previously unreported cause of candidal vaginitis.

Subject Headings: [Administration Intravaginal](#)
[Middle Aged](#)
[Candidiasis Vulvovaginal](#)
[Humans](#)
[Index Medicus](#)
[Female](#)
[Boric Acids](#)
[Candida](#)

Source: Medline

Full Text: Available from *National Library of Medicine* in [Infectious Diseases in Obstetrics and Gynecology](#)

20. Boric acid susceptibility testing of non-C. albicans Candida and Saccharomyces cerevisiae: comparison of three methods.

Citation: Medical mycology, Jun 2002, vol. 40, no. 3, p. 319-322, 1369-3786 (June 2002)

Author(s): Otero, L; Palacio, V; Mendez, F J; Vazquez, F

Abstract: To establish the best method for boric acid susceptibility testing, we compared two agar dilution methods (high and low inoculum) and a standard broth microdilution method (from the National Committee for Clinical Laboratory Standards document NCCLS M-27A). *Saccharomyces cerevisiae* (37) and non-*C. albicans* *Candida* (39) isolates, as well as one isolate of *Trichosporon* sp., were included. All were isolated from female workers with vulvovaginitis. Good agreement within a fourfold dilution range was found between the three methods, and only the broth microdilution method versus the agar dilution method with high inoculum showed significant discrepancies. Reading results

was easier with the broth microdilution method than with the agar dilution methods because of partial growth inhibition in the latter. In conclusion, broth microdilution is a suitable method for testing yeast susceptibility to boric acid.

Subject Headings: [Trichosporon](#)
[Humans](#)
[Candidiasis Vulvovaginal](#)
[Antifungal Agents](#)
[Vulvovaginitis](#)
[Index Medicus](#)
[Agar](#)
[Anti-Infective Agents Local](#)
[Female](#)
[Boric Acids](#)
[Candida](#)
[Saccharomyces cerevisiae](#)
[Mycoses](#)
[Microbial Sensitivity Tests](#)
[Culture Media](#)

Source: Medline

21. Vulvovaginal trichosporonosis.

Citation: Infectious diseases in obstetrics and gynecology, Jan 2003, vol. 11, no. 2, p. 131-133, 1064-7449 (2003)

Author(s): Makela, Paul; Leaman, Debbie; Sobel, Jack D

Abstract: Isolation of *Trichosporon* species from vaginal secretions is a rare event, and no data are available on its pathogenic role. A case series is presented to determine the pathogenic role of *Trichosporon* species in vulvovaginal infections. We performed a retrospective chart review of patients seen in the W.S.U. Vaginitis Clinic in order to identify patients from whom *Trichosporon* species were isolated. Between 1986 and 2001, a total of 13 patients had a total of 18 positive vaginal cultures for *Trichosporon* species. All 18 vaginal isolates were *T. inkin*. In general, positive vaginal cultures were accompanied by low yeast colony counts. Four out of 18 positive *T. inkin* cultures were obtained from visits by asymptomatic patients. Of the remaining 14 positive *T. inkin* cultures from patients with symptoms, nine out of 14 cultures had other diagnoses (*Candida albicans*, six cases; bacterial vaginosis, two cases; *Trichomonas*, one case). Five positive *T. inkin* cultures were obtained from visits at which patients had symptoms and no associated diagnosis. In only one of the five episodes could we establish a clear pathogenic role for *Trichosporon*. In this case the patient was treated with boric acid and had resolution of symptoms and a negative culture at follow-up. In-vitro susceptibility tests revealed that *T. inkin* was resistant to flucytosine and susceptible to all topical and oral azoles. *T. inkin* is occasionally found in vulvovaginal cultures and is usually a non-pathogen. Transient colonization tended to occur in women, usually of African-American origin, with major perturbations in vaginal flora (bacterial vaginosis and trichomoniasis) and increased pH. Pathogenic consequences of *Trichosporon* colonization appear to be rare.

Subject Headings: [Trichosporon](#)
[Hydrogen-Ion Concentration](#)
[Humans](#)
[Antifungal Agents](#)
[Vaginal Diseases](#)
[Colony Count Microbial](#)
[Index Medicus](#)
[Vagina](#)
[Adult](#)
[Female](#)
[Mycoses](#)
[Candida](#)

[African Americans](#)
[Retrospective Studies](#)

Source: Medline

Full Text: Available from *National Library of Medicine* in [Infectious Diseases in Obstetrics and Gynecology](#)

22. Phenotypic diversity of oral *C. albicans* isolated on single and sequential visits in an HIV-infected Chinese cohort.

Citation: APMIS : acta pathologica, microbiologica, et immunologica Scandinavica, Feb 2003, vol. 111, no. 2, p. 329-337, 0903-4641 (February 2003)

Author(s): Samaranayake, Y H; Samaranayake, L P; Yau, J Y Y; Dassanayake, R S; Li, T K L; Anil, S

Abstract: HIV-infected individuals maintain multiple oral *C. albicans* strains over time that are thought to undergo microevolution in terms of both phenotypic and genotypic features. To study this phenomenon, a 12-month prospective study was conducted in a cohort of 16 HIV-infected ethnic Chinese individuals with (A) and without (B) symptoms of oropharyngeal candidiasis to evaluate the phenotype distribution among oral *C. albicans* isolates during disease progression. Oral rinse samples were obtained and up to five *C. albicans* colony-forming units were selected per each visit, during the one year period of multiple visits. The isolates were phenotyped using two commercially available biotyping kits, the API 20C system, API ZYM system, and a plate test for resistance to boric acid. A total of 261 *C. albicans* strains in group A were differentiated into 67 biotypes, while 42 biotypes were seen amongst the 182 isolates from group B. The major biotypes in the two groups were similar and were in decreasing order of prevalence J1R, J1S, J6S, J6R, J2S, K1S, J10R, K1R, and K6R; 48 different biotypes were seen in group A and 24 in group B, with some uniquely represented in each group, leading to a significant association between the prevalence of the biotypes J1S and J2S and symptomatic candidiasis ($p < 0.05$). Taken together this study illustrates the wide phenotypic spectrum of oral *C. albicans* associated with HIV-infection.

Subject Headings: [Male](#)
[Genotype](#)
[Candida albicans](#)
[Humans](#)
[Cohort Studies](#)
[Candidiasis Oral](#)
[Disease Progression](#)
[Index Medicus](#)
[Sexuality](#)
[China](#)
[Adult](#)
[Female](#)
[Middle Aged](#)
[HIV Infections](#)
[Carrier State](#)

Source: Medline

Full Text: Available from *EBSCOhost* in [APMIS](#)

23. Common complementary and alternative therapies for yeast vaginitis and bacterial vaginosis: a systematic review.

Citation: Obstetrical & gynecological survey, May 2003, vol. 58, no. 5, p. 351-358, 0029-7828 (May 2003)

Author(s): Van Kessel, Katherine; Assefi, Nassim; Marrazzo, Jeanne; Eckert, Linda

Abstract: This article is a systematic review of the literature regarding the most commonly used complementary and alternative medicine (CAM) therapies for yeast vaginitis and bacterial vaginosis. A search was conducted of all published literature on conventional search engines (PubMed, EMBASE, the Cochrane Registry, CINAHL, LILACS) and alternative medicine databases (Natural Medicines Comprehensive Database, Longwood

Herbal Taskforce, and Alternative Medicine Alert), for all studies of the five most commonly used CAM treatments of vaginitis. Inconsistencies in definition of vaginitis, type of intervention, control groups, and outcomes prevented performance of a meta-analysis, and paucity of high-quality studies made ranking by evidence-based scales unsuitable. Lactobacillus recolonization (via yogurt or capsules) shows promise for the treatment of both yeast vaginitis and bacterial vaginosis with little potential for harm. Boric acid can be recommended to women with recurrent vulvovaginal Candidal infections who are resistant to conventional therapies, but can occasionally cause vaginal burning. Because of associated risks in the absence of well-documented clinical benefits, douching remains a practice that should not be recommended for the treatment of vaginitis. Finally, tea tree oil and garlic show some in vitro potential for the treatment of vaginitis, but the lack of in vivo studies preclude their recommendation to patients for the time-being. The available evidence for CAM treatments of vaginitis is of poor quality despite the prevalent use of these therapies. Well-designed randomized, controlled trials investigating the efficacy and safety of these therapies for vaginitis are needed before any reliable clinical recommendations can be made. Obstetricians & Gynecologists, Family Physicians. After completion of this article, the reader will be able to list the most common complementary and alternative medicine therapies for vaginitis, summarize the data surrounding the efficacy of each therapy, describe the adverse affects of each therapy, and outline which therapies are recommended and not recommended for vaginitis.

Subject Headings:

[Phytotherapy](#)
[Lactobacillus](#)
[Drug Resistance](#)
[Vaginitis](#)
[Yeasts](#)
[Humans](#)
[Candidiasis](#)
[Index Medicus](#)
[Recurrence](#)
[Therapeutic Irrigation](#)
[Anti-Infective Agents Local](#)
[Garlic](#)
[Female](#)
[Yogurt](#)
[Treatment Outcome](#)
[Tea Tree Oil](#)
[Vaginosis Bacterial](#)
[Complementary Therapies](#)

Source: Medline

24. Treatment of vaginitis caused by *Candida glabrata*: use of topical boric acid and flucytosine.

Citation: American journal of obstetrics and gynecology, Nov 2003, vol. 189, no. 5, p. 1297-1300, 0002-9378 (November 2003)

Author(s): Sobel, Jack D; Chaim, Walter; Nagappan, Viji; Leaman, Deborah

Abstract: The purpose of this study was to review the treatment outcome and safety of topical therapy with boric acid and flucytosine in women with *Candida glabrata* vaginitis. This was a retrospective review of case records of 141 women with positive vaginal cultures of *C glabrata* at two sites, Wayne State University School of Medicine and Ben Gurion University. The boric acid regimen, 600 mg daily for 2 to 3 weeks, achieved clinical and mycologic success in 47 of 73 symptomatic women (64%) in Detroit and 27 of 38 symptomatic women (71%) in Beer Sheba. No advantage was observed in extending therapy for 14 to 21 days. Topical flucytosine cream administered nightly for 14 days was associated with a successful outcome in 27 of 30 of women (90%) whose condition had failed to respond to boric acid and azole therapy. Local side effects were uncommon with both regimens. Topical boric acid and flucytosine are useful additions to therapy for women with azole-refractory *C glabrata* vaginitis.

Subject Headings: [Vaginitis](#)

[Index Medicus](#)
[Adolescent](#)
[Abridged Index Medicus](#)
[Flucytosine](#)
[Candidiasis Vulvovaginal](#)
[Antifungal Agents](#)
[Administration Topical](#)
[Humans](#)
[Adult](#)
[Female](#)
[Middle Aged](#)
[Boric Acids](#)
[Ointments](#)
[Aged](#)
[Candida glabrata](#)
[Retrospective Studies](#)
[Retreatment](#)

Source: [Medline](#)

25. Biotypes and randomly amplified polymorphic DNA (RAPD) profiles of subgingival *Candida albicans* isolates in HIV infection.

Citation: [The new microbiologica, Jan 2005, vol. 28, no. 1, p. 75-82, 1121-7138 \(January 2005\)](#)

Author(s): [Pizzo, Giuseppe; Giammanco, Giovanni M; Pecorella, Sonia; Campisi, Giuseppina; Mammina, Caterina; D'Angelo, Matteo](#)

Abstract: A group of subgingival isolates of *C. albicans* recovered from Italian HIV-positive (HIV+) subjects were characterized both phenotypically and genotypically. Phenotyping of the isolates was carried out by a biotyping method based on the enzyme profiles, carbohydrate assimilation patterns and boric acid resistance of the yeasts. Genotyping was performed through randomly amplified polymorphic DNA (RAPD) analysis. Five biotypes were found among the 29 subgingival *C. albicans* strains examined. The predominant biotypes were A1R (55.17%), A1S (24.14%), and A2R (13.79%), while the biotypes A11R and A13R were represented by a single isolate each. RAPD profiles identified 15 genotypes among the 29 isolates. Almost every individual harboured his/her own specific isolate and in three out of the six subjects with multiple isolates (two to six each) more than one genotype (two to six) was found. The biotype distribution we found is consistent with previous reports on *C. albicans* isolates from other oral sources, whereas the resistance to boric acid was highly frequent in subgingival strains. RAPD analysis showed high genetic heterogeneity within subgingival isolates, also when isolates were phenotypically identical. These findings, obtained from HIV+ subjects living in Southern Italy, may be useful as baseline information on subgingival *C. albicans* colonization in the Mediterranean area.

Subject Headings:
[Gingival Diseases](#)
[Drug Resistance Fungal](#)
[Italy](#)
[Genotype](#)
[Candida albicans](#)
[Humans](#)
[Candidiasis Oral](#)
[Antifungal Agents](#)
[Index Medicus](#)
[Male](#)
[Adult](#)
[Female](#)
[Boric Acids](#)
[Random Amplified Polymorphic DNA Technique](#)
[Mycological Typing Techniques](#)
[DNA Fingerprinting](#)
[Phenotype](#)

DNA Fungal
AIDS-Related Opportunistic Infections

Source: Medline

26. Biotypes and randomly amplified polymorphic DNA (RAPD) profiles of subgingival *Candida albicans* isolates in HIV infection

Citation: New Microbiologica, January 2005, vol./is. 28/1(75-82), 1121-7138 (January 2005)

Author(s): Pizzo G.; Giammanco G.M.; Pecorella S.; Campisi G.; Mammina C.; D'Angelo M.

Institution: (Pizzo, Pecorella, Campisi, D'Angelo) Department of Oral Sciences, University of Palermo, Italy; (Giammanco, Mammina) Dept. of Hygiene and Microbiology, University of Palermo, Italy; (Pizzo) Dipto. di Scienze Stomatologiche, Università di Palermo, Via del Vespro 129, 90127 Palermo, Italy

Language: English

Abstract: A group of subgingival isolates of *C. albicans* recovered from Italian HIV-positive (HIV+) subjects were characterized both phenotypically and genotypically. Phenotyping of the isolates was carried out by a biotyping method based on the enzyme profiles, carbohydrate assimilation patterns and boric acid resistance of the yeasts. Genotyping was performed through randomly amplified polymorphic DNA (RAPD) analysis. Five biotypes were found among the 29 subgingival *C. albicans* strains examined. The predominant biotypes were A1R (55.17%), A1S (24.14%), and A2R (13.79%), while the biotypes A11R and A13R were represented by a single isolate each. RAPD profiles identified 15 genotypes among the 29 isolates. Almost every individual harboured his/her own specific isolate and in three out of the six subjects with multiple isolates (two to six each) more than one genotype (two to six) was found. The biotype distribution we found is consistent with previous reports on *C. albicans* isolates from other oral sources, whereas the resistance to boric acid was highly frequent in subgingival strains. RAPD analysis showed high genetic heterogeneity within subgingival isolates, also when isolates were phenotypically identical. These findings, obtained from HIV+ subjects living in Southern Italy, may be useful as baseline information on subgingival *C. albicans* colonization in the Mediterranean area.

Country of Publication: Italy

Publisher: Luigi Ponzio e figlio Editori

CAS Registry Number: 10043-35-3 (boric acid); 11113-50-1 (boric acid); 11129-12-7 (boric acid); 14213-97-9 (boric acid)

Publication Type: Journal: Article

Subject Headings: [adult](#)
[aged](#)
[article](#)
[biotype](#)
[*Candida albicans](#)
[clinical article](#)
[controlled study](#)
[female](#)
[fungal strain](#)
[fungus isolation](#)
[genetic heterogeneity](#)
[genotype](#)
[human](#)
[*Human immunodeficiency virus](#)
["*Human immunodeficiency virus infection/et \[Etiology\]"](#)
[male](#)
[Mediterranean Sea](#)
[nonhuman](#)
[*periodontics](#)
[phenotype](#)

*random amplified polymorphic DNA
 yeast
 boric acid
 carbohydrate
 enzyme

Source: EMBASE

27. In vitro activity of bergamot natural essence and furocoumarin-free and distilled extracts, and their associations with boric acid, against clinical yeast isolates

Citation: Journal of Antimicrobial Chemotherapy, January 2005, vol./is. 55/1(110-114), 0305-7453 (January 2005)

Author(s): Romano L.; Battaglia F.; Masucci L.; Sanguinetti M.; Posteraro B.; Plotti G.; Zanetti S.; Fadda G.

Institution: (Romano, Masucci, Sanguinetti, Posteraro, Fadda) Institute of Microbiology, Catholic Univ. of the Sacred Heart, Rome, Italy; (Battaglia, Plotti) Unit of Gynaecology and Obstetrics, Hospital of San Filippo Neri, Rome, Italy; (Zanetti) Department of Biomedical Sciences, University of Sassari, Sassari, Italy

Language: English

Abstract: Objectives: There is very little information, to date, on the antifungal activity of bergamot oil. In this study, we investigated the in vitro activity of three bergamot oils (natural essence, furocoumarin-free extract and distilled extract) against clinically relevant *Candida* species. We studied the two derivatives, components of Italian pharmaceutical products, that are supposed to be less toxic than the essential oil. Methods: In vitro susceptibility of 40 clinical isolates of *Candida* spp. (*Candida albicans*, n = 20; *Candida glabrata*, n = 13; *Candida krusei*, n = 4; *Candida tropicalis*, n = 2; *Candida parapsilosis*, n = 1), associated with symptomatic and asymptomatic vulvovaginal candidiasis, was determined using a modification of the NCCLS M27-A2 broth microdilution method. MICs were evaluated for each of the oils alone and combined with sub-inhibitory concentrations of the well-known antiseptic, boric acid. To boric acid, all isolates had MIC values ranging from 0.094% to 0.187% (w/v). Results: At 24 h readings, the MIC₉₀s (for all isolates) were (v/v): 5% for natural essence of bergamot, 2.5% for the furocoumarin-free extract, and 1.25% for the distilled extract. At the 48 h reading, these values increased to >10%, 5% and 2.5%, respectively. At both readings, MIC₉₀s for all oil + boric acid combinations were significantly lower than corresponding values for the oils alone (P < 0.05). Conclusions: These data indicate that bergamot oils are active in vitro against *Candida* spp., suggesting their potential role for the topical treatment of *Candida* infections. © The British Society for Antimicrobial Chemotherapy 2004; all rights reserved.

Country of Publication: United Kingdom

Publisher: Oxford University Press

CAS Registry Number: 8006-85-7 (bergamot oil); 8007-75-8 (bergamot oil); 10043-35-3 (boric acid); 11113-50-1 (boric acid); 11129-12-7 (boric acid); 14213-97-9 (boric acid); 86386-73-4 (fluconazole)

Publication Type: Journal: Article

Subject Headings: antibiotic resistance
 article
Candida albicans
Candida glabrata
Candida krusei
Candida parapsilosis
Candida tropicalis
 clinical article
 distillation
 female
 fungus isolation
 human

[in vitro study](#)
[methodology](#)
[minimum inhibitory concentration](#)
[symptomatology](#)
["*vagina candidiasis/et \[Etiology\]"](#)
["*bergamot oil/cb \[Drug Combination\]"](#)
["*bergamot oil/tp \[Topical Drug Administration\]"](#)
["boric acid/cb \[Drug Combination\]"](#)
[fluconazole](#)
["*furocoumarin/cb \[Drug Combination\]"](#)
["*furocoumarin/tp \[Topical Drug Administration\]"](#)

Source: EMBASE

28. In vitro activity of bergamot natural essence and furocoumarin-free and distilled extracts, and their associations with boric acid, against clinical yeast isolates.

Citation: The Journal of antimicrobial chemotherapy, Jan 2005, vol. 55, no. 1, p. 110-114, 0305-7453 (January 2005)

Author(s): Romano, L; Battaglia, F; Masucci, L; Sanguinetti, M; Posteraro, B; Plotti, G; Zanetti, S; Fadda, G

Abstract: There is very little information, to date, on the antifungal activity of bergamot oil. In this study, we investigated the in vitro activity of three bergamot oils (natural essence, furocoumarin-free extract and distilled extract) against clinically relevant *Candida* species. We studied the two derivatives, components of Italian pharmaceutical products, that are supposed to be less toxic than the essential oil. In vitro susceptibility of 40 clinical isolates of *Candida* spp. (*Candida albicans*, n=20; *Candida glabrata*, n=13; *Candida krusei*, n=4; *Candida tropicalis*, n=2; *Candida parapsilosis*, n=1), associated with symptomatic and asymptomatic vulvovaginal candidiasis, was determined using a modification of the NCCLS M27-A2 broth microdilution method. MICs were evaluated for each of the oils alone and combined with sub-inhibitory concentrations of the well-known antiseptic, boric acid. To boric acid, all isolates had MIC values ranging from 0.094% to 0.187% (w/v). At 24 h readings, the MIC(90)s (for all isolates) were (v/v): 5% for natural essence of bergamot, 2.5% for the furocoumarin-free extract, and 1.25% for the distilled extract. At the 48 h reading, these values increased to >10%, 5% and 2.5%, respectively. At both readings, MIC(90)s for all oil+boric acid combinations were significantly lower than corresponding values for the oils alone (P <0.05). These data indicate that bergamot oils are active in vitro against *Candida* spp., suggesting their potential role for the topical treatment of *Candida* infections.

Subject Headings: [Drug Interactions](#)
[Humans](#)
[Candidiasis Vulvovaginal](#)
[Antifungal Agents](#)
[Vagina](#)
[Plant Oils](#)
[Plant Extracts](#)
[Coumarins](#)
[Female](#)
[Boric Acids](#)
[Candida](#)
[Index Medicus](#)
[Microbial Sensitivity Tests](#)

Source: Medline

29. Vaginal *Candida parapsilosis*: pathogen or bystander?

Citation: Infectious diseases in obstetrics and gynecology, Mar 2005, vol. 13, no. 1, p. 37-41, 1064-7449 (March 2005)

Author(s): Nyirjesy, Paul; Alexander, Alynn B; Weitz, M Velma

- Abstract:** Candida parapsilosis is an infrequent isolate on vaginal cultures; its role as a vaginal pathogen remains unstudied. This retrospective study of women with positive culture for *C. parapsilosis* sought to characterize the significance of this finding and its response to antifungal therapy. From February 2001 to August 2002, we identified all individuals with positive fungal isolates among a population of women with chronic vulvovaginal symptoms. Charts of women with *C. parapsilosis* cultures were reviewed with regard to patient demographics, clinical presentation and therapeutic response. Mycological cure, defined as a negative fungal culture at the next office visit, and clinical cure, i.e. symptom resolution, were determined for each subject. A total of 582 women had positive vaginal cultures for 635 isolates, of which 54 (8.5%) were *C. parapsilosis*. The charts of 51 subjects with *C. parapsilosis* were available for review and follow-up cultures and clinical information were available for 39 (76.5%). Microscopy was positive in 9 (17.6%). Antifungal treatment resulted in mycological cure in 17/19 patients with fluconazole, 7/7 with butoconazole, 6/6 with boric acid, 1/1 with miconazole and occurred spontaneously in 6/7: 24/37 (64.9%) patients with a mycological cure experienced clinical cure. Although *C. parapsilosis* is often a cause of vaginal symptoms, it seems to respond to a variety of antifungal agents and may even be a transient vaginal colonizer.
- Subject Headings:** [Vaginitis](#)
[Humans](#)
[Candidiasis Vulvovaginal](#)
[Antifungal Agents](#)
[Index Medicus](#)
[Aged 80 and over](#)
[Adult](#)
[Female](#)
[Middle Aged](#)
[Candida](#)
[Aged](#)
[Retrospective Studies](#)
- Source:** Medline
- Full Text:** Available from *EBSCOhost* in [Infectious Diseases in Obstetrics & Gynecology](#)
Available from *ProQuest* in [Infectious Diseases in Obstetrics and Gynecology](#)
Available from *National Library of Medicine* in [Infectious Diseases in Obstetrics and Gynecology](#)

30. Vaginal Candida parapsilosis: Pathogen or bystander?

- Citation:** Infectious Disease in Obstetrics and Gynecology, March 2005, vol./is. 13/1(37-41), 1064-7449;1098-0997 (March 2005)
- Author(s):** Nyirjesy P.; Alexander A.B.; Weitz M.V.
- Institution:** (Nyirjesy, Weitz) Department of Obstetrics, Drexel University College of Medicine, Philadelphia, PA, United States; (Alexander) Department of Obstetrics, Jefferson Medical College, Philadelphia, PA, United States; (Nyirjesy) New College Building, 245 N. 15th Street, Philadelphia, PA 19102, United States
- Language:** English
- Abstract:** Objective: *Candida parapsilosis* is an infrequent isolate on vaginal cultures; its role as a vaginal pathogen remains unstudied. This retrospective study of women with positive culture for *C. parapsilosis* sought to characterize the significance of this finding and its response to antifungal therapy. Methods: From February 2001 to August 2002, we identified all individuals with positive fungal isolates among a population of women with chronic vulvovaginal symptoms. Charts of women with *C. parapsilosis* cultures were reviewed with regard to patient demographics, clinical presentation and therapeutic response. Mycological cure, defined as a negative fungal culture at the next office visit, and clinical cure, i.e. symptom resolution, were determined for each subject. Results: A total of 582 women had positive vaginal cultures for 635 isolates, of which 54 (8.5%) were *C. parapsilosis*. The charts of 51 subjects with *C. parapsilosis* were available for review and follow-up cultures and clinical information were available for 39 (76.5%).

Microscopy was positive in 9 (17.6%). Antifungal treatment resulted in mycological cure in 17/19 patients with fluconazole, 7/7 with butoconazole, 6/6 with boric acid, 1/1 with miconazole and occurred spontaneously in 6/7: 24/37 (64.9%) patients with a mycological cure experienced clinical cure. Conclusions: Although *C. parapsilosis* is often a cause of vaginal symptoms, it seems to respond to a variety of antifungal agents and may even be a transient vaginal colonizer. © 2005 Taylor & Francis Group Ltd.

Country of Publication: United Kingdom
Publisher: Taylor and Francis Ltd.
CAS Registry Number: 10043-35-3 (boric acid); 11113-50-1 (boric acid); 11129-12-7 (boric acid); 14213-97-9 (boric acid); 64872-76-0 (butoconazole); 64872-77-1 (butoconazole); 86386-73-4 (fluconazole); 22916-47-8 (miconazole)
Publication Type: Journal: Review
Subject Headings: [*Candida parapsilosis](#)
[clinical feature](#)
[controlled study](#)
[demography](#)
[female](#)
[follow up](#)
[fungus culture](#)
[fungus isolation](#)
[human](#)
[major clinical study](#)
[priority journal](#)
[review](#)
[treatment outcome](#)
["*vagina candidiasis/dt \[Drug Therapy\]"](#)
["*vagina candidiasis/et \[Etiology\]"](#)
["boric acid/dt \[Drug Therapy\]"](#)
["butoconazole/dt \[Drug Therapy\]"](#)
["fluconazole/dt \[Drug Therapy\]"](#)
["miconazole/dt \[Drug Therapy\]"](#)

Source: EMBASE

Full Text: Available from *EBSCOhost* in *Infectious Diseases in Obstetrics & Gynecology*
 Available from *ProQuest* in *Infectious Diseases in Obstetrics and Gynecology*
 Available from *National Library of Medicine* in *Infectious Diseases in Obstetrics and Gynecology*

31. Recurrent vulvovaginal candidiasis

Citation: Missouri medicine, March 2006, vol./is. 103/2(165-168), 0026-6620 (2006 Mar-Apr)
Author(s): Ringdahl E.N.
Institution: (Ringdahl) Department of Family and Community Medicine, University of Missouri, Columbia, USA.
Language: English
Abstract: Recurrent vulvovaginal candidiasis affects five percent of women of child-bearing age. The most common organism is *Candida albicans*, but an increasing number of infections are caused by nonalbicans species. Fungal culture directs treatment as nonalbicans species may be azole resistant. *C. albicans* will respond to anyazole antifungal. Treat *C. glabrata* with boric acid. Maintenance therapy should be started immediately after treatment of the acute episode and should last for six months.
Country of Publication: United States
CAS Registry Number: 10043-35-3 (boric acid); 11113-50-1 (boric acid); 11129-12-7 (boric acid); 14213-97-9 (boric acid); 65277-42-1 (ketoconazole)
Publication Type: Journal: Review

Subject Headings: acute disease
Candida albicans
Candida glabrata
drug effect
female
human
patient care
"recurrent disease/pc [Prevention]"
review
"*vagina candidiasis/di [Diagnosis]"
"*vagina candidiasis/dt [Drug Therapy]"
"*vagina candidiasis/pc [Prevention]"
"*antifungal agent/dt [Drug Therapy]"
"boric acid/dt [Drug Therapy]"
"ketoconazole/dt [Drug Therapy]"

Source: EMBASE

32. Recurrent vulvovaginal candidiasis.

Citation: Missouri medicine, Mar 2006, vol. 103, no. 2, p. 165-168, 0026-6620 (2006 Mar-Apr)

Author(s): Ringdahl, Erika N

Abstract: Recurrent vulvovaginal candidiasis affects five percent of women of child-bearing age. The most common organism is *Candida albicans*, but an increasing number of infections are caused by nonalbicans species. Fungal culture directs treatment as nonalbicans species may be azole resistant. *C. albicans* will respond to anyazole antifungal. Treat *C. glabrata* with boric acid. Maintenance therapy should be started immediately after treatment of the acute episode and should last for six months.

Subject Headings: Ketoconazole
Candida albicans
Humans
Candidiasis Vulvovaginal
Antifungal Agents
Secondary Prevention
Index Medicus
Female
Boric Acids
Acute Disease
Candida glabrata
Episode of Care

Source: Medline

33. Entrapment of lipase in polymer of polyvinyl alcohol-boric acid for esterification in organic media

Citation: Indian Journal of Biotechnology, July 2006, vol./is. 5/3(368-372), 0972-5849 (July 2006)

Author(s): Dave R.; Madamwar D.

Institution: (Dave, Madamwar) Post-Graduate Department of Biosciences, Sardar Patel University, Vallabh Vidyanagar 388 120, India

Language: English

Abstract: Polyvinyl alcohol (PVA)-boric acid method has been utilized for entrapment of *Candida rugosa* lipase. Immobilized lipase was used to produce ethyl butyrate, a flavour ester showing 80.2% conversion in 72 h. Lipase in PVA-boric acid beads possessed the ability to synthesize variety of esters and was stable in various organic solvents with varying log P value from 2 to 8 under incubation at 50degreeC for 1 h. The immobilized lipase showed nearly full retention of activity even after 8 cycles of use, the activity then gradually decreased reaching to 56% conversion efficiency after 20 cycles and possesses a shelf-life of 10 months. The thermostability of the lipase increased three times upon

immobilization. The immobilized enzyme possessed 40% higher activity compared to its free counterpart.

Country of Publication: India

Publisher: National Institute of Science Communication and Information Resources (NISCAIR)

CAS Registry Number: 10043-35-3 (boric acid); 11113-50-1 (boric acid); 11129-12-7 (boric acid); 14213-97-9 (boric acid); 105-54-4 (butyric acid ethyl ester); 37380-95-3 (polyvinyl alcohol); 9002-89-5 (polyvinyl alcohol); 9001-62-1 (triacylglycerol lipase)

Publication Type: Journal: Conference Paper

Subject Headings: [Candida rugosa](#)
[conference paper](#)
[enzyme activity](#)
[enzyme immobilization](#)
[enzyme stability](#)
[esterification](#)
[thermostability](#)
[boric acid](#)
[butyric acid ethyl ester](#)
[*fungal enzyme](#)
[organic solvent](#)
[polymer](#)
[polyvinyl alcohol](#)
[*triacylglycerol lipase](#)

Source: EMBASE

34. Boric acid for refractory candida glabrata vaginitis

Citation: Journal of Obstetrics and Gynaecology, August 2006, vol./is. 26/6(584), 0144-3615;1364-6893 (01 Aug 2006)

Author(s): Dhingra S.; Roseblade C.K.

Institution: (Dhingra, Roseblade) Department of Obstetrics and Gynaecology, Wrexham Maelor Hospital, Wrexham, United Kingdom; (Dhingra) 15 Heol Mynydd Bychan, Heath, Cardiff CF14 4NL, United Kingdom

Language: English

Country of Publication: United Kingdom

Publisher: Taylor and Francis Ltd.

CAS Registry Number: 12633-72-6 (amphotericin); 10043-35-3 (boric acid); 11113-50-1 (boric acid); 11129-12-7 (boric acid); 14213-97-9 (boric acid); 86386-73-4 (fluconazole); 2022-85-7 (flucytosine); 84625-61-6 (itraconazole)

Publication Type: Journal: Article

Subject Headings: [adult](#)
[article](#)
[*Candida glabrata](#)
[case report](#)
[drug safety](#)
[female](#)
[fungus culture](#)
[human](#)
[nonhuman](#)
[priority journal](#)
[symptomatology](#)
[treatment response](#)
["unspecified side effect/si \[Side Effect\]"](#)
[vagina smear](#)
["*vaginitis/dt \[Drug Therapy\]"](#)

"*vaginitis/et [Etiology]"
 "amphotericin/cb [Drug Combination]"
 "amphotericin/dt [Drug Therapy]"
 "amphotericin/tp [Topical Drug Administration]"
 "*boric acid/ae [Adverse Drug Reaction]"
 "*boric acid/dt [Drug Therapy]"
 "*boric acid/va [Intravaginal Drug Administration]"
 "fluconazole/dt [Drug Therapy]"
 "fluconazole/po [Oral Drug Administration]"
 "flucytosine/cb [Drug Combination]"
 "flucytosine/dt [Drug Therapy]"
 "flucytosine/tp [Topical Drug Administration]"
 itraconazole

Source: EMBASE

Full Text: Available from *EBSCOhost* in *Journal of Obstetrics & Gynaecology*

35. Boric acid for refractory *Candida glabrata* vaginitis.

Citation: Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology, Aug 2006, vol. 26, no. 6, p. 584., 0144-3615 (August 2006)

Author(s): Dhingra, S; Roseblade, C K

Subject Headings: [Vaginitis](#)
[Middle Aged](#)
[Humans](#)
[Candidiasis](#)
[Index Medicus](#)
[Female](#)
[Boric Acids](#)
[Candida glabrata](#)

Source: Medline

Full Text: Available from *EBSCOhost* in *Journal of Obstetrics & Gynaecology*

36. Candidiasis (vulvovaginal).

Citation: BMJ clinical evidence, Jan 2007, vol. 2007, 1752-8526 (2007)

Author(s): Spence, Des

Abstract: Vulvovaginal candidiasis is estimated to be the second most common cause of vaginitis after bacterial vaginosis. *Candida albicans* accounts for 85-90% of cases. We conducted a systematic review and aimed to answer the following clinical questions: What are the effects of drug treatments, alternative or complementary treatments for acute vulvovaginal candidiasis in non-pregnant symptomatic women? What are the effects of treating a male sexual partner to resolve symptoms and prevent recurrence in non-pregnant women with symptomatic acute vulvovaginal candidiasis? What are the effects of drug treatments, alternative or complementary treatments for recurrent vulvovaginal candidiasis in non-pregnant symptomatic women? What are the effects of treating a male sexual partner in non-pregnant women with symptomatic recurrent vulvovaginal candidiasis? What are the effects of treating asymptomatic non-pregnant women with a positive swab for candidiasis? We searched: Medline, Embase, The Cochrane Library and other important databases up to October 2006 (Clinical Evidence reviews are updated periodically, please check our website for the most up-to-date version of this review). We included harms alerts from relevant organisations such as the US Food and Drug Administration (FDA) and the UK Medicines and Healthcare products Regulatory Agency (MHRA). We found 58 systematic reviews, RCTs, or observational studies that met our inclusion criteria. We performed a GRADE evaluation of the quality of evidence for interventions. In this systematic review we present information relating to the effectiveness and safety of the following interventions: alternative or complementary treatments, douching, drug treatments, garlic, intravaginal preparations (boric acid,

nystatin, imidazoles, tea tree oil), oral fluconazole, oral itraconazole, treating a male sexual partner, and yoghurt containing *Lactobacillus acidophilus* (oral or vaginal).

Subject Headings: [Administration Intravaginal](#)
[Humans](#)
[Administration Oral](#)
[Candidiasis Vulvovaginal](#)
[Intraabdominal Infections](#)
[Clinical Trials as Topic](#)
[Index Medicus](#)
[Vaginosis Bacterial](#)
[United States Food and Drug Administration](#)

Source: Medline

Full Text: Available from *National Library of Medicine* in [Clinical Evidence](#)
 Available from *National Library of Medicine* in [BMJ Clinical Evidence](#)

37. Candidiasis (vulvovaginal)

Citation: BMJ clinical evidence, 2007, vol./is. 2007/(no pagination), 1752-8526 (2007)

Author(s): Spence D.

Institution: (Spence) General Practice, Glasgow University, Glasgow, Scotland

Language: English

Abstract: INTRODUCTION: Vulvovaginal candidiasis is estimated to be the second most common cause of vaginitis after bacterial vaginosis. *Candida albicans* accounts for 85-90% of cases. METHODS AND OUTCOMES: We conducted a systematic review and aimed to answer the following clinical questions: What are the effects of drug treatments, alternative or complementary treatments for acute vulvovaginal candidiasis in non-pregnant symptomatic women? What are the effects of treating a male sexual partner to resolve symptoms and prevent recurrence in non-pregnant women with symptomatic acute vulvovaginal candidiasis? What are the effects of drug treatments, alternative or complementary treatments for recurrent vulvovaginal candidiasis in non-pregnant symptomatic women? What are the effects of treating a male sexual partner in non-pregnant women with symptomatic recurrent vulvovaginal candidiasis? What are the effects of treating asymptomatic non-pregnant women with a positive swab for candidiasis? We searched: Medline, Embase, The Cochrane Library and other important databases up to October 2006 (Clinical Evidence reviews are updated periodically, please check our website for the most up-to-date version of this review). We included harms alerts from relevant organisations such as the US Food and Drug Administration (FDA) and the UK Medicines and Healthcare products Regulatory Agency (MHRA). RESULTS: We found 58 systematic reviews, RCTs, or observational studies that met our inclusion criteria. We performed a GRADE evaluation of the quality of evidence for interventions. CONCLUSIONS: In this systematic review we present information relating to the effectiveness and safety of the following interventions: alternative or complementary treatments, douching, drug treatments, garlic, intravaginal preparations (boric acid, nystatin, imidazoles, tea tree oil), oral fluconazole, oral itraconazole, treating a male sexual partner, and yoghurt containing *Lactobacillus acidophilus* (oral or vaginal).

Country of Publication: United Kingdom

Publication Type: Journal: Review

Subject Headings: [abdominal infection](#)
[clinical trial\(topic\)](#)
[food and drug administration](#)
[human](#)
[intravaginal drug administration](#)
[oral drug administration](#)
[*vagina candidiasis](#)
[*vaginitis](#)

Source: EMBASE

Full Text: Available from *National Library of Medicine* in [Clinical Evidence](#)
Available from *National Library of Medicine* in [BMJ Clinical Evidence](#)

38. Prevalence of *Candida glabrata* and its response to boric acid vaginal suppositories in comparison with oral fluconazole in patients with diabetes and vulvovaginal candidiasis

Citation: Diabetes Care, February 2007, vol./is. 30/2(312-317), 0149-5992;0149-5992 (February 2007)

Author(s): Ray D.; Goswami R.; Banerjee U.; Dadhwal V.; Goswami D.; Mandal P.; Sreenivas V.; Kochupillai N.

Institution: (Ray, Goswami, Kochupillai) Department of Endocrinology and Metabolism, All India Institute of Medical Sciences, New Delhi, India; (Banerjee, Mandal) Department of Microbiology, All India Institute of Medical Sciences, New Delhi, India; (Dadhwal) Department of Obstetrics and Gynecology, All India Institute of Medical Sciences, New Delhi, India; (Goswami) Department of Obstetrics and Gynecology, Maulana Azad Medical College, New Delhi, India; (Sreenivas) Department of Biostatistics, All India Institute of Medical Sciences, New Delhi, India; (Goswami) Department of Endocrinology and Metabolism, All India Institute of Medical Sciences, New Delhi 110029, India

Language: English

Abstract: OBJECTIVE - A large proportion of vulvovaginal candidiasis (VVC) in diabetes is due to non-albicans *Candida* species such as *C. glabrata* and *C. tropicalis*. Observational studies indicate that diabetic patients with *C. glabrata* VVC respond poorly to azole drugs. We evaluated the response to oral fluconazole and boric acid vaginal suppositories in diabetic patients with VVC. RESEARCH DESIGN AND METHODS - A total of 112 consecutive diabetic patients with VVC were block randomized to receive either single-dose oral 150-mg fluconazole or boric acid vaginal suppositories (600 mg/day for 14 days). The primary efficacy outcome was the mycological cure in patients with *C. glabrata* VVC in the two treatment arms. The secondary outcomes were the mycological cure in *C. albicans* VVC, overall mycological cure irrespective of the type of *Candida* species, frequencies of yeast on direct microscopy, and clinical symptoms and signs of VVC on the 15th day of treatment. Intention-to-treat (ITT; n = 111) and per-protocol (PP; n = 99) analyses were performed. RESULTS - *C. glabrata* was isolated in 68 (61.3%) and *C. albicans* in 32 (28.8%) of 111 subjects. Patients with *C. glabrata* VVC showed higher mycological cure with boric acid compared with fluconazole in the ITT (21 of 33, 63.6% vs. 10 of 35, 28.6%; P = 0.01) and PP analyses (21 of 29, 72.4% vs. 10 of 30, 33.3%; P = 0.01). The secondary efficacy outcomes were not significantly different in the two treatment arms in the ITT and PP analyses. CONCLUSIONS - Diabetic women with *C. glabrata* VVC show higher mycological cure with boric acid vaginal suppositories given for 14 days in comparison with single-dose oral 150-mg fluconazole. © 2007 by the American Diabetes Association.

Country of Publication: United States

Publisher: American Diabetes Association Inc.

CAS Registry Number: 10043-35-3 (boric acid); 11113-50-1 (boric acid); 11129-12-7 (boric acid); 14213-97-9 (boric acid); 86386-73-4 (fluconazole); 62572-11-6 (hemoglobin A1c); 9004-10-8 (insulin)

Publication Type: Journal: Article

Subject Headings: [adult](#)
[article](#)
[Candida albicans](#)
[Candida glabrata](#)
[clinical trial](#)
[controlled clinical trial](#)
[controlled study](#)
[drug efficacy](#)
[drug withdrawal](#)

female
 fungus isolation
 hemoglobin blood level
 human
 "*insulin dependent diabetes mellitus/dt [Drug Therapy]"
 major clinical study
 "*non insulin dependent diabetes mellitus/dt [Drug Therapy]"
 patient compliance
 prevalence
 randomized controlled trial
 single drug dose
 suppository
 treatment outcome
 "*vagina candidiasis/co [Complication]"
 "*vagina candidiasis/di [Diagnosis]"
 "*vagina candidiasis/dt [Drug Therapy]"
 "*vagina candidiasis/et [Etiology]"
 "vaginal burning sensation/si [Side Effect]"
 "*boric acid/ae [Adverse Drug Reaction]"
 "*boric acid/ct [Clinical Trial]"
 "*boric acid/cm [Drug Comparison]"
 "*boric acid/dt [Drug Therapy]"
 "*boric acid/va [Intravaginal Drug Administration]"
 "*fluconazole/ct [Clinical Trial]"
 "*fluconazole/cm [Drug Comparison]"
 "*fluconazole/dt [Drug Therapy]"
 "*fluconazole/po [Oral Drug Administration]"
 "hemoglobin A1c/ec [Endogenous Compound]"
 "insulin/dt [Drug Therapy]"
 "oral antidiabetic agent/dt [Drug Therapy]"

Source: EMBASE

Full Text: Available from *ProQuest* in *Diabetes Care*

39. Prevalence of *Candida glabrata* and its response to boric acid vaginal suppositories in comparison with oral fluconazole in patients with diabetes and vulvovaginal candidiasis.

Citation: Diabetes care, Feb 2007, vol. 30, no. 2, p. 312-317, 0149-5992 (February 2007)

Author(s): Ray, Debarati; Goswami, Ravinder; Banerjee, Uma; Dadhwal, Vatsla; Goswami, Deepti; Mandal, Piyali; Sreenivas, Vishnubhatla; Kochupillai, Narayana

Abstract: A large proportion of vulvovaginal candidiasis (VVC) in diabetes is due to non-albicans *Candida* species such as *C. glabrata* and *C. tropicalis*. Observational studies indicate that diabetic patients with *C. glabrata* VVC respond poorly toazole drugs. We evaluated the response to oral fluconazole and boric acid vaginal suppositories in diabetic patients with VVC. A total of 112 consecutive diabetic patients with VVC were block randomized to receive either single-dose oral 150-mg fluconazole or boric acid vaginal suppositories (600 mg/day for 14 days). The primary efficacy outcome was the mycological cure in patients with *C. glabrata* VVC in the two treatment arms. The secondary outcomes were the mycological cure in *C. albicans* VVC, overall mycological cure irrespective of the type of *Candida* species, frequencies of yeast on direct microscopy, and clinical symptoms and signs of VVC on the 15th day of treatment. Intention-to-treat (ITT; n = 111) and per-protocol (PP; n = 99) analyses were performed. *C. glabrata* was isolated in 68 (61.3%) and *C. albicans* in 32 (28.8%) of 111 subjects. Patients with *C. glabrata* VVC showed higher mycological cure with boric acid compared with fluconazole in the ITT (21 of 33, 63.6% vs. 10 of 35, 28.6%; P = 0.01) and PP analyses (21 of 29, 72.4% vs. 10 of 30, 33.3%; P = 0.01). The secondary efficacy outcomes were not significantly different in the two treatment arms in the ITT and PP analyses. Diabetic women with *C. glabrata* VVC show higher mycological cure with boric acid vaginal suppositories given for 14 days in comparison with single-dose oral 150-mg fluconazole.

Subject Headings: [Candida albicans](#)
[Humans](#)
[Administration Oral](#)
[Candidiasis Vulvovaginal](#)
[Antifungal Agents](#)
[Index Medicus](#)
[Vagina](#)
[Adult](#)
[Female](#)
[Middle Aged](#)
[Boric Acids](#)
[Fluconazole](#)
[Suppositories](#)
[Candida glabrata](#)

Source: Medline

Full Text: Available from *ProQuest* in *Diabetes Care*

40. Study on physicochemical properties and pharmacodynamic action of recombinant uricase

Citation: Pharmaceutical Biotechnology, April 2007, vol./is. 14/2(131-135), 1005-8915 (April 2007)

Author(s): Li X.-J.; Li Y.-X.; Chen J.-H.

Institution: (Li, Li, Chen) Department of Molecular Biology, China Pharmaceutical University, Nanjing 210009, China

Language: Chinese

Abstract: The uricase of *Candida utilis* was expressed in recombinant *Escherichia coli*. Its physico-chemical properties and pharmacodynamic action was studied. Its subunit molecular weight was analysed by SDS-PAGE. Its optimum temperature and pH value were detected, and its thermal and pH stability were also found. A mouse hyperuricemia model was established and the pharmacodynamic action of the recombinant uricase was studied in vivo on the established model. Molecular weight of the recombinant uricase subunit was 32.4 ku in SDS-PAGE. The recombinant enzyme had the strongest reactive ability in pH 8.0 boric acid buffer at 40degreeC. It also showed good stability at pH 6-12, and at the temperature 20degreeC-60degreeC. The pharmacodynamic experiment showed that the recombinant uricase could greatly reduce the level of uric acid in the model mouse's serum.

Country of Publication: China

Publisher: China Pharmaceutical University

Publication Type: Journal: Article

Subject Headings: [animal cell](#)
[animal experiment](#)
[animal model](#)
[article](#)
[Candida utilis](#)
[controlled study](#)
[drug screening](#)
[drug stability](#)
[Escherichia coli](#)
[expression vector](#)
["*hyperuricemia/dt \[Drug Therapy\]"](#)
[in vivo study](#)
[molecular weight](#)
[mouse](#)
[nonhuman](#)
[pH](#)
[pharmacodynamics](#)

physical chemistry
 polyacrylamide gel electrophoresis
 temperature measurement
 thermostability
 "*recombinant enzyme/an [Drug Analysis]"
 "*recombinant enzyme/dv [Drug Development]"
 "*recombinant enzyme/dt [Drug Therapy]"
 "*recombinant enzyme/pd [Pharmacology]"
 "*recombinant urate oxidase/an [Drug Analysis]"
 "*recombinant urate oxidase/dv [Drug Development]"
 "*recombinant urate oxidase/dt [Drug Therapy]"
 "*recombinant urate oxidase/pd [Pharmacology]"
 unclassified drug

Source: EMBASE

41. Phospholipase, proteinase and haemolytic activities of *Candida albicans* isolated from oral cavities of patients with type 2 diabetes mellitus

Citation: Journal of Medical Microbiology, October 2007, vol./is. 56/10(1393-1398), 0022-2615 (October 2007)

Author(s): Tsang C.S.P.; Chu F.C.S.; Leung W.K.; Jin L.J.; Samaranayake L.P.; Siu S.C.

Institution: (Tsang, Chu, Leung, Jin, Samaranayake) Faculty of Dentistry, University of Hong Kong, Prince Philip Dental Hospital, Hong Kong, Hong Kong; (Siu) Integrated Diabetes Mellitus Research and Training Centre, Department of Medicine and Rehabilitation, Tung Wah Eastern Hospital, Hong Kong, Hong Kong

Language: English

Abstract: The aim of this study was to biotype and characterize phospholipase, proteinase and haemolytic activities of oral *Candida albicans* isolates from 210 Chinese patients with type 2 diabetes mellitus (DM) and 210 age- and sex-matched healthy controls. Seventy-six and 50 *C. albicans* isolates were obtained from type 2 DM patients and controls, respectively, using the oral rinse technique. The isolates were characterized with a biotyping system based on enzyme profiles, carbohydrate assimilation patterns and boric acid resistance of the yeasts, and the isolates were further tested for in vitro phospholipase, proteinase and haemolytic activities. The major biotypes of *C. albicans* isolates from the type 2 DM and control groups were A1R (42.1 %) and J1R (36.0%), respectively. Significantly higher proteinase and haemolytic activities were found in the isolates from the type 2 DM group ($P < 0.05$). Proteinase activity was higher in isolates from patients with > 10 years of DM history than those with < 10 years ($P < 0.05$). Haemolytic activity was significantly higher in isolates from female DM patients than in those from male counterparts ($P < 0.05$). These data provide evidence of increased extracellular enzyme activity in *Candida* isolates taken from DM patients. © 2007 SGM.

Country of Publication: United Kingdom

Publisher: Society for General Microbiology

CAS Registry Number: 10043-35-3 (boric acid); 11113-50-1 (boric acid); 11129-12-7 (boric acid); 14213-97-9 (boric acid); 9013-93-8 (phospholipase); 9001-92-7 (proteinase)

Publication Type: Journal: Article

Subject Headings: adult
 article
 biotype
 **Candida albicans*
 controlled study
 enzyme activity
 female
 fungus isolation
 human

[in vitro study](#)
[major clinical study](#)
[male](#)
[mouth cavity](#)
[*non insulin dependent diabetes mellitus](#)
[priority journal](#)
[sex difference](#)
[boric acid](#)
[carbohydrate](#)
[hemolysin](#)
[*phospholipase](#)
[*proteinase](#)

Source: EMBASE

42. Prolonged (3-month) mycological cure rate after boric acid suppositories in diabetic women with vulvovaginal candidiasis.

Citation: The Journal of infection, Oct 2007, vol. 55, no. 4, p. 374-377, 1532-2742 (October 2007)

Author(s): Ray, Debari; Goswami, Ravinder; Dadhwal, Vatsla; Goswami, Deepti; Banerjee, Uma; Kochupillai, Narayana

Abstract: Patients with diabetes mellitus (DM) are at increased risk of vulvovaginal candidiasis (VVC) due to *C. glabrata*. In our previous study we had shown that patients with diabetes mellitus and VVC show an overall superior mycological cure rate (74% versus 51%) with boric acid therapy at 15th day as compared to fluconazole. Present study was carried out to assess long term response to boric acid in diabetic women with VVC. Subjects included 40 consecutive diabetic women (type 2 DM=26 and type 1 DM=14) who had achieved mycological cure (high vaginal swab culture negativity) on day 15 of therapy following single-dose oral-150 mg fluconazole (n=21) or 600 mg of boric acid suppositories given daily for 14 days (n=19). At third month of follow up, patients were assessed for signs and symptoms of VVC and a repeat HVS was collected for fungal culture. HbA1c was measured to assess glycaemic control. The mean age, BMI, HbA1c and frequency of various *Candida* species isolated at initial diagnosis were comparable in the fluconazole and boric acid treatment groups. Fifteen of 21 (71.4%) and 12 of 19 (63.1%) women who achieved mycological cure at 15 day remain cured at three months in the fluconazole and boric acid treated groups, respectively (P=0.83). With 74% mycological cure at 15th day, this would indicate that on an average only 46.6% of diabetic women with VVC would remain cured at 3 months after a course of 14 days boric acid therapy. Most of the patients relapsed with no change in *Candida* species. The demographic profile and mean HbA1c (8.6+/-2.2 versus 8.8+/-2.4%, P=0.83) were comparable in patients with (n=27) and without mycological cure (n=13). The results of the current study indicating comparable mycological cure rate at 3 months between fluconazole and boric acid treated patients would support use of boric acid in the acute management of VVC in view of its superior short term response in diabetic women with *C. glabrata* infections. However, there is need to explore other therapeutic regimens which are effective in achieving long term mycological cure in diabetic women with VVC.

Subject Headings: [Time Factors](#)
[Prospective Studies](#)
[Humans](#)
[Administration Oral](#)
[Candidiasis Vulvovaginal](#)
[Antifungal Agents](#)
[Index Medicus](#)
[Treatment Outcome](#)
[Adult](#)
[Female](#)
[Middle Aged](#)
[Boric Acids](#)
[Fluconazole](#)

Suppositories
Diabetes Mellitus Type 2

Source: Medline
Full Text: Available from *Elsevier* in *Journal of Infection*

43. Prolonged (3-month) mycological cure rate after boric acid suppositories in diabetic women with vulvovaginal candidiasis

Citation: Journal of Infection, October 2007, vol./is. 55/4(374-377), 0163-4453 (October 2007)

Author(s): Ray D.; Goswami R.; Dadhwal V.; Goswami D.; Banerjee U.; Kochupillai N.

Institution: (Ray, Goswami, Kochupillai) Department of Endocrinology and Metabolism, All India Institute of Medical Sciences, Ansari Nagar, New Delhi, 110029, India; (Banerjee) Department of Microbiology, All India Institute of Medical Sciences, Ansari Nagar, New Delhi, 110029, India; (Dadhwal) Department of Obstetrics and Gynecology, All India Institute of Medical Sciences, Ansari Nagar, New Delhi, 110029, India; (Goswami) Maulana Azad Medical College, New Delhi, India

Language: English

Abstract: Objective: Patients with diabetes mellitus (DM) are at increased risk of vulvovaginal candidiasis (VVC) due to *C. glabrata*. In our previous study we had shown that patients with diabetes mellitus and VVC show an overall superior mycological cure rate (74% versus 51%) with boric acid therapy at 15th day as compared to fluconazole. Present study was carried out to assess long term response to boric acid in diabetic women with VVC. Material and methods: Subjects included 40 consecutive diabetic women (type 2 DM = 26 and type 1 DM = 14) who had achieved mycological cure (high vaginal swab culture negativity) on day 15 of therapy following single-dose oral-150 mg fluconazole (n = 21) or 600 mg of boric acid suppositories given daily for 14 days (n = 19). At third month of follow up, patients were assessed for signs and symptoms of VVC and a repeat HVS was collected for fungal culture. HbA1c was measured to assess glycaemic control. Results: The mean age, BMI, HbA1c and frequency of various *Candida* species isolated at initial diagnosis were comparable in the fluconazole and boric acid treatment groups. Fifteen of 21 (71.4%) and 12 of 19 (63.1%) women who achieved mycological cure at 15 day remain cured at three months in the fluconazole and boric acid treated groups, respectively (P = 0.83). With 74% mycological cure at 15th day, this would indicate that on an average only 46.6% of diabetic women with VVC would remain cured at 3 months after a course of 14 days boric acid therapy. Most of the patients relapsed with no change in *Candida* species. The demographic profile and mean HbA1c (8.6 +/- 2.2 versus 8.8 +/- 2.4%, P = 0.83) were comparable in patients with (n = 27) and without mycological cure (n = 13). Conclusion: The results of the current study indicating comparable mycological cure rate at 3 months between fluconazole and boric acid treated patients would support use of boric acid in the acute management of VVC in view of its superior short term response in diabetic women with *C. glabrata* infections. However, there is need to explore other therapeutic regimens which are effective in achieving long term mycological cure in diabetic women with VVC. © 2007 The British Infection Society.

Country of Publication: United Kingdom

Publisher: W.B. Saunders Ltd

CAS Registry Number: 10043-35-3 (boric acid); 11113-50-1 (boric acid); 11129-12-7 (boric acid); 14213-97-9 (boric acid); 86386-73-4 (fluconazole); 62572-11-6 (hemoglobin A1c)

Publication Type: Journal: Article

Subject Headings: [adult](#)
[age](#)
[article](#)
[body mass](#)
[Candida](#)
[Candida glabrata](#)
[clinical article](#)
[clinical trial](#)

controlled clinical trial
 controlled study
 diabetes control
 *diabetes mellitus
 drug efficacy
 drug response
 female
 follow up
 fungus culture
 fungus isolation
 hemoglobin blood level
 human
 insulin dependent diabetes mellitus
 long term care
 non insulin dependent diabetes mellitus
 randomized controlled trial
 relapse
 single drug dose
 statistical significance
 suppository
 treatment duration
 "*vagina candidiasis/dt [Drug Therapy]"
 vagina smear
 "*boric acid/ct [Clinical Trial]"
 "*boric acid/cm [Drug Comparison]"
 "*boric acid/dt [Drug Therapy]"
 "*boric acid/va [Intravaginal Drug Administration]"
 "*fluconazole/ct [Clinical Trial]"
 "*fluconazole/cm [Drug Comparison]"
 "*fluconazole/dt [Drug Therapy]"
 "*fluconazole/po [Oral Drug Administration]"
 "hemoglobin A1c/ec [Endogenous Compound]"

Source: EMBASE

Full Text: Available from *Elsevier* in *Journal of Infection*

44. Local treatment of vulvovaginal candidosis: General and practical considerations

Citation: Drugs, 2008, vol./is. 68/13(1787-1802), 0012-6667;0012-6667 (2008)

Author(s): Das Neves J.; Pinto E.; Teixeira B.; Dias G.; Rocha P.; Cunha T.; Santos B.; Amaral M.H.; Bahia M.F.

Institution: (Das Neves, Pinto) Department of Microbiology, Faculty of Pharmacy, University of Porto, Porto, Portugal; (Das Neves, Amaral, Bahia) Department of Pharmaceutical Technology, Faculty of Pharmacy, University of Porto, Porto, Portugal; (Das Neves, Teixeira, Dias, Rocha, Cunha, Santos) Department of Pharmacy, Hospital Geral de Santo Antonio, Porto, Portugal; (Das Neves) Department of Pharmaceutical Technology, Faculty of Pharmacy, University of Porto, Rua Anibal Cunha, 164, 4050-047, Porto, Portugal

Language: English

Abstract: Vulvovaginal candidosis is a common worldwide female medical problem, occurring mostly in women of childbearing age. Currently available options for the treatment of this condition include local and oral (systemic) therapy. Both alternatives have been considered equally effective in the treatment of uncomplicated vulvovaginal candidosis, although oral regimens are often preferred by physicians and women. However, local treatment presents several advantageous and unique features that may favour this therapeutic approach. The availability of numerous antifungal drugs and products for topical administration makes the selection quite challenging as this task is mostly based on personal experience or anecdotal data. Also, recent advances have been made in topical antifungal formulations and there is an increasing availability of over-the-counter

products. Therefore, a review of both general and practical considerations related to the local treatment of vulvovaginal candidosis is timely. In summary, azoles and short-term regimens are usually recommended for the local treatment of vulvovaginal candidosis, with nystatin and boric acid considered as second-line alternatives. Unconventional approaches may also be regarded as suitable in patients refractory to usual treatments. In addition to the susceptibility of implicated *Candida* spp. to the antifungal agents, this choice should take into consideration other important issues such as particular situations (e.g. pregnancy, menopause, drug hypersensitivity), women's preferences, and the availability, particularities and cost of antifungal formulations. © 2008 Adis Data Information BV. All rights reserved.

Country of Publication:	New Zealand
Publisher:	Adis International Ltd
CAS Registry Number:	1397-89-3 (amphotericin B); 30652-87-0 (amphotericin B); 10043-35-3 (boric acid); 11113-50-1 (boric acid); 11129-12-7 (boric acid); 14213-97-9 (boric acid); 64872-76-0 (butoconazole); 64872-77-1 (butoconazole); 189768-38-5 (caspofungin); 29342-05-0 (ciclopirox); 23593-75-1 (clotrimazole); 80619-41-6 (echinocandin); 24169-02-6 (econazole); 27220-47-9 (econazole); 72479-26-6 (fenticonazole); 86386-73-4 (fluconazole); 2022-85-7 (flucytosine); 50-23-7 (hydrocortisone); 24168-96-5 (isoconazole); 27523-40-6 (isoconazole); 208538-73-2 (micafungin); 22916-47-8 (miconazole); 1400-61-9 (nystatin); 34786-70-4 (nystatin); 62997-67-5 (nystatin); 171228-49-2 (posaconazole); 7681-11-0 (potassium iodide); 67915-31-5 (terconazole); 8007-46-3 (thyme oil); 61675-64-7 (tioconazole); 65899-73-2 (tioconazole); 137234-62-9 (voriconazole)
Publication Type:	Journal: Review
Subject Headings:	<ul style="list-style-type: none"> Candida cream drug choice drug contraindication drug cost drug effect drug efficacy "drug hypersensitivity/si [Side Effect]" drug safety drug sensitivity female human immunotherapy menopause "mucocutaneous reaction/si [Side Effect]" ointment pregnancy review single drug dose "skin manifestation/si [Side Effect]" suppository "unspecified side effect/si [Side Effect]" "*vagina candidiasis/di [Diagnosis]" "*vagina candidiasis/dm [Disease Management]" "*vagina candidiasis/dr [Drug Resistance]" "*vagina candidiasis/dt [Drug Therapy]" "*vagina candidiasis/ep [Epidemiology]" "vagina disease/si [Side Effect]" "vagina irritation/si [Side Effect]" "vaginal burning sensation/si [Side Effect]" "amphotericin B/dt [Drug Therapy]" "amphotericin B/va [Intravaginal Drug Administration]" "anticoagulant agent/cb [Drug Combination]" "anticoagulant agent/po [Oral Drug Administration]"

"*antifungal agent/ae [Adverse Drug Reaction]"
 "*antifungal agent/dt [Drug Therapy]"
 "*antifungal agent/va [Intravaginal Drug Administration]"
 "*antifungal agent/po [Oral Drug Administration]"
 "*antifungal agent/pr [Pharmaceutics]"
 "*antifungal agent/pe [Pharmacoeconomics]"
 "*antifungal agent/tp [Topical Drug Administration]"
 "antiinfective agent/dt [Drug Therapy]"
 "*boric acid/dt [Drug Therapy]"
 "*boric acid/va [Intravaginal Drug Administration]"
 "*boric acid/pe [Pharmacoeconomics]"
 "*boric acid/tp [Topical Drug Administration]"
 "butoconazole/dt [Drug Therapy]"
 "butoconazole/pr [Pharmaceutics]"
 "butoconazole/pe [Pharmacoeconomics]"
 "caspofungin/dt [Drug Therapy]"
 "ciclopirox/dt [Drug Therapy]"
 "*clotrimazole/do [Drug Dose]"
 "*clotrimazole/dt [Drug Therapy]"
 "*clotrimazole/va [Intravaginal Drug Administration]"
 "*clotrimazole/pr [Pharmaceutics]"
 "*clotrimazole/pe [Pharmacoeconomics]"
 "*clotrimazole/tp [Topical Drug Administration]"
 "echinocandin/dt [Drug Therapy]"
 "econazole/do [Drug Dose]"
 "econazole/dt [Drug Therapy]"
 "econazole/va [Intravaginal Drug Administration]"
 "econazole/pe [Pharmacoeconomics]"
 ecostatin 1 er
 "fenticonazole/dt [Drug Therapy]"
 "fenticonazole/va [Intravaginal Drug Administration]"
 "*fluconazole/dt [Drug Therapy]"
 "*fluconazole/po [Oral Drug Administration]"
 "*fluconazole/pe [Pharmacoeconomics]"
 "flucytosine/ae [Adverse Drug Reaction]"
 "flucytosine/dt [Drug Therapy]"
 gynazole 1
 gyno aktarin
 gynopevaryl lp
 "hydrocortisone/dt [Drug Therapy]"
 "isoconazole/do [Drug Dose]"
 "isoconazole/dt [Drug Therapy]"
 "isoconazole/va [Intravaginal Drug Administration]"
 "micafungin/dt [Drug Therapy]"
 "miconazole/do [Drug Dose]"
 "miconazole/dt [Drug Therapy]"
 "miconazole/va [Intravaginal Drug Administration]"
 "miconazole/pr [Pharmaceutics]"
 monistat 1
 monistat 1 combination pack
 "*nystatin/dt [Drug Therapy]"
 "*nystatin/va [Intravaginal Drug Administration]"
 "*nystatin/pe [Pharmacoeconomics]"
 "*nystatin/tp [Topical Drug Administration]"
 "polyene antibiotic agent/ae [Adverse Drug Reaction]"
 "polyene antibiotic agent/dt [Drug Therapy]"
 "posaconazole/dt [Drug Therapy]"
 potassium iodide
 "probiotic agent/dt [Drug Therapy]"
 "probiotic agent/va [Intravaginal Drug Administration]"

"probiotic agent/tp [Topical Drug Administration]"
 "pyrrole derivative/cb [Drug Combination]"
 "pyrrole derivative/dt [Drug Therapy]"
 "pyrrole derivative/tp [Topical Drug Administration]"
 "tea tree oil/dv [Drug Development]"
 "*terconazole/dt [Drug Therapy]"
 "*terconazole/va [Intravaginal Drug Administration]"
 "*terconazole/pr [Pharmaceutics]"
 "thyme oil/dv [Drug Development]"
 "tioconazole/dt [Drug Therapy]"
 "tioconazole/va [Intravaginal Drug Administration]"
 "tioconazole/pe [Pharmacoeconomics]"
 unclassified drug
 unindexed drug
 "voriconazole/dt [Drug Therapy]"

Source: EMBASE

Full Text: Available from *EBSCOhost* in *Drugs*
 Available from *Springer NHS Pilot 2014 (NESLi2)* in *Drugs*; Note: ; Collection notes:
 Academic-License. Please when asked to pick an institution please pick NHS. Please also
 note access is from 1997 to date only.
 Available from *ProQuest* in *Drugs*
 Available from *EBSCOhost* in *Drugs*

45. Recalcitrant *Trichomonas Vaginalis* Infections Successfully Treated With Vaginal Acidification

Citation: Journal of Obstetrics and Gynaecology Canada, 2008, vol./is. 30/1(55-58), 1701-2163 (2008)

Author(s): Aggarwal A.; Shier R.M.

Institution: (Aggarwal, Shier) Department of Obstetrics and Gynaecology, University of Toronto, Toronto, ON, Canada

Language: English

Abstract: Background: Recalcitrant vaginal trichomoniasis is extremely distressing for patients and frustrating for physicians because there are no current guidelines for treatment. Numerous studies have shown that an increase in vaginal pH creates a better environment for the growth of *Trichomonas vaginalis*. We describe two patients with recalcitrant trichomoniasis who were successfully treated using vaginal acidification. Cases: The first patient with trichomoniasis had a severe reaction to metronidazole, but the infection subsequently resolved after treatment with a combination of boric acid and clotrimazole. The second patient with resistant trichomoniasis had been treated unsuccessfully with multiple courses of metronidazole but was treated successfully with vaginal acidification using boric acid. Conclusion: A process of vaginal acidification resulted in resolution of recalcitrant *Trichomonas vaginalis* in two patients.

Country of Publication: United States

Publisher: Elsevier Inc.

CAS Registry Number: 127-08-2 (acetic acid); 127-09-3 (acetic acid); 64-19-7 (acetic acid); 71-50-1 (acetic acid); 10043-35-3 (boric acid); 11113-50-1 (boric acid); 11129-12-7 (boric acid); 14213-97-9 (boric acid); 23593-75-1 (clotrimazole); 467-63-0 (crystal violet); 548-62-9 (crystal violet); 86386-73-4 (fluconazole); 39322-38-8 (metronidazole); 443-48-1 (metronidazole); 11035-13-5 (paromomycin); 1263-89-4 (paromomycin); 1390-73-4 (paromomycin); 51795-47-2 (paromomycin); 54597-56-7 (paromomycin); 7542-37-2 (paromomycin); 84420-34-8 (paromomycin); 25655-41-8 (povidone iodine)

Publication Type: Journal: Article

Subject Headings: [adult](#)
[antibiotic resistance](#)
[article](#)
[bacterium culture](#)

case report
 colposcopy
 debridement
 disease severity
 dose response
 "drug hypersensitivity/dt [Drug Therapy]"
 female
 gynecologic care
 human
 middle aged
 nonhuman
 "respiratory tract disease/si [Side Effect]"
 sexual behavior
 single drug dose
 *therapy
 treatment outcome
 "*trichomoniasis/di [Diagnosis]"
 "*trichomoniasis/dr [Drug Resistance]"
 "*trichomoniasis/th [Therapy]"
 "*trichomoniasis/dt [Drug Therapy]"
 "urticaria/si [Side Effect]"
 "vagina mycosis/dt [Drug Therapy]"
 *vaginal acidification
 vaginitis
 acetic acid
 "*boric acid/va [Intravaginal Drug Administration]"
 "*boric acid/dt [Drug Therapy]"
 "clotrimazole/va [Intravaginal Drug Administration]"
 "clotrimazole/dt [Drug Therapy]"
 "conjugated estrogen/va [Intravaginal Drug Administration]"
 "conjugated estrogen/dt [Drug Therapy]"
 crystal violet
 "fluconazole/po [Oral Drug Administration]"
 "fluconazole/dt [Drug Therapy]"
 "metronidazole/ae [Adverse Drug Reaction]"
 "metronidazole/po [Oral Drug Administration]"
 "metronidazole/dt [Drug Therapy]"
 "paromomycin/tp [Topical Drug Administration]"
 "paromomycin/dt [Drug Therapy]"
 povidone iodine

Source: EMBASE

Full Text: Available from *Elsevier* in *Journal of Obstetrics and Gynaecology Canada*

46. Recalcitrant *Trichomonas vaginalis* infections successfully treated with vaginal acidification

Citation: Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC, January 2008, vol./is. 30/1(55-58), 1701-2163 (Jan 2008)

Author(s): Aggarwal A.; Shier R.M.

Institution: (Aggarwal, Shier) Department of Obstetrics and Gynaecology, University of Toronto, Toronto ON.

Language: English

Abstract: BACKGROUND: Recalcitrant vaginal trichomoniasis is extremely distressing for patients and frustrating for physicians because there are no current guidelines for treatment. Numerous studies have shown that an increase in vaginal pH creates a better environment for the growth of *Trichomonas vaginalis*. We describe two patients with recalcitrant trichomoniasis who were successfully treated using vaginal acidification. CASES: The first patient with trichomoniasis had a severe reaction to metronidazole, but the infection subsequently resolved after treatment with a combination of boric acid and

clotrimazole. The second patient with resistant trichomoniasis had been treated unsuccessfully with multiple courses of metronidazole but was treated successfully with vaginal acidification using boric acid. CONCLUSION: A process of vaginal acidification resulted in resolution of recalcitrant *Trichomonas vaginalis* in two patients.

Country of Publication: Canada

CAS Registry Number: 127-08-2 (acetic acid); 127-09-3 (acetic acid); 64-19-7 (acetic acid); 71-50-1 (acetic acid); 10043-35-3 (boric acid); 11113-50-1 (boric acid); 11129-12-7 (boric acid); 14213-97-9 (boric acid); 23593-75-1 (clotrimazole); 467-63-0 (crystal violet); 548-62-9 (crystal violet)

Publication Type: Journal: Article

Subject Headings: [adult](#)
[animal](#)
[article](#)
[case report](#)
[drug effect](#)
[female](#)
[human](#)
[middle aged](#)
[parasitology](#)
[pH](#)
[recurrent disease](#)
[treatment outcome](#)
["*Trichomonas vaginalis/dt \[Drug Therapy\]"](#)
[*vagina](#)
["acetic acid/dt \[Drug Therapy\]"](#)
["*antiprotozoal agent/dt \[Drug Therapy\]"](#)
["*boric acid/dt \[Drug Therapy\]"](#)
["*boric acid/pd \[Pharmacology\]"](#)
["*clotrimazole/dt \[Drug Therapy\]"](#)
["crystal violet/dt \[Drug Therapy\]"](#)
["topical antiinfective agent/dt \[Drug Therapy\]"](#)

Source: EMBASE

Full Text: Available from *Elsevier* in *Journal of Obstetrics and Gynaecology Canada*

47. Recalcitrant *Trichomonas vaginalis* infections successfully treated with vaginal acidification.

Citation: Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstétrique et gynécologie du Canada : JOGC, Jan 2008, vol. 30, no. 1, p. 55-58, 1701-2163 (January 2008)

Author(s): Aggarwal, Anjali; Shier, R Michael

Abstract: Recalcitrant vaginal trichomoniasis is extremely distressing for patients and frustrating for physicians because there are no current guidelines for treatment. Numerous studies have shown that an increase in vaginal pH creates a better environment for the growth of *Trichomonas vaginalis*. We describe two patients with recalcitrant trichomoniasis who were successfully treated using vaginal acidification. The first patient with trichomoniasis had a severe reaction to metronidazole, but the infection subsequently resolved after treatment with a combination of boric acid and clotrimazole. The second patient with resistant trichomoniasis had been treated unsuccessfully with multiple courses of metronidazole but was treated successfully with vaginal acidification using boric acid. A process of vaginal acidification resulted in resolution of recalcitrant *Trichomonas vaginalis* in two patients.

Subject Headings: [Antiprotozoal Agents](#)
[Animals](#)
[Clotrimazole](#)
[Hydrogen-Ion Concentration](#)
[Middle Aged](#)
[Humans](#)

Trichomonas vaginalis
 Recurrence
 Vagina
 Anti-Infective Agents Local
 Adult
 Female
 Boric Acids
 Treatment Outcome
 Index Medicus
 Trichomonas Vaginitis
 Acetic Acid
 Gentian Violet

Source: Medline

Full Text: Available from Elsevier in *Journal of Obstetrics and Gynaecology Canada*

48. Biotypes, genotypes and ketoconazole susceptibility of *Candida albicans* isolates from a group of Thai AIDS patients

Citation: New Microbiologica, July 2008, vol./is. 31/3(409-416), 1121-7138 (July 2008)

Author(s): Teanpaisan R.; Niyombandith M.; Pripatnanant P.; Sattayasanskul W.

Institution: (Teanpaisan) Department of Stomatology, Faculty of Dentistry, Prince of Songkla University, Hat-Yai, Songkhla, Thailand; (Niyombandith, Pripatnanant, Sattayasanskul) Department of Oral and Maxillofacial Surgery, Faculty of Dentistry, Prince of Songkla University, Hat-Yai, Songkhla, Thailand; (Teanpaisan) Department of Stomatology, Faculty of Dentistry, Prince of Songkla University, Hat-Yai, Songkhla 90112, Thailand

Language: English

Abstract: A total of eighty-seven *Candida albicans* isolates from a group of Thai AIDS patients were characterized for phenotypic and genotypic profiles and antifungal susceptibility to ketoconazole. Phenotyping of the isolates was carried out by a biotyping method based on the enzyme profiles, carbohydrate assimilation patterns and boric acid resistance of the yeasts. Genotyping was performed through randomly amplified polymorphic DNA (RAPD) analysis. Antifungal susceptibility of ketoconazole was performed using the NCCLS broth microdilution method. Combination of the biotypic tests revealed a total of 49 different biotypes. The most predominant was AIS (31%), the remaining biotypes represented only few isolates in each. RAPD profiles identified 14 clusters of genotype among the 87 isolates. Almost every individual harboured his/her own specific isolate and in 25 of 26 (96.2%) harboured more than one clonal type. The heterogeneity of both phenotypic and genotypic profiles of *C. albicans* isolates in this study was similar to previous reports from other oral sources in different geographic areas. All isolates were susceptible to ketoconazole. The findings may be useful as baseline information of oral *C. albicans* colonization in Thai population living in the south of Thailand.

Country of Publication: Italy

Publisher: Luigi Ponzio e figlio Editori

CAS Registry Number: 65277-42-1 (ketoconazole)

Publication Type: Journal: Article

Subject Headings: *acquired immune deficiency syndrome
 article
 *Candida albicans
 drug effect
 genetics
 genotype
 human
 isolation and purification
 microbiological examination
 microbiology
 polymerase chain reaction

Thailand
 "*antifungal agent/pd [Pharmacology]"
 "*ketoconazole/pd [Pharmacology]"

Source: EMBASE

49. Vulvovaginal candidiasis

Original Title: Vulvovaginal candidiasis

Citation: Tijdschrift voor Geneeskunde, 2009, vol./is. 65/23(1105-1110), 0371-683X (2009)

Author(s): Maurissen W.; Van Meensel B.; Verguts J.; Donders G.; Lagrou K.

Institution: (Maurissen, Lagrou) Dienst Laboratoriumgeneeskunde, UZ Leuven Campus Gasthuisberg, Herestraat 49, 3000 Leuven, Belgium; (Van Meensel) Medisch Centrum Huisartsen (MCH), Leuven, Belgium; (Verguts, Donders) Dienst Gynaecologie en Verloskunde, UZ Leuven Campus Gasthuisberg, Belgium; (Donders) Dienst Gynaecologie en Verloskunde, Regionaal Ziekenhuis Heilig Hart Tienen, Belgium; (Donders) Dienst Gynaecologie en Verloskunde, Hopital Citadelle, Lie, Belgium

Language: Dutch

Abstract: As many as 75 percent of the women report having at least one episode of vulvovaginal candidosis during their lifetime. The diagnosis of vulvovaginal candidosis requires clinical data as well as a positive microscopic examination and/or a positive culture. A vaginal culture is indicated only if the microscopic examination is negative during an acute vulvovaginal candidiasis episode. During a recurrent vulvovaginitis a vaginal culture has to be performed to confirm the diagnosis and to identify the specific *Candida* species involved. It is important to detect if a recurrent infection is caused by *Candida glabrata*. The physician may inform the patient that this species remains difficult to treat and select a treatment with an other antifungal agent than fluconazole (e.g. boric acid capsules). Recurrent vulvovaginal candidiasis is defined as four or more proven *Candida* vaginitis episodes yearly, and is actually treated with a maintenance therapy. Optimally this therapy is executed on degressive and individual basis applying strict follow-up criteria to decide if the medication may be altered. A correlation between in vitro antifungal susceptibility to fluconazole or other antimycotic drugs and clinical outcome has not been proven.

Country of Publication: Belgium

Publisher: Tijdschrift voor Geneeskunde (De Pintelaan 185, Gent B-9000, Belgium)

CAS Registry Number: 123-30-8 (4 aminophenol); 86386-73-4 (fluconazole); 84625-61-6 (itraconazole)

Publication Type: Journal: Article

Subject Headings: article
Candida albicans
Candida glabrata
Candida krusei
Candida parapsilosis
Candida tropicalis
 fungal detection
 fungus culture
 human
 maintenance therapy
 microscopy
 "*recurrent infection/dt [Drug Therapy]"
Saccharomyces cerevisiae
 "*vagina candidiasis/dt [Drug Therapy]"
 "4 aminophenol/dt [Drug Therapy]"
 "4 aminophenol/tp [Topical Drug Administration]"
 "fluconazole/dt [Drug Therapy]"
 "fluconazole/po [Oral Drug Administration]"
 "itraconazole/dt [Drug Therapy]"
 "itraconazole/po [Oral Drug Administration]"

Source: EMBASE

50. Boric acid addition to suppressive antimicrobial therapy for recurrent bacterial vaginosis

Citation: Sexually Transmitted Diseases, 2009, vol./is. 36/11(732-734), 0148-5717 (2009)

Author(s): Reichman O.; Akins R.; Sobel J.D.

Institution: (Reichman, Sobel) Division of Infectious Disease, Department of Medicine, Wayne State University School of Medicine, Detroit, MI, United States; (Akins) Department of Biochemistry and Molecular Biology, Wayne State University School of Medicine, Detroit, MI, United States

Language: English

Abstract: BACKGROUND:: Recurrent bacterial vaginosis (RBV) is extremely common and a source of frustration to patient and practitioners alike. In the absence of curative therapy, practitioners resort to retreating each individual episode. It has been suggested that vaginal biofilm in BV facilitates persistence of bacterial pathogens. Accordingly, topical boric acid (BA) aimed at biofilm removal was added to nitroimidazole induction and maintenance therapy creating a triple phase regimen to reduce symptomatic recurrence of BV in high-risk patients. METHOD:: Uncontrolled, nonrandomized, retrospective chart review of patients with RBV treated with 7 days of oral nitroimidazole; followed by 21 days of intravaginal BA 600 mg/day and if in remission treated with metronidazole gel twice weekly for 16 weeks. Outcome was determined using Amsel criteria. RESULTS:: Fifty-eight women were treated for a total of 77 episodes of RBV. Sixty episodes of BV were available for a follow-up evaluation 4 to 12 weeks after enrollment, having completed both nitroimidazole and BA therapy and before initiating vaginal metronidazole gel. Cure after nitroimidazole and BA therapy ranged from 88% to 92%, 7 and 12 weeks after the initial visit, respectively. Cumulative cure at 12, 16, and 28 weeks from initial visit was 87%, 78%, and 65%, respectively. A failure rate of 50% was documented by 36 weeks of follow-up. No adverse effects of BA were observed. CONCLUSION:: Clinical experience with a triple phase maintenance regimen for women with RBV was encouraging but requires validation in a prospective randomized controlled study. Copyright © 2009 American Sexually Transmitted Diseases Association All rights reserved.

Country of Publication: United States

Publisher: Lippincott Williams and Wilkins (530 Walnut Street,P O Box 327, Philadelphia PA 19106-3621, United States)

CAS Registry Number: 10043-35-3 (boric acid); 11113-50-1 (boric acid); 11129-12-7 (boric acid); 14213-97-9 (boric acid); 39322-38-8 (metronidazole); 443-48-1 (metronidazole); 19387-91-8 (tinidazole)

Publication Type: Journal: Article

Subject Headings: [adult](#)
[antibiotic therapy](#)
[article](#)
[biofilm](#)
[drug efficacy](#)
[drug treatment failure](#)
[female](#)
[follow up](#)
[human](#)
[major clinical study](#)
[recurrent infection](#)
["*vaginitis/dt \[Drug Therapy\]"](#)
["*boric acid/dt \[Drug Therapy\]"](#)
["*boric acid/va \[Intravaginal Drug Administration\]"](#)
["*metronidazole/dt \[Drug Therapy\]"](#)
["*metronidazole/po \[Oral Drug Administration\]"](#)

"*tinidazole/dt [Drug Therapy]"
 "*tinidazole/po [Oral Drug Administration]"

Source: EMBASE

51. Antifungal mechanisms supporting boric acid therapy of *Candida* vaginitis

Citation: Journal of Antimicrobial Chemotherapy, 2009, vol./is. 63/2(325-336), 0305-7453;1460-2091 (2009)

Author(s): De Seta F.; Schmidt M.; Vu B.; Essmann M.; Larsen B.

Institution: (De Seta) Burlo Garofolo, University of Trieste, Trieste, Italy; (De Seta, Essmann, Larsen) Department of University Research, Des Moines University, Des Moines, IA, United States; (Schmidt) Department of Biochemistry and Nutrition, Des Moines University, Des Moines, IA, United States; (Vu) Department of Pharmaceutical Science, Drake University, Des Moines, IA, United States

Language: English

Abstract: Background: Boric acid is a commonly cited treatment for recurrent and resistant yeast vaginitis, but data about the extent and mechanism of its antifungal activity are lacking. Objectives: The aim of this study was to use in vitro methods to understand the spectrum and mechanism of boric acid as a potential treatment for vaginal infection. Methods Yeast and bacterial isolates were tested by agar dilution to determine the intrinsic antimicrobial activity of boric acid. Established microbial physiology methods illuminated the mechanism of the action of boric acid against *Candida albicans*. Results: *C. albicans* strains (including fluconazole-resistant strains) were inhibited at concentrations attainable intravaginally; as were bacteria. Broth dilution MICs were between 1563 and 6250 mg/L and boric acid proved fungistatic (also reflected by a decrease in CO₂ generation); prolonged culture at 50 000 mg/L was fungicidal. Several organic acids in yeast nitrogen broth yielded a lower pH than equimolar boric acid and sodium borate but were less inhibitory. Cold or anaerobic incubation protected yeast at high boric acid concentrations. Cells maintained integrity for 6 h in boric acid at 37degreeC, but after 24 h modest intrusion of propidium iodide occurred; loss of plate count viability preceded uptake of vital stain. Growth at sub-MIC concentrations of boric acid decreased cellular ergosterol. The drug efflux pump CDR1 did not protect *Candida* as CDR1 expression was abrogated by boric acid. Boric acid interfered with the development of biofilm and hyphal transformation. Conclusions: Boric acid is fungistatic to fungicidal depending on concentration and temperature. Inhibition of oxidative metabolism appears to be a key antifungal mechanism, but inhibition of virulence probably contributes to therapeutic efficacy in vivo. © The Author 2008. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved.

Country of Publication: United Kingdom

Publisher: Oxford University Press (Great Clarendon Street, Oxford OX2 6DP, United Kingdom)

CAS Registry Number: 12447-40-4 (borate sodium); 1303-96-4 (borate sodium); 1330-43-4 (borate sodium); 1333-73-9 (borate sodium); 32446-62-1 (borate sodium); 61028-24-8 (borate sodium); 10043-35-3 (boric acid); 11113-50-1 (boric acid); 11129-12-7 (boric acid); 14213-97-9 (boric acid); 23637-22-1 (ergosterol); 2418-45-3 (ergosterol); 3992-98-1 (ergosterol); 57-87-4 (ergosterol)

Publication Type: Journal: Article

Subject Headings: [*antifungal activity](#)
[article](#)
[bacterial growth](#)
[bacterial viability](#)
[bacterium isolate](#)
[biofilm](#)
[*Candida albicans](#)
[concentration response](#)
[controlled study](#)
[fungal strain](#)

fungal viability
 fungus growth
 fungus hyphae
 fungus isolation
 gene expression
 in vitro study
 incubation time
 minimum inhibitory concentration
 nonhuman
 pH
 *vagina candidiasis
 "borate sodium/an [Drug Analysis]"
 "*boric acid/an [Drug Analysis]"
 "Cerebellar degeneration-related protein 1/ec [Endogenous Compound]"
 "ergosterol/ec [Endogenous Compound]"
 "fungal protein/ec [Endogenous Compound]"
 unclassified drug

Source: EMBASE

52. Evaluation of biotyping of medically important *Candida* spp [Czech] Hodnoceni biotypizace lekarsky vyznamny ch kandid

Original Title: Hodnoceni biotypizace lekarsky vyznamny ch kandid

Citation: Klinicka Mikrobiologie a Infekcni Lekarstvi, 2009, vol./is. 15/4(116-124), 1211-264X (2009)

Author(s): Hamal P.; Koukalova D.

Institution: (Hamal, Koukalova) Ustav Mikrobiologie LF UP a FNOL, Hnevotinska 3, 775 15 Olomouc, Czech Republic

Language: Czech

Abstract: Background: The biotyping system according to Odds and Abbott belongs to the most frequently used phenotypic methods. The aim of the study was to evaluate its discriminatory power in our laboratory. In addition, biotypes of isolates obtained from various body locations, present in defined age groups of patients and in males and females were also compared. Material and methods: A total of 343 clinical isolates were typed belonging to six most frequent *Candida* spp. Nine types of tests for biotyping were prepared: sorbose, citrate and urea assimilation, tolerance to pH 1.4, pH 1.55 and higher concentration of NaCl, resistance to sodium periodate and boric acid and the ability to grow on MacConkey agar. Results: Forty-one biotypes were found among 230 *C. albicans* isolates, nine among 21 *C. glabrata*, 13 among 25 *C. parapsilosis*, 12 among 25 *C. krusei* and five biotypes among 18 *C. lusitaniae* isolates. Contrary to other species, all of 18 *C. tropicalis* isolates belonged to the same biotype. In accordance with previously published reports, high discriminatory power of the method was found with Simpson's diversity index for *C. albicans* reaching 0.92. On the other hand, reproducibility was relatively low; from 12 randomly chosen *C. albicans* isolates tested repeatedly, only two showed identical results, five differed in one test and the others in several tests. Analysis of the occurrence of individual biotypes related to different anatomical locations, age groups and sexes of patients revealed neither statistically significant variations in distribution nor predilection of any single biotype. These findings suggest that the source of infection was endogenous in most cases. In comparison with results of similar studies, marked discrepancies in profiles of predominant biotypes were found, probably due to slight differences in composition of the test media or distinctive evaluation of results; however, it may reflect also geographical specificity of isolates. Conclusion: It can be concluded that the main advantages of the Odds biotyping system are high discriminatory power and cost-effectiveness. On the other hand, discrepancies in reproducibility of results as well as relatively long period for preparation of test media and for achieving of results decline its usefulness for epidemiological studies.

Country of Publication: Czech Republic

Publisher: Trios spol. s.r.o. (Zakourilova 142, Praha 4 149 00, Czech Republic)

Publication Type: Journal: Article

Subject Headings: [article](#)
[*bacterium identification](#)
[*biotyping](#)
[*Candida albicans](#)
[Candida glabrata](#)
[Candida krusei](#)
[candida lusitaniae](#)
[Candida parapsilosis](#)
[Candida tropicalis](#)
[controlled study](#)
[female](#)
[human](#)
[major clinical study](#)
[male](#)

Source: EMBASE

53. Antifungal mechanisms supporting boric acid therapy of Candida vaginitis.

Citation: The Journal of antimicrobial chemotherapy, Feb 2009, vol. 63, no. 2, p. 325-336, 1460-2091 (February 2009)

Author(s): De Seta, Francesco; Schmidt, Martin; Vu, Bao; Essmann, Michael; Larsen, Bryan

Abstract: Boric acid is a commonly cited treatment for recurrent and resistant yeast vaginitis, but data about the extent and mechanism of its antifungal activity are lacking. The aim of this study was to use in vitro methods to understand the spectrum and mechanism of boric acid as a potential treatment for vaginal infection. Yeast and bacterial isolates were tested by agar dilution to determine the intrinsic antimicrobial activity of boric acid. Established microbial physiology methods illuminated the mechanism of the action of boric acid against *Candida albicans*. *C. albicans* strains (including fluconazole-resistant strains) were inhibited at concentrations attainable intravaginally; as were bacteria. Broth dilution MICs were between 1563 and 6250 mg/L and boric acid proved fungistatic (also reflected by a decrease in CO₂ generation); prolonged culture at 50,000 mg/L was fungicidal. Several organic acids in yeast nitrogen broth yielded a lower pH than equimolar boric acid and sodium borate but were less inhibitory. Cold or anaerobic incubation protected yeast at high boric acid concentrations. Cells maintained integrity for 6 h in boric acid at 37 degrees C, but after 24 h modest intrusion of propidium iodide occurred; loss of plate count viability preceded uptake of vital stain. Growth at sub-MIC concentrations of boric acid decreased cellular ergosterol. The drug efflux pump CDR1 did not protect *Candida* as CDR1 expression was abrogated by boric acid. Boric acid interfered with the development of biofilm and hyphal transformation. Boric acid is fungistatic to fungicidal depending on concentration and temperature. Inhibition of oxidative metabolism appears to be a key antifungal mechanism, but inhibition of virulence probably contributes to therapeutic efficacy in vivo.

Subject Headings: [Ergosterol](#)
[Candida albicans](#)
[Humans](#)
[Candidiasis Vulvovaginal](#)
[Antifungal Agents](#)
[Colony Count Microbial](#)
[Microbial Sensitivity Tests](#)
[Microbial Viability](#)
[Female](#)
[Boric Acids](#)
[Index Medicus](#)
[Bacteria](#)

Source: Medline

54. Recurrent vaginal infections. Candidosis, bacterial vaginosis [German] Rezidivierende vaginalinfektionen : Candidose, bakterielle vaginose

Original Title: Rezidivierende vaginalinfektionen : Candidose, bakterielle vaginose

Citation: Gynakologe, October 2009, vol./is. 42/10(766-771), 0017-5994 (October 2009)

Author(s): Mendling W.

Institution: (Mendling) Vivantes-Frauenkliniken im Friedrichshain und Am Urban, Landsberger Allee 49, 10249 Berlin, Germany

Language: German

Abstract: Chronic recurrent vulvovaginal candidosis (CRVVC) is caused by *Candida albicans* in 90% of cases with regional differences. Non-*albicans* species are more frequent in patients with immunodepression or diabetes mellitus. CRVVC is influenced by immunosuppression, gene polymorphisms, allergic factors, serum glucose levels, antibiotics, psychosocial stress and estrogen-induced vaginal factors. Therapy of CRVVC and of non-*albicans* vaginitis is difficult. Resistance of *C. albicans* seems to be clinically unimportant. Because CRVVC cannot yet be treated immunologically, a degressive oral therapy with 200 mg fluconazole is recommended. Boric acid or flucytosine is recommended in some countries against *C. glabrata* vaginitis. In Germany 800 mg posaconazole/day for 15 days is recently recommended together with local cyclopyroxolamine. *C. krusei* is resistant to triazoles, but can be treated with local antimycotics. Future studies should include a candida autovaccination or antibodies against candida virulence factors. Patient self-therapy is often incorrect. In patients with bacterial vaginosis (BV) there is an adherent bacterial biofilm consisting mainly of *Gardnerella (G.) vaginalis* and *Atopobium (A.) vaginae*. About 60% of the patients suffer from recurrences after a standard therapy with metronidazole or clindamycine due to persistence of the biofilm. Epithelial cells in the urine of women with BV and their partners are the same bacterial biofilms as in the vagina. Thus BV seems to be a sexually transmitted disease. This bacterial biofilm cannot at present be eradicated with medications. Certain strains of vaginal or oral lactobacilli or improvement of vaginal pH-values reduce recurrences after standard treatment. © 2009 Springer Medizin Verlag.

Country of Publication: Germany

Publisher: Springer Verlag (Tiergartenstrasse 17, Heidelberg D-69121, Germany)

CAS Registry Number: 10043-35-3 (boric acid); 11113-50-1 (boric acid); 11129-12-7 (boric acid); 14213-97-9 (boric acid); 41621-49-2 (ciclopiroxolamine); 18323-44-9 (clindamycin); 86386-73-4 (fluconazole); 2022-85-7 (flucytosine); 50-99-7 (glucose); 84778-64-3 (glucose); 39322-38-8 (metronidazole); 443-48-1 (metronidazole); 171228-49-2 (posaconazole)

Publication Type: Journal: Review

Subject Headings: antibiotic resistance
Candida albicans
DNA polymorphism
human
mental stress
*recurrent infection
review
"*vagina candidiasis/dt [Drug Therapy]"
vaginitis
"boric acid/dt [Drug Therapy]"
"ciclopiroxolamine/cb [Drug Combination]"
"ciclopiroxolamine/dt [Drug Therapy]"
"clindamycin/dt [Drug Therapy]"
"fluconazole/dt [Drug Therapy]"
"fluconazole/po [Oral Drug Administration]"
"flucytosine/dt [Drug Therapy]"
glucose

"metronidazole/dt [Drug Therapy]"
 "posaconazole/cb [Drug Combination]"
 "posaconazole/dt [Drug Therapy]"

Source: EMBASE

Full Text: Available from *Springer NHS Pilot 2014 (NESLi2)* in *Der Gynäkologe*; Note: ; Collection notes: Academic-License. Please when asked to pick an institution please pick NHS. Please also note access is from 1997 to date only.

55. Azole resistant *Candida glabrata* vulvovaginitis treated with boric acid

Citation: European Journal of Obstetrics Gynecology and Reproductive Biology, November 2009, vol./is. 147/1(112), 0301-2115 (November 2009)

Author(s): Savini V.; Catavitello C.; Bianco A.; Balbinot A.; D'Antonio F.; D'Antonio D.

Institution: (Savini, Catavitello, Bianco, Balbinot, D'Antonio) Clinical Microbiology and Virology Unit, Department of Transfusion Medicine, 'Spirito Santo' Hospital, via Fonte Romana 8, CAP 65100, Pescara (Pe), Italy; (D'Antonio) Department of Gynecology, 'SS. Annunziata' Hospital, Chieti, Italy

Language: English

Country of Publication: Ireland

Publisher: Elsevier Ireland Ltd (P.O. Box 85, Limerick, Ireland)

CAS Registry Number: 74469-00-4 (amoxicillin plus clavulanic acid); 79198-29-1 (amoxicillin plus clavulanic acid); 10043-35-3 (boric acid); 11113-50-1 (boric acid); 11129-12-7 (boric acid); 14213-97-9 (boric acid); 86386-73-4 (fluconazole); 84625-61-6 (itraconazole); 22916-47-8 (miconazole); 1400-61-9 (nystatin); 34786-70-4 (nystatin); 62997-67-5 (nystatin); 109-97-7 (pyrrole)

Publication Type: Journal: Letter

Subject Headings: [adult](#)
[anamnesis](#)
[antibiotic resistance](#)
[Candida glabrata](#)
[case report](#)
[clinical feature](#)
[female](#)
[human](#)
[letter](#)
[priority journal](#)
["tonsillitis/dt \[Drug Therapy\]"](#)
[*vagina candidiasis](#)
["vulvovaginitis/dt \[Drug Therapy\]"](#)
["amoxicillin plus clavulanic acid/dt \[Drug Therapy\]"](#)
["boric acid/dt \[Drug Therapy\]"](#)
["boric acid/va \[Intravaginal Drug Administration\]"](#)
["fluconazole/dt \[Drug Therapy\]"](#)
["fluconazole/po \[Oral Drug Administration\]"](#)
["itraconazole/dt \[Drug Therapy\]"](#)
["miconazole/tp \[Topical Drug Administration\]"](#)
[nystatin](#)
[pyrrole](#)

Source: EMBASE

Full Text: Available from *Elsevier* in *European Journal of Obstetrics and Gynecology and Reproductive Biology*

56. Boric acid addition to suppressive antimicrobial therapy for recurrent bacterial vaginosis.

- Citation:** Sexually transmitted diseases, Nov 2009, vol. 36, no. 11, p. 732-734, 1537-4521 (November 2009)
- Author(s):** Reichman, Orna; Akins, Robert; Sobel, Jack D
- Abstract:** Recurrent bacterial vaginosis (RBV) is extremely common and a source of frustration to patient and practitioners alike. In the absence of curative therapy, practitioners resort to retreating each individual episode. It has been suggested that vaginal biofilm in BV facilitates persistence of bacterial pathogens. Accordingly, topical boric acid (BA) aimed at biofilm removal was added to nitroimidazole induction and maintenance therapy creating a triple phase regimen to reduce symptomatic recurrence of BV in high-risk patients. Uncontrolled, nonrandomized, retrospective chart review of patients with RBV treated with 7 days of oral nitroimidazole; followed by 21 days of intravaginal BA 600 mg/day and if in remission treated with metronidazole gel twice weekly for 16 weeks. Outcome was determined using Amsel criteria. Fifty-eight women were treated for a total of 77 episodes of RBV. Sixty episodes of BV were available for a follow-up evaluation 4 to 12 weeks after enrollment, having completed both nitroimidazole and BA therapy and before initiating vaginal metronidazole gel. Cure after nitroimidazole and BA therapy ranged from 88% to 92%, 7 and 12 weeks after the initial visit, respectively. Cumulative cure at 12, 16, and 28 weeks from initial visit was 87%, 78%, and 65%, respectively. A failure rate of 50% was documented by 36 weeks of follow-up. No adverse effects of BA were observed. Clinical experience with a triple phase maintenance regimen for women with RBV was encouraging but requires validation in a prospective randomized controlled study.
- Subject Headings:** [Administration Intravaginal](#)
[Drug Administration Schedule](#)
[Administration Oral](#)
[Index Medicus](#)
[Humans](#)
[Secondary Prevention](#)
[Retrospective Studies](#)
[Metronidazole](#)
[Treatment Failure](#)
[Adult](#)
[Female](#)
[Anti-Bacterial Agents](#)
[Boric Acids](#)
[Treatment Outcome](#)
[Drug Therapy Combination](#)
[Vaginosis Bacterial](#)
[Follow-Up Studies](#)
[Nitroimidazoles](#)
- Source:** Medline

57. Azole resistant *Candida glabrata* vulvovaginitis treated with boric acid.

- Citation:** European journal of obstetrics, gynecology, and reproductive biology, Nov 2009, vol. 147, no. 1, p. 112., 1872-7654 (November 2009)
- Author(s):** Savini, Vincenzo; Catavittello, Chiara; Bianco, Azaira; Balbinot, Andrea; D'Antonio, Francesco; D'Antonio, Domenico
- Subject Headings:** [Treatment Outcome](#)
[Humans](#)
[Insecticides](#)
[Antifungal Agents](#)
[Candidiasis](#)
[Vulvovaginitis](#)
[Index Medicus](#)
[Adult](#)
[Female](#)

[Itraconazole](#)
[Boric Acids](#)
[Fluconazole](#)
[Drug Resistance Fungal](#)
[Candida glabrata](#)

Source: Medline

Full Text: Available from *Elsevier* in [European Journal of Obstetrics and Gynecology and Reproductive Biology](#)

58. Candidiasis (vulvovaginal).

Citation: BMJ clinical evidence, Jan 2010, vol. 2010, 1752-8526 (2010)

Author(s): Spence, Des

Abstract: Vulvovaginal candidiasis is estimated to be the second most common cause of vaginitis after bacterial vaginosis. *Candida albicans* accounts for 85% to 90% of cases. We conducted a systematic review and aimed to answer the following clinical questions: What are the effects of drug treatments for acute vulvovaginal candidiasis in non-pregnant symptomatic women? What are the effects of alternative or complementary treatments for acute vulvovaginal candidiasis in non-pregnant symptomatic women? What are the effects of treating a male sexual partner to resolve symptoms and prevent recurrence in non-pregnant women with symptomatic acute vulvovaginal candidiasis? What are the effects of alternative or complementary treatments for symptomatic recurrent vulvovaginal candidiasis in non-pregnant women? What are the effects of treating a male sexual partner in non-pregnant women with symptomatic recurrent vulvovaginal candidiasis? What are the effects of treating asymptomatic non-pregnant women with a positive swab for candidiasis? We searched: Medline, Embase, The Cochrane Library, and other important databases up to March 2009 (Clinical Evidence reviews are updated periodically; please check our website for the most up-to-date version of this review). We included harms alerts from relevant organisations such as the US Food and Drug Administration (FDA) and the UK Medicines and Healthcare products Regulatory Agency (MHRA). We found 61 systematic reviews, RCTs, or observational studies that met our inclusion criteria. We performed a GRADE evaluation of the quality of evidence for interventions. In this systematic review, we present information relating to the effectiveness and safety of the following interventions: alternative or complementary treatments; douching; drug treatments; garlic; intravaginal preparations (boric acid, nystatin, imidazoles, tea tree oil); oral fluconazole; oral itraconazole; treating a male sexual partner; and yoghurt containing *Lactobacillus acidophilus* (oral or vaginal).

Subject Headings: [Candida albicans](#)
[Vaginosis Bacterial](#)
[Administration Oral](#)
[Candidiasis Vulvovaginal](#)
[Humans](#)
[Index Medicus](#)
[Itraconazole](#)
[Fluconazole](#)
[Acute Disease](#)
[Evidence-Based Medicine](#)

Source: Medline

Full Text: Available from *National Library of Medicine* in [Clinical Evidence](#)
 Available from *National Library of Medicine* in [BMJ Clinical Evidence](#)

59. Management of recurrent vulvo-vaginal candidosis as a chronic illness.

Citation: Gynecologic and obstetric investigation, Jan 2010, vol. 70, no. 4, p. 306-321, 1423-002X (2010)

Author(s): Donders, Gilbert G G; Bellen, Gert; Mendling, Werner

Abstract:

For sporadic acute *Candida* vaginitis, any oral or local antifungal therapy can be used. For women with recurrent vulvo-vaginal candidosis (RVC), on the other hand, such simple approaches are insufficient, regardless of the product chosen. Instead, RVC should be managed as any other chronic disease and requires long-term, prophylactic, suppressive antifungal treatment. A regimen using individualized, decreasing doses of oral fluconazole (the ReCiDiF regimen) was proven to be highly efficient and offered great comfort to the patients. During this regimen, it is crucial that patients are carefully examined by anamnestic, clinical, microscopic and culture-proven absence of *Candida*. If a relapse occurs, the medication is adjusted and efforts are taken to find a possible triggering factor for the reactivation of the infection. Care has to be taken not to accumulate 'don't do's', unless the efficiency of a measure has been proven, by trying to eliminate one risk factor at a time for 2 months. Known possible triggers to be kept in mind are (1) antibiotic use, (2) use of specific contraceptives, especially combined contraceptive pills, (3) disturbed glucose metabolism, (4) the use of personal hygienic products, and (5) tight clothing or plastic panty liners. In therapy-resistant cases, non-albicans infection must be ruled out, and alternative therapies should be tried. Boric acid is proven to be efficient in most of these resistant cases, but other non-azoles like amphotericin B, flucytosine, gentian violet, and even caspofungin may have to be tried. As a final remark it has to be said that many patients feel poorly understood and inefficiently managed by many care-givers, increasing their feelings of guilt and sexual inferiority. Therefore, attention has to be given to take the disease seriously, follow strict treatment regimens, and advise precisely and based on individual evidence concerning any possible risk factors for recurrence. In case of therapy-resistant vulvo-vaginitis, reconsider your diagnosis and/or consider referral to specialized therapists. Copyright © 2010 S. Karger AG, Basel.

Subject Headings:

[Vulva](#)
[Contraceptive Agents Female](#)
[Candidiasis Vulvovaginal](#)
[Humans](#)
[Female](#)
[Clothing](#)
[Genotype](#)
[Candida albicans](#)
[Diagnosis Differential](#)
[Recurrence](#)
[Vagina](#)
[Drug Resistance Fungal](#)
[Immunity](#)
[Antifungal Agents](#)
[Feminine Hygiene Products](#)
[Genetic Predisposition to Disease](#)
[Candida](#)
[Dietary Carbohydrates](#)
[Sexual Behavior](#)
[Hydrogen-Ion Concentration](#)
[Saliva](#)
[Index Medicus](#)
[Sexually Transmitted Diseases](#)
[Male](#)
[Chronic Disease](#)

Source:

Medline

Full Text:

Available from *S. Karger AG* in *Gynecologic and Obstetric Investigation*; Note: ;
 Collection notes: Academic-License: Only available from an NHS networked computer
 Available from *ProQuest* in *Gynecologic and Obstetric Investigation*
 Available from *EBSCOhost* in *Gynecologic & Obstetric Investigation*

60. Candidiasis (vulvovaginal)**Citation:**

BMJ clinical evidence, 2010, vol./is. 2010/(no pagination), 1752-8526 (2010)

Author(s): Spence D.

Institution: (Spence) General Practice, Glasgow University, Glasgow, Scotland

Language: English

Abstract: INTRODUCTION: Vulvovaginal candidiasis is estimated to be the second most common cause of vaginitis after bacterial vaginosis. *Candida albicans* accounts for 85% to 90% of cases. METHODS AND OUTCOMES: We conducted a systematic review and aimed to answer the following clinical questions: What are the effects of drug treatments for acute vulvovaginal candidiasis in non-pregnant symptomatic women? What are the effects of alternative or complementary treatments for acute vulvovaginal candidiasis in non-pregnant symptomatic women? What are the effects of treating a male sexual partner to resolve symptoms and prevent recurrence in non-pregnant women with symptomatic acute vulvovaginal candidiasis? What are the effects of alternative or complementary treatments for symptomatic recurrent vulvovaginal candidiasis in non-pregnant women? What are the effects of treating a male sexual partner in non-pregnant women with symptomatic recurrent vulvovaginal candidiasis? What are the effects of treating asymptomatic non-pregnant women with a positive swab for candidiasis? We searched: Medline, Embase, The Cochrane Library, and other important databases up to March 2009 (Clinical Evidence reviews are updated periodically; please check our website for the most up-to-date version of this review). We included harms alerts from relevant organisations such as the US Food and Drug Administration (FDA) and the UK Medicines and Healthcare products Regulatory Agency (MHRA). RESULTS: We found 61 systematic reviews, RCTs, or observational studies that met our inclusion criteria. We performed a GRADE evaluation of the quality of evidence for interventions. CONCLUSIONS: In this systematic review, we present information relating to the effectiveness and safety of the following interventions: alternative or complementary treatments; douching; drug treatments; garlic; intravaginal preparations (boric acid, nystatin, imidazoles, tea tree oil); oral fluconazole; oral itraconazole; treating a male sexual partner; and yoghurt containing *Lactobacillus acidophilus* (oral or vaginal).

Country of Publication: United Kingdom

CAS Registry Number: 86386-73-4 (fluconazole); 84625-61-6 (itraconazole)

Publication Type: Journal: Review

Subject Headings: acute disease
Candida albicans
 "*Candidiasis Vulvovaginal/di [Diagnosis]"
 evidence based medicine
 human
 oral drug administration
 vaginitis
 "*fluconazole/ad [Drug Administration]"
 "itraconazole/dt [Drug Therapy]"

Source: EMBASE

Full Text: Available from *National Library of Medicine* in [Clinical Evidence](#)
 Available from *National Library of Medicine* in [BMJ Clinical Evidence](#)

61. Antifungal activity of chemical agents against *Candida albicans*

Citation: Journal of Hospital Infection, October 2010, vol./is. 76/(S23), 0195-6701 (October 2010)

Author(s): Silva A.P.; Figueiredo S.; Lisboa C.; Rocha R.; Pina-Vaz C.; Rodrigues A.G.

Institution: (Silva, Figueiredo, Lisboa, Rocha, Pina-Vaz, Rodrigues) Microbiology Department, Faculty of Medicine, Portugal

Language: English

Abstract: Hospital reservoirs of *Candida* organisms may include not only human endogenous sources, but also environmental and the hands of health care personnel. The activity of several chemical germicides commonly used to disinfect surfaces, medical devices, as

well as hands or wound lesions was assessed regarding *Candida* species. Ten strains of each *C. albicans*, *C. parapsilosis*, *C. glabrata*, *C. tropicalis*, *C. krusei* and *C. guilliermondii* were used. Chlorhexidine (C), ethanol (E), sodium hypochlorite (SH), hydrogen peroxide (HP), potassiumpermanganate (PP), boric acid (BA) and cerium nitrate (CN) were studied. The minimal inhibitory concentration (MIC) and minimal lethal concentration (MLC) of each chemical agent was assessed according to the CLSI M27-A3 protocol. Additionally, the growth inhibition potential of each agent (commercial solutions) was determined following time killing assays. Flow cytometry analysis after staining the cells with propidium iodide was performed. For all *Candida* strains, MIC and MLC values ranged between 0.004-0.06% for C, 1.25-10% for E, 3.125-25 ml/ml for SH, 0.03-0.12% for HP, 0.008-2 g/l for PP, 0.78-25 mg/ml for BA and 0.75-12.5mM for CN. C, E and SH inhibited 100% the growth soon after 1 min of contact. HP, PP and CN were able to inhibit 100% the growth, but only after 30 min for the first two agents and 10 min for the last. BA inhibited the growth at a maximum of 66.7%. Flow cytometry confirmed the fungicidal activity of the different chemical agents. Under the experimental conditions of the study, all solutions studied showed antifungal activity; however chlorhexidine, ethanol and sodium hypochlorite revealed to be the most effective, thus supporting its use for disinfection procedures.

Conference Information: 7th International Conference of the Hospital Infection Society Liverpool United Kingdom. Conference Start: 20101010 Conference End: 20101013

Publisher: W.B. Saunders Ltd

Publication Type: Journal: Conference Abstract

Subject Headings: [*society](#)
[*antifungal activity](#)
[*Candida albicans](#)
[*hospital infection](#)
[Candida](#)
[flow cytometry](#)
[minimum inhibitory concentration](#)
[health care personnel](#)
[device](#)
[wound](#)
[species](#)
[growth inhibition](#)
[assay](#)
[staining](#)
[fungicidal activity](#)
[disinfection](#)
[hospital](#)
[human](#)
[*chemical agent](#)
[hypochlorite sodium](#)
[alcohol](#)
[hydrogen peroxide](#)
[boric acid](#)
[cerium nitrate](#)
[propidium iodide](#)
[chlorhexidine](#)

Source: EMBASE

Full Text: Available from *UHB Online* in *Journal of Hospital Infection*
 Available from *Elsevier* in *Journal of Hospital Infection*

62. Management of recurrent vulvo-vaginal candidosis as a chronic illness

Citation: Gynecologic and Obstetric Investigation, November 2010, vol./is. 70/4(306-321), 0378-7346 (November 2010)

Author(s): Donders G.G.G.; Bellen G.; Mendling W.

Institution: (Donders, Bellen) Femicare, Clinical Research for Women, Tienen, Belgium; (Donders) Departments of Obstetrics and Gynaecology, University Hospital Gasthuisberg Leuven, Leuven, Belgium; (Donders) University Hospital Gasthuisberg Leuven, Leuven, Belgium; (Donders) General Hospital Heilig Hart, Tienen, Belgium; (Donders) University Hospital Citadelle Liege, Liege, Belgium; (Mendling) Klinik für Gynäkologie und Geburtsmedizin, Vivantes-Klinika im Friedrichshain und am Urban, Berlin, Germany

Language: English

Abstract: For sporadic acute Candida vaginitis, any oral or local antifungal therapy can be used. For women with recurrent vulvo-vaginal candidosis (RVC), on the other hand, such simple approaches are insufficient, regardless of the product chosen. Instead, RVC should be managed as any other chronic disease and requires long-term, prophylactic, suppressive antifungal treatment. A regimen using individualized, decreasing doses of oral fluconazole (the ReCiDiF regimen) was proven to be highly efficient and offered great comfort to the patients. During this regimen, it is crucial that patients are carefully examined by anamnestic, clinical, microscopic and culture-proven absence of Candida. If a relapse occurs, the medication is adjusted and efforts are taken to find a possible triggering factor for the reactivation of the infection. Care has to be taken not to accumulate 'don't do's', unless the efficiency of a measure has been proven, by trying to eliminate one risk factor at a time for 2 months. Known possible triggers to be kept in mind are (1) antibiotic use, (2) use of specific contraceptives, especially combined contraceptive pills, (3) disturbed glucose metabolism, (4) the use of personal hygienic products, and (5) tight clothing or plastic panty liners. In therapy-resistant cases, non-albicans infection must be ruled out, and alternative therapies should be tried. Boric acid is proven to be efficient in most of these resistant cases, but other non-azoles like amphotericin B, flucytosine, gentian violet, and even caspofungin may have to be tried. As a final remark it has to be said that many patients feel poorly understood and inefficiently managed by many care-givers, increasing their feelings of guilt and sexual inferiority. Therefore, attention has to be given to take the disease seriously, follow strict treatment regimens, and advise precisely and based on individual evidence concerning any possible risk factors for recurrence. In case of therapy-resistant vulvo-vaginitis, reconsider your diagnosis and/or consider referral to specialized therapists. Copyright © 2010 S. Karger AG, Basel.

Country of Publication: Switzerland

Publisher: S. Karger AG (Allschwilerstrasse 10, P.O. Box, Basel CH-4009, Switzerland)

CAS Registry Number: 1397-89-3 (amphotericin B); 30652-87-0 (amphotericin B); 10043-35-3 (boric acid); 11113-50-1 (boric acid); 11129-12-7 (boric acid); 14213-97-9 (boric acid); 189768-38-5 (caspofungin); 467-63-0 (crystal violet); 548-62-9 (crystal violet); 24169-02-6 (econazole); 27220-47-9 (econazole); 86386-73-4 (fluconazole); 2022-85-7 (flucytosine); 84625-61-6 (itraconazole); 65277-42-1 (ketoconazole); 11121-32-7 (mepartricin); 62534-68-3 (mepartricin); 62534-69-4 (mepartricin); 22916-47-8 (miconazole); 1400-61-9 (nystatin); 34786-70-4 (nystatin); 62997-67-5 (nystatin); 67915-31-5 (terconazole); 137234-62-9 (voriconazole)

Publication Type: Journal: Review

Subject Headings: [Candida](#)
[Candida albicans](#)
["*candidiasis/di \[Diagnosis\]"](#)
["*candidiasis/dr \[Drug Resistance\]"](#)
["*candidiasis/dt \[Drug Therapy\]"](#)
["*candidiasis/et \[Etiology\]"](#)
[caregiver](#)
[chronic disease](#)
[clinical trial](#)
[contraception](#)
[diet](#)
[differential diagnosis](#)
[drug dose reduction](#)
[fungus culture](#)

gene amplification
 glucose metabolism
 human
 hygiene
 immunity
 "liver toxicity/si [Side Effect]"
 microscopy
 nonhuman
 priority journal
 review
 risk factor
 sexual behavior
 single drug dose
 treatment response
 vagina
 "*vulvovaginal disease/di [Diagnosis]"
 "*vulvovaginal disease/dr [Drug Resistance]"
 "*vulvovaginal disease/et [Etiology]"
 "amphotericin B/dt [Drug Therapy]"
 "antibiotic agent/ad [Drug Administration]"
 "antibiotic agent/dt [Drug Therapy]"
 "antibiotic agent/iv [Intravenous Drug Administration]"
 "antibiotic agent/po [Oral Drug Administration]"
 "antifungal agent/dt [Drug Therapy]"
 "boric acid/dt [Drug Therapy]"
 "butaconazole/dt [Drug Therapy]"
 "Candida albicans vaccine/dt [Drug Therapy]"
 "casprofungin/dt [Drug Therapy]"
 "crystal violet/dt [Drug Therapy]"
 "econazole/dt [Drug Therapy]"
 "fluconazole/ct [Clinical Trial]"
 "fluconazole/do [Drug Dose]"
 "fluconazole/dt [Drug Therapy]"
 "fluconazole/po [Oral Drug Administration]"
 "flucytosine/dt [Drug Therapy]"
 hormone
 "itraconazole/dt [Drug Therapy]"
 "itraconazole/po [Oral Drug Administration]"
 "ketoconazole/ae [Adverse Drug Reaction]"
 "ketoconazole/dt [Drug Therapy]"
 "mepartricin/dt [Drug Therapy]"
 "mepartricin/po [Oral Drug Administration]"
 "miconazole/dt [Drug Therapy]"
 "nystatin/dt [Drug Therapy]"
 placebo
 "terconazole/dt [Drug Therapy]"
 unclassified drug
 "voriconazole/dt [Drug Therapy]"

Source: EMBASE

Full Text: Available from *S. Karger AG* in *Gynecologic and Obstetric Investigation*; Note: ;
 Collection notes: Academic-License: Only available from an NHS networked computer
 Available from *ProQuest* in *Gynecologic and Obstetric Investigation*
 Available from *EBSCOhost* in *Gynecologic & Obstetric Investigation*

63. *Candida glabrata* complicating in vitro pregnancy: Successful management of subsequent pregnancy

Citation: Fertility and Sterility, February 2011, vol./is. 95/2(803.e1-803.e2), 0015-0282 (February 2011)

Author(s): Asemota O.A.; Nyirjesy P.; Fox R.; Sobel J.D.

Institution: (Asemota, Nyirjesy, Fox) Department of Obstetrics and Gynecology, Drexel University, College of Medicine, Philadelphia, PA, United States; (Sobel) Division of Infectious Diseases, Wayne State University, School of Medicine, Detroit, MI, United States

Language: English

Abstract: Objective: To report the occurrence of *Candida glabrata* chorioamnionitis complicating an in vitro fertilization (IVF) pregnancy. Design: Case report. Setting: University hospital. Patient(s): A 30-year-old woman, primagravida, with an IVF dichorionic-diamniotic pregnancy who presented at 15 weeks with vaginal bleeding. Intervention(s): Before embryo transfer in next IVF cycle, vaginal culture from the patient revealed colonization with *C. glabrata*, which was treated with boric acid. Main Outcome Measure(s): Subsequent pregnancy after eradication of fungal organisms. Result(s): The patient's first pregnancy was treated with indomethacin and broad-spectrum antibiotics, but her membranes ruptured, and she delivered both twins at 16 weeks; the autopsy and pathology reports were consistent with *C. glabrata* chorioamnionitis. After boric acid treatment eradicated the organisms, two embryos were transferred in subsequent IVF treatment; the second pregnancy was uncomplicated, with dichorionic- diamniotic twins, delivered by cesarean section at 38 weeks. Conclusion(s): Eradication of vaginal colonization with *C. glabrata* may prevent infection of the next IVF pregnancy. © 2011 American Society for Reproductive Medicine, Published by Elsevier Inc.

Country of Publication: United States

Publisher: Elsevier Inc. (360 Park Avenue South, New York NY 10010, United States)

CAS Registry Number: 10043-35-3 (boric acid); 11113-50-1 (boric acid); 11129-12-7 (boric acid); 14213-97-9 (boric acid); 53570-76-6 (cyanocobalamin); 68-19-9 (cyanocobalamin); 8064-09-3 (cyanocobalamin); 679809-58-6 (enoxaparin); 59-30-3 (folic acid); 6484-89-5 (folic acid); 53-86-1 (indometacin); 74252-25-8 (indometacin); 7681-54-1 (indometacin); 1400-61-9 (nystatin); 34786-70-4 (nystatin); 62997-67-5 (nystatin); 12001-77-3 (pyridoxine); 58-56-0 (pyridoxine); 65-23-6 (pyridoxine); 8059-24-3 (pyridoxine)

Publication Type: Journal: Article

Subject Headings: adult
 article
 autopsy
Candida glabrata
 "*candidiasis/co [Complication]"
 "*candidiasis/dt [Drug Therapy]"
 case report
 cesarean section
 "*chorioamnionitis/co [Complication]"
 "*chorioamnionitis/dt [Drug Therapy]"
 delivery
 dichorionic diamniotic pregnancy
 embryo transfer
 female
 *fertilization in vitro
 fetus wastage
 fibrin deposition
 gestational age
 human
 premature fetus membrane rupture
 priority journal
 spontaneous abortion
 twin pregnancy
 vagina bleeding
 "antibiotic agent/dt [Drug Therapy]"
 "boric acid/dt [Drug Therapy]"
 "boric acid/va [Intravaginal Drug Administration]"
 cyanocobalamin
 enoxaparin

folic acid
 "indometacin/dt [Drug Therapy]"
 "nystatin/dt [Drug Therapy]"
 pyridoxine

Source: EMBASE

Full Text: Available from *Elsevier* in *Fertility and Sterility*

64. *Candida glabrata* complicating in vitro pregnancy: successful management of subsequent pregnancy.

Citation: Fertility and sterility, Feb 2011, vol. 95, no. 2, p. 803.e1, 1556-5653 (February 2011)

Author(s): Asemota, Obehi A; Nyirjesy, Paul; Fox, Rachel; Sobel, Jack D

Abstract: To report the occurrence of *Candida glabrata* chorioamnionitis complicating an in vitro fertilization (IVF) pregnancy. Case report. University hospital. A 30-year-old woman, primagravida, with an IVF dichorionic-diamniotic pregnancy who presented at 15 weeks with vaginal bleeding. Before embryo transfer in next IVF cycle, vaginal culture from the patient revealed colonization with *C. glabrata*, which was treated with boric acid. Subsequent pregnancy after eradication of fungal organisms. The patient's first pregnancy was treated with indomethacin and broad-spectrum antibiotics, but her membranes ruptured, and she delivered both twins at 16 weeks; the autopsy and pathology reports were consistent with *C. glabrata* chorioamnionitis. After boric acid treatment eradicated the organisms, two embryos were transferred in subsequent IVF treatment; the second pregnancy was uncomplicated, with dichorionic-diamniotic twins, delivered by cesarean section at 38 weeks. Eradication of vaginal colonization with *C. glabrata* may prevent infection of the next IVF pregnancy. Published by Elsevier Inc.

Subject Headings: Parity
 Pregnancy Multiple
 Humans
 Antifungal Agents
 Candidiasis
 Index Medicus
 Pregnancy Complications Infectious
 Pregnancy
 Fetal Death
 Twins
 Adult
 Female
 Boric Acids
 Treatment Outcome
 Candida glabrata
 Fertilization in Vitro

Source: Medline

Full Text: Available from *Elsevier* in *Fertility and Sterility*

65. Boric acid for recurrent vulvovaginal candidiasis: The clinical evidence

Citation: Clinical Microbiology and Infection, May 2011, vol./is. 17/(S758), 1198-743X (May 2011)

Author(s): Iavazzo C.; Gkegkes I.; Zarkada I.; Falagas M.

Institution: (Iavazzo, Gkegkes, Zarkada, Falagas) AthensGreece

Language: English

Abstract: Objectives: Recurrent vulvovaginal candidiasis remains a challenge to manage in clinical practice. Recent epidemiological studies indicate that non-albicans *Candida* spp. are more resistant to conventional antifungal treatment with azoles and are considered as causative pathogens of vulvovaginal candidiasis. Methods: We searched PubMed and Scopus, for studies that reported clinical evidence on the intravaginal use of boric acid for vulvovaginal candidiasis. Results: We identified 14 studies (2 RCTs, 8 case series and 4

case reports) as eligible for inclusion in this review. In 7 studies, boric acid was compared either with nystatin, or azoles (terconazole, flucytosine, itraconazole, clotrimazole, ketoconazole, fluconazole, buconazole and miconazole), while as monotherapy boric acid was studied in 7 studies. The mycological cure rates varied from 40% to 100% in patients treated with boric acid. Four of the 9 included case series reported statistically significant outcomes regarding cure (both mycological and clinical) rates. None of the included studies reported statistical significant difference in recurrence rates. Regarding the adverse effects caused by boric acid use, vaginal burning sensation (<10% of the cases), water discharge during treatment and vaginal erythema were identified in 7 studies. Conclusion: Our findings suggest that boric acid is a safe, alternative, economic option for women with recurrent and chronic symptoms of vaginitis when conventional treatment fails due to the involvement of non-albicans Candida species or azole-resistant strains.

Conference Information: 21st ECCMID/27th ICC Milan Italy. Conference Start: 20110507 Conference End: 20110510

Publisher: Blackwell Publishing Ltd

Publication Type: Journal: Conference Abstract

Subject Headings: [*vagina candidiasis](#)
[Candida](#)
[case study](#)
[human](#)
[monotherapy](#)
[female](#)
[patient](#)
[recurrence risk](#)
[adverse drug reaction](#)
[vaginal burning sensation](#)
[erythema](#)
[vaginitis](#)
[species](#)
[clinical practice](#)
[pathogenesis](#)
[Medline](#)
[case report](#)
[intravaginal drug administration](#)
[*boric acid](#)
[pyrrole derivative](#)
[fluconazole](#)
[miconazole](#)
[water](#)
[pyrrole](#)
[antifungal agent](#)
[terconazole](#)
[flucytosine](#)
[itraconazole](#)
[clotrimazole](#)
[ketoconazole](#)
[nystatin](#)

Source: EMBASE

Full Text: Available from *EBSCOhost* in [Clinical Microbiology & Infection](#)

66. Boric acid for recurrent vulvovaginal candidiasis: the clinical evidence.

Citation: Journal of women's health (2002), Aug 2011, vol. 20, no. 8, p. 1245-1255, 1931-843X (August 2011)

Author(s): Iavazzo, Christos; Gkegkes, Ioannis D; Zarkada, Ioanna M; Falagas, Matthew E

Abstract: Recurrent vulvovaginal candidiasis (VVC) remains a challenge to manage in clinical practice. Recent epidemiologic studies indicate that non-albicans *Candida* spp. are more resistant to conventional antifungal treatment with azoles and are considered as causative pathogens of vulvovaginal candidiasis. We searched PubMed and Scopus for studies that reported clinical evidence on the intravaginal use of boric acid for vulvovaginal candidiasis. We identified 14 studies (2 randomized clinical trials [RCTs], 9 case series, and 4 case reports) as eligible for inclusion in this review. Boric acid was compared with nystatin, terconazole, flucytosine, itraconazole, clotrimazole, ketoconazole, fluconazole, buconazole, and miconazole; as monotherapy, boric acid was studied in 7 studies. The mycologic cure rates varied from 40% to 100% in patients treated with boric acid; 4 of the 9 included case series reported statistically significant outcomes regarding cure (both mycologic and clinical) rates. None of the included studies reported statistically significant differences in recurrence rates. Regarding the adverse effects caused by boric acid use, vaginal burning sensation (<10% of cases), water discharge during treatment, and vaginal erythema were identified in 7 studies. Our findings suggest that boric acid is a safe, alternative, economic option for women with recurrent and chronic symptoms of vaginitis when conventional treatment fails because of the involvement of non-albicans *Candida* spp. or azole-resistant strains.

Subject Headings: [Case-Control Studies](#)
[Administration Intravaginal](#)
[Randomized Controlled Trials as Topic](#)
[Flucytosine](#)
[Candidiasis Vulvovaginal](#)
[Antifungal Agents](#)
[Vaginal Diseases](#)
[Secondary Prevention](#)
[Index Medicus](#)
[Humans](#)
[Anti-Infective Agents Local](#)
[Treatment Outcome](#)
[Female](#)
[Biological Availability](#)
[Boric Acids](#)
[Candida](#)
[Azoles](#)
[Suppositories](#)
[Drug Resistance Multiple Fungal](#)

Source: Medline

Full Text: Available from *EBSCOhost* in *Journal of Women's Health (15409996)*

67. Boric acid for recurrent vulvovaginal candidiasis: The clinical evidence

Citation: Journal of Women's Health, August 2011, vol./is. 20/8(1245-1255), 1540-9996;1931-843X (01 Aug 2011)

Author(s): Iavazzo C.; Gkegkes I.D.; Zarkada I.M.; Falagas M.E.

Institution: (Iavazzo, Gkegkes, Zarkada, Falagas) Alfa Institute of Biomedical Sciences (AIBS), 9 Neapoleos Street, 151 23 Marousi, Athens, Greece; (Falagas) Department of Medicine, Henry Dunant Hospital, Athens, Greece; (Falagas) Department of Medicine, Tufts University School of Medicine, Boston, MA, United States

Language: English

Abstract: Background: Recurrent vulvovaginal candidiasis (VVC) remains a challenge to manage in clinical practice. Recent epidemiologic studies indicate that non-albicans *Candida* spp. are more resistant to conventional antifungal treatment with azoles and are considered as causative pathogens of vulvovaginal candidiasis. Methods: We searched PubMed and Scopus for studies that reported clinical evidence on the intravaginal use of boric acid for vulvovaginal candidiasis. Results: We identified 14 studies (2 randomized clinical trials [RCTs], 9 case series, and 4 case reports) as eligible for inclusion in this review. Boric

acid was compared with nystatin, terconazole, flucytosine, itraconazole, clotrimazole, ketoconazole, fluconazole, buconazole, and miconazole; as monotherapy, boric acid was studied in 7 studies. The mycologic cure rates varied from 40% to 100% in patients treated with boric acid; 4 of the 9 included case series reported statistically significant outcomes regarding cure (both mycologic and clinical) rates. None of the included studies reported statistically significant differences in recurrence rates. Regarding the adverse effects caused by boric acid use, vaginal burning sensation (<10% of cases), water discharge during treatment, and vaginal erythema were identified in 7 studies.

Conclusions: Our findings suggest that boric acid is a safe, alternative, economic option for women with recurrent and chronic symptoms of vaginitis when conventional treatment fails because of the involvement of non-albicans *Candida* spp. or azole-resistant strains. Copyright 2011, Mary Ann Liebert, Inc.

Country of Publication:	United States
Publisher:	Mary Ann Liebert Inc. (140 Huguenot Street, New Rochelle NY 10801-5215, United States)
CAS Registry Number:	12633-72-6 (amphotericin); 10043-35-3 (boric acid); 11113-50-1 (boric acid); 11129-12-7 (boric acid); 14213-97-9 (boric acid); 64872-76-0 (butoconazole); 64872-77-1 (butoconazole); 23593-75-1 (clotrimazole); 467-63-0 (crystal violet); 548-62-9 (crystal violet); 86386-73-4 (fluconazole); 2022-85-7 (flucytosine); 84625-61-6 (itraconazole); 65277-42-1 (ketoconazole); 22916-47-8 (miconazole); 1400-61-9 (nystatin); 34786-70-4 (nystatin); 62997-67-5 (nystatin); 67915-31-5 (terconazole)
Publication Type:	Journal: Review
Subject Headings:	<p>Candida "erythema/si [Side Effect]" fungal strain human monotherapy mycology priority journal randomized controlled trial (topic) recurrent disease review single drug dose systematic review treatment outcome "*vagina candidiasis/dt [Drug Therapy]" "vagina discharge/si [Side Effect]" "vaginal burning sensation/si [Side Effect]" "vaginal erythema/si [Side Effect]" yeast "amphotericin/cb [Drug Combination]" "amphotericin/dt [Drug Therapy]" "amphotericin/tp [Topical Drug Administration]" "*boric acid/ae [Adverse Drug Reaction]" "*boric acid/cm [Drug Comparison]" "*boric acid/dt [Drug Therapy]" "*boric acid/va [Intravaginal Drug Administration]" "butoconazole/cm [Drug Comparison]" "butoconazole/dt [Drug Therapy]" "butoconazole/va [Intravaginal Drug Administration]" "clotrimazole/cm [Drug Comparison]" "clotrimazole/dt [Drug Therapy]" "crystal violet/dt [Drug Therapy]" "crystal violet/tp [Topical Drug Administration]" "fluconazole/cm [Drug Comparison]" "fluconazole/dt [Drug Therapy]" "fluconazole/po [Oral Drug Administration]" "flucytosine/cb [Drug Combination]"</p>

"flucytosine/cm [Drug Comparison]"
 "flucytosine/dt [Drug Therapy]"
 "flucytosine/va [Intravaginal Drug Administration]"
 "flucytosine/tp [Topical Drug Administration]"
 "itraconazole/cm [Drug Comparison]"
 "itraconazole/dt [Drug Therapy]"
 "ketoconazole/cm [Drug Comparison]"
 "ketoconazole/dt [Drug Therapy]"
 "miconazole/cm [Drug Comparison]"
 "miconazole/dt [Drug Therapy]"
 "miconazole/va [Intravaginal Drug Administration]"
 "nystatin/cm [Drug Comparison]"
 "nystatin/dt [Drug Therapy]"
 "nystatin/tp [Topical Drug Administration]"
 "terconazole/cm [Drug Comparison]"
 "terconazole/dt [Drug Therapy]"
 "terconazole/va [Intravaginal Drug Administration]"

Source: EMBASE

Full Text: Available from *EBSCOhost* in *Journal of Women's Health (15409996)*

68. Impact of platinum on the soil invertebrate *Folsomia candida*

Citation: Neuroendocrinology Letters, 2012, vol./is. 33/SUPPL. 3(173-178), 0172-780X (2012)

Author(s): Nemcova B.; Bednarova I.; Mikulaskova H.; Beklova M.

Institution: (Nemcova, Bednarova, Mikulaskova, Beklova) Department of Veterinary Ecology and Environmental Protection, Faculty of Veterinary Hygiene and Ecology, University of Veterinary and Pharmaceutical Sciences Brno, Palackeho 1/3, CZ-612 42 Brno, Czech Republic

Language: English

Abstract: OBJECTIVES: Regarding the environmental pollution, platinum group elements (PGE) are in the centre of interest of current research. These rare elements are used as effective substances in automotive catalysts to reduce pollution by emissions originating from fuel combustion. Due to their harmful potential, it is necessary to monitor their content and behaviour in different samples. Comprehensive studies on PGE behaviour and effects are still lacking. Their distribution in the food chain and data on bioaccumulation has not been described so far. METHODS: We focused on reproductive effects of platinum (PtCl₄), in particular. Our study is based on a collembolan laboratory breed, test optimization and validation according to the OECD 232 standards [CSN ISO 11267 - Soil quality - Inhibition of reproduction of Collembola (*Folsomia candida*) by soil pollutants]. The concentrations of PtCl₄ tested were as follows: 5, 10, 25, 50 and 100 µM. The EC₅₀ was determined after 28 days of testing. RESULTS: The results were evaluated using the inhibition of reproduction compared with controls. The EC₅₀ was determined after the 28-day test. The value of 28dEC₅₀ of the boric acid test was estimated at 120 mg/kg and the measured 28dEC₅₀ of PtCl₄ was 200.4 µM. CONCLUSION: The presented data can be considered as a step forward in the assessment of the potential risk of platinum in the terrestrial environment. However, more toxicity data for various species are needed to evaluate the environmental risk of platinum in soils. ©; 2012 Neuroendocrinology Letters.

Country of Publication: Sweden

Publisher: Maghira and Maas Publications (P.O. Box 26132, Stockholm S-100 41, Sweden)

CAS Registry Number: 10043-35-3 (boric acid); 11113-50-1 (boric acid); 11129-12-7 (boric acid); 14213-97-9 (boric acid); 7440-06-4 (platinum)

Publication Type: Journal: Article

Subject Headings: [article](#)
[breed](#)

controlled study
 *Folsomia candida
 laboratory
 nonhuman
 process optimization
 reproduction
 soil pollutant
 *soil quality
 standard
 validation process
 boric acid
 *platinum

Source: EMBASE

69. Symptomatic Trichomonas vaginalis infection in the setting of severe nitroimidazole allergy: Successful treatment with boric acid

Citation: Sexual Health, 2012, vol./is. 9/4(389-391), 1448-5028;1449-8987 (2012)

Author(s): Muzny C.; Barnes A.; Mena L.

Institution: (Muzny) Division of Infectious Diseases, University of Alabama at Birmingham, ZRB 242, 1530 3rd Avenue South, Birmingham, AL 35294, United States; (Barnes, Mena) Division of Infectious Diseases, University of Mississippi, Medical Center, 2500 North State Street, Jackson, MS 2500, United States

Language: English

Abstract: This report describes a patient with symptomatic Trichomonas vaginalis infection who was unable to tolerate nitroimidazole drugs because of severe hypersensitivity, for which desensitisation was not possible. Use of intravaginal clotrimazole, intravaginal paromomycin, intravaginal furazolidone, povidoneiodine douches, and oral nitazoxanide were unsuccessful in eradicating the patient's T. vaginalis infection. A 2-month course of intravaginal topical boric acid subsequently achieved a complete symptomatic cure and the patient remained T. vaginalis wet prep- and culture-negative 60 days after treatment. © 2012 CSIRO.

Country of Publication: Australia

Publisher: CSIRO (P.O. Box 1139, Collingwood VIC 3066, Australia)

CAS Registry Number: 10043-35-3 (boric acid); 11113-50-1 (boric acid); 11129-12-7 (boric acid); 14213-97-9 (boric acid); 18323-44-9 (clindamycin); 23593-75-1 (clotrimazole); 67-45-8 (furazolidone); 39322-38-8 (metronidazole); 443-48-1 (metronidazole); 55981-09-4 (nitazoxanide); 11035-13-5 (paromomycin); 1263-89-4 (paromomycin); 1390-73-4 (paromomycin); 51795-47-2 (paromomycin); 54597-56-7 (paromomycin); 7542-37-2 (paromomycin); 84420-34-8 (paromomycin); 25655-41-8 (povidone iodine)

Publication Type: Journal: Article

Subject Headings: adult
 article
 case report
 disease severity
 "*drug hypersensitivity/si [Side Effect]"
 female
 follow up
 human
 hypertension
 kidney failure
 non insulin dependent diabetes mellitus
 nonhuman
 sexual behavior
 sexuality
 treatment duration

treatment outcome
 "*trichomoniasis/dt [Drug Therapy]"
 vagina discharge
 vaginal burning sensation
 vaginal pruritus
 "*boric acid/dt [Drug Therapy]"
 "*boric acid/va [Intravaginal Drug Administration]"
 "*boric acid/tp [Topical Drug Administration]"
 "clindamycin/dt [Drug Therapy]"
 "clindamycin/po [Oral Drug Administration]"
 "clotrimazole/dt [Drug Therapy]"
 "clotrimazole/va [Intravaginal Drug Administration]"
 "clotrimazole/tp [Topical Drug Administration]"
 "furazolidone/dt [Drug Therapy]"
 "furazolidone/va [Intravaginal Drug Administration]"
 "*metronidazole/ae [Adverse Drug Reaction]"
 "*metronidazole/dt [Drug Therapy]"
 "nitazoxanide/dt [Drug Therapy]"
 "nitazoxanide/po [Oral Drug Administration]"
 "paromomycin/dt [Drug Therapy]"
 "paromomycin/va [Intravaginal Drug Administration]"
 "povidone iodine/dt [Drug Therapy]"

Source: EMBASE

70. Yeast vaginitis during pregnancy: Susceptibility testing of 13 antifungal drugs and boric acid and the detection of four virulence factors

Citation: Medical Mycology, 2012, vol./is. 50/6(585-593), 1369-3786;1460-2709 (2012)

Author(s): Kalkanci A.; Guzel A.B.; Khalil I.I.J.; Aydin M.; Ilkit M.; Kustimur S.

Institution: (Kalkanci, Khalil, Aydin, Kustimur) Department of Medical Microbiology, Faculty of Medicine, University of Gazi, Ankara, Turkey; (Guzel) Department of Obstetrics and Gynecology, Faculty of Medicine, University of Cukurova, Adana, Turkey; (Ilkit) Department of Microbiology, Faculty of Medicine, University of Cukurova, Adana 01330, Turkey

Language: English

Abstract: A higher prevalence of vulvovaginal candidiasis (VVC) is seen in pregnant women compared with those who are not pregnant. Recurrence is also more common in pregnant women, and therapeutic responses are reduced. In this investigation, 207 vaginal yeast isolates recovered from pregnant women were tested for susceptibility to 13 antifungal drugs and boric acid and through these studies four virulence factors were also determined. The isolates were recovered from vaginal samples of patients with acute VVC [AVVC, (n = 73)], symptomatic recurrent VVC [RVVC, (n = 89)], asymptomatic RVVC (n = 27), and those without signs and symptoms (n = 18). *Candida albicans* was the most common species found (59.9%), followed by *C. glabrata* (19.8%), other *Candida* spp., (19.8%), and *Saccharomyces cerevisiae* (0.5%). Antifungal susceptibility testing was performed as described in CLSI document M27-A3. Additionally, we examined phospholipase and proteinase production, adhesion to vaginal epithelial cells and hemolytic activity. Notably, the MIC values of *Candida* spp. isolates derived from patients with VVC were no different from those of the controls (P > 0.05). In addition, *Candida* isolates derived from patients with AVVC or RVVC produced significantly higher amounts of phospholipase and proteinase compared with the controls (P < 0.05). Antifungal testing and the determination of virulence factors may lead to the effective and prompt treatment of VVC, particularly in pregnant women.

Country of Publication: United Kingdom

Publisher: Oxford University Press

CAS Registry Number: 1397-89-3 (amphotericin B); 30652-87-0 (amphotericin B); 10043-35-3 (boric acid); 11113-50-1 (boric acid); 11129-12-7 (boric acid); 14213-97-9 (boric acid); 23593-75-1

(clotrimazole); 24169-02-6 (econazole); 27220-47-9 (econazole); 86386-73-4 (fluconazole); 2022-85-7 (flucytosine); 84625-61-6 (itraconazole); 65277-42-1 (ketoconazole); 22916-47-8 (miconazole); 1400-61-9 (nystatin); 34786-70-4 (nystatin); 62997-67-5 (nystatin); 9013-93-8 (phospholipase); 9001-92-7 (proteinase); 61318-90-9 (sulconazole); 61318-91-0 (sulconazole); 91161-71-6 (terbinafine); 61675-64-7 (tioconazole); 65899-73-2 (tioconazole)

Publication Type: Journal: Article

Subject Headings: [adhesion](#)
[adult](#)
[*antifungal susceptibility](#)
[article](#)
[Candida](#)
[Candida albicans](#)
[controlled study](#)
[female](#)
[fungus isolation](#)
[hemolysis](#)
[human](#)
[major clinical study](#)
[minimum inhibitory concentration](#)
[nonhuman](#)
[*pregnancy](#)
[pregnant woman](#)
[recurrent infection](#)
[Saccharomyces cerevisiae](#)
["*vagina candidiasis/dt \[Drug Therapy\]"](#)
[vagina epithelium](#)
["amphotericin B/dt \[Drug Therapy\]"](#)
["*antifungal agent/dt \[Drug Therapy\]"](#)
["*boric acid/dt \[Drug Therapy\]"](#)
["clotrimazole/dt \[Drug Therapy\]"](#)
["econazole/dt \[Drug Therapy\]"](#)
["fluconazole/dt \[Drug Therapy\]"](#)
["flucytosine/dt \[Drug Therapy\]"](#)
["itraconazole/dt \[Drug Therapy\]"](#)
["ketoconazole/dt \[Drug Therapy\]"](#)
["miconazole/dt \[Drug Therapy\]"](#)
["nystatin/dt \[Drug Therapy\]"](#)
["phospholipase/ec \[Endogenous Compound\]"](#)
["proteinase/ec \[Endogenous Compound\]"](#)
["sulconazole/dt \[Drug Therapy\]"](#)
["terbinafine/dt \[Drug Therapy\]"](#)
["tioconazole/dt \[Drug Therapy\]"](#)
[*virulence factor](#)

Source: EMBASE

Full Text: Available from *EBSCOhost* in [Medical Mycology](#)

71. Boric acid as reference substance: Pros, cons and standardization

Citation: Ecotoxicology, April 2012, vol./is. 21/3(919-924), 0963-9292;1573-3017 (April 2012)

Author(s): Amorim M.J.B.; Natal-Da-Luz T.; Sousa J.P.; Loureiro S.; Becker L.; Rombke J.; Soares A.M.V.M.

Institution: (Amorim, Loureiro, Soares) Department of Biology and CESAM, University of Aveiro, Campus Universitario de Santiago, 3810-193 Aveiro, Portugal; (Natal-Da-Luz, Sousa) Department of Life Sciences, IMAR-CMA, Apartado 3046, EC Universidade de Coimbra, 3001-401 Coimbra, Portugal; (Becker) Research Centre for BioSystems, Institute of Soil Science and Soil Conservation, Justus Liebig University Giessen,

Heinrich-Buff-Ring 26, 35392 Giessen, Germany; (Rombke) ECT Oekotoxikologie GmbH, 65439 Floersheim, Germany

Language:

English

Abstract:

Boric acid (BA) has been successfully used as reference substance in some standard test guidelines. Due to the fact that previously selected reference substances present a significant risk to human health and/or are banned for environmental reasons, BA is being discussed for broader adoption in OECD or ISO guidelines. To provide input on BA data and contribute to the discussion on its suitability as a reference substance, in the present study BA was tested with two standard soil organisms, *Enchytraeus albidus* and *Folsomia candida*, in terms of survival, reproduction and avoidance. Additionally, published data on other organisms was analysed to derive the most sensitive soil dwelling invertebrate (hazard concentration-HC5). Results showed that BA affected the tested organisms, being two times more toxic for collembolans (LC50 = 96; EC50 = 54 mg/kg) than for enchytraeids (LC50 = 325; EC50 = 104 mg/kg). No avoidance behaviour occurred despite the fact that BA affects earthworms. Actually, it is the recommended reference substance for the earthworm avoidance test. Clearly, the suitable performance of BA in one species should not be generalized to other species. Absolute toxicity is not an important criterion for the selection of a reference substance, but it has been proposed that effects should occur within a reasonable range, i.e. <1,000 mg/kg. We could confirm, compiling previous data that for most soil invertebrates, the EC50 is expected to be below 1,000 mg/kg. From these data it could be derived that the most sensitive soil dwelling invertebrate (HC5, 50%) is likely to be affected (EC10) at 28 (8-53) mg H³/BO³/Kg, equivalent to 4.6 (1.4-8.7) mg boron/kg. © 2011 Springer Science+Business Media, LLC.

Country of Publication:

Netherlands

Publisher:

Springer Netherlands (Van Godewijkstraat 30, Dordrecht 3311 GZ, Netherlands)

CAS Registry Number:

10043-35-3 (boric acid); 11113-50-1 (boric acid); 11129-12-7 (boric acid); 14213-97-9 (boric acid)

Publication Type:

Journal: Article

Subject Headings:

article
avoidance behavior
Collembola
controlled study
dose response
earthworm
Enchytraeus albidus
Folsomia candida
microorganism
nonhuman
priority journal
reproduction
risk factor
*standardization
survival
toxicity testing
*boric acid

Source:

EMBASE

Full Text:

Available from *Springer NHS Pilot 2014 (NESLi2)* in *Ecotoxicology*; Note: ; Collection notes: Academic-License. Please when asked to pick an institution please pick NHS. Please also note access is from 1997 to date only.
Available from *ProQuest* in *Ecotoxicology*

72. Rapid separations of Nile blue stained microorganisms as cationic charged species by chip-CE with LIF**Citation:**

Electrophoresis, May 2012, vol./is. 33/9-10(1421-1426), 0173-0835;1522-2683 (May 2012)

Author(s): Nuchtavorn N.; Bek F.; Macka M.; Suntornsuk W.; Suntornsuk L.

Institution: (Nuchtavorn, Suntornsuk) Department of Pharmaceutical Chemistry, Faculty of Pharmacy Mahidol University, Bangkok, Thailand; (Bek) Agilent Technologies, Waldbronn, Germany; (Macka) Australian Centre for Research on Separation Science, School of Chemistry, University of Tasmania, Tasmania, Australia; (Suntornsuk) Department of Microbiology, Faculty of Science, King Mongkut's University of Technology, Thonburi, Bangkok, Thailand

Language: English

Abstract: Rapid detection of microorganisms by alternative methods is desirable. Electromigration separation methods have the capability to separate microorganisms according to their charge and size and laser-induced fluorescence (LIF) detection have single-cell detection capability. In this work, a new combined separation and detection scheme was introduced using chip-based capillary electrophoresis (chip-CE) platform with LIF detection. Three microorganisms *Escherichia coli*, *Staphylococcus aureus*, and *Candida albicans* were selected as representatives of Gram-positive bacteria, Gram-negative bacteria, and fungi. While their cells carry an overall negative charge in neutral to alkaline pH, staining them with Nile blue (NB) provided highly sensitive LIF detection with excitation and emission wavelengths at 635 nm and 685 nm, respectively, and at the same time, the overall charge was converted to positive. Electrolyte pH and concentration of polyethylene oxide (PEO) significantly affected the resolution of the microorganisms. Their optimal separation in the 14 mm separation channel was achieved in less than 30 s ($R_{s} > 5.3$) in an electrolyte consisting of 3.94 mM Tris, 0.56 mM boric acid, 0.013 mM ethylenediaminetetraacetic acid disodium salt dihydrate (pH 10.5), and 0.025% PEO, with injection/separation voltages of +1000/+1000 V. The separation mechanism is likely employing contributions to the overall cationic charge from both the prevalently anionic membrane proteins and the cationic NB. Importantly, the resulting cationic NB-stained cells exhibited excellent separation selectivity and efficiency of ~38000 theoretical plates for rapid separations within 30-40 s. The results indicate the potential of chip-CE for microbial analysis, which offers separations of a wide range of species with high efficiency, sensitivity, and throughput. © 2012 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Country of Publication: Germany

Publisher: Wiley-VCH Verlag (P.O. Box 101161, Weinheim D-69451, Germany)

CAS Registry Number: 139-33-3 (edetate disodium); 25322-68-3 (macrogol)

Publication Type: Journal: Article

Subject Headings: [*analytic method](#)
[article](#)
[Candida albicans](#)
[*capillary electrophoresis](#)
[controlled study](#)
[Escherichia coli](#)
[flow cytometry](#)
[fungus](#)
[Gram negative bacterium](#)
[Gram positive bacterium](#)
[high throughput screening](#)
[*laser induced fluorescence](#)
[*microorganism](#)
[nonhuman](#)
[pH](#)
[*separation technique](#)
[single cell analysis](#)
[Staphylococcus aureus](#)
[edetate disodium](#)
[electrolyte](#)

macrogol
"membrane protein/ec [Endogenous Compound]"

Source: EMBASE

73. Chronically recurrent vulvovaginal candidosis-problems and chances

Citation: Mycoses, June 2012, vol./is. 55/(37-38), 0933-7407 (June 2012)

Author(s): Mendling W.

Institution: (Mendling) Private Center for Gynecological Infections, Berlin, Germany

Language: English

Abstract: Acute vulvovaginal candidosis (AVC) and chronically recurrent vulvovaginal candidosis (CRVC) are both in about 90% caused by *Candida (C.) albicans*. CRVC needs a 'chronically recurrent' treatment similar to other chronic diseases, because the underlying vaginal immunological deficiencies, which allow repeated vaginal infections, and hypersensitivity against *C. albicans* antigens, which can cause inflammation, could not be treated up to now. Therefore are repeated oral doses of 100-200 mg fluconazole for months in different treatment regimes recommended to achieve symptom-free, but not always *Candida*-free periods. Vaginal 'chronically repeated' clotrimazole 500 mg treatments are shown to be as successful as oral fluconazole, but there seems to be a risk of the emergence of vulvodynia/burning vulva syndrome. Fluconazole should not be taken during pregnancy, although some cases with neonatal bone defects were recently only reported after high fluconazole doses in the first trimester. Resistance of *C. albicans* against fluconazole plays no clinically important role, but needs further control. Typical risk factors for CRVC are use of antibiotics and elevated serum glucose levels, but often are such factors not be found in otherwise healthy patients with CRVC. *C. glabrata* vaginitis occurs in only 2-3% of cases with AVC or CRVC according to some central european studies, but needs doses of at least 800 mg oral fluconazole or vaginal boric acid treatment, which is not allowed in Germany. *C. krusei*- vaginitis is rare and should be vaginally treated with clotrimazole or ciclopiroxolamine for 1-2 weeks, because it is resistant to fluconazole. Other non *albicans* species are susceptible to vaginal imidazoles or oral fluconazole. One of the main *Candida* virulence factors is secretory aspartyl protease (SAP) 2. Its expression correlates directly with pathogenicity and symptoms. A recombinant, modified, enzymatically inactive form of SAP 2 has been developed (Pevion Biotech, Ittigen/Switzerland), which induced significant serum IgG antibody titers after intramuscular injection and significant cervical IgG antibody titers after vaginal application in healthy premenopausal women with negative vaginal *Candida* culture before immunization. The titers were elevated for at least 6 months without boosting. It seems, therefore, possible to test SAP 2 vaccination in patients with CRVC to reduce or avoid fluconazole doses.

Conference Information: 18th Congress of the International Society for Human and Animal Mycology Berlin Germany. Conference Start: 20120611 Conference End: 20120615

Publisher: Blackwell Publishing Ltd

Publication Type: Journal: Conference Abstract

Subject Headings: *human
*society
*mycology
*candidiasis
female
Candida
vaginitis
Candida albicans
patient
hypersensitivity
chronic disease
premenopause
intramuscular drug administration
pregnancy

bone defect
vulva
serum
risk
species
Germany
pathogenicity
inflammation
glucose blood level
risk factor
first trimester pregnancy
immunization
vaccination
immune deficiency
fluconazole
immunoglobulin G
clotrimazole
antigen
aspartic proteinase
virulence factor
imidazole derivative
ciclopiroxolamine
boric acid
antibiotic agent

Source: EMBASE

Full Text: Available from *EBSCOhost* in *Mycoses*

74. Guideline vulvovaginal candidosis (2010) of the German Society for Gynecology and Obstetrics, the Working Group for Infections and Infectimmunology in Gynecology and Obstetrics, the German Society of Dermatology, the Board of German Dermatologists and the German Speaking Mycological Society.

Citation: *Mycoses*, Jul 2012, vol. 55 Suppl 3, p. 1-13, 1439-0507 (July 2012)

Author(s): Mendling, W; Brasch, J; German Society for Gynecology and Obstetrics; Working Group for Infections and Infectimmunology in Gynecology and Obstetrics; German Society of Dermatology, the Board of German Dermatologists; German Speaking Mycological Society

Abstract: *Candida* (*C.*) species colonize the estrogenized vagina in at least 20% of all women. This statistic rises to 30% in late pregnancy and in immunosuppressed patients. The most often occurring species is *Candida albicans*. Host factors, especially local defense deficiencies, gene polymorphisms, allergic factors, serum glucose levels, antibiotics, psychosocial stress and estrogens influence the risk for a *Candida* vulvovaginitis. In less than 10% of all cases, non-*albicans* species, especially *C. glabrata*, but in rare cases also *Saccharomyces cerevisiae*, cause a vulvovaginitis, often with fewer clinical signs and symptoms. Typical symptoms include premenstrual itching, burning, redness and non-odorous discharge. Although pruritus and inflammation of the vaginal introitus are typical symptoms, only less than 50% of women with genital pruritus suffer from a *Candida* vulvovaginitis. Diagnostic tools are anamnesis, evaluation of clinical signs, the microscopic investigation of the vaginal fluid by phase contrast (400 x), vaginal pH-value and, in clinically and microscopically uncertain or in recurrent cases, yeast culture with species determination. The success rate for treatment of acute vaginal candidosis is approximately 80%. Vaginal preparations containing polyenes, imidazoles and ciclopiroxolamine or oral triazoles, which are not allowed during pregnancy, are all equally effective. *C. glabrata* is resistant to the usual dosages of all local antimycotics. Therefore, vaginal boric acid suppositories or vaginal flucytosine are recommended, but not allowed or available in all countries. Therefore, high doses of 800 mg fluconazole/day for 2-3 weeks are recommended in Germany. Due to increasing resistance, oral posaconazole 2 × 400 mg/day plus local ciclopiroxolamine or nystatin for 15 days was discussed. *C. krusei* is resistant to triazoles. Side effects, toxicity, embryotoxicity and allergy are not clinically important. A vaginal clotrimazole treatment in the first trimester

of pregnancy has shown to reduce the rate of preterm births in two studies. Resistance of *C. albicans* does not play a clinically important role in vulvovaginal candidosis. Although it is not necessary to treat vaginal candida colonization in healthy women, it is recommended in the third trimester of pregnancy in Germany, because the rate of oral thrush and diaper dermatitis in mature healthy newborns, induced by the colonization during vaginal delivery, is significantly reduced through prophylaxis. Chronic recurrent vulvovaginal candidosis requires a "chronic recurrent" suppression therapy, until immunological treatment becomes available. Weekly to monthly oral fluconazole regimens suppress relapses well, but cessation of therapy after 6 or 12 months leads to relapses in 50% of cases. Decreasing-dose maintenance regime of 200 mg fluconazole from an initial 3 times a week to once monthly (Donders 2008) leads to more acceptable results. Future studies should include candida autovaccination, antibodies against candida virulence factors and other immunological trials. Probiotics should also be considered in further studies. Over the counter (OTC) treatment must be reduced. © 2012 Blackwell Verlag GmbH.

Subject Headings: [Antifungal Agents](#)
[Candidiasis Vulvovaginal](#)
[Humans](#)
[Index Medicus](#)
[Pregnancy Complications Infectious](#)
[Female](#)
[Pregnancy](#)
[Candida](#)

Source: Medline

Full Text: Available from *EBSCOhost* in [Mycoses](#)

75. Guideline vulvovaginal candidosis (2010) of the german society for gynecology and obstetrics, the working group for infections and infectimmunology in gynecology and obstetrics, the german society of dermatology, the board of german dermatologists and the german speaking mycological society

Citation: Mycoses, July 2012, vol./is. 55/SUPPL. 3(1-13), 0933-7407;1439-0507 (July 2012)

Author(s): Mendling W.; Brasch J.

Institution: (Mendling) Vivantes - Klinikum im Friedrichshain and Am Urban, Landsberger Allee 49, 10249 Berlin, Germany; (Brasch) University Hospitals of Schleswig - Holstein, Campus Kiel, Department of Dermatology, Venerology and Allergology, Schittenhelmstrasse 7, 24105 Kiel, Germany

Language: English

Abstract: *Candida* (*C.*) species colonize the estrogenized vagina in at least 20% of all women. This statistic rises to 30% in late pregnancy and in immunosuppressed patients. The most often occurring species is *Candida albicans*. Host factors, especially local defense deficiencies, gene polymorphisms, allergic factors, serum glucose levels, antibiotics, psychosocial stress and estrogens influence the risk for a *Candida* vulvovaginitis. In less than 10% of all cases, non-*albicans* species, especially *C. glabrata*, but in rare cases also *Saccharomyces cerevisiae*, cause a vulvovaginitis, often with fewer clinical signs and symptoms. Typical symptoms include premenstrual itching, burning, redness and non-odorous discharge. Although pruritus and inflammation of the vaginal introitus are typical symptoms, only less than 50% of women with genital pruritus suffer from a *Candida* vulvovaginitis. Diagnostic tools are anamnesis, evaluation of clinical signs, the microscopic investigation of the vaginal fluid by phase contrast (400 x), vaginal pH-value and, in clinically and microscopically uncertain or in recurrent cases, yeast culture with species determination. The success rate for treatment of acute vaginal candidosis is approximately 80%. Vaginal preparations containing polyenes, imidazoles and ciclopiroxolamine or oral triazoles, which are not allowed during pregnancy, are all equally effective. *C. glabrata* is resistant to the usual dosages of all local antimycotics. Therefore, vaginal boric acid suppositories or vaginal flucytosine are recommended, but not allowed or available in all countries. Therefore, high doses of 800mg fluconazole/day for 2-3weeks are recommended in Germany. Due to increasing resistance, oral posaconazole 2x400mg/day plus local ciclopiroxolamine or nystatin for 15days was

discussed. *C. krusei* is resistant to triazoles. Side effects, toxicity, embryotoxicity and allergy are not clinically important. A vaginal clotrimazole treatment in the first trimester of pregnancy has shown to reduce the rate of preterm births in two studies. Resistance of *C. albicans* does not play a clinically important role in vulvovaginal candidosis. Although it is not necessary to treat vaginal candida colonization in healthy women, it is recommended in the third trimester of pregnancy in Germany, because the rate of oral thrush and diaper dermatitis in mature healthy newborns, induced by the colonization during vaginal delivery, is significantly reduced through prophylaxis. Chronic recurrent vulvovaginal candidosis requires a "chronic recurrent" suppression therapy, until immunological treatment becomes available. Weekly to monthly oral fluconazole regimens suppress relapses well, but cessation of therapy after 6 or 12 months leads to relapses in 50% of cases. Decreasing-dose maintenance regime of 200mg fluconazole from an initial 3 times a week to once monthly (Donders 2008) leads to more acceptable results. Future studies should include candida autovaccination, antibodies against candida virulence factors and other immunological trials. Probiotics should also be considered in further studies. Over the counter (OTC) treatment must be reduced. © 2012 Blackwell Verlag GmbH.

Country of Publication:	United Kingdom
Publisher:	Blackwell Publishing Ltd (9600 Garsington Road, Oxford OX4 2XG, United Kingdom)
CAS Registry Number:	1397-89-3 (amphotericin B); 30652-87-0 (amphotericin B); 10043-35-3 (boric acid); 11113-50-1 (boric acid); 11129-12-7 (boric acid); 14213-97-9 (boric acid); 41621-49-2 (ciclopiroxolamine); 23593-75-1 (clotrimazole); 24169-02-6 (econazole); 27220-47-9 (econazole); 73151-29-8 (fenticonazole nitrate); 86386-73-4 (fluconazole); 2022-85-7 (flucytosine); 50-99-7 (glucose); 84778-64-3 (glucose); 1467-16-9 (imidazole); 288-32-4 (imidazole); 84625-61-6 (itraconazole); 22832-87-7 (miconazole nitrate); 52882-37-8 (natamycin); 7681-93-8 (natamycin); 1400-61-9 (nystatin); 34786-70-4 (nystatin); 62997-67-5 (nystatin); 171228-49-2 (posaconazole); 99592-32-2 (sertaconazole); 67915-31-5 (terconazole); 61675-64-7 (tioconazole); 65899-73-2 (tioconazole); 37306-44-8 (triazole)
Publication Type:	Journal: Article
Subject Headings:	allergy anamnesis article "burn/si [Side Effect]" Candida albicans Candida glabrata candida krusei dermatologist diabetic patient diaper dermatitis DNA polymorphism estrogen blood level female first trimester pregnancy fungal colonization fungal virulence fungus culture genital pruritus Germany glucose blood level "headache/si [Side Effect]" human immune deficiency immunosuppressive treatment impaired glucose tolerance inflammation medical society mental stress

nonviral gene delivery system
 pathogenicity
 pH
 phase contrast microscopy
 pregnancy
 "premature labor/dt [Drug Therapy]"
 priority journal
 "recurrent disease/th [Therapy]"
 Saccharomyces cerevisiae
 sexual behavior
 skin redness
 third trimester pregnancy
 thrush
 "unspecified side effect/si [Side Effect]"
 "*vagina candidiasis/di [Diagnosis]"
 "*vagina candidiasis/dt [Drug Therapy]"
 "*vagina candidiasis/et [Etiology]"
 "*vagina candidiasis/th [Therapy]"
 vagina discharge
 vaginal burning sensation
 vaginal delivery
 vaginal pruritus
 "virus hepatitis/si [Side Effect]"
 vulvovaginitis
 yeast
 "amphotericin B/dt [Drug Therapy]"
 "amphotericin B/tp [Topical Drug Administration]"
 boric acid
 "ciclopiroxolamine/ae [Adverse Drug Reaction]"
 "ciclopiroxolamine/cb [Drug Combination]"
 "ciclopiroxolamine/dt [Drug Therapy]"
 "clotrimazole/cb [Drug Combination]"
 "clotrimazole/dt [Drug Therapy]"
 "econazole/dt [Drug Therapy]"
 estrogen
 "fenticonazole nitrate/dt [Drug Therapy]"
 "fluconazole/ae [Adverse Drug Reaction]"
 "fluconazole/dt [Drug Therapy]"
 "fluconazole/po [Oral Drug Administration]"
 "flucytosine/tp [Topical Drug Administration]"
 glucose
 host factor
 "imidazole/ae [Adverse Drug Reaction]"
 "imidazole/cb [Drug Combination]"
 "imidazole/dt [Drug Therapy]"
 "imidazole/po [Oral Drug Administration]"
 "itraconazole/ae [Adverse Drug Reaction]"
 "itraconazole/dt [Drug Therapy]"
 "miconazole nitrate/dt [Drug Therapy]"
 "natamycin/dt [Drug Therapy]"
 "natamycin/tp [Topical Drug Administration]"
 "nystatin/cb [Drug Combination]"
 "nystatin/dt [Drug Therapy]"
 "nystatin/tp [Topical Drug Administration]"
 "polyene/dt [Drug Therapy]"
 "posaconazole/cb [Drug Combination]"
 "posaconazole/dt [Drug Therapy]"
 "posaconazole/po [Oral Drug Administration]"
 "sertaconazole/dt [Drug Therapy]"
 "terconazole/dt [Drug Therapy]"

"tioconazole/dt [Drug Therapy]"
 "triazole/po [Oral Drug Administration]"

Source: EMBASE

Full Text: Available from *EBSCOhost* in *Mycoses*

76. Yeast vaginitis during pregnancy: susceptibility testing of 13 antifungal drugs and boric acid and the detection of four virulence factors.

Citation: Medical mycology, Aug 2012, vol. 50, no. 6, p. 585-593, 1460-2709 (August 2012)

Author(s): Kalkanci, Ayşe; Güzel, Ahmet Barış; Khalil, Israa Ibrahim Jabban; Aydin, Merve; Ilkit, Macit; Kuştimur, Semra

Abstract: A higher prevalence of vulvovaginal candidiasis (VVC) is seen in pregnant women compared with those who are not pregnant. Recurrence is also more common in pregnant women, and therapeutic responses are reduced. In this investigation, 207 vaginal yeast isolates recovered from pregnant women were tested for susceptibility to 13 antifungal drugs and boric acid and through these studies four virulence factors were also determined. The isolates were recovered from vaginal samples of patients with acute VVC [AVVC, (n = 73)], symptomatic recurrent VVC [RVVC, (n = 89)], asymptomatic RVVC (n = 27), and those without signs and symptoms (n = 18). *Candida albicans* was the most common species found (59.9%), followed by *C. glabrata* (19.8%), other *Candida* spp., (19.8%), and *Saccharomyces cerevisiae* (0.5%). Antifungal susceptibility testing was performed as described in CLSI document M27-A3. Additionally, we examined phospholipase and proteinase production, adhesion to vaginal epithelial cells and hemolytic activity. Notably, the MIC values of *Candida* spp. isolates derived from patients with VVC were no different from those of the controls ($P > 0.05$). In addition, *Candida* isolates derived from patients with AVVC or RVVC produced significantly higher amounts of phospholipase and proteinase compared with the controls ($P < 0.05$). Antifungal testing and the determination of virulence factors may lead to the effective and prompt treatment of VVC, particularly in pregnant women.

Subject Headings: [Young Adult](#)
[Female](#)
[Candidiasis Vulvovaginal](#)
[Humans](#)
[Pregnancy](#)
[Hemolysis](#)
[Amphotericin B](#)
[Boric Acids](#)
[Saccharomyces cerevisiae](#)
[Microbial Sensitivity Tests](#)
[Fungal Proteins](#)
[Adolescent](#)
[Candida albicans](#)
[Epithelial Cells](#)
[Recurrence](#)
[Vagina](#)
[Cell Adhesion](#)
[Itraconazole](#)
[Candida glabrata](#)
[Antifungal Agents](#)
[Phospholipases](#)
[Adult](#)
[Fluconazole](#)
[Animals](#)
[Middle Aged](#)
[Index Medicus](#)
[Pregnancy Complications Infectious](#)
[Virulence Factors](#)

Source: Medline

Full Text: Available from *EBSCOhost* in [Medical Mycology](#)

77. Yeast vaginitis during pregnancy: Susceptibility testing of 13 antifungal drugs and boric acid and the detection of four virulence factors

Citation: Medical Mycology, August 2012, vol./is. 50/6(585-593), 1369-3786;1460-2709 (August 2012)

Author(s): Kalkanci A.; Guzel A.B.; Khalil I.I.J.; Aydin M.; Ilkit M.; Kustimur S.

Institution: (Kalkanci, Khalil, Aydin, Kustimur) Department of Medical Microbiology, Faculty of Medicine, University of Gazi, Ankara, Turkey; (Guzel) Department of Obstetrics and Gynecology, Faculty of Medicine, University of Cukurova, Adana, Turkey; (Ilkit) Department of Microbiology, Faculty of Medicine, University of Cukurova, Adana 01330, Turkey

Language: English

Abstract: A higher prevalence of vulvovaginal candidiasis (VVC) is seen in pregnant women compared with those who are not pregnant. Recurrence is also more common in pregnant women, and therapeutic responses are reduced. In this investigation, 207 vaginal yeast isolates recovered from pregnant women were tested for susceptibility to 13 antifungal drugs and boric acid and through these studies four virulence factors were also determined. The isolates were recovered from vaginal samples of patients with acute VVC [AVVC, (n = 73)], symptomatic recurrent VVC [RVVC, (n = 89)], asymptomatic RVVC (n = 27), and those without signs and symptoms (n = 18). *Candida albicans* was the most common species found (59.9%), followed by *C. glabrata* (19.8%), other *Candida* spp., (19.8%), and *Saccharomyces cerevisiae* (0.5%). Antifungal susceptibility testing was performed as described in CLSI document M27-A3. Additionally, we examined phospholipase and proteinase production, adhesion to vaginal epithelial cells and hemolytic activity. Notably, the MIC values of *Candida* spp. isolates derived from patients with VVC were no different from those of the controls ($P > 0.05$). In addition, *Candida* isolates derived from patients with AVVC or RVVC produced significantly higher amounts of phospholipase and proteinase compared with the controls ($P < 0.05$). Antifungal testing and the determination of virulence factors may lead to the effective and prompt treatment of VVC, particularly in pregnant women. © 2012 ISHAM.

Country of Publication: United Kingdom

Publisher: Informa Healthcare (69-77 Paul Street, London EC2A 4LQ, United Kingdom)

CAS Registry Number: 1397-89-3 (amphotericin B); 30652-87-0 (amphotericin B); 10043-35-3 (boric acid); 11113-50-1 (boric acid); 11129-12-7 (boric acid); 14213-97-9 (boric acid); 189768-38-5 (caspofungin); 23593-75-1 (clotrimazole); 24169-02-6 (econazole); 27220-47-9 (econazole); 86386-73-4 (fluconazole); 2022-85-7 (flucytosine); 84625-61-6 (itraconazole); 65277-42-1 (ketoconazole); 22916-47-8 (miconazole); 1400-61-9 (nystatin); 34786-70-4 (nystatin); 62997-67-5 (nystatin); 9013-93-8 (phospholipase); 9001-92-7 (proteinase); 61318-90-9 (sulconazole); 61318-91-0 (sulconazole); 91161-71-6 (terbinafine); 61675-64-7 (tioconazole); 65899-73-2 (tioconazole)

Publication Type: Journal: Article

Subject Headings: [adult](#)
[antifungal susceptibility](#)
[article](#)
[Candida albicans](#)
[Candida glabrata](#)
[cell adhesion](#)
[controlled study](#)
[epithelium cell](#)
[female](#)
[fungal detection](#)
[*fungal virulence](#)
[hemolysis](#)
[human](#)

human tissue
 major clinical study
 minimum inhibitory concentration
 nonhuman
 *pregnancy complication
 recurrent disease
 Saccharomyces cerevisiae
 statistical significance
 vagina candidiasis
 vagina epithelium
 "*vagina mycosis/di [Diagnosis]"
 "*vagina mycosis/et [Etiology]"
 amphotericin B
 antifungal agent
 *boric acid
 caspofungin
 clotrimazole
 econazole
 fluconazole
 flucytosine
 itraconazole
 ketoconazole
 miconazole
 nystatin
 "phospholipase/ec [Endogenous Compound]"
 "proteinase/ec [Endogenous Compound]"
 sulconazole
 terbinafine
 tioconazole
 "*virulence factor/ec [Endogenous Compound]"

Source: EMBASE

Full Text: Available from *EBSCOhost* in *Medical Mycology*

78. Genotyping Reveals no Link Between *Candida albicans* Genotype and Vaginitis Severity in Turkish Women

Citation: Mycopathologia, 2013, vol./is. 175/3-4(287-294), 0301-486X (2013)

Author(s): Guzel A.B.; Dogen A.; Aydin M.; Serin A.; Serin M.S.; Kalkanci A.; Ilkit M.

Institution: (Guzel) Department of Obstetrics and Gynecology, Faculty of Medicine, University of Cukurova, Adana, Turkey; (Dogen, Serin) Department of Pharmaceutical Microbiology, Faculty of Pharmacy, University of Mersin, Mersin, Turkey; (Aydin, Kalkanci) Department of Microbiology, Faculty of Medicine, University of Gazi, Ankara, Turkey; (Aydin) Department of Microbiology, Faculty of Medicine, University of Erzincan, Erzincan, Turkey; (Serin) Department of Forensic Medicine, Faculty of Medicine, University of Cukurova, Adana, Turkey; (Ilkit) Division of Mycology, Department of Microbiology, Faculty of Medicine, University of Cukurova, 01330 Adana, Turkey

Language: English

Abstract: Recent studies have clearly defined the vaginopathic *Candida albicans* strains that cause severe vulvovaginal candidiasis (VVC). Therefore, genotyping *C. albicans* isolates may predict the success of and assist in choosing the appropriate antifungal therapy. The purpose of this study was to compare the genotypes of *C. albicans* isolates causing VVC with those found in asymptomatic healthy pregnant and non-pregnant women in Adana, Turkey, as well as the antifungal susceptibility profiles of these isolates. A total of 216 independent *C. albicans* isolates were genotyped by allelic combination based on the microsatellite marker analysis of one such microsatellite, present in the promoter region of the elongation factor 3-encoding gene (CEF3) of *C. albicans*. The susceptibility testing profiles of all of the isolates against five antifungals and boric acid were obtained retrospectively from our laboratory records. We identified 20 genotypes on the basis of different allelic combinations at the CEF3 locus with a discriminatory power of 0.85.

Genotypes 136-144 and 126-135 were present in 50 % of the isolates. No differences existed in the genotypic profiles of fungal isolates between pregnant and non-pregnant women. Remarkably, we did not find a single vaginopathic genotype. All of the isolates were susceptible to amphotericin B and 5-fluorocytosine, and the fluconazole and ketoconazole resistance rates were 0.9 and 3.7 %, respectively. Therefore, we did not find any correlation between genotype, severity of VVC, and antifungal resistance ($P > 0.05$). Even so, additional molecular data may provide new insights into the management of VVC. [#9](#); 2013 Springer Science+Business Media Dordrecht.

Country of Publication: Netherlands
Publisher: Springer Netherlands (Van Godewijkstraat 30, Dordrecht 3311 GZ, Netherlands)
Publication Type: Journal: Article
Subject Headings: [article](#)
[*Candida albicans classification](#)
[female](#)
[genetics](#)
[genotype](#)
[human](#)
[isolation and purification](#)
[microbial sensitivity test](#)
[*microbiological examination](#)
[microbiology](#)
[*molecular typing](#)
[pathogenicity](#)
[pathology](#)
[pregnancy](#)
["Turkey \(republic\)/ep \[Epidemiology\]"](#)
["*vagina candidiasis/ep \[Epidemiology\]"](#)
["antifungal agent/pd \[Pharmacology\]"](#)
[fungal DNA](#)
[microsatellite DNA](#)

Source: EMBASE

Full Text: Available from *ProQuest* in *Mycopathologia*
 Available from *Springer NHS Pilot 2014 (NESLi2)* in *Mycopathologia*; Note: ; Collection notes: Academic-License. Please when asked to pick an institution please pick NHS. Please also note access is from 1997 to date only.

79. Genotyping reveals no link between *Candida albicans* genotype and vaginitis severity in Turkish women.

Citation: Mycopathologia, Apr 2013, vol. 175, no. 3-4, p. 287-294, 1573-0832 (April 2013)

Author(s): Güzel, Ahmet Barış; Döğen, Aylin; Aydın, Merve; Serin, Ayşe; Serin, Mehmet Sami; Kalkancı, Ayşe; Ilkit, Macit

Abstract: Recent studies have clearly defined the vaginopathic *Candida albicans* strains that cause severe vulvovaginal candidiasis (VVC). Therefore, genotyping *C. albicans* isolates may predict the success of and assist in choosing the appropriate antifungal therapy. The purpose of this study was to compare the genotypes of *C. albicans* isolates causing VVC with those found in asymptomatic healthy pregnant and non-pregnant women in Adana, Turkey, as well as the antifungal susceptibility profiles of these isolates. A total of 216 independent *C. albicans* isolates were genotyped by allelic combination based on the microsatellite marker analysis of one such microsatellite, present in the promoter region of the elongation factor 3-encoding gene (CEF3) of *C. albicans*. The susceptibility testing profiles of all of the isolates against five antifungals and boric acid were obtained retrospectively from our laboratory records. We identified 20 genotypes on the basis of different allelic combinations at the CEF3 locus with a discriminatory power of 0.85. Genotypes 136-144 and 126-135 were present in 50 % of the isolates. No differences existed in the genotypic profiles of fungal isolates between pregnant and non-pregnant women. Remarkably, we did not find a single vaginopathic genotype. All of the isolates

were susceptible to amphotericin B and 5-fluorocytosine, and the fluconazole and ketoconazole resistance rates were 0.9 and 3.7 %, respectively. Therefore, we did not find any correlation between genotype, severity of VVC, and antifungal resistance ($P > 0.05$). Even so, additional molecular data may provide new insights into the management of VVC.

Subject Headings: [Turkey](#)
[Molecular Typing](#)
[Genotype](#)
[Candida albicans](#)
[Humans](#)
[Candidiasis Vulvovaginal](#)
[Antifungal Agents](#)
[Microsatellite Repeats](#)
[DNA Fungal](#)
[Female](#)
[Pregnancy](#)
[Mycological Typing Techniques](#)
[Index Medicus](#)
[Microbial Sensitivity Tests](#)

Source: Medline

Full Text: Available from *ProQuest* in [Mycopathologia](#)
 Available from *Springer NHS Pilot 2014 (NESLi2)* in [Mycopathologia](#); Note: ; Collection notes: Academic-License. Please when asked to pick an institution please pick NHS. Please also note access is from 1997 to date only.

80. FLUCONAZOLE AND BORIC ACID FOR TREATMENT OF VAGINAL CANDIDIASIS--NEW WORDS ABOUT OLD ISSUE.

Citation: East African medical journal, Apr 2013, vol. 90, no. 4, p. 117-123, 0012-835X (April 2013)

Author(s): Khameneie, K M; Arianpour, N; Roozegar, R; Aklamli, M; Amiri, M M

Abstract: To compare boric acid as an effective treatment for VVC compared to fluconazole. We also studied the efficiency of these drugs in preventing recurrence of VVC. A cross sectional, randomized, double-blind study. Gynaecology clinic of Imam Reza hospital, Tehran - Iran Women with signs and symptoms related to Vulvo Vaginal Candidiasis. Seventy five patients out of total 150 patients with signs and symptoms related to Vulvo Vaginal Candidiasis were treated with boric acid powder every night for a week and the remaining 75 patients received Fluconazole. The cure rate in first group was 46.7% but the cure rate in second group was 37.3%. The difference was not statistically significant ($P > 0.3$). Difference between the efficacy of the two drugs was not significant either ($P = 0.47$). The recurrence rate among patients in first group was 35% while it was 32% in second group. Their difference was not statistically significant ($P = 0.54$). According to our findings, treatment of vaginal candidiasis with boric acid is as effective as fluconazole. The availability of boric acid and its relatively low cost suggests it as a safe and effective drug for treatment of candidiasis.

Subject Headings: [Treatment Outcome](#)
[Iran](#)
[Administration Intravaginal](#)
[Humans](#)
[Administration Oral](#)
[Candidiasis Vulvovaginal](#)
[Antifungal Agents](#)
[Secondary Prevention](#)
[Index Medicus](#)
[Adult](#)
[Female](#)
[Fluconazole](#)
[Boric Acids](#)

Candida
Double-Blind Method

Source: Medline

81. FLUCONAZOLE AND BORIC ACID FOR TREATMENT OF VAGINAL CANDIDIASIS--NEW WORDS ABOUT OLD ISSUE

Citation: East African medical journal, April 2013, vol./is. 90/4(117-123), 0012-835X (01 Apr 2013)

Author(s): Khameneie K.M.; Arianpour N.; Roozegar R.; Aklamli M.; Amiri M.M.

Institution: (Khameneie, Arianpour, Roozegar, Aklamli, Amiri) Department of Obstetrics and Gynecology, Imam Reza hospital, Tehran - Iran

Language: English

Abstract: OBJECTIVE: To compare boric acid as an effective treatment for VVC compared to fluconazole. We also studied the efficiency of these drugs in preventing recurrence of VVC.DESIGN: A cross sectional, randomized, double-blind study.SETTINGS: Gynaecology clinic of Imam Reza hospital, Tehran - IranSUBJECTS: Women with signs and symptoms related to Vulvo Vaginal Candidiasis.RESULTS: Seventy five patients out of total 150 patients with signs and symptoms related to Vulvo Vaginal Candidiasis were treatedwith boric acidpowder everynight for a week and the remaining 75 patients received Fluconazole. The cure rate in first group was 46.7% but the cure rate in second group was 37.3%. The difference was not statistically significant (P>0.3). Difference between the efficacy of the two drugs was not significant either (P=0.47). The recurrence rate among patients in first group was 35% while it was 32% in second group. Their difference was not statistically significant (P=0.54).CONCLUSION: According to our findings, treatment of vaginal candidiasis with boric acid is as effective as fluconazole. The availability of boric acid and its relatively low cost suggests it as a safe and effective drug for treatment of candidiasis.

Country of Publication: Kenya

CAS Registry Number: 10043-35-3 (boric acid); 11113-50-1 (boric acid); 11129-12-7 (boric acid); 14213-97-9 (boric acid); 86386-73-4 (fluconazole)

Publication Type: Journal: Article

Subject Headings: adult
*Candida
"*Candidiasis Vulvovaginal/di [Diagnosis]"
"*Candidiasis Vulvovaginal/dt [Drug Therapy]"
controlled study
double blind procedure
drug effects
female
human
intravaginal drug administration
Iran
isolation and purification
oral drug administration
pathophysiology
procedures
randomized controlled trial
secondary prevention
treatment outcome
"antifungal agent/ad [Drug Administration]"
"boric acid/ad [Drug Administration]"
"fluconazole/ad [Drug Administration]"

Source: EMBASE

82. Candida vaginitis in non-pregnant patients: A study of antifungal susceptibility testing and virulence factors

Citation: Journal of Obstetrics and Gynaecology, May 2013, vol./is. 33/4(378-383), 0144-3615;1364-6893 (May 2013)

Author(s): Kalkanci A.; Guzel A.B.; Jabban I.I.K.; Aydin M.; Ilkit M.; Kustimur S.

Institution: (Kalkanci, Jabban, Aydin, Kustimur) Department of Microbiology, Faculty of Medicine, University of Gazi, Ankara, Turkey; (Guzel) Department of Obstetrics and Gynaecology, Faculty of Medicine, University of Cukurova, Adana, 01330, Turkey; (Ilkit) Division of Mycology, Department of Microbiology, University of Cukurova, Adana, Turkey

Language: English

Abstract: Vulvovaginal candidosis (VVC) is a major problem for the female population worldwide, and considerably little is known about the difference between acute VVC (AVVC) and recurrent VVC (RVVC). We investigated the susceptibility to six antifungal agents and boric acid of *Candida* spp. isolated from vaginal cultures, as described in the CLSI document M27-A3, from 228 non-pregnant sexually active women (aged 18-49 years), and the virulence factors of these isolates. The isolates were derived from patients with AVVC (n = 64), those with RVVC (n = 125) and those without signs or symptoms (n = 39). In total, *C. albicans* was the most commonly isolated species (50%), followed by *C. glabrata* (35.5%) and other *Candida* spp. (14.5%). We observed slightly different minimum inhibitory concentration (MICs) for various antifungals among the species and study groups that could have potential therapeutic benefits for the treatment. Analysis of the virulence factors revealed that haemolytic activity is not involved in VVC pathogenesis but that germ-tube formation, adhesion to VECs, and proteinase and phospholipase production may be important in the pathogenesis of VVC. © 2013 Informa UK, Ltd.

Country of Publication: United Kingdom

Publisher: Informa Healthcare (69-77 Paul Street, London EC2A 4LQ, United Kingdom)

CAS Registry Number: 1397-89-3 (amphotericin B); 30652-87-0 (amphotericin B); 10043-35-3 (boric acid); 11113-50-1 (boric acid); 11129-12-7 (boric acid); 14213-97-9 (boric acid); 86386-73-4 (fluconazole); 2022-85-7 (flucytosine); 84625-61-6 (itraconazole); 65277-42-1 (ketoconazole); 1400-61-9 (nystatin); 34786-70-4 (nystatin); 62997-67-5 (nystatin)

Publication Type: Journal: Article

Subject Headings: [adult](#)
[*antifungal susceptibility](#)
[article](#)
[asymptomatic disease](#)
[bacterium carrier](#)
[*Candida](#)
[Candida glabrata](#)
[controlled study](#)
[female](#)
[*fungal virulence](#)
[fungus culture](#)
[fungus isolation](#)
[human](#)
[major clinical study](#)
[minimum inhibitory concentration](#)
[priority journal](#)
[*recurrent vulvovaginal candidosis](#)
[*vagina candidiasis](#)
[*vulvovaginal candidosis](#)
[*amphotericin B](#)
[boric acid](#)
[*fluconazole](#)
[*flucytosine](#)
[*itraconazole](#)
[*ketoconazole](#)

*nystatin
virulence factor

Source: EMBASE

Full Text: Available from *EBSCOhost* in *Journal of Obstetrics & Gynaecology*

83. Candida vaginitis in non-pregnant patients: a study of antifungal susceptibility testing and virulence factors.

Citation: Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology, May 2013, vol. 33, no. 4, p. 378-383, 1364-6893 (May 2013)

Author(s): Kalkanç, A; Güzel, A B; Jabban, I I K; Aydin, M; Ilkit, M; Kuştimur, S

Abstract: Vulvovaginal candidosis (VVC) is a major problem for the female population worldwide, and considerably little is known about the difference between acute VVC (AVVC) and recurrent VVC (RVVC). We investigated the susceptibility to six antifungal agents and boric acid of *Candida* spp. isolated from vaginal cultures, as described in the CLSI document M27-A3, from 228 non-pregnant sexually active women (aged 18-49 years), and the virulence factors of these isolates. The isolates were derived from patients with AVVC (n = 64), those with RVVC (n = 125) and those without signs or symptoms (n = 39). In total, *C. albicans* was the most commonly isolated species (50%), followed by *C. glabrata* (35.5%) and other *Candida* spp. (14.5%). We observed slightly different minimum inhibitory concentration (MICs) for various antifungals among the species and study groups that could have potential therapeutic benefits for the treatment. Analysis of the virulence factors revealed that haemolytic activity is not involved in VVC pathogenesis but that germ-tube formation, adhesion to VECs, and proteinase and phospholipase production may be important in the pathogenesis of VVC.

Subject Headings: [Case-Control Studies](#)
[Adolescent](#)
[Humans](#)
[Candidiasis Vulvovaginal](#)
[Antifungal Agents](#)
[Index Medicus](#)
[Recurrence](#)
[Young Adult](#)
[Virulence Factors](#)
[Adult](#)
[Female](#)
[Middle Aged](#)
[Candida](#)
[Microbial Sensitivity Tests](#)

Source: Medline

Full Text: Available from *EBSCOhost* in *Journal of Obstetrics & Gynaecology*

84. 2nd National Congress on Medicinal Plants

Citation: Iranian Journal of Pharmaceutical Research, October 2013, vol./is. 12/(43), 1735-0328;1726-6890 (Oct 2013)

Author(s): anonymous

Language: English

Abstract: The proceedings contain 1453 papers. The special focus in this conference is on Medicinal Plants. The topics include: Repellency effects of commercial formulation of eucalyptus extract on red flour beetle, *tribolium castaneum* herbst; antifungal effects of fennel oil on the growth of *aspergillus flavus*; in vitro antifungal affects essential oil of *origanum vulgare* L. and comparison with synthetic thymol on *aspergillus flavus*; antimicrobial activity of *avicennia marina* extract against *staphylococcus aureus*; antimicrobial activity of *avicennia marina* extract against *escherichia coli*; study of milk thistle (*silybum marianum* L) germination attributes and seed vigor under salinity stress by osmopriming accelerators; evaluation of hesperidin flavonoid in different tissues

during fruit development of limon (*C. limon* Cv. eureka); inhibitory effect of tea tree oil and aloe vera leaf gel shampoo on *malassezia furfur*; effect of gamma irradiation on antioxidant and antimicrobial activities of *echinacea* (*echinacea purpurea* L.); development of a validated high pressure liquid chromatography method for simultaneous determination of stevioside and rebudioside A in sweeteners; allelopathic potential of madder (*rubia tinctorum*) extracts on field bindweed (*convolvulus arvensis* L.) and corn (*Zea mays* L.) germination characteristics; suppressing effects of rhubarb (*rheum ribe*) extracts on purslane (*portulaca oleracea*) and alfalfa (*medicago sativa*) seedling growth; effect of dormancy breaking treatments on germination characteristics of acacia (*Albizia Lebbeck*); investigation of chemical essential oil components of *Chaerophyllum macrospermum* in Kandovan; evaluation effects of antimicrobial thyme essential oil on loads microbial and qualitative characteristics of fresh-cut carrot (*Daucus carota*) in duration storage; the study of effects of *Berberis vulgaris* hydroethanolic extracts on serum bilirubin level and enzymes of the liver in male cholestatic rats; the effect of aqueous extract of *Allium sativum* on behavioral changes in parkinson male rat; investigation of chemical essential oil components of *Thymus eriocalyx* in Peresk area (in Alashtar-lorestan province); investigation of chemical essential oil components of *Thymus lancifolius* in Zagheh area (in Lorestan province); effect of different soil series and manure application on dried flower yield, essential oil and chamazulene content and essential oil yield of German chamomile; effect of manure application on essential oil content, essential oil yield and chamazulene content of German chamomile in different soil series of Chaharmahal-Va-bakhtiari province; chemical compositions and antimicrobial activity of essential oil of *Phlomis cancellata* Bunge from Mazandaran; effect of *Ruta graveolens* extract on histopathologic changes in mice livers; composition of free and glycosidically bound volatile components of *Achillea tenuifolia* Lam. root; study gene expressions of cinnamyl alcohol--dehydrogenase, lignin and lignan compounds at different organs of *Linum album*; antiproliferative effects of *Ferula gummosa* extracts on different cancer cell lines; investigation antibacterial activity of essential oils from plant family Lamiaceae on tree bacterial species; effects of biologic and organic fertilizers on *Mentha piperita* in hydroponic condition; investigate effect of different nursery bed on marcotting rosemary cutting; comparative studies on phosphomolybdenum assay, DPPH and reducing power antioxidant properties in microshoots of five Persian walnuts; the effects of salinity on soluble sugars and proline in the medicinal plant *Borago officinalis* L. on the hydroponic conditions; the effects of salinity on chlorophyll content and growth of *Borago officinalis* L.; introduction of medicinal plants in the upper Giyan region in Tafresh area; comparative study of anti-inflammatory effects of *rubia tinctorum* L. extracts in carrageenan-induced paw edema in rats; effect of microwave radiation on seed germination and seedling growth of thyme; effect of B vitamins on germination factors of fennel; introduction of medicinal plants of Ashtian mountain protected area; effect of NaCl and gibberellic acid on seed germination and seedling growth of 5 medicinal plants; investigation of medicinal plant consumption in Khorram Abad township viewpoint herbal grocery; effect of different levels of irrigation and plant growth promoting rhizobacteria on grain yield and root change of chamomile (*matricaria recutita* L.); effect of bio-fertilizer on germination and seedling of chamomile (*matricaria recutita* L.) cultivars; antimicrobial effects of alcohol extract of *Curcuma longa* L. on some of bacteria; antioxidative, antimicrobial and cytotoxic activities of *Kunstlerone* from *Beilschmiedia* species; alkaloidal compounds from bark of *Beilschmiedia*; bioactivities of *Kunstleramide* as a dienamide from Lauraceae family; alkaloidal natural products in the leaf of Malaysian *Beilschmiedia*; identification of agronomic traits influencing seed yield of some Iranian fenugreek (*Trigonella foenum-graecum* L.) ecotypes; the effect of salinity stress on germination in *Dracocephalum moldavica* seeds; study of genetic diversity in Persian shallot (*Allium hirtifolium*) based on morphological traits; amount of micro and macro elements in leaves of medicinal plant *Calendula officinalis* L. with foliar application of bio-stimulators; the effects of different nitrogen levels on yield, yield components and oil percentage of spring safflower cultivars in Kerman, Iran; protective effects of green tea on antioxidative biomarkers in chemical laboratory workers; effect of IBA as a root promoting hormone and bio-fertilizers in propagating of *Lavandula* (*lavandula officinalis*) by cutting; shoot initiation of bistort (*Polygonum bistorta*) explants under in vitro condition; antihypertensive effect of celery seed on rat blood pressure in chronic administration; investigation of salicylic acid and kinetin effects on seed germination and seedling growth

of lemon balm (*Melissa officinalis* L.) under salinity stress; investigation the amount of fiber and phenolic compounds in *Sclerorhachis leptoclada* from south Khorasan; the effect of different super absorbent polymer and drought stress on grain yield and essential oil of chamomile; the effect of strains of *Pseudomonas* on growth and development of root in thyme (*Thymus vulgaris* L.); isolation, structural characterization and antioxidant activity of a new water-soluble polysaccharide from *Acanthophyllum squarrosum* roots; the study of polyphenols profiles, carbohydrates content and antioxidant capacities in *Sophora pachycarpa* C. A. Mey; evaluation of nutrient content (crude protein, fat content, crude fiber, neutral detergent fiber and acid detergent fiber) and heavy metals in *Sophora pachycarpa* C. A. Mey; effects of mulching on quantity and quality yield of garlic populations (*Allium sativum* L.); study of different weed management methods of thyme (*Thymus vulgaris* L.); effect of humic acid and vermicompost on flower yield, seed yield and yield components of safflower in Kerman, Iran; introduction of medicinal plants of Zalian area in the city Sareband located in the Markazi province; effect of wormwood (*Artemisia absinthium*) essential oil on antioxidant status and lipid peroxidation in broiler chickens; effect of essential oil of cumin (*Cuminum cyminum*) medicinal herb on antioxidant status, lipid peroxidation and serum metabolites in broiler chickens; effect of different salinity levels on germination and early seedling growth of medicinal plant *Capparis spinosa* L.; studies on seed germination and seedling growth in *Mentha longifolia* L. under abiotic stress conditions; evaluation of heavy metals in some medicinal plants growing in Sistan region; antibacterial activity of *Teucrium polium* essential oil against clinical isolates of *Klebsiella pneumoniae*; the effect of methanol and nano-iron chelate fertilizer on chlorophyll content, some morphological and agronomical traits of *Ocimum basilicum* L.; new trends in the utilization of medicinal and aromatic plants; response of anticancer compounds to nitrogen fertilizer in *Naein-E Havandi* (*Andrographis paniculata*); photosynthesis and antioxidative systems of *Naein-E Havandi* (*Andrographis paniculata*) as affected by compost tea rates; effects of water stress (drought) on the mineral and vitamin content of the leaves of a medicinal plant *Brassica rapa* L.; the effects of hydroalcoholic extract of *Nigella sativa* on the activity of liver enzymes in female rats; influence of some environmental factors on the morphological traits of *Thymus daenensis* Celak; improvement of solvent systems in TLC chromatography of flavonoids from leaves of *Glycyrrhiza glabra* L. and *Fritillaria imperialis* L. using a software system; distribution of spirulina the blue-green gold of Iran; electrobotany of medicinal algae of Iran; introduction to engineering for medicinal plants of Iran; the sites and medicinal plants of Iran; the importance for aquatic medicinal plants of Iran; the prospects and challenges for algae therapy in Iran; optimization of microencapsulation of pomegranate seed oil by response surface methodology; effect of sucrose concentration on the growth and trigonelline production in hairy root culture of Iranian fenugreek (*Trigonella foenum-graecum* L.); investigation the sustainability of mazooj gall and its inducer agent wasp in oak forests of West-Azerbaijan; volatile oil of *Artemisia santolina* decreased the morphine withdrawal jumping in mice; species diversity and distribution of the medicinal galls by oak gall wasps species in West-Azerbaijan; identifying the best time to harvest of mazooj gall in oak forests of West-Azerbaijan province; bioactive sesquiterpene lactone from *Artemisia santolina*; presence of monoterpene synthase in four Labiatae species and SPME- GC-MS analysis of their aroma profiles; monoterpene synthase from *Lavandula angustifolia* and solid-phase microextraction- gas chromatography-mass spectroscopy analysis of its aroma profile; antioxidant and hydroxyl radical scavenging activity of *Phoenix dactylifera* L. var. *deyry* fruit and seed; GC/Mass analysis of the volatile compounds of *P. hyrcanicum* diethyl ether extract and GC profiling of some Iranian *Polygonum* species; effects of sowing date in spring and summer, and various amounts of vermicompost on growth and yield of fenugreek; effect of salt stress on germination factors of lemon balm (*Melissa officinalis* L.); chemical composition and antioxidant activity of essential oils of three Iranian herbs (Apiaceae family); effects of drought stress and different nitrogen levels on the quantitative and qualitative yield of black cumin (*Nigella sativa* L.) in Sistan region; evaluation of free radical scavenging activity of plant extracts and essential oil of *Mentha aquatica* L.; analysis of volatile oil components extracted by SDE technique and antioxidant activity of oily components of "water mint"; analysis of the essential oil components of *Mentha aquatica* L. collected in Tehran province; changes in oil yield and chemical components of the essential oil of *Satureja bachtiarica* Bunge under five drying methods; effects of cold stress and seed scratching on seed

germination and some growth related characteristics of wild pistachio (*pistacia atlantica* Desf.); evaluation of medical and pharmaceutical effects of extract bark of tree species beech, spruce and oak; callus induction evaluation of two Iranian native seashore iris subspecies, using different explants through in vitro culture; effect of drought stress in different growth stages on some of morphological traits of peppermint (*mentha piperita* L.); effect of osmopriming on seed germination of *osimum basilicum* under drought stresses; chemical constituents of the essential oil of *artemisia aucheri* Boiss from high altitude of Chaharmahal va Bakhtiari; study of effects on wounds healing of rhubarb extract in rat; local effect of eugenol oil on the skin wound healing in rat; comparison of carvacrol level and antibacterial properties of industrial and laboratory extracted essential oils of the wild and cultivated *satureja khuzestanica*; effect of phytohormones on composition of *sambucus nigra* L. essential oil; oleuropein extracted from olive tree leaves maceration and Soxhlet method and measured with high performance liquid chromatography; the effect of salinity stress from NaCl on seedling growth of *docrosia anethifolia* herb in hydroponic irrigation condition and determination its salinity tolerance threshold; investigation of in vitro apocarotenoid gene expression in perianth of saffron (*crocus sativus*) Iran; effect of height on hypericin content of St. John's wort; effect of *elaegnus angustifolia* L. hydroethanolic leaf extract on serum triglycerides, LDL, HDL and total cholesterol of male rats; the investigation of the some chemical components of volatile oil of four species *MINT* leaves in the various growth stages; antifungal activity of the essential oil of *salvia virgata*; evaluation of the effect of organic fertilizers and mulch application on growth, development, essential oil content, and microbial load in peppermint (*mentha piperita* L.); the comparison GC and GC-MS of *allium ampeloprasum* L. var. *atroviolaceum* Regel and *allium italicum* Wendelbo (Wendelbo); in vitro antimicrobial activity of *allium ampeloprasum* L. var. *atroviolaceum* Regel; effect of methanol and nano-iron chelated fertilizer application on activity of polyphenol oxidase, glutathione peroxidase and essential oils content in basil (*ocimum basilicum* L.); diterpene compounds in essential oils of *juniperus excelsa*; in vivo effect of *melissa officinalis* essential oil on growth and aflatoxin production by *aspergillus flavus* isolated from stored corn; clinical acute toxicity information of *mentha longifolia* essential oil investigation of medicinal plant consumption in Khorram Abad township viewpoint customers; evaluation of different drying methods on essential oil and chamazulene contents of chamomile flowers; study of different drying methods on qualitative characteristics of thyme; analysis of seed germination in two medicinal species of *salvia* under different chemical treatments; the survey on effects of irrigation and weed control on yield, yield component and seed oil contents of marigold (*calendula officinalis* L.); the survey on effects of nitrogen fertilizer application and density on seed yield, yield components and oil content of marigold (*calendula officinalis* L.); evaluation of antiradical activity and antioxidant capacity of methanolic extract of gorg tigh plant (*lycium ruthenicum* Murry); determination of total phenolic, tannin and flavonoid content in *lycium ruthenicum* Murry; anticonvulsive effects of vitexin, a flavonoid, on pentylenetetrazole-induced seizure in rats; correlation and path coefficient analysis of seed yield and yield components of flax; effect of NO on Fe deficiency-induced chlorosis in *melissa officinalis*; effect of *valeriana officinalis* on FSH and estrogen in female mature rats; investigation of antioxidant enzymes activities, soil texture, and stigma-like structures in petals culture of saffron (*crocus sativus* L.); phylogenetic analysis of the tribe *Fabeae* based on plastid DNA sequences; effect of UV-C radiation on some physico-chemical on pomegranate in warehouse (*punica granatum* L.); preparation of nanoniosomal paclitaxel formulation and evaluation its effects on the breast cancer cell line (MCF-7); heavy metal accumulation in medicinal plants *chenopodium album* collected from environmentally different sites; aerial parts flavonoids of *eleocharis uniglumis* (Link) Schult. (Cyperaceae); root flavonoids of *cyperus* L. (Cyperaceae) species in Markazi province, Iran; antibacterial activities of *euphorbia splendida* Mobayen (Euphorbiaceae); chemical constituents of *artemisia kopetdaghensis* Krasch; antimicrobial activity and essential oil composition of *thymus transcaucasicus* Ronniger; chemical composition and antibacterial activity of essential oil of *nepeta asterotricha* Rech. f. from Iran; the study of the essential oil constituents of various species of the mint flower in the flowering and after flowering stages; cadmium increase glycyrrhizic acid content in *glycyrrhiza glabra* var. *glandulifera* Calli; the effect of salicylic acid on anthocyanin content in licorice; silymarin attenuated thymicophenolate mofetil-induced villous

atrophy and lipid peroxidation in the duodenum of rat; effect of *Cynara scolymus* on the fat metabolism under heat stress condition in broiler chickens; compare of the *Crataegus* extract and nimodipine effect on passive avoidance learning of male wistar rats; NAA and IBA as plant growth regulators for micro propagation of *Thymus vulgaris* L.; recycling preparative high performance liquid chromatography for separation of the curcumin from curcuminoids present in *Curcuma longa* L.; in vitro micropropagation of *Lavandula angustifolia* L.; evaluation on the effects of nitrogen and potassium fertilizers on growth and yield of roselle (*Hibiscus sabdariffa* var. L.) in Iranshahr; biological activities of *Stachys kermanshahensis* Rech. f. essential oil; effect of olive leaves as a phytobiotic feed additive on performance, antioxidant status and ascites mortality reduction in broiler chickens; streptozotocin-induced diabetic rats; effects of environmental factors on rooting of (*Pistacia mutica*) micropropagation; studies on bacterial contamination of *Pistacia mutica* seeds and leaves through DNA fingerprinting; evaluation of the use of herbal medicines by the people in the Karaj city; investigation on development and promotion of herbal medicines in Karaj pharmacies; in vitro culture of *Pistacia mutica* (baneh); the effects of red dried stigmas of *Crocus sativus* L. flowers (saffron) on growth and maturation of oocytes in female three spot gourami (*Trichogaster trichopterus*); foliar application of salicylic acid changes essential oil content and compositions of peppermint (*Mentha piperita* L.); chemical composition and biological activities of *Salvia compressa* essential oil; evaluation of salicylic acid on tolerance to salt and alkali stresses in peppermint (*Mentha piperita* L.); evaluation of growth response in *Echinacea purpurea* to application of zinc sulphate under drought stress; evaluation of the *Achillea millefolium* effect in nausea and vomiting of early pregnancy; the insecticidal effects of *Laurus nobilis* and *Myrtus communis* essential oils against immature stages of *Ephestia kuehniella* Zeller; chemical constituents of the essential oil of *Tanacetum persicum* (Boiss.) Mozaff from Kallar mountain; chemical composition of the essential oil of *Valeriana sisymbriifolia* Vahl from Kallar mountain; the oviposition deterrence of two plant essential oils from, *Laurus nobilis* and *Myrtus communis* on the adults of Mediterranean flour moth, *Ephestia kuehniella* Zeller; the medicinal effect of lavender on nervous system; influences of salicylic acid and drought stress on growth characteristics of *Thymus daenensis* Celak; study of tissue culture and callus induction in *Papaver bracteatum*; root and shoot growth of isabgol (*Plantago ovata*) under organic manure, phosphate bio-fertilizer and chemical fertilizer treatments; analysis of the volatile compounds in *Origanum vulgare* L. subsp. *viride* using HS-SPME-GC-MS and comparison with conventional method; effect of *Calendula officinalis* powder on broiler chickens weight and lymphoid organ weights under heat stress condition; diversity of chemical compositions of essential oil of various landraces of *Cuminum cyminum* L. from northeast Iran; enhancement of extracellular baccatin III production and *Dbat* gene expression in cell suspension culture of *Taxus* treated by methyl jasmonate; jasmonic and salicylic acid effects on chemical composition of *Melissa officinalis* L. oil; effect of essential oil of *Thymus daenensis* Celak, *Satureja bachtiarica* Bung and *Ziziphora clinopodioides* Lam on hematological parameters in rats; effects of plant density on yield, yield components of medicinal plant coneflower (*Echinacea purpurea*); comparison on quality and quantity of essential oil six cultivated *Thymus* species at before flowering and full flowering stages; ecological investigation of 10 aromatic plant species of Asteraceae family in Yazd province; survey on phenology and acclimatization some *Thymus* species in field; the effect of salinity on seed germination and early seedling growth *Satureja bachtiarica*; survey on quality and quantity of essential oil cultivated accessions of *Thymus lancifolius* in province Yazd; survey on quality and quantity of essential oil cultivated accessions of *Thymus kotschyanus* in province Yazd; study of the effect of hydroalcoholic extract of walnut leaves on blood factor changes of LDL, HDL, triglyceride and full cholesterol in female hypercholesterolemic rabbits; effect of different biofertilizers on some physiological of three ecotypes of hemp under saline soils and saline waters; evaluation the response of inoculation black cumin seed (*Nigella sativa* L.) with *Azospirillum* and *Azotobacter*; effect of spraying amino acid on thymoquinone, carvone and yield of black cumin (*Nigella sativa* L.); the effect of salinity stress on germination and plantlet growth of safflower medicinal plants genotypes; inhibitory effect of medicinal plant aqueous and ethanolic extracts on *Alternaria solani* mycelial growth; solvent effects on extraction and determination of the isoflavone daidzein in soybean and its extracts by high-performance liquid chromatography; hawthorn berries hydroalcoholic extract with high triterpenic acid content reduces the

experimentally-induced colitis damages in rat; in vitro establishment and control of browning in seedless berberis vulgaris; effect of different nursery bed on lavandula's marcotting; the effects of allium hirtifolium boiss. on cardiovascular risk factors in hypercholesterolemic rabbit; comparing various methods of seed and embryo culture and charcoal effect in optimizing in vitro culture of ferula assa-foetida; comparative pollen morphology of the genera allium and calochortus of order liliales; the effect of salinity stress on seed germination and seedling growth in desert rod (eremostachys laciniata (L.) bunge); the antibacterial effect of the total methanol extract of the petal and stamen of saffron flowers (crocus sativus) against five bacterial food borne strains; allelopathy effects of lavender, absinthium and walnut on germination and growth of convolvulus arvensis, portulaca oleracea and triticum aestivum; protective effects of ocimum basilicum L. (basil) on electrocardiogram, cardiac function and histopathology in isoproterenol induced myocardial infarction in rats; study of the medicinal plants biodiversity species of dashtestan county in bushehr province; determination of total phenolic content in two extracts from cruciferous plants and its correlation with their antioxidant capacities; study of the primary ethnobotanical of genaveh county in bushehr province; allelopathic effect of different concentrations of caraway essential oil on germination characteristics in amaranth and barnyardgrass; antibacterial activity of polyphenol and anthocyanin-rich extracts of thymus kotschyanus aerial parts; antioxidant activity of flavonoid-rich fraction from thymus kotschyanus aerial parts; effect of different levels of nitrogen fertilizer on essential oil component in "dicrosia anethifolia"; computational identification of novel conserved microRNAs, and their targets in eucalyptus grandis; evaluation of digitalis nervosa performance in northern parts of Iran; allelopathic potential of galbanum different tissues on germination traits and preliminary growth of lambsquarters; effect of irrigation intervals and phosphorous content carvacrol and essential oils of thymus vulgaris L.; the role of the use of the phosphorus and duration of irrigation on yield and thymol of thymus vulgaris L.; the comparison between arbuscular mycorrhizal and salicylic acid on some antioxidant compounds in ocimum basilicum L. under salinity stress; evaluation of different drying methods on essential oil and estragol contents of tarragon; comparison between foeniculum vulgare and vitex agnus castus on ovulation in three spot gouirami; design and fabrication of magnetic nanoparticles for herbal medicine delivery applications; chemical composition and biological activities of phlomis rigida labill essential oil; polymer coated magnetic nanoparticles as a novel carrier in curcumin nanomedicine; effect of altitude on the rutin and chlorogenic acid content of sambucus ebulus leaves in golestan province; the effect of irrigation interval and plant density on the amount of active ingredient linoleic acid and oleic acid in the oil of black cumin (nigella sativa); the effect of drought stress on some biochemical and physiological parameters of the lippiacitriodora; silymarin regulates pharmacokinetic of atorvastatin in diabetic rats; effect of salicylic acid and nitric oxide on germination and subsequently seedling growth of borage officinalis under drought stress; determination the critical period of weed control in medicinal plants of safflower (carthamus tinctorius) cultivar sofe in the arak; determination of heavy metals in lycium ruthenicum murry plant; effect of magnetic field and nano-particles of titanium dioxide (TiO_2) on seed germination and seedlings early growth of ajowan (ammi copticum L.); effect of Si nano-particles and magnetic fields on seed germination and seedling growth characteristics of (securigera securidaca L.); determination of total phenolic, flavonoid contents and antioxidant activity in aqueous and alcoholic extracts of crocus sativus L. stigma; effect of different nitrogen sources on quantitative and qualitative characteristics of parsley (petroselinum crispum mill.) in jiroft region; woody branch and leaf anatomy of two subspecies of fraxinus angustifolia vahl.(oleaceae) in Iran; the effect of nutrition with microelements on yield of rosa damascena mill; the application of medicinal plants, antibiotic and their effects on serum composition in broiler chickens; effect of bio-fertilizers and micronutrients on germination characteristics of ajowan (carum copticum); effect of hydroalcoholic effect of citrullus colocynthis fruits on cysts of giardia lamblia in vitro; evidence of antifungal activity of madder (rubia tinctorum L.) on some fungal plant pathogens; diversity of chemical compositions of the essential oils of wild populations of myrtus communis L from khuzestan and lorestan provinces, southwest Iran; antimicrobial effects of zingiber officinale; extraction of volatile compounds of thymus vulgaris L. by microwave radiation and comparison with hydrodistillation method; response of costmary (tanacetum balsamita) to foliar application of urea and

amino acids; influence of iron on the accumulation of some medicinal compounds in parsley; evaluation of cytotoxic effect of nanoliposomal 6-gingerol on breast cancer MCF-7 cell line; evaluation of gingerol extracted from *Zingiber officinale* against breast cancer; effect of growth regulators on callus induction in saffron; fumigant toxicity of two essential oils on the mediterranean flour moth, *ephestia kuehniella* zeller and identify of their chemical component; effect of different drying methods on drying time and essential oil content of anise hyssop (*agastache foeniculum* L.); chemical constituents of the essential oil of *tanacetum kotschy* (boiss.) from kallar mountain; chemical composition of the essential oil of *heracleum lasiopetalum* boiss leaves; chemical composition of the essential oils of wild populations of *myrtus communis* L from chaharmahal va bakhtiari provinces, Iran; red clover hydroalcoholic extract with high phenol content scavenges free radicals; the parthenolide concentration of *tanacetum parthenium* in culture condition; a study on trace elements and heavy metals purchased in camel's thorn manna, willow manna, pocks pray manna, oak manna from selected market in Tehran; effect of salicylic acid and salt stress on organosulphur anticancer compound in broccoli sprouts; investigation the cardinal temperatures of sagebrush (*artemisia abrotanum*) and artichoke (*cynarascolumus*); the effects of time harvesting and irrigation intervals on the active ingredient of stinging nettle (*urtica dioica* L.) leaf; effect of shallot extract on fat quality of silver carp (*hypophthalmichthys molitrix*) paste during frozen storage; the effects of mycorrhiza and thiobacillus inoculation and sulfur application on garlic (*allium sativum*) growth; analgesic property of aqueous extract of *ajuga chamaecistus* ssp. *tomentella*; analysis of diosgenin in wild yam extracts by high-performance liquid chromatography; evaluation of UV-B effects on morphological and physiological characteristics of two cultivars of coriander (*coriandrum sativum* L.); determination of fatty acid profile in the oils of *cydonia oblonga* and *mespilus germanica* by NMR techniques; comparative survey effects *coriandrum sativum* and *ziziphora clinopodioides* powder in dietary onrbc, HB, HCT in common carp (*cyprinus carpio*); furanocoumarins from root of *prangos ferulaceae*; performance and blood parameter of broiler chickens given clove powder and essential oil reared under heat stress; study the effect of salt stress on some morphological and biochemical parameters of artichoke under invitro conditions; the study of different hormones level in callus production in garlic (*allium sativum*) tissue culture; evaluation of phenolic compounds contents and antioxidative activity in leaf and seed of (*peganum harmala* L.); effect of pectic acid (PA) on induction of apoptosis via no release in human prostate cancer cell line DU145; hypoglycemic effect of hydroalcoholic extract of *parstinaca sativa* seeds in normal and streptozotocin induced diabetic rats; effect of apple pectin or pectic acid and modified citrus pectin on no release and inhibition of cell proliferation in rat pituitary tumor cells GH3/B6; hypolipidemic effect of hydroalcoholic extract of *parstinaca sativa* seeds in normal and streptozotocin induced diabetic rats; stem anatomical structure in *stellaria* (*caryophyllaceae*) in Iran; effects of hydroalcoholic extract of *parstinaca sativa* seeds on activity of liver enzymes in normal and streptozotocin induced diabetic rats; assessment of salinity tolerance in Iranian fennel landraces in seed germination stage; effect of seed priming by salicylic acid on germination improvement and seedling growth parameters in garden cress (*lepidium sativum*) under saline conditions; investigation of different concentrations of Fe ions on rosmarinic acid biosynthesis in *melissa officinalis*; assessment of drought tolerance in Iranian fennel landraces in seed germination stage; role of mucilage in germination of medicinal plants; investigation of flavonoid content and anti-oxidant enzymes activity in *tristedmelissa officinalis* seedling with Fe ions; study of some characteristics related to primer after using rapid marker in order to evaluation of genetic diversity among *cuminum cyminum* L. accessions; the evaluation of vitamin C, anthocyanin and flavonoid in three cultivars of pomegranate in mazandaran province; in vitro evaluating the effect of heavy metals on germination and growth parameters of some medicinal plants; study the effect of seed priming by plant growth regulators on seed germination and seedling growth criteria in *matricaria aurea*; the effect of hydro alcoholic extract of *glycyrrhizaglabra* on some electrocardiogram parameters and its interaction with nitric oxide system of male rat; the effect of *campylobacter jejuni* vaccine and extract of *echinacea purpurea* on colonization of *campylobacter jejuni* in gastrointestinal of broilers; the effect of organic acid, probiotic, and *echinacea purpurea* application on *campylobacter jejuni* colonization in gastrointestinal of broilers; effect of resveratrol on teratogenicity in experimental model of preeclampsia in rat; microwave and ultrasound assisted hydrodistillation of

rosemary antioxidants and comparison with conventional hydrodistillation; antibacterial activity of salvia limbata essential oil; nano Cu and Zn application affect phenolic compounds production in licorice seedlings; evaluation and comparison of anti-inflammatory and analgesia effects of three plants tanacetum parthenium, anethum graveolens L., apium graveolens (celery); effect of organic and chemical fertilizers on yield and essential oil on two savory (satureja hortensis L.) ecotypes, under drought stress condition; effect of aqueous and ethanolic extracts of nigella sativa seeds on milk production in rats; study the effect of natural compounds and essential oils of medicinal plants on improving maintenance of fresh cut cucumber; study of cell cycle changes in human prostate cancer cell line DU145 after treatment with combination of beta-glucan and doxorubicin; the effects of different temperatures and osmotic potentials on germination of scrophularia striata; effect of melissa officinalis hydro alcoholic extract on liver enzymes ALP, AST, ALT in mice; effects of echinacea purpurea, levamisole and propolis on serum biochemical metabolites in broiler chicks; effect of nanosilver particles on medicinal plant germination index of cumin (cuminum cyminum); effect of phytobiotic collected by honey bee on intestine morphology in broiler chicks; the effect of information and communication technologies (ICT) and technology on sustainable agriculture; analysis of the effect of different concentrations of Fe ion on the biosynthesis pathway of sulforaphane in lepidium draba seedlings; isolation and determination of sulforaphane from lepidium draba; biomass and essential oil content of spearmint (mentha spicata L.) harvested in different months in semi tropical climate; the effect of salt stress on aloe vera; effect of nitrogen different levels on yield and mucilage content of isabgol (plantago ovata L.); changes in essential oil content of myrtle myrtle (myrtus communis) during different months of year in ahvaz condition; evaluation of qualitative and quantitative yield of isabgol affected by different vermicompost levels; optimization of atropine extraction process from atropa belladonna by modified bubble column extraction with ultrasonic bath (BCE-UB) method; effect of salicylic acid on quality and essential oil components of moldavian balm (dracocephalum moldavica L.); the study of two ecotypes of german chamomile (matricaria chamomila) in climatic condition of ahvaz; study of seed and biological yield and mucilage content of isabgol affected by different cow manure amounts; effect of arbuscularmycorrhiza on content of essential oils in mint; phylogeny of tanacetum L. sect. xanthoglossa based on CpDNA Ndhf-Rpl32 spacer sequences data; a new method based on the UV-visible spectroscopy for quantitative analysis of atropine in biological extracts; inhibitory effect of helichrysum arenarium L essential oil on growth of food contaminated fungal; marketing the medicinal plants products based on its qualities; antifungal activity of essential oil of ziziphora clinopodioides L; liquoric triterpenoids transport via CaCo-2 cells monolayer; phylogenetic relationships of some spiny astragalus (astragalus, fabaceae) using nrDNA sequences; silymarin down regulated the varicocele-induced protein oxidation and E2F1 expression in the testis; pollen morphology of some silene species of lasiostemon section in Iran; effect of different cultivars on naringin and hesperidin flavonoid contents in different fruit parts on citrus aurantium rootstock; a study on total chlorophyll content in leaves of daucus carota L. grown in two provinces of Iran and its correlation with some meteorological parameters and carotenoids levels; evaluation of agronomic characteristics, seed germination mass of thyme (thymus vulgaris L.) by gibberellic acid and salicylic acid; comparison of total phenolic contents in three infusions of black tea; antifungal activity of the essential oil of salvia officinalis; effect of deficit irrigation and salicylic acid on free proline and some of physiological characteristics of basil (ocimum basilica L.); study the effect of strip intercropping patterns on morphological characteristics of bean and dill in tabriz region, Iran; effect of strip intercropping on leaf area index of bean (phaseolus vulgaris) and dill (anethum graveolens); germination improvement in tanacetum polycephalum; evaluation of medicinal organs of plant species in miankaleh; ecological studies of salvia sahandica; evaluation of medicinal flora in summer rangeland of arjmand in firozkoh; evaluation of medicinal flora in summer rangeland of arjmand in firozkoh; a new avenue for prediction of pseudo chamomile using decision tree; effect of salinity treatment on colocynth seedling growth; enzymatic treatment of aloe vera gel to reduce viscosity for pharmaceutical applications; effect of potassium nitrate priming on seed germination of colocynth; the effects of bio-fertilizers and bio-stimulators on chlorophyll content and leaves properties of ocimum basilicum L.; study of ocimum (ocimum basilicum L.) germination attributes and seed vigor under

salinity stress; the effects of drought stress on germination of thymus species (*T. Daenensis*, *T. Eriocalyx*, *T. Vulgaris*); the effects of bio-fertilizers and bio-stimulators on morphophysiological properties of *ocimum basilicum*; fumigant toxicity and median lethal time (LT50) on the immature stages of mediterranean flour moth, *ephestia kuehniella* zeller; fumigant toxicity and persistence of two medicinal plant essential oils from *laurus nobilis* and *myrtus communis* against adult stages of mediterranean flour moth *ephestia kuehniella* zeller; the effect of Pb on leaf of *matricaria chamomilla* in vegetative and reproductive stages; effect of different concentrations of colchicine on ploidy levels and morphology of *dracocephalum kotschy* boiss; application of natural essential oils, silver and copper nano-particles to extend the vase life of two carnation cut flower cultivars; effect of some bio and chemical fertilizers on some morphological characteristics and percent of root colonization of dill (*anethum graveolens* L.); evaluation of different sowing dates on yield and yield components in saffron (*crocus sativus* L.); the effect of elicitor methyl jasmonate on secondary metabolites of medicinal plant pot marigold (*calendula officinalis* L.); effect of coronatine pretreatment in basil plant (*ocimum basilicum*) subjected to arsenic toxicity on difference phenolic compounds and PAL activity; study of yield and yield components in different ecotypes of saffron (*crocus sativus* L.); effect of coronatine pretreatment in basil plant (*ocimum basilicum*); micro-morphological study of mericarp and seed in different *erodium* (*geraniaceae*) species of Iran; the effect of plant density and date of planting on total phenol and flavonoid of artichoke (*cynara scolymus* L.) in Gorgan and Ilam conditions; selenium improves growth and antioxidant defense system in *melissa officinalis*; interaction of the auxin hormone and rooting media in cuttings of the medicinal plant *myrtus* (*myrtus communis*); the influence of exogenous ABA on photosynthesis and antioxidative enzymes activity in *melissa officinalis*; the effect of application of phosphorus fertilizer and mycorrhizal fungus on yield, yield component and effective material of pot marigold (*calendula officinalis* L.); the effect of different sugar on rosmarinic acid production in *salvia reuterana* hairy root culture; cytotoxicity effects of *scorzonera grossheimii* Lipsch. & Vassilcz extract on HeLa cell line and MCF-7 cell line; evaluation of in vitro culture of Mohr-E Khosh medicinal plant species; the effect of antioxidant attributes of aqueous garlic extract in mice; evaluation of Mohr-E Khosh (*Zhmeriamajda* Rech. F. & Wendelbo) tissue culture; effect of BAP hormone treatment on in vitro shoot regeneration and proliferation of medicine herb *hyoscyamus reticulatus* L.; antioxidant activity of two sea cucumber species and brown algae from Persian Gulf; comparison of 1,8-cineole in the essence of four wild populations of yellow yarrow (*achillea wilhelmsii* Koch) in Fars province; the effect of planting date and harvest stage on growing indexes and percentage thymol in *satureja hortensis* L.; chemical analysis of hops (*humulus lupulus* L.) extract collected from Zarrin Gol zone, Golestan province, Iran; local effect of eugenol oil on the skin wound healing in rat; influence of manure, compost and biofertilizer on growth and yield of ajowan (*trachyspermum ammi* Sprague); variation of rutin content in caper leaves during their phenological cycles; the changes of hypothalamic hormones in PCOS rats that treated with aqueous fennel extract; the effect of aqueous and methanolic extract of caper leaf and GA³ on germination of *capparis spinosa*; effect of density on quantity characteristics of thymus species (*T. Daenensis*, *T. Eriocalyx*, *T. Vulgaris*) in dryland condition of Kermanshah; autecology and phenology study of *salvia leriifolia*; hairy root cultures of *salvia reuterana* transformed with *Agrobacterium rhizogenes*; comparison of *salvia* (*salvia sclarea* L.) accessions according to morphological traits, essence yield and chemical compounds; the evaluation effects of plant density and sowing dates on yield and yield components of black cumin (*nigella sativa*) under Ilam climate condition; investigation on morphology and root yield of chicory (*C. Intybus*) landraces for inulin production; effect of eugenol in the context of ethanol test microbial load on dairy cow; the effect of slope direction on morphological characteristics of *juniperus polycarpos* Koch needles; effect of thymol and carvacrol on two cultivars of cut gerbera flowers vase life; influence of arbuscular mycorrhizal fungi and salt stress on essential oil content of summer savory (*satureja hortensis* L.); influence of arbuscular mycorrhizal fungi on growth and morphological characteristics of summer savory (*satureja hortensis* L.) plant under salt stress conditions; antimicrobial activity of five plant essential oils on *Bacillus* sp.; study of protective effect of pollen in proportion to royal jelly on liver tissue in experimental polycystic ovary syndrome in adult female rats; curcumin nanomedicine; applications of beta-cyclodextrin in cumin

solubility enhancement; investigation of the effects of different rate of nitrogen and zinc on yield of chamomile (*matricaria chamomilla* L.); protective effect of parsley aqueous extract versus glyburide on diabetes-induced derangement in the ovary; evidence for follicular growth and biochemical alteration; phytochemical screening, antioxidant and burn healing potential of galium odoratum ethanolic extract; evaluation hydroalcoholic extract of plantago major leaf on sperm count and FSH, LH levels in streptozotocine (STZ) induced diabetic rat; the effect of indole butyric acid (IBA) and naphthalene acetic acid (NAA) on stem cuttings of myrtle (*myrtus communis* L.); effect of hydroalcoholic extract of descourainia sophia seed on sperm morphology and FSH, LH levels in streptozotocine (STZ) induced diabetic rat; determination of total phenolic, flavonoid contents and inhibitory effect of euphorbia spinidens methanolic extract against HSV1; effect of sesame oil (*sesamum indicum* L.) on sperm parameters in streptozotocine (STZ)- induced diabetic rat; improvement in germination and seedling growth of hyoscyamus squarrosus griff; recognition and usage of medicinal plants according to the views of local communities (sample studying of top taleghan in alborz province); comparison of morphological and agronomical traits of fenugreek (*trigonella foenum-gracum* L.) under drought stress and biostimulators in greenhouse and field crops; effect drought stress and biostimulators on morphological traits of fenugreek (*trigonella foenum-gracum* L.); endometrial changes in PCOS female rats that treated with aqueous fennel extraction; effect of priming on seed vigor and antioxidant enzymes activities in thyme (*thymus vulgaris* L.) under salinity stress; effect of potassium nitrate on some germination traits of balango (*lallemtiaroyleana* L.) under salinity stress; comparison of the essential oil components in wild and cultivate population of salvia lachnocalyx; effect of irrigation intervals on yield and yield components of degen & Drfi (*securiger securidaca* L.); the anatomical properties of alyssum (sect. *gamosepalum* dudley); comparison of the essential oil components in wild and cultivate population of salvia verticillata; comparison of the essential oil components in wild and cultivate population of salvia virgata; the effect of different kind of salt on seed germination and seedling growth of nigella sativa L. and guizotia abyssinica cass; high-frequency in vitro direct shoots regeneration from axillary nodal and shoot tips explants of clary sage (*salvia sclarea* L.); essential oil composition in stachys byzantina cultivated in Iran; antioxidant activities of the bark of pterocarya fraxinifolia L.; isolation and purification of terpenoids from aerial parts of echinophora cinerea; induction of salt stress resistance in foeniculum vulgar by application of hydro and halo seed priming; chemical composition of stem essential oils of pterocarya fraxinifolia L.; effect of sowing date and growing season on agronomical characters of isfahanian and indian black cumin; effect of different vermicompost levels and ecotype on growth parameters of basil (*ocimum basilicum* L.); the effect of bacterial inoculation on qualitative and quantitative yield of the aloe vera plant; triterpene constituents of euphorbia erythradenia boiss; evaluation of the effect of three biologic fertilizers on aloe vera plant; introduce some medicinal plants used for gastro-intestinal diseases in east-mazandaran region; histopathologic changes in rat liver treated with quercetin extracted from onion after infected by toxoplasma gondii; effect of growing media on rooting of stem cuttings in hana (*lawsonia inermis* L.); effect of colchicines treatments on some morphological and cytological characteristics of agastache foeniculum; antiradical, antioxidant and antimicrobial activities of crataegus elbursensis extracts; evaluation of some secondary metabolites in three olive genotypes and two harvesting time; ovicidal activity of essential oils from three plants against mould mite (*tyrophagus putrescentiae* schrank); role of mycorrhizal fungi and salicylic acid in resistance of ocimum basilicum L. to aluminum toxicity; investigation of histological effects of humulus lupulus on ovarian tissue of female three spot gourami; phenolic acid analysis and antioxidant activity determination of froriepia subpinnata; study of antimicrobial effect thyme and mint essential oils and edta, on staphylococcus aureus; the effect of corn oil on liberkuhn glands goblet cells secretion activity in rabbit; effects of elicitation on alkaloids production in suspension cell cultures of papaver somniferum; effect of plant growth regulators on in vitro culture of artemisia aucheri; effect of echinacea extract on parenteral lysozyme activity in serum of beluga (*huso huso*); survey of antimicrobial effect thyme and peppermint essential oils and edta, on salmonella typhimurium; total phenolic content, antiradical and antioxidant activities of eryngium caucasicum extracts; effects of plant growth regulators on callus formation fenugreek (*trigonella foenum-graecum* L.) of in vitro; influence of different concentration of 2,4-D and kinetin on callus formation milk

thistles (*Silybum marianum*) plants; the effect of nitrogen fertilizer and plant density on quantitative and qualitative characteristics of castor (*Ricinus communis* L.); evaluation of genetic diversity in some linseed (*Linum usitatissimum* L.) genotypes using EST-SSR markers; effect of altitude on some of the morphological characteristic and chlorophyll content of nettle in mazandaran and golestan conditions; evaluation of primers indices used in the study of genetic diversity of papaver macrostemum ecotypes via SSR marker; studies on the amino acids, flavonoids and total phenolics in ziziphus jujuba; comparison study of antibacterial effect essential oils oregano and cumin and EDTA on salmonella typhimurium by disc diffusion and broth microdilution MIC testing; comparison study of antibacterial effect oregano and cumin essential oils and EDTA on staphylococcus aureus by disc diffusion method and broth microdilution MIC testing; the study of antioxidant activity of phenol compounds inartemisia fragranswilld. and artemisia vulgaris L.; impact of planting patterns on weed density, and growth characteristics of caraway; effect of drying methods on essential oil contents and citronellal of lemon balm; a comparison on effect of the thiobacillus biological fertilizer and superabsorbent on the morphological traits and essential oil yield of thymus vulgaris t. daenensis; investigation of effect of different doses of hydroalcoholic extract of glycyrrhiza glabra's rhizom on the mechanical activity of isolated trachea of male rat; aloe vera gel concentration by reverse osmosis method (reduction energy consumption); the effect of drought stress on germination characteristics and preliminary growth of fleawort and purple coneflower; preparation of an herbal emulgel for treatment of hemorrhoids; effect of varying level of biological and chemical phosphors on same morphological traits summer savory (*Satureja hortensis* L.) plant; study on the technical efficiency in rose water industry in city of kashan, Iran; the effects of corn oil on colonic mucosal thickness in rabbit; estimation of the milk thistle oil percent by using stepwise regression; the effects of mycorrhiza, thiobacillus inoculation and sulfur application on some physiological parameters of garlic (*Allium sativum* L.); the study of some medicinal-chemical characteristics in four olive cultivars; allelopathic effects of citrullus (*Citrullus colocynthis* L.) extract on seed germination and seedling growth of ocimum (*Ocimum basilicum* L.); the effect of polyamines (putrescine, spermidin and spermin) on growth, yield and essential oil of moldavian dracocephalum L.; effect of different density levels on marigold yield; allelopathic effects of citrullus (*Citrullus colocynthis* L.) extract on seed germination and seedling growth of purslane (*Portulaca oleracea* L.); sterols from *Nizamudiinia zanardinii*, a brown alga of oman sea; analyzing of 4 medicinal plants essential oil's potential allelopathic activity on pigweed seeds (*Amaranthus retroflexus* L.) germination and growth; flavonol glycosides from *Paliurus spina-christi*; physiological responses of anise hyssop (*Agastache foeniculum* L.) to drought stress; potential allelopathic activity of 4 medicinal plants essential oil on lamb's-quarters weed seeds (*Chenopodium album*) germination and growth; humic acid counteracts the ecotoxicological effects of arsenic on seed germination and seedling growth parameters of savory; effect of different planting beds on yield and yield components of garlic (*Allium sativum* L.); the effect of cadmium on phenol and flavonoid contents in basil (*Ocimum basilicum* L.); yield and yield components of different species of *Lallemantia* Sp; effect of temperature and rosemary (*Rosmarinus officinalis* L.) essential oils in potato sprout inhibition and tuber quality after post harvest; comparison of anti-inflammatory and analgesic activity of the artemisia absinthium and its main component; improvement of antioxidant production in *Rosmarinus officinalis* by tissue culture; two new dammarane type terpenoids from *Geum heterocarpum*; absorption spectra of chlorophyll A and B and fresh weight of leaves in different ecotypes of *Lallemantia* Sp as affected by deficit irrigation; morphological investigation of hairy roots induced in *Hyoscyamus niger*; germination of *Balangu* (*Lallemantia royleana*) as affected by hydropriming and germination temperatures; yield potential assessment of cumin ecotypes under irrigated and water-stressed conditions; investigation of growth rate and antifungal effects of *Ganoderma lucidum* on plant pathogen karst (*Basidiomycota*); effects of artemisia dracunculoides on the clotting time; the effects of explants and growth regulators on callus induction of *Lippia citriodora* L., an important medicinal plant; aquatic and alcohol extract effect consideration of *Equisetum arvense* on the wound and skin inflammations amendment; the comparison the effects of humic acid and thiobacillus biofertilizer on morphological characteristics on two species of thymus (*T. Vulgaris* and *T. Kotschyanus*); antioxidant activities of some pepper (*Capsicum annum* L.) varieties phenolic extracts; antioxidant and toxicological evaluation of hydroethanol

extract of *Troglodytes buphthalmoides* aerial parts; aquatic and alcohol extract effect consideration of *Ephedra intermedia* on the wound and skin inflammations amendment; study on different levels of annatto seed meal (*Bixa orellana*) in the diet on some biological indices of rainbow trout (*Oncorhynchus mykiss*); cytotoxic evaluation of 24-hydroperoxy-24-vinyl cholesterol isolated from *Nizamuddinina zanardinii*, a brown alga from Oman sea; effects of salicylic acid on total phenolic and rosmarinic acid contents in lemon balm (*Melissa officinalis* L.) plants exposed to nickel stress; determination of total phenolic and scavenging activity of free radicals in 4 species fruits of Solanaceae; determination of antioxidant activities of two *Adonis* species; in vitro changes of chlorogenic and caffeic acids of artichoke under salin stress; effect of PGPR inoculation on the quality and quantity of summer savory (*Satureja hortensis* L.); the economic result of *Tragacanth astragalus* and sell product; two new diterpenoids from the root of *Salvia chloroleuca*; effect of putrescine spraying on the quality and quantity of summer savory (*Satureja hortensis* L.); effect of salicylic acid spraying on the quality and quantity of summer savory (*Satureja hortensis* L.); study of physiological and biochemical responses of saffron (*Crocus sativus* L.) to salt stress and alleviative effects of salicylic acid; the effect of selenium (So₂) on ionic content of *Melissa officinalis*; of gene flow and genetic differentiation among populations of species *Anthemis tinctoria* using peroxidase isozymes; evaluating the germination of *Artemisia* populations in different temperatures and polyethylene glycol; study of physiological and biochemical responses of saffron (*Crocus sativus* L.) to drought stress and alleviative effects of salicylic acid; a study of generative organs characteristics of *Avicennia marina* (Forsk.) Vierh (Avicenniaceae); histopathological changes of spleen in PCOS female rats treated with aqueous extraction of *Foeniculum vulgare*; semi-preparative LC-MS of taxane diterpenoids; influences of drought stress on seed germination parameters in (*Ruta graveolens* L.); fabrication of albumin nanoparticles contains model drug; optimization of in vitro regeneration of some *Salvia* species via nodal explants culture; medicinal and antioxidant properties of kernel and green shell among some pistachio genotypes; comparison of chemical constituent of essential oil of *Stachys lavandulifolia* Vahl from Kaboodarahang and Roodsar; effect of ecotype on total phenol and flavonoids content of *Sambucus ebulus* leaves; anticancer activity evaluation of the *Acinos graveolens* aerial parts; phenotypic variation of *Colocynthis* accession from different Iran geographical area of (*Citrullus colocynthis*); phenolic content and DPPH radical scavenging activity and total protein of Cucurbitaceae in Iran; the effect of water deficit and spraying on agronomic traits and yield of dragonhead; investigation of anti-inflammatory effect of N-hexane extract of leaves of *Ziziphora clinopodioides* Lam on NMRI male mice; evaluation of the antioxidant activity of the *Acinos graveolens* aerial parts from Qamsar area; the relation of traits in *Artemisia* of Tehran Province, Iran; study of different drying methods on essential oil and menthol contents of peppermint; genetic diversity among naked seed of *Cucurbita pepo* var. *styriaca* and comparison with other varieties of *pepo* species; effect of osmopriming with KNO₃ on seed germination of *Lallemantia royleana*; study on seed morphological markers of naked seed and other cucurbits to evaluate genetic variation; comparison of the effects of drought and salinity stress on fennel seed germination under hydropriming condition; evaluation of allelopathic activity of *Juniperus sabina*; effect of ethanolic extract of barberry root (*Berberis vulgaris*) on renal toxicity of the drug cisplatin; callus induction from different parts of milk thistle (*Silybum marianum* L.); anticancer activity of *Nigella arvensis*; radical scavenging activity and total phenolic content of three species of pear (*Pyrus* L.); effects of various salts on the germination of *Silybum marianum*; evaluation phenol and flavonoid level in seven genotypes of olive maturity; allelopathic potential of common mallow (*Malva sylvestris*) on the germination and the initial growth of blanket flower, Cock's comb and sweet william; mathematical study of *Dorema aucheri* extraction with supercritical carbon dioxide; cheminformatics study of natural thujone like compounds for pharmacologic activity; application of response surface methodology for the optimization of ultrasound assisted emulsification microextraction of fatty acids from pomegranate seed; study effect of parsley (*Petroselinum crispum*) as an abortifacient on pregnant rats; phytochemical study on dichloromethane extract of *Artemisia ciniformis*; comparison of the effects of drought and salinity stresses on linseed seed germination under hydropriming condition; salicylic acid and salinity effects on proline content and growth characteristics in *Thymus daenensis*; optimization of ultrasound assisted emulsification microextraction for separation of fatty acids of Iranian (Bandar Abbas)

Jatropha curcas seed; effects of dietary cinnamon oil (*Cinnamomum verum*) supplementation on growth performance in Japanese quail; phytochemistry study on medicine plant of *Artemisia sieberi* and assessing its allelopathic effect on *Agropyrum elongatum* seeds; optimization of media for in vitro callus growth of *Taxus baccata*; optimization of sterile treatments for in vitro culture of *Taxus baccata* and *T. brevifolia*; identification and medicinal characteristics investigation of some of the most important medicinal trees, shrubs and grass in Lorestan province (case study in Yaftehkouh, Khorramabad); haploid induction in medicinal pumpkin using gamma irradiated pollen technique; effect of thymus extract on meat quality in Japanese quail chicks; the effect of chamomile extract on reproductive system in male mice; the effect of biological and chemical nitrogen fertilizer on dry flower yield and essential oil content of *Calendula officinalis*; yield potential evaluation of different cumin ecotypes in different winter sowing dates; antibacterial activity of *Eremurus persicus* Boiss. leaves and flowers; effect of leaf kind on the secondary metabolites certain in olive (*Olea europaea* L.); extraction and identification of a new ester coumarin from *Ferula orientalis* roots; the effect of different levels of vermicompost on nutrients balance of *Dracocephalum moldavica*; a new PH-responsive polymer coated magnetic nanoparticles for loading and delivery of quercetin; the study of genetic parameter related of salinity tolerance in sunflower; amino-silane modified magnetic nanoparticles for loading and delivery of chlorogenic acid; study of correlation between yield and yield components of cumin under different irrigation intervals treated with iron chelate nano fertilizer; evaluation of effect attract moisture substances and organic fertilizers on quality and quantity yield of purslane (*Portulaca oleracea* L.) in Ahvaz region; gene mapping of quantitative trait for salinity tolerance in sunflower; changes in the amount of essential oil eucalyptus species grown in Qom and Behshahr, and its relation to morphological characteristics of leaves; study of antimicrobial effects of *Narcissus jonquilla* essence on common gram positive and negative bacteria (*E. coli*, *B. cereus*, *S. aureus*); the effect of different levels zeolite on carotenoid and chlorophyll of *Calendula officinalis* L.; the effect of lettuce hydro alcoholic extract on some blood parameters in mice; designing of herbal based inhibitory bioactive molecules for VEGFR in angiogenesis; the effect of harvest time and density on essence yield of biennial tarragon (*Artemisia dracunculoides* L.); study effect of organic, inorganic fertilizers and cutting on agronomic characteristics in common purslane (*Portulaca oleracea* L.); influence of calcium nitrate on the change of morphological characteristics and mucilage content of borage; effects of drought stress induced by polyethylene glycol on germination and morphophysiological characteristics of *Dracocephalum moldavica*; study of the chemical characteristics of some pomegranate cultivars in Mazandaran and Khorasan; the effect of optimum planting date and harvest stage on essential oil of *Satureja hortensis* in Saveh; the effects of boric acid and seed osmopriming on germination and early seedling growth of *Petroselinum crispum*; antioxidant activity of some extracts from aerial parts of *Ajuga reptans* L. ssp. *tomentella*; evaluation of silver nanoparticles influence on abscission and oil content of seed borage; effect of priming with polyethylene glycol and NaCl salinity on germination herb purslane (*Portulaca oleracea* L.); effect of altitude on some of the secondary metabolites of nettle in Golestan and Mazandaran conditions; Effect of sowing date and pattern on growth physiologic AI parameters of purslane (*Portulaca oleracea*) under Ahvaz climatic conditions; study on the tissue damage of oral administration of different doses of *Zataria multiflora* essential oil in Persian sturgeon (*Acipenser persicus*); effect of hormones and explant in callus induction and shoot organogenesis in tissue culture of *Echinacea purpurea*; antiaging effects of *Glycyrrhiza glabra*, *Hypericum perforatum*, *Silybum marianum* and mixture of them on D-galactose induced aging in male mice; assessment of some biochemical parameters in two *Rosa damascena* mill genotypes in dry cold weather conditions (case study of Semnan city); comparison of antioxidant properties *Mentha longifolia* L. *hudson* var. *chlorodictya* Rech.f. in Sabzevar and Gorgan; effect of growth regulators, explants source and light/dark condition on in vitro callus growth of *Artemisia vulgaris*; applicability of flavonoid spot profiles in taxonomic circumscription of *Fritillaria* L. species in Iran; optimization suspension culture of medicinal plant *Artemisia dracunculoides*; the effect of salinity on germination factors and growth of five medicinal plants (*Carthamus tinctorius*, *Carum carvi*, *Sesamum indicum*, *Foeniculum vulgare* and cultivated endive); investigation of exclusive and synergistic antibacterial activity of edible medicinal vegetables; kinetic

study of mechanism of an enzymatic reaction catalyzed with esterase enzyme; the concentration of parthenolide in native *tanacetum parthenium*; investigation on the effect of hormonal regulators on the adventitious shoot and root regeneration in *artemisia vulgaris*; effects of aloe vera cream on healing diabetic foot ulcer; antibacterial potential of some Iranian medicinal plant extracts on *pseudomonas aeruginosa*; survey of callogenesis by two *artemisia* species (*artemisia vulgaris* and *artemisia deracunculus*); enhancement of flavonoid content by squalenstatin and methyl jasmonate in cell suspension culture yew; screening of antibacterial effects of aerial shoot extracts from some medicinal vegetables; the correlation between malone dealdehyde (MDA) and proline content and stigma-like structures (SLSS) in tissue culture of saffron; a survey on the antibacterial properties of the *achille millefolium* against some pathogene bacteria; effect of biological and chemical fertilizer on morphological characteristics in two basil (*ocimum basilicum* L.) landraces; effect of *cinnamomun zeylanicum* neeson LH and estrogen in female rats; effect of arbuscularmycorrhizas on metals absorption on three genotype of *mentha spicata*; comparison the antibacterial activities of ajowan, black zira and cinnamon essential oils using agar diffusion method; investigation of *mentha pulegium* L. effects on broiler chickens; the economic estimate of the biological and chemical fertilizers cost toward biomass and essential oil yield in two basil (*ocimum basilicum* L.) landraces; expression profile of some genes involve in nicotiana benthamiana alkaloid biosynthesis pathway under abiotic stresses; ethnobotanical study of medicinal plant of sirjan district, province Kerman; evaluating antibacterial property of eucalyptus essence on superficial sores of grass carp (*ctenopharyngodon idella*) juveniles' skin; evaluation effect of medicinal plants intercropping with garlic (*allium sativum* L.) on garlic yield in ahvaz conditions; the effects of lead heavy metal on purslane (*portulaca oleraceae* L.) seed germination and seedling traits; effect of drought stress and plant growth promoting rhizobacteria (PGPR) on physiology basil herb; the effect of *salvia officinalis* on lipid peroxidation of kidney tissue in diabetic rats; study the ethnobotany of medicinal plants in arsanjan, fars province; study of in vitro culture in *foeniculum vulgare* mill explants; investigation of rutin content in black henbane (*hyoscyamus niger*) seeds from three different regions of Iran; effect of different drying methods on quality of artichoke leaf; the effect of magnified salin water on the phenolics and flavonoids compounds of artichoke leaves; effect of salicylic acid and salinity on morphological characteristics in *mentha piperita* L.; the study of phytochemistry and ecology of *origanum vulgare* plant in the region of mazandaran province; the effect of arbuscular mycorrhizal fungi on some growth factors and photosynthesis pigments of *juniperus excelsa*. M.Bieb.; the effect of vermicompost and nano chelated iron fertilizer on yield and growth of safflower; antioxidant activities of fractions from different parts of mangrove plant *avicennia marina* (forsk.) vierh.; evaluation antioxidant activity of leaf and seed extracts of *pimpinella anisum*; the effect of worm tea and nano iron fertilizer on saffron flowering; comparative study of total phenolic contents and antimicrobial activities for flowers, leaves and stems of *sophora mollis* backer; the effect of sowing dates on growth, yield and essential oil content of *ocimum basilicum* L.; antioxidant activity of methanol extract from aerial parts of *sophora mollis* backer from kashan; effects of Fe and Zn foliar application on growth *thymus vulgaris* L. and contents of thymol and carvacrol; green synthesis of silver nanoparticles using *scropholaria striata* L, *thymus daenensis* subsp. *lancifolius* and *artemisia annua* extracts; expression profile of some genes involve in nicotiana benthamiana alkaloid biosynthesis pathway under abiotic stresses; study on the potential of *vitex pseudo-negundo* to regulate the steroid hormone levels of rainbow trout (*oncorhynchus mykiss*) broodstocks fed with fishmeal-free diets; total phenolic content in gum tragacanth of *astragalus gossypinus* and *astragalus parrowianus*; effects of UV on anatomical structure in *viola tricolor*; the effect of biological fertilizer on essential oil weight percent and yield of *thymus pubescence*; field evaluation of nanoencapsulated *cuminum cyminum* essential oil on citrus red mite; evaluation of antioxidant compounds of *physalis alkekengi* in different phenological stages; comparative analysis of headspace volatiles of Iranian damask rose genotypes (*rosa damascena* mill); prediction of rupture force and shrinkage for terebinth fruit in infrared dryers using artificial neural networks; study of UV effects on flavonoids content in *viola tricolor*; comparative germination characteristics and initial growth in tow cultivars of basil (*ocimum basilicum* L.) under drought stress; antioxidant activity of methanolic extracts of leave, stem and flower of

dorema aucheri; effect of salt stress on germination and seedling growth of fennel (*foeniculum vulgare*. mill); growth analyse of dill influenced by strip intercropping with bean; study on the antimicrobial effect of extracts of stigmas and stamens of saffron on the growth of *staphylococcus aureus* in hamburger; comparison of chemical components and yield of the essential oil of myrtleleaves under drying methods; formation of a plant database for tubercular therapy; the effect of inoculated seeds with arbuscular mycorrhiza fungi on essential oil compounds of *thymus pubescence*; in vitro anthelmintic activity of tobacco extracts against *marshallagia marshalli*; anatomical, physiological and morphological variation of different *colocynth* accession seeds; the effect of kaempferol and G alangin on serum paraoxonase activity in rats; study of methanol extract activity of *cuscuta* Ssp. from alhaji hostplants on human lymphocyte cells; study of the effect of 200 Mg/Kg dose of saffron extract on eosinophil changes in environmental blood circulation of rat's with experimental asthma; the effect of salinity on seed germination and plant growth parameters of the vitex of a drug (*vitex agnus-castus*); the effect of thiamethoxam and plant extracts on biological parameters of *chrysoperla carnea* (stephens) (neu. chrysopidae) in laboratory condition; study of coumarin presence and amounts of total flavonoids in yellow gerberas; effects of chemical scarification and growing medium on seed germination and seedling performance of *myrtus communis* L.; study of shoot dry yield, morphological and essential oil content in six *satureja rechingeri* populations grown in tehran, Iran; investigation of methods for application of medicinal plants in different areas at different altitudes of Iran; effect of exogenous nitric oxide application on seed germination improvement of eastern purple coneflower (*echinacea purpurea* L.) under salinity stress; biotransformation in *artemisia aucheri* boiss. suspension culture; phytochemical study on polar extract of *artemisia incana* (L.) druce; effect of harvesting time on secondary metabolites of saffron; insecticidal activity of capsulated tablet form of *artemisia siebrion sitophilus oryzae*; anti-bacterial properties of ethanolic extracts of algae (*entreromorpha intestinalis*, *cystoseira myrica*, *gracilaria corticata*) against the bacterium *salmonella typhimurium* (PTCC1596); the onion effect on episiotomy wound healing; evaluation of planting arrangement and straw mulch on yield and yield components of pumpkin under relay intercropping with chickpea; study on the biological activities of essential oils in *vitex pseudo-negundo* and *calotropis persica*; effect of chemical and biological fertilizers on vegetative characteristic of saffron corm (*crocus sativus* L.); the phylogeny of tribe rumiceae (polygonaceae) based on nuclear ribosomal DNA ITS sequences; effect of essential oils to extend vase-life of lily cut flower; in vitro anthelmintic activity of *artemisia santolina* against *haemonchus contortus*; effects of different manganese treatments on some morphological parameters of *cuminum cyminum* L.; effect of fermentation and inorganic acids treatments on removing mucilage layer of *cordia myxa* seeds; a new coumarin ester from *ferula persica* roots; phytochemical investigation of *acantholimon collare* plant native of south khurasan province; the effect of lavender ethanolic extract on learning and memory in rat; essential oil constituents of several organs of fennel (*foeniculum vulgare* var. *vulgare*) under arid climatic condition; the effect of water deficit stress on geraniol and methyl chavicol as main compounds of essential oils in three ecotypes of basil (*ocimum basilicum* L.); phenolic compounds from two cultivars of olive leaves collected in tarom and rudbar and effect of harvesting times in golestan province; study of chemical profile of anthocyanins as a part of influential compounds in purple - blue flowers of *centaurea cyanus*; the effects of drying methods on essential oil content and appearance characteristics of *thymus vulgaris*, *hyssopus officinalis* L. and *lavandula angustifolia*; comparison of phenolic compounds and antioxidant activity of 6 medicinal pasture plants in methanol and ethanol extracts by HPLC and spectrophotometry; drug effects of *artemisia* plant essential oil on some dermatitis bacteria; chemical analysis of the essential oil of two *mentha* species (*mentha aquatica* and *mentha spicata*) and evaluation of the antioxidant activities and antimicrobial activities; effects of water deficit and prolinifoliar application on morphological characteristics of german chamomile (*matricaria chamomilla* L.); investigating the effects of the chemical-physical properties on the performance and composition of essential oils in the *stachys lavandulifolia*. vahl; cytotoxic evaluation of *haplophyllum robustum* against hela cells; effect of different levels of nitrogen and water deficit on morphological characteristics and antioxidative enzymes of pot marigold (*calendula officinalis* L.); optimization of plant cell suspension cultures of garlic (*allium sativum*); evaluation the yield and yield components of cumin landraces (*cuminum*

cyminum L.) as affected by the bio--fertilizer under drought stress; investigating the effects of the chemical-physical properties on the performance and composition of essential in the tanacetum polycephalum schultz-bip. polycephalum; seed germination in alderbuckthorn (*frangula alnus mill*); introducing the flora and chorology medicinal plants in summer rangelands of sari; effect of biological and chemical fertilizers on morphology, yield and land equivalent ratio in mixed cropping of alfalfa and fennel; histological and histocheical study and the effect of fennel on the structure of kidney in alloxen-induced diabetic rats; medicinal plant and resistive economy; effect of priming with polyethylen glycol and drought germination herb purslane (*portulaca oleraceae L.*); identification of medicinal plants in ghareche region, northeastern of khorasan, Iran; the effect of dorema aucheri- hydroalcoholic extract on Lipid Factors (LDL, HDL, VLDL, TG and Cholestrol) in STZ-nicotinamide induced type 2 diabete in male rats model of diabetes; investigation of floristic, life forms and chorotype of medicinal plants of summer rangelands of noor mazandaran; comparative study of antioxidant activity of polar and non-polar extracts from aerial parts of *salvia ceratophylla L.*; effects boron and nitrogen on growth and quantity yield of purslane in ahvaz region; bioassay study of saffron extract'S allelopathic effects on quantitative and qualitative traits of some of medicinal plants; the effect of planting pattern on weed diversity and some physio-morphological characteristics of black cumin (*bunium persicum L.*); investigation of marigold allelopathic effect on weed composition and diversity of tomato in an intercropping system; direct adventitious shoot induction and plant regeneration form shoot apex explants of fennel (*foeniculum vulgare miller*); adventitious shoot formation in decapitated dicotyledonous seedlings of *scrophularia striata*; increased production of sesquiterpenes in hairy root cultures of *teucrium chamaedrys* by elicitation with chitosan; indirect adventitious shoot induction and plant regeneration form leaf explants of *valeriana officinalis L.*; autecology of rhubarb (*rheum ribes*) in yazd province; the essential oil composition of *origanum vulgare L. subsp. gracile* at different developmental stages; investigate on the possibility of improving the quality and quantity of essential oil peppermint with a change in the extraction system; green synthesis of silver nanoparticles using *crocus sativus* petals extract; effect of drought stress on *scrophularia striata*; *calendula officinalis* methanolic extract used as green synthesis of silver nanoparticles; development of an innovative herbal beverage from soymilk -bilberry juice; primary study of some secondary compounds in the extract of *atriplex cansenses* and evaluation of its allelopathic impacts on *agropayrun elongatum* seed; examination of antioxidant activity of Iranian walnut's green husk; effect of drought stress and different planting dates on yield and quality of safflower; germination characteristics of the medicinal plant pumpkin (*cucurbita pepo*) caused by drought stress caused by polyethylene glycol 6000 and salinity stress caused by sodium chloride; investigation of phytochemical some of the aromatic plants (15 species) from *lamiaceae* family in province of mazandaran; nanoemulsification *salvia officinalis* essential oil for topical delivery; phylogenetic relationships between members of the genus *teucrium L.* in Iran; harvest time effect on the herb yield and essential oil content of sweet basil (*ocimum basilicum L.*); antioxidant and free radical scavenging activity of methanolic extract of wild *stachys lavandulifolia* (vahl.) population in Iran; investigation of marigold allelopathic effect on insect diversity and diseases of tomato in an intercropping system; introduction of medicinal plants of asadabad area; using of cumin essential oil to control of food poisoning in dry whey; study of inhibitory effect of *zataria multiflora* boiss essential oil, nisin and their combination on the production of *staphylococcus aureus* (Atcc 6538) enterotoxin C; antimicrobial properties of *salvia officinalis* essential oil in vapour phase; the effect of nanoemulsification; seed oil chemical composition determination of dog rose (*rosa canina L.*); extraction and determination of buglass (*anchusa italica retz.*) seed oil chemical composition; effect of different levels of salinity stress on germination indices and seedling growth of fenugreek (*trigonella foenum L.*); the effects of saline and drought stress on germination characteristics of globe artichoke (*cynarascolymus*); study of yield and yield components in different ecotypes of saffron (*crocus sativus L.*); evaluation of different sowing dates on yield and yield components in saffron (*crocus sativus L.*); antidepressant like effect of ethanolic extract of *avena sativa L.* in the forced swim test and tail suspension test in male mice; identification the volatile oil compounds in (*hypricum perforatum L.*) by spme-GC/MS method; introduction and identification of medicinal plants of zarghan region in fars province; effect of seed pretreatment with

nano-particle of titanium dioxide, ascorbic acid and salicylic acid on storability of *nigella sativa* L. seeds; antimicrobial effect of extract of *allium sativum* and *lavandula officinalis* on *bacillus cereus* and *pseudomonas aeruginosa*; in vitro callus induction and production of antitumor triterpenoids in callus culture of *salvia sahendica*; antibacterial activity of extracts of *salvia ceratophylla* L. from kashan; production of rosmarinic acid in callus culture of *satureja khuzistanica* and *satureja rechingeri*; comparison of allelopathic action of three groups of medicinal plants (essential oil plants, alkaloid plants and flavonoid plants) on three weed species; allelopathic effects of medicinal plant of *salicornia herbacea* L. extracts on germination and seedling growth of *hyssopus officinalis* and *taraxacum officinalis*; the evaluation of changes in polyphenolic acid at vegetative, flowering and post flowering stages in *hibiscus sabdariffa* Linn; the influence of embryo stage on haploid induction in medicinal pumpkin; effect of phytohormones with different concentrations on chemical components of essential oil of *sambucus candensis* L.; comparison of hormonal changes (IAA, GA₃) of the composition of essential oil from *sambucus racemosa* L. leaf; effects of planting time and spraying on yield and oil production of peppermint (*mentha peperita* L.) in mazandaran; influence of vacuum packaging and different storage conditions on quality and ascorbic acid of fresh seedless barberry fruit; germination response of pomegranate seeds to potassium nitrate, sulfuric acid and hot water pretreatments; the changes of hypophysys hormones in PCOS rats that treated with aqueous fennel extract; effects of biofertilizers and chemical on quantitative and qualitative yield of dragonhead (*dracocephalum moldavica* L.); study on effect of some environmental factors on morphological traits and essential oil productivity of *thymus caramanicus* Jalas; anti-bacterial properties of ethanol extracts of algae (*Enteromorpha intestinalis*, *Cystoseira myrica*, *Gracilaria corticata*) against the bacteria, *Bacillus cereus* (PTCC1015) and *Staphylococcus aureus* (PTCC1112); essential oil variability among some populations of *thymus caramanicus* Jalas from Iran; antibacterial effects of water and alcoholic extract of rhizopogon roseolus macroscopic fungi by the disc diffusion method; the studying of antibacterial properties of water and alcoholic extract of macroscopic fungus *Tuber latisporum*; the influence of fennel harvest time on omega-3 and omega-6 contents in shoots, leaves, stems and inflorescences under Ahwaz climatic condition; variability in concentration of phenolic acid derivatives among wild *Zataria multiflora* accessions from Iran; effects of solvent type on phenolics, flavonoids and saponins content and antioxidant activities in *dianthus orientalis* Rech.F.; the study & comparison of leaves & fruit antioxidant activity of *Laurus nobilis* L. (bay leaf); the ability of callus culture of *salvia sahendica* in production of rosmarinic acid; antibacterial effects of extracts of *allium sativum* and *allium ascalonicum* on *Staphylococcus aureus* and *Salmonella enteritidis*; comparison of quantitative and qualitative composition of the essential oil of *thymus daenensis* and *thymus fedtschenkoi* in the Kurdistan habitats; essential oil composition of *Echinophora orientalis* from Iran; exploring the effect of aromatherapy using lavender oil on the patients with ischemic heart disease in the intensive care units (ICU) of the hospitals of the city of Isfahan in 2009; an investigation into the effect of chamomile on decreasing the pre-menstrual symptoms in the female high school students in the city of Burojen, Iran, in 2012; investigation of habitat and distribution of different species of *thymus* genus in Iran (Kurdistan province); kinetics and inactivation study of bitter melon (*Citrullus colocynthis*) peroxidase in different conditions; evaluation of antioxidant and free radical scavenging activity of the *Citrullus colocynthis* fruit grown in Kerman province; effect of postharvest treatments of plant essential oil on qualitative attributes in apricot (*Prunus armeniaca* CV. Askarabad); yield, chemical elements and morphophysiological traits of *calendula officinalis* L. in response to foliar application of bio-stimulators in Karaj climate; six weeks of aerobic exercise and peppermint on inflammatory markers and lung function and aerobic power; amelioration of non-alcoholic fatty liver disease (NAFLD)/non-alcoholic steatohepatitis (NASH) by chicory seed extract via modulation of PPAR α and SREBP-1; the effects of soil and foliar application of mog bio-fertilizer on morphophysiological traits of moldavian balm (*dracocephalum moldavica*); effect of mobile phone radiations on morphological and biochemical parameters of sunflower seedlings; evaluation of phytochemical and antibacterial effects of basil essential oils in hamburger; investigation of morphophysiological traits of savory (*satureja hortensis* L.) to foliar application of methanol and bio-stimulators; interaction of iron and cadmium on growth and some anatomical parameters of *carum copticum*; comparison of nano iron and iron chelate effect

on ion content in melissa officinalis under aluminum stress; physiological and biochemical responses of marigold medicinal plant (calendula officinalis L.) to drought stress; study on the effect of peppermint essential oils on some bacteria; comparison of antimicrobial effect of essential oil of vitex agnus - castus with common antibiotics invitro; identification of optimum growth in green microalgae tetraselmis suecica and fatty acid composition in different light and salinity; evaluation of seed germination characteristics balango (lallelantia royleana) in response to different levels of temperature; the examination of the effects of three levels of mycorrhiza and four levels of cultivation bed on the rate of seed germination, wet and dry weight of shoot tips containing the effective matters of catnaranthus alba; chemical composition and antimicrobial activity of leaves of cirsium strigosum (M.B.) M.B. strigosum; chemical compositions of essential oil of flower of artemisia kopetdaghensis from Iran; chemical composition of the essential oils of ocimum basilicum L. cultivated in Iran; evaluation of antimicrobial activities of methanolic extract of seed of citrullus colocynthis (L.) schard. from Iran; essential oil yield and composition of pelargonium graveolens L. under thidiazuron application; antimicrobial activity and chemical composition of flower of cirsium turkestanicum (regel) from Iran; effect of red light and seed coat removing on seed germination of kelussia odoratissima mozaff; composition of essential oil from aegle marmelos peel extracted by microwave-assisted hydrodistillation with pre treatment ultrasound; effect of different extraction methods (hydrodistillation and microwave-assisted hydrodistillation) on the extraction efficiency and essential oil composition from aegle marmelos peel; storage changes in essential oil composition of thymus daenensis celak; storage changes in essential oil composition of myrtus communis L.; composition of the volatile component of valeriana ficariifolia boiss. roots using headspace/GC-MS; chemical constituent and polyphenol compounds of gaillonia eriantha jaub. & spach; exogenous salicylic acid improves growth and antioxidant defense system in phlomis tuberosa; effect of mycorrhiza fungi as an organic biofertilizer on growth and some physiological characteristics of calendula (calendula officinalis L.) as a medicinal plant; effect of different drying methods on drying time, essential oil content and color characteristics of mentha piperita; drought stress affects essential oil yield in leaf, stem, inflorescence and flowering shoot of nepeta racemosa; solvent-free microwave extraction of essential oil from citrus limon (eureka variety); effect of drought stress on leaf, stem and inflorescence yield of nepeta racemosa; effect of different drying methods on some biochemical properties of mentha piperita; study the effects of treatment time with silicon in improving some physiological and biochemical characteristics of Iranian borage (echium amoenum fisch & C.A. Mey); effect of pinching on growth, yield and essential oil content of pelargonium graveolens L.; the study of distribution and ecology of medicinal species from compositae (asteraceae) family in boushehr province; genetic diversity assessment of Iranian wild almond populations by using inter simple sequence repeats; improvement on the situation of regeneration of medicinal plant satureja hortensis L.; an investigation on the effect of curcumin on the peroxidase enzyme; effect of chemical treatments on the germination of fennel (foeniculum vulgare mill); protective effect of some medicinal plants against Aaph-induced hemolysis of human erythrocytes; antioxidant properties and free radical scavenging activity of euphorbia amygdaloides leaves; effect of biological fertilizers on the quantitative and qualitative characteristics of thymus daenensis medicinal plant; steviol glycosides from stevia rebaudiana bertonii cultivated in three different climatic regions; evaluation antimicrobial activity of methanol extract of plant aloe vera (xerophytic) marrubium vulgare and (trachyspermum ammi L) against strains of staphylococcus aureus in the antibiotic-resistant; effect of different levels of artichoke powder (cynara scolymus L) and vitamin E on performance of japanese quail; antioxidant activities of fractions from different parts of mangrove plant rhizophora mucronata (Lam.); effect of biofertilizers on morphological features of nepeta racemosa; study the effect of biofertilizers on some of characteristics of milk thistle (silybum marianum L.); efficiency of biofertilizers and chemical fertilizer on yield and yield components of dragonhead (dracocephalum moldavica L.); comparison of volatile components of leaves and flowers of citrus aurantium L. using headspace/GC-MS; evaluation of essential oil components of ligoecia cuminoides L.; effect of magnesium sulphate osmopriming on germination and seedling growth of silybum marianum; effect of different concentrations nitroxin and plant density on morphological traits and oil harvest index in medicinal plant of anise (pimpinella anisum L.); effects of rosemary

(*rosmarinus officinalis*) extract on some blood parameters and immune system of markhoz strain newborn kids; effects of rosemary (*rosmarinus officinalis*) extract on growth performance and cell-mediate immune response of markhoz strain newborn kids; antioxidant properties of different extracts of green tea and rosemary; neuroprotective effects of *salvia choleroleuca* leaves alcoholic extract on neuronal density of alpha-motoneurons after sciatic nerve compression in rats; the effects of *salvia choleroleuca* leave ethyl asetat fraction on motoneurons degeneration after sciatic nerve compression in rats; effect of nano-organic iron chelated fertilizer and iron sulphate on dry matter yield, essential oil percent and essential oil yield of daenian thymus; assessing growth changes and hyper accumulation potential in coriander (*coriandrum sativum* L.) under three heavy metals; cadmium, lead and nickel; effect of different levels of N fertilizer and row spacing on growth, development, oil content and herbage yield of moldavian dragonhead (*dracocephalum moldavica* L.); the study of medicago (*fabaceae*) species based on nuclear ribosomal dna its sequences in Iran; fumigant toxicity of some terpenoids of *elettaria cardamomum* (*zingiberaceae*) seed essential oils against the indianmeal moth; toxicity of plant extract *rubia tinctorum* in comparison with thiamethoxam on green lacewing *chrysoperla carnea* (*stephens*); toxicity of plant extracts *aniethum graveolens* and *ferula gummosa* on green lacewing *chrysoperla carnea* (*stephens*); cytotoxicity effect of *orchismasculata* extract on cancer cell line; physicochemical properties of natural honey from ilam and its effect on oxidative stress in streptozotocin-induced diabetic rats; moisture transport in hawthorn (*crataegus oxyacantha*) undergoing microwave- convective drying; effect of *berberis vulgaris* grain on some blood parameters of broiler; study on the effect of the "ethanol" and essential oil of medicinal plants "*satureja hortensis*" on post--harvesting quality of davoodi cut flowers white engineering number; essential oil yield and compositionchanges in *kelussia odoratissima* mozaff using different drying treatments; the effect of carvacrol and thymol on increase of lifetime of davoodi cut flowers white engineering number; introduction of medicine plants in asadly of bojnourd; the predication of garlic (*allium sativum* L.) drying rate (DR) and moisture ratio (MR) using a neural network method; identification of conserved domains for codeine O--demethylase (CODM) in *papaver somniferum* L.; the effect of different irrigation intervals on growth parameters and essential oil of *salvia macrosiphon boiss*; investigation changes in chlorophyll, carotenoid and proline contents in response to different irrigation intervals in *salvia macrosiphon boiss*; a study of *punica granatum* L. pollen grains total flavonoid extract on immune system responses; the effects of salicyl hydroxamic acid on germination indices and biochemistry *hypericum perforatum*l. seed; the effect of soaking duration on seed dormancy breaking and seedling growth of *kelussia odoratissima* mozaff; pot planting and mycorrhiza inoculation useful methods for establishing *ziziphora clinopodoides* in rangelands; effects of mycorrhiza symbiosis on initial establishment and morphological traits of *thymus vulgaris* under field conditions; investigation of essential oil properties of different varieties of lemon (*citruslimon*) peel extracted by hydrodistillation; a study on antimicrobial properties of *rosa foetida* against various pathogens; screening the medicinal potential of some weeds by HPTLC method; investigation on changes of protein pattern in embyonic and non-embryonic callus, matured embryo and plantlet of *rumex tuberosus* L. subsp. *horizontalis*; UV irradiation effects on seed germination and growth, protein content, peroxidase and protease activity in *portulaca grandiflora* and *portulaca oleracea*; comparative effects of menthol and ultraviolet radiation on percentage of thyme and althea seed germination; increaese of phenolic compounds of yarrow treated by silver nanoparticles; floral development, stigma receptivity and pollen viability in *satureja rechingery jamzad*; evolotion of relationship between *satureja khuzistanica* and *S. rechingery jamzad* using with morphological markers; antibacterial activity and chemical composition of ajowan (*trachyspermum ammi*) essential oil against some pathogens with macro dilution method; antimicrobial activity of leaves oils (*marrobbium vulgare*) against *staphylococcus aureus* resistant antibiotic; antimicrobial activity of ethanol extract of eucalyptus (*eucalyptus globules*) and (*satureja hortensis*) against of *staphylococcus aureus* diefficalt antibiotic-resistant; the effect of garlic (*allium sativum*) extract on immune response and growth of markhoz newborn kids; evaluation antimicrobial activity hydroalekol thyme extract (*zataria multiflora boiss*) against antibiotic--resistant strains of *E. coli*; comparative polyphenolic and total phenolic contents of *teucrium polium* in different growth stages; the effect of vermicompost on morphology and yield of balm

(*melissa officinalis*); improving balm (*melissa officinalis*) growth and yield by biofertilizers application; determination of nutritive value of rheum-L using in vitro gas production technique; callus induction from different explants *ocimum basilicum* with the plant growth regulators; antioxidant and free radical scavenging activity of *ilex spinigera*; composition and antibacterial potential of essential oil from *thymus migricus* klokov & desj.-shost; characterization of volatile components of leaves and flowers of sweet orange (*citrus sinensis* L.) using headspace/GC-MS; variation in essential oil content and composition of *assafoetida* (*ferula assafoetida*) in Kerman province; comparison of some vegetative characteristics and investigating the changes of essential oils of *T. kotschyanus* in west Azarbaijan; diuretic effect of extract of *lippia citriodora*, *echium amoenum* and *urtica pilulifera* in male rat; essential oils composition and antioxidant properties of two *thymus* species; in vitro callus induction from different explants of sage (*salvia officinalis* L.); comparison of cytotoxic effect of aqueous and methanolic extracts of *pterocarya fraxinifolia* leaves on HT-29 and K562 cell lines; investigation of allelopathic activity of medicinal plant *vinca rosea* L. on seedling growth of three test plant species; effects of aromatic water of *salix aegyptiaca* L. and its major compound, 1, 4-dimethoxybenzene, on rabbit behavior pattern; the potential of essential oils of *satureia hortensis* and *zataria multiflora* to control ruminal acidosis; evaluation of anticonvulsant, antidepressant and sedative-hypnotic activities of *asperugo procumbens* leaves; the effect of chemical fertilizers on lavender essential oil percentage; effect of cadmium toxicity on growth, biochemical parameters and metal accumulation in parsley (*petroselinum crispum* L.); study of the haemostatic effect of some plant extracts; diuretic effect of *allium porrum* L. ethanolic extract in male wistar rats; anti-inflammatory effects of *artemisia dracuncululus* L. ethanolic extract in mice; essential oil composition, flavonoid and anthocyanin content of *artemisia annua* L. treated with methyl jasmonate and silver nano particles; the effect of spraying the methanol solution on morphological characteristics of *plantago psyllium*; microalgae *dunaliella salina* as a functional food and nutraceutical source; assessment of different plant density and arrangements on quantitative and qualitative performance of *calendula officinalis* L.; essential oil composition of *rosa foetida* from Iran; ethno-pharmacology of *ferula gummosa* boiss. and *ferula assa-foetida* among kurmanj people of northern khorasan province; determination of total antioxidant effect of six Iranian pomegranate flowers by HPLC-DPPH; study of dry matter yield, and essential oil percent in three species of *satureja* (*S. Rechingeri*, *S. Khuzestanica* and *S. Mutica*) grown in khorramabad climate condition; screening the potential allelopathic chemicals from the medicinal plant of *artemisia sieberi*; modified dna extraction method in *myrtus communis* for optimal Pcr amplification; sustainable beneficiary of savory genetic resources in Lorestan province; *artemisia* species from Iran are different in antioxidant activity and total phenol content; variation of trans- anethol content in fennel (*foeniculum vulgare*) during different developmental stage; effect of salty solutions osmopriming on germination and seedling growth of *cynara scolymus*; variation of the essential oil yield and composition of *pelargonium graveolens* L. under nanosilver particles treatment; composition of essential oil of *leucanthemum vulgare*; evaluation of the phenol and flavonoid contents in some local and foreign apple cultivars; the effect of irrigation and time of micronutrient foliar application on yield and yield components of black cumin (*nigella sativa* L.) in birjand area; phytochemistry study on the two species of *achillea* in different region; comparison of the effect of alcohol spray and bio--stimulators on the mucilage yield of *psyllium*; effect of spray application of zinc and manganese on yield and yield components of safflower; the effect of *daphne mucronata* leaves extract on viability of primary rat glial cells; foliar application of amino acid active compounds on the reproductive of *plantago psyllium*; variation of colchicine content in different seasons among three *colchicum* species; determining the best extraction solvent of glabridin from licorice root and measuring it in species native to Kermanshah; investigation the effect of integrated mineral nutrient managements on seed yield and essential oil efficiency of fennel (*foeniculumvulgare*); phytochemical and antioxidant activity of *atropa belladonna*.in mountainous area golestan province; effect of different rates of chemical fertilizer (NKP), manure and mix of them on growth, yield, and essential oil of *satureja khuzistanica* jamzad; comparison of mucilage amount and morphological traits in native ecotypes of *plantago* in plant in golestan province; study of phenological stages in four native ecotypes of *plantago* in climate condition golestan province (azadshahr); effect of different levels of manure on anise essential oil percentage and yield; chromosom

counting of six population of *Leonurus cardiaca* from Iran; comparison of essential oil contents of six populations of motherwort (*Leonurus cardiaca*) in Iran; evaluating the allelopathic potential of medicine plant of *Polygonum convolvulus*; phytochemical and antioxidant activity of *Atropa belladonna* in forest area of Golestan province; antifungal effect of dry and Caspian regions fig leaf extract on *Candida albicans* yeast; study effects of methanol extracts of four Iranian thymus cultivars on proliferation of human lymphocytes; effect of ascorbic acid foliar application on growth and antioxidant enzymes activity of basil (*Ocimum basilicum*) under different soil moisture levels; the effect of drought stress on morphologic characteristics, proline and soluble sugars of anise (*Pimpinella anisum* L.); study of stem anatomy in genera of malva and althea (*Malva*); a novel approach to application of weeds as medicinal plant; influence of ethanolic extract of *Melia azedarach* L. on percentage of *Encarsia formosa* emergence from the parasitized puparium of *Trialeurodes vaporariorum*; toxicity of essential oils from *Lavandula angustifolia* and *Cinnamomum zeylanicum* against *Agonoscena pistaciae* in laboratory conditions; toxicity of essential oils from *Eucalyptus globulus* and *Rosemarinus officinalis* on *Agonoscena pistaciae* in laboratory conditions; evaluation of yield and its components in intercropping of fennel (*Foeniculum vulgare* Mill.) and fenugreek (*Trigonella foenum-graecum* L.); effect of haloprimer technique on improvement of some physiological traits of medicinal plant caper (*Capparis spinosa parviflora* L.) seeds; plasma matrix metalloproteinase 2, 9 levels are reduced following purslane seed supplementation in patients with type 2 diabetes mellitus; effect of storage time of aqueous saffron extract on secondary metabolites; effect of *Cinnamomum zeylanicum*, *Allium sativum* and *Urtica dioica* alcoholic extracts on activity and control of the *Fusarium oxysporum*; comparison of the antioxidant activity of the flowers methanolic extract of two plants of the family (Boraginaceae); evaluate postharvest aloe vera gel-coating on storage life and quality attributes of peach (*Prunus persica* cv. Elberta); fermentation distillation chemical composition, antibacterial and antifungal activity of the essential oil of *Thymus fallax* Fisch. Mey.; comparison of salinity effects of essential oil yield and components of *Achillea millefolium* L. in greenhouse and natural conditions; the effect of Fe chelate application on *Rosa damascena* Mill.; the effect of growth regulators on morphophysiology and agronomic characteristics of psyllium (*Plantago psyllium*); effect of culture filtrate of *Fusarium graminearum* on total phenol and flavonol content in cell culture of *Linum album*; effect of organic matter, iron and zinc on cumin cyminum production in calcareous soils; effect of NaCl salinity and ascorbic acid on biomass yield and essential oil content of *Pelargonium graveolens* L.; evaluation of radiation use efficiency and extinction coefficient in summer pumpkin (*Cucurbita pepo* L.); evaluation the allelopathic effect of shoot aquatic extract of bermudagrass (*Cynodon dactylon*) on germination and seedling growth of fennel (*Foeniculum vulgare*); effect of ascorbic acid on vegetative characteristics of *Pelargonium graveolens* L. under NaCl salinity; protective effects of *Portulaca oleracea* L. against carbon tetrachloride-induced hepatotoxicity in rats; the study of antibacterial effects of *Lawsonia inermis*, *Zataria multiflora* Boiss and *Urtica dioica* alcoholic extracts on *Pseudomonas syringae*; purslane extract ameliorates carbon tetrachloride--induced acute hepatic injury in rats; application of plant growth regulators on morphophysiological and agronomical properties of fenugreek (*Trigonella foenum-graecum* L.); effect of plant growth regulators and media on micropropagation of *Artemisia aucheri* Boiss; investigation of row arrangement and planting date on quality and quantity of *Cucurbita pepo* L.; virus induced gene silencing in *Cannabis sativa*; chemical composition comparing, of essential oils of *Heracleum persicum* L. seeds in conditions of Deh-bala and Manshad areas of Yazd province; introducing the best method for DNA extraction and comparing it with common methods in medicinal plant of noruzak (*Salvia leriifolia*); effect of grape seed's extract on some secondary metabolites and fungal decay of table grape (CV. Fakhri.) over postharvest life; determining the best hormonal treatment and media for propagation of *Artemisia sieberi* in vitro; the effect of *Medicago sativa* supplementation on serum lipid profile in low weight girls; morphophysiological changes of fenugreek (*Trigonella foenum-graecum* L.) leaves to foliar application of methanol and nano-iron chelated in field; effect of thymus essential oil, salicylic acid (SA) and methyl jasmonate (MJ) on storage life and quality of red table grapes (CV. Sahebi.); effect of *Terminalia chebula* on growth performance, serum biochemical parameters and organs weight in broiler chickens; effects of dietary administration of aloe vera on serum antioxidant enzymes in rainbow trout fingerlings; a survey on mycorrhizal symbiosis with

the thymus daenensis and its effects on the root growth; effects of dietary administration of aloe vera on serum mda in rainbow trout fingerlings; effect of drought stress on morphology of dill; the amount of essential fatty acids in extra virgin oil in four olive cultivars; study of microspore development stages in thymus daenensis; the study of antioxidant activity of ethanolic and methanolic extracts of quercus infectoria galls; antimicrobial activity of zataria multiflora boiss. essential oil against vancomycin-resistant enterococci (VRE) in minced broiler meat; antimicrobial activity of saffron against salmonella enteritidis in food; character association and path analysis of black seed (nigella sativa L.) genotypes under different irrigation regimes; the study of growth regulator composition and type of explant on callus formation in sebestan medicine plant (cordia myxa L.); arsenic determination in garlic by gfaas after subcritical water extraction; comparison of cytotoxic effects of methanolic extract and essential oil of achillea wilhelmsii C. koch on HT29 cell line; study the effects of organic manure and water deficiency on qualitative and quantitative yield of peppermint (mentha piperital.); investigation of anthocyanins amount in three species of medicinal forestal fruit in golestan province; evaluation of phytochemical activity of achillea micranta and achillea millefolium L. extract in east north of golestan province; evaluation of antioxidant activity of methanol extract of two achillea species in east north of golestan province; changes in essential oil percent and yield of pot marigold (calendula officinalis) in different doses and times of nano-iron foliar application; effects of organic fertilizers on grain and fruit yield of pumpkin (cucurbita pepo convar. pepo var. styriaca); the effect of planting density and planting time on satureja sahendica; anti-oxidant and anti-bacterial properties of ethanol extracts of algae (entreromorpha intestinalis, cystoesira myrica, gracilaria corticata) from the coastal waters of bushehr province (northern persian) with phenol & Rp tests; evaluating the effect of drought stress on morphology of chamomile from khuzestan, Iran; response of two chamomile populations to drought stress and harvest time; chemical compositions of the essential oils of scaligeria meifolia; comparison of hydro distillation (HD), steam distillation (SD) and microwave free solvent extraction (SFME) on flowers essential oil of hypericum perforatum; antioxidant properties of chloroform, methanol and water extract of hyrcanian ganoderma lucidum karst; optimization of HPLC-FLD method for determination of psp toxins in persian gulf and oman sea shellfish; effect of plant density on yield and yield components of various land races of fenugreek (trigonella foenum gracum L.) in Kerman climatologic conditions; comparison of chemical constituents of essential oil and polyphenol and antioxidant activity of methanolic extracts the pycnocycla nodiflora; comparison of chemical constituents of polyphenol and antioxidant activity of areal parts of pycnocycla nodiflora at different growth stage; production of lignans in callus culture of linum mucronatum subsp. orientale (boiss); effects of cattle manure, vermicompost and humic acid on grain yield and its components of fennel (foeniculum vulgare mill.); antioxidant activity of melissa officinalis leaves extracts during the different stages of plant growth; antibacterial activity of hidroalcoholic extract and butanol fraction of solanum nigrum L. leaves; microwave-assisted and conventional hydrodistillation methods in the extraction of essential oil from achillea santolina; ethnopharmacology and antioxidant activity of thymus kotschyanus boiss.et hohen.in north of Iran; national production and procreation of medicinal and organic plant "kelussia odoratissima" and its economic consequences; comparison of total phenolic content and anti-oxidant activity of achillea nobilis, A. filipendulina and A. millefolium; effect of foliar salicylic acid and cycocel applications on some physiological parameters of sweet basil; foliar application of salicylic acid and cycocel improved physiological parameters in dragonhead; introduction of achillea kellalensis as a new source of natural antioxidant; the effects of hidroalcoholic extract of garlic on serum levels of No in male rats; a comparison of alpha-tocopherol content of laurus nobilis leaves in different harvesting season (spring & fall) by reverse-phase high performance liquid chromatography (RP-HPLC); yield and yield components of fennel (foeniculum vulgar mill.) in response to foliar application of micronutrients (iron and zinc); effect of magnetic field and nano-particles of titanium oxide (TiO_2) on seed germination and early growth characteristics of ajowan (ammi copticum L.) in premature senescence; analgesic effect of hypericum perforatum extract in rat by using hot plate test; using some essential oils in the control of bacterial canker disease of stone fruit; the effect of drought stress on total phenolic, prolin content and antioxidant activity of achillea millefolium L.; formulation of the horse chestnut emulgel for chronic venous

insufficiency; evaluation of antioxidant activity of ethanolic and methanolic extracts of purslane seeds; the effect of drying methods on yield and chemical composition of the essential oil of *rosa foetida*; alterations in seed vigor and antioxidant enzymes activities in *satureja hortensis* L. under seed priming; effect of *achillea millefolium* L. aerial parts on serum glucose in alloxan-induced diabetic rats; effect of growth media on the vegetative characteristics, physiological parameters and oil production of valerian; introducing some diseases agents of thyme plants in hamadan province of Iran; dormancy breaking of imperial crown seeds; estimation of milk thistle seed silybin by using of multiple regression models; estimation of active substances contents of milk thistle by using stepwise regression; karyotype study of four *capsicum annum* L. population, native to Iran; cell suspension culture establishment of *taxus baccata* for the production of the anticancer drug taxol; mycelium growth characteristics of a valuable medicinal mushroom *ganoderma* from golestan and mazandaran province; influence of salicylic acid on yield and some morphological parameters of dragonhead under water stress; study of the effects of essential oils of cumin, savory and cardamom as natural antioxidants on the flavor and oxidative stability of soybean oil during the storage; diagnostic value of leaf anatomical features in *silene commelinifolia* (caryophyllaceae) complex; antioxidant activity, total phenolic and flavonoid compounds of *mespilus germanical.* (rosaceae) leaf methanolic extract in different altitudes; chemical composition of the essential oil of *pistacia atlantica* galls and leaves by combipal system technique; intraspecific variability of the essential oil of *ocimum basilicum* L. var. *purpurascens* and var. *dianatnejadii* from Iran; effect of gamma irradiation on the tannins and phenolics of *artemisia aucheri* boiss; morphological characterization of some *cannabis* accessions from different regions of Iran in relation to their medicinal or fiber production efficiency; effects of nano fertilizers and heavy metals on some physio-morphological traits of three medicinal species at seedling stage; path analysis of the relationships between seed yield and some morphological traits in cumin (*cuminum cyminum* L.) to drought stress; effect of sowing dates and depths on emergence characteristics and tuber production of medico-industrial *ferula assa-foetida*; separation of DNA for molecular markers analysis from leaves of the *matricaria chamomilla*; investigation of the effect of nutrient resources on weed diversity and quantitative and qualitative traits of cat thyme (*teucrium polium*); antihyperglycemic activity of hydro-alcoholic extract of *urtica dioica* on type 1 diabetic male mice; identification and quantification of antioxidants found in lemon juice; anti-ulcerogenic activity of the pomegranate peel (*punica granatum* L.) methanol extract; survey of phytochemical constituents and antimicrobial activities of aloe vera; the effects of some heavy metals on psoralen anti cancerous compound in vitro culture conditions; chemical-genetic profile analysis of eugenol in *saccharomyces cerevisiae*; effect of seed coat colour on salinity tolerance in mustard (*brassica campestris* var. *parkland*) as a medicinal plant; isolation, purification and structure elucidation of flavonoids from *lagochilus cabulicus* benth; the effect of drought stress on some factors of quantity and quality of *artemisia dracunculus* L.; chemical constituents of the essential oil of *artemisia aucheri* boiss from alpine in Kerman; determination of carbohydrate and nutrient content in *lycium ruthenicum* murry plant; comparison of total phenolic content (TPC) and flavonoids in *lamiaceae* and *plumbaginaceae* family; chemical composition of the essential oils of two aromatic plants species (*asteraceae*); improve in vitro culture of *lippia citriodora* by using garlic extract; the effect of various hormones on in vitro embryo germination and callus induction in *ferulago angulata* subsp *carduchorum*, an endangered medicinal plant; design and development of self-nanoemulsifying drug delivery system (SNEDDS) of *boswellia serrata* extract for oral drug delivery; chemical composition and antimicrobial activity of *ferula behboudiana* essential oil from Iran; establishment of callus and cell suspension culture of *scrophularia striata* boiss. for echinacoside production; determination fatty acids in *moringa peregrina* oil from different location in sistan and balochestan proviance; effects of different culture media on rooting of *passiflora incarnata* stem cuttings; seasonal fluctuation of the essential oil and 1,8-cineole compound in adapted eucalyptus species in fars provience; cytogenetic variability and new chromosome number reports in some species of *helichrysum* mill. (*compositae*); effects of antiaging (aloe vera, *satureja hortensis*, *teucrium scordium*) and mixture of them on D-- galactose induced aging in male mice; evaluation of germination characteristics of fleatwort and purple coneflower affected by different salinity stress levels; the effect of plant regulators on callus induction of thyme (*thymus vulgaris*.l and *thymus daenensis*);

effects of different salinity levels of NaCl and CaCl₂ on germination of safflower (*carthamus tinctorius* L.); investigation of possible anti-aflatoxicosis properties of savory essential oil; phytochemical analysis and antibacterial effect of *achillea tenuifolia* Lam.; changes in essential oils content and chemical composition of *artemisia sieberi* during different phenological stages; the effect of imidacloprid and plant extract on biological parameters of *chrysoperla carnea* (Stephens) (neu. chrysopidae) in laboratory condition; investigation on imidacloprid and plant extracts effects on stable population growth parameters of *chrysoperla carnea* (Stephens); determination of inhibitory effect of *anthemis gayana* flower essential oil against pathogenic fungi; the effect of *dorema aucheri*- hydroalcoholic extract on blood glucose, insulin and leptin in STZ- nicotinamide induced type 2 diabetes in male rats model of diabetes; antioxidant, antimicrobial and antitumor activity evaluation of total methanolic extracts from *dendrostellera lessertii* (Wikstr.) Van Tiegh. from Kashan; in vitro radical scavenging activity of *zataria multiflora* accessions in relation to their rosmarinic acid content; total phenolic and total flavonoid contents, antioxidant activity of *zataria multiflora* accessions from Iran; the effects of different organic fertilizers on chlorophyll and some characteristics of basil medicinal plants (*ocimum basilicum*); biological control of three weeds by allelopathic properties of *aloe vera*; allelopathic effect of *artemisia* sp. on germination of purslane (*portulacaoleracea* L.); effect of three grocery herbs on growth of *klebsiella pneumoniae* in vitro; assessment of the nitrogen and compost different levels effects on qualitative and quantitative performance of *calendula officinalis* L.; cytotoxic effect of plant extracts of *ammi visnaga* in HeLa and MCF7 cell lines; determination of total flavonoid and tannic contents of six Iranian pomegranate flowers; influence of elevation on morphological and physiological features of local populations of mountain pride in Zanjan; influence of elevation on morphological and physiological features of local populations of mountain pride in Tarom; studying medical plant of *ferula assa foetida* and its characteristics, economical importance, export and global marketing in South Khorasan Province - Iran; performance, biochemistry profile of serum and organs weight of broiler chickens as influenced by dietary *echinacea purpurea* supplementation; effects of water stress on germination of Persian poppy; investigation of vermicompost and humic acid effects on quantitative qualitative traits of *satureia hortensis* L.; effect of *teucrium polium* (L.) extract on biological parameter of *bemisia tabaci* (Genn.) under semi-field condition; study of karyological characteristics in several accessions of castor (*ricinus communis* L.); seed priming improve the germination performance of common chicory (*cichorium intybus* L.) under drought stress; effect of *fumaria parviflora* (Lam.) extract on biological parameter of *bemisia tabaci* (Genn.) under semi-field condition; the comparison of Iranian and Indian extract of *cynara scolymus* L.; evaluation of callus production potential in leaf explants of Persian shallot (*allium hirtifolium*); an endemic and endangered plant species; cytogenetic study of four *satureja* (Lamiaceae) species and populations in Iran; interactive effects of arbuscular mycorrhizal, salicylic acid and drought stress on fruit yield, morphological characteristics, root colonization, physiological traits and secondary metabolites of ajowan (*trachyspermum ammi* L.); effect of salicylic acid and cycocel (cholomequat chlorid) application on yield and morphological traits of Moldavian balm (*dracocephalum moldavica* L.); compare the weight efficiency of the essential oil *stachys byzantina* plants in both regions growing of the Mazandaran province; effect of *urtica dioica* hydro-alcoholic extract on serum testosterone level of STZ - diabetic mice; ethnopharmacological uses of *A. Millefolium* L. (yarrow) growing wild in east north of Iran (Chaharbagh region); the study of quantitative and qualitative changes of heat shock proteins and peroxidase enzyme activity, the effect of repeated heat stress on micropropagated *zataria multiflora* Boiss in vitro condition; variability of photosynthetic pigments in rosemary (*rosmarinus officinalis*) under arbuscular mycorrhizal fungi symbiosis and heavy metals stress; evaluation of sowing dates and planting depth on emergence characteristics and producing tuber of medico- industrial plant of *ferula gummosa*; study the effect of harvest time and plant density on agronomic attributes of thyme (*thymus vulgaris* L.) in second year; study the effect of harvest time and plant density on tarragon (*artemisia dracunculus* L.) yield in third year; the effect of salicylic acid hormone (SA) on some anatomical and morphological characteristics of watercress (*nasturtium officinale* R. Br.); modeling color and shrinkage variations of terebinth in a semicontinuous dryer; hypolipidemic effect of hydro-alcoholic extract of *urtica dioica* in STZ - diabetic mice; effect of applying chemical fertilizers and municipal

solid waste compost on amount of flavonoid, anthocyanin and morphological parameters of herb coneflower (*echinacea purpurea* L.); ethnobotanical study of paband national park (mazandaran province); investigation of carvacrol and gamma-terpinene contents of summer savory (*satureja hortensis* L.) essential oil in sari climatic condition; the influence of salicylic acid levels on morphological traits and essence yield of german chamomile (*matricaria chamomila* L. Cv bodegold) under normal and heat stress conditions; introduction of medicinal plants species with the most traditional usage in kaland protected area; determination antioxidant capacity and rate of phenol under salinity in *artemisia aucheri* boiss; application of chemical fertilizers, manure and their incorporation on some of the morphological and biochemical attributes of coneflower (*echinacea purpurea* L.); fumigant toxicity of essential oils from *achillea wilhelmssi* and *ziziphora clinopoides* on *ephestia kuehniella* zeller; study the effect of drought stress and spraying salicylic acid on some growth parameters of sweet basil cultivars; response of basil (*ocimum basilicum* L.) to different rates of nitrogen fertilizer; effect of irrigation with treated municipal wastewater on growth and yield of different aloe vera cultivars; the effect of salinity on growth and yield of different aloe vera cultivars; study of the effect of bisdemethoxycurcumin on the amyloid fibrillogenesis of lysozyme; influence of arbuscular mycorrhizal fungi on occurrence time of generative growth and chlorophyll content of pot marigold (*calendula officinalis*) under heavy metals stress; influence organic manures and nitrogen fertilizer on growth, yield and essential oil composition of agastache (*agastache foeniculum*); the effects of nitroxine, bio sulfur fertilizers and super absorbent polymer on essential oil quantity and quality of vegetable parts of *ocimum ciliatum* hornem; the study on phenological properties, yield and anthocyanin content of roselle (*hibiscus sabdariffa* L.) cultivated in mashhad climate; anti apoptotic effect of aquatic extract of *cannabis sativa* (9 tetra hydro cannabinol) and *prosopis farcta* (quercetin) on cell body of motoneurons after nerve crush; effect of alcoholic extract of nettle (*urtica dioica*) and shallot (*allium ascalonicum*) on control of the *penicillium digitatum*; effect of plant growth promoting rhizobacteria on morphological parameters in coriander (*coriandrum sativum*) under salt stress condition; sedative-hypnotic effects of *myrtus communis* L.; investigation the effect of *hypericum perforatum* on cecum and big intestinal morphometric in male wistar rats; the effect of different treatments for breaking dormancy and germination of some population of *allium hirtifolium* seeds in different regions; study of inhibitory effects of hydroalcoholic extract of *stachys lavandulifolia* vahl. aerial parts on xanthine oxidase and xanthine dehydrogenase activities in mice; effect of plant growth promoting rhizobacteria on chlorophyll and carotenoid contents in coriander (*coriandrum sativum*) under drought stress condition; histopathological study of the effect of oral administration of green tea extract on spermatogenesis in mice; response of the growth and production pumpkin to the application of phosphorus chemical fertilizer and phosphate solubilizing microorganisms; effect of bio and chemical fertilizers of phosphorus on some agronomic characteristics and yield of *cucurbita pepo* L.; evaluation the response of yield, yield components and essential oil of fennel (*foeniculum vulgare*) to the using of mycorrhiza and different doses of phosphorus fertilizer; optimizing p availability for medicinal pumpkin and its effects on yield using arbuscular mycorrhizal fungi; evaluation of the reduction of nitrogen fertilizer application using nitroxin biofertilizer at the production of anise (*pimpinella anisum* L.) medicinal plant; salicylic acid improves germination characteristics in fenugreek under salinity stress; the performance of some fennel (*foeniculum vulgare* mill.) accessions under drought-stress conditions; change in the antioxidant activity of fenugreek plants induced by salicylic acid and salinity; medicinal plant (*nepeta binaludensis* jamzad) tissue culture and A-terpinene variations of essential oil in vivo and in vitro; leaves essential oil composition of lemon verbena grown in aggregate media and aeroponic system; phytochemical investigation on *salvia sahendica* and study of the cytotoxic activities of its active components; an analysis of genetic diversity of *tripleurospermum sevanense*, *anthesis tinctoria*, *matricaria recutita* species using peroxidases markers; effects of biological manure on seed germination characteristics and enzyme activity in *dracocephalum moldavica*; investigating the effects of *lavandula angustifolia* essential oils on fermentation and gas production parameters of alfalfa; effect of two extraction methods of *rubia tinctorum* on mortality of cotton whitefly, *bemisia tabaci* (Genn.); an analysis of genetic diversity of *anthesis*, *matricaria*, *tripleurospermum* species using populations using total proteins and its association with geographical factors;

investigating the effects of *lavandula angustifolia* essential oils on fermentation and gas production parameters of straw; the new perspective of mitigating effect of silicon on *borago officinalis* L. under salinity condition; ecological, phytochemical and antioxidant activities of *nasturtium officinale* R. Br. in ziarat mountain (golestan province); effect of salicylic acid and gibberlic acid on flowering time, leaves and rhizome number in turmeric (*curcuma longa*); an investigation on some mineral elements amount in *urtica dioica* plant in golestan province; investigating the effects of different doses of wild sage seed (*salvia macrosiphon*) on fermentation and gas production parameters diet with high concentrate; investigation the effects of using different levels of *saturea (satureia hortensis)* medicinal plant and salinomycin on performance and carcasses quality in broiler chickens stricken with coccidiosis; assessment of traditional medicinal plants commercialized in the markets of mashhad, Iran; effect of some medicinal plant extracts on stable population parameters of *chrysoperla carnea* (stephens); effect of foliar application of humic acid and pollen type on quantitative and qualitative criteria of medicinal pumpkin (*cucurbita pepo* var. *styriaca*); antibacterial effects of some marine and terrestrial plant extracts on *listeria monocitogenes* and *bacillus cereus*; effects of salinity stress on yield and essential oil of *mentha (mentha piperata)*; evaluation of lipoprotein levels and hepatotoxicity of *teucrium polium* in male rats; effect of seed's coat of madder (*rubia tinctorum*) on indices germination; effect of silicon treatment on some morphological and physiological traits of salt-stressed *calendula (calendula officinalis* L.); nanoemulsification of *satureja khuzistanica* essential oil; investigation of the antibacterial activity of *satureja khuzistanica* essential oil in the vapor phase; combination effect of methanolic extract of *fumaria parviflora*, pymetrozine and Cal-J-N3 tomato variety on prematurity stage mortality of *bemisiatabaci* (Genn.); effects of different fertilizer treatments on the properties of essential oil of *lippie citrodora* repellency on *trubolium castaneum*; investigation of pyridoxine priming effects on seed *carthamus tinctorius* germination and seedling growth and peroxidase & catalase activity under drought stress; effect of gibberlic acid and ethanol alcohol on *calendula officinalis* L.; effect of water stress on the tymol content in *thymus daenensis* celak; investigation of salicylic hydroxamic acid (SHAM) priming effects on seed *carthamus tinctorius* germination and seedling growth and peroxidase & catalase activity under drought stress; histopathologic effect of *ruta graveolens* extract on changes of gastric tissue in mice; effects of weed interference and plant density on morphological characteristics and yields of fenugreek (*trigonella foenum-grarcum*); evaluation of genotypexenvironment interaction analysis and adaptability of different ecotypes of cumin at Kerman; effects of methanol and bio-stimulators as growth promoters for biomass and growth characters of *satureja hortensis* L.); microwave irradiations effect on amount of phenolic compounds of *marrubium anisodon*; new report of *fusarium* Sp. causing leaf spot *aloe vera* in north of Iran; efficacy of repellency pure essential oils and formulation of nanoencapsulated essential oil of *carum copticum* on diamondback moth larvae; effect of different irrigation levels on yield, yield components and essential oil content of basil herb (*ocimum basilicum* L.); evaluation of the effects of irrigation frequency and glycin betaine on qualitative and quantitative traits in *dracocephalum moldavica* (L.); effects of neem extracts on carbohydrate reserves in adults of sun pest (*eurygaster integriceps* put); response of *nepeta poganosperma* to drought stress; antibacterial effect of *pistacia khinjuk* extract against some gram positive and negative bacteria; evaluation of the effect of cropping time and climate on amount of essence in *mentha piperita*; chemical composition, antibacterial and antioxidant activity of the essential oils from aerial parts of *thecocarpus meifolius* growing in Iran; identification and diversity of medicinal plants in tonekabon forests, mazandaran; identification, collection, conservation and determination geographical distribution of *withania coagulans* genetic resources in Iran; evaluation of culture substrate on seed germination of marsh mallow, *althaea officinalis*; effects of different of nitrogen fertilizers and manure on physiological traits on *balangu shirazi (lallamenta royleana)*; effect of plant essential oils on mycelial growth of *fusarium graminearum* in laboratory condition; investigation of the effect of substituting alfalfa with thyme (*thymus vulgaris*) extraction by-product in ruminant nutrition using gas production technique; effect of chemical and bio fertilizers on balm (*melissa officinalis*) morphology and shoot yield; effect of different levels of crushed black seed (*nigella sativa*) on some blood parameters in laying hens; effect of chemical and biological sources of sulfur on balm (*melissa officinalis*); effect of different seed harvesting times on

seed germination and seedling emergence indices of rumex (*rumex tuberosus* L.); effect of different levels of crushed anise (*pimpinella anisum* L.) on egg quality parameters in laying hens; the best planting density of nepeta poganosperma; effect of cold stratification, chemical scarification and Ga³ on dormancy break in *schrophularia striata*; the effect of corm number on saffron yield components; the study micropropagation of *satureia khuzistanica*; the effect of planting density on saffron morphology and yield; effect of planting time and plant density on morphological characters and yield of *achillea millefolium*; effects of different jasmonic acid levels on growth and chemical composition of marigold single flower; impact of foliar application of putrescine on growth and photosynthetic pigments of marigold single flower; structure elucidation of marine alga *sargassum angustifolium* collected from the persian gulf coastal waters of bushehr; the effect of different N fertilizers and weed management on basil ry yield, oil percent, oil yield and linalol percent of basil in berseem clover and basil intercropping system; hepatoprotective effect of methanolic extract *berberis integerrima* root on carbon tetrachloride--induced acute hepatotoxicity in rats; evaluation of antioxidant activity and phenolic compound of *gavan-E-gaz-angubini* (*astragalus adscendens*); the effect of methyl jasmonate on some ionic and pigment content in *thymus daenesis* grown under salinity; effect of drought stress on peroxidase and chlorophyll contents in *hibiscus sabdariffa* Linn; the effect of different vermicompost concentration on biochemical characteristics of the savory (*satureja hortensis* L.) cultivars; effects of salinity and water stress on germination characteristics of hyssop (*hyssopus officinalis* L.); investigation the effects of plant growth promoting rhizobacteria (PGPR) on the amount of essential oil of medicinal plant of tarragon; morphological traits reaction and Npk uptake of two savory of (*satureja hortensis* L.) cultivars to different vermicompost concentration; antidepressant-like potential of ethanolic extract of *apium graveolens* L. in the forced swim test and tail suspension test in mice; investigation the effects of biofertilizers on the morphological traits of medicinal plant of tarragon; PTLC isolation of marine alga *sargassum angustifolium* collected from the persian gulf coastal waters of bushehr; effect of different phenological stages on the essential oil content and chemical compositions of tancy (*tanacetum vulgare* L.); effects of cadmium and lead on seed germination and early seedling growth of fenugreek (*trigonella foenum graecum* L.); the effect of PH on seed germination of *ruta graveolens* L.; high scolicedal effect of ajowan (*trachyspermum ammi*) essential oil on protoscolices of hydatid cyst; the protective effect of henna and methylgreen on the *bacillus thuringiensis* against UV for control *pieris brassicae*; the effect of vermiwash foliar application and EM1 baikal fertilizer on morphological characteristics and essential oil content of *satureja hortensis* L.; optimum growth condition for fatty acids-rich microalgae *isochrysis* Sp; the effects of different drying methods on essential oil content and composition of on quantity and quality of essential oils of three genotypes of *lippia citriodora* in mazandaran; influences of drought stress on seed germination parameters in (*ruta graveolens* L.); the effect of altitude and harvesting time on chlorophyll content and essential oil of *salvia macrosiphon* Boiss; essential oil composition of flower of *citrus aurantium* and its effect on microbial properties of goat milk; comparison of *artemisia annua* essential oil quality on three habitats in east of mazandaran; computational analysis of 2-phenylethanol (2Pe) biosynthesis pathway in damask rose; study of pre-treatments on seed germination of *securigera securidaca* L., *salvia sclarea* L., *soponaria officinalis* L. and *malva sylvestris* L.; the protective effect of methanolic extract of *berberis integerrima* root on kidney damage in carbon tetrachloride - induced nephrotoxicity in rats; influence of different growth media on emergence percentage and growth parameters of seedling in *rumex tuberosus* L.; estimation of total phenolic content in *dracocephalum kotschy* Boiss., *melissa officinalis* L., *achillea millefolium* L., *valeriana officinalis* L., *juglans nigra* L., *artemisia absinthium* L., and *rosmarinus officinalis* L.; use of *plantago psyllium* seeds as holding valuable medicinal plant and an alternative to agar in tissue culture *fritillaria imperialis*; essential oil composition of flower of *citrus aurantium* and its effect on microbial properties of goat milk; the effect of different levels of dietary clove essential oil on water holding capacity (Whc) and meat moisture in broiler chickens; the block structure of sodium alginate from *sargassum*; milk-clotting activity of fruit extracts from *cucumis melo*; investigation the effects of clove essential oil on growth performance in broiler chicken; the anti-candida effects of ethanolic extracts of *berberis vulgaris* root and *zataria multiflora* Boiss in vitro and their comparison with clotrimazole and amphotericin B.; evaluation of antioxidant

activity and total phenolic content of three thyme species at different heights; histopathologic study on the effect of *tribulus terrestris* extract on mice testicles after heating; germination and seedling growth of flax under different salinity levels of sodium chloride; antimicrobial and antioxidant activities of flavonoid-rich fraction of *froriepia subpinata*; the effects of biological fertilizer and intercropping on some quantity and quality characteristics of fennel (*foeniculum vulgare* L.); benefit of alfalfa and fennel intercropping in different levels of planting pattern and biofertilizer; formulation of solid lipid nanoparticles containing herbal extracts of *dracocephalum moldavica* L. and *viola tricolor* L. as a sunscreen; chemical composition of *pelargonium quercetorum* essential oil; evaluating the effect of heavy metals on germination parameters of medicine plant of *cannabis sativa* L.; antioxidant activity of some extracts from aerial parts of *ajuga chamaecistus* SSP. *tomentella*; anatomical study of leaf and stem of *carthamus tinctorius* L. in Iran; histopathologic effect of *ruta graveolens* extract on changes of kidney tissue in mice; the effect of some treatments on seed dormancy and germination of *ferulago angulata*; evaluation of antibacterial effects of different fractions of ethanol extract of *teucrium polium* on selected gram positive and gram negative bacteria by bio-autography method and determination mic; an evaluation of the antimicrobial effect of *allium sativum* (garlic) on *staphylococcus aureus*, *escherichia coli*, *salmonella*, *bacillus subtilis*, *staphylococcus epidermidis*, *pseudomonas aeruginosa*, *bacillus cereus* & *streptococcus pyogenes*; effect of halopriming on germination of *ocimum basilicum* and *coriandrum sativum*; growth indices of sweet basil (*ocimum basilicum*) affected by combination of biologic and priming seed treatments; effect of combined biologic and priming seed treatments on P and K concentration in shoot of *nigella sativa* L.; effects of different treatments on microspore embryogenesis in *thymus daenensis*; knowledge, attitude and practice of people in rural area of Sihakal toward medicinal plants, Guilan, 2012; the effect of feeding different levels of sunflower seed on dissipation count of white blood cells in laying hens; effect of solvent on the quality and quantity of tannin extraction from *mentha piperita*; effect of extraction solvent on the extraction of anthocyanins from mint; phylogenetic studies of *crocus* species native to Iran with survey protein profiles; morphological diversity among wild populations of *salvia sahendica* (Lamiaceae) in Iran; chemical variability in the essential oil constituents of *salvia hypoleuca*, an endemic species from Iran; effect propagation conditions on rooting of *zataria multiflora* wood cuttings; a study on antibacterial properties of *zataria multiflora* plant; effect of curcumin on serum enzyme activity and histological changes in liver tissue in adrenalectomized rats; preparation of human serum albumin nanoparticles for natural compound delivery; investigation of anti *helicobacter pylori* activity of four Iranian medicinal plants; effects of *rosmarinus officinalis* and *peganum harmala* on isolated rat pancreatic islets; comparative anatomical study of the stem in *dracocephalum* species (Lamiaceae) in Iran; extraction of glycyrrhizic acid from licorice root using ultrasonic technique; nanoemulsification of *thymus daenensis* essential oil; estimation of radiation use efficiency in fenugreek (*trigonella foenum-graecum* L.) under different treatments of animal manure; leaf area index simulation of fenugreek (*trigonella foenum-graecum* L.) under optimum condition in Mashhad; leaf area estimation of summer savory (*satureja hortensis* L.) by total dry weight equation in different plant density; effect of plant density on radiation interception and use efficiency of summer savory (*satureja hortensis* L.); in vivo spawn production of wild and domestic white button mushroom (*agaricus bisporus*); the effect of different concentrations of BA and 2, 4-D on tissue culture of neem (*azadirachta indica* L.); variability of essential oil content and morphological traits of wild myrtle (*myrtus communis*) populations in Iran; relationship of stomatal length and frequency with ploidy level in *satureja* species (Lamiaceae); variability of agro-morphological traits and oil content among Iranian *artemisia dracunculoides* L. accessions; the effect of drying method on the essential oil yield and carvacrol content of *satureja khuzistanica* Jamzad and *satureja rechingeri* Jamzad; rosmarinic acid content and in vitro antibacterial activity of the methanolic extract of endemic *satureja* species growing in Iran; morphological diversity among wild populations of *salvia mirzayanii* (Lamiaceae) in Iran; phytochemical investigation on *nepeta denudata* Benth. and study of the biological activities of its components; micropropagation of lemon verbena (*lippiacitriodora*); enantioseparation of atropine and ammonium glufosinate by cellulose tris-phenylcarbamate chiral stationary phase in analytical scale; purification, identification and bio assays studies of cyclic peptides from

viola ignobilis; evaluation of anti-viral effects of *thymus vulgaris* L. extract against of herpes simplex virus type 1 on human cell culture; evaluation of anti-viral effects of *rutagraveolens* L. extract against of herpes simplex virus type 1 on human cell culture; effect of green tea (*camellia sinensis*) extract on sperm parameters in adult male rats; effects of copper and zinc on chlorophyll content, leaf area, biomass and essential oil content in savory (*satureja hortensis* L.); essential oil composition of *tanacetum abrotanifolium* (asteraceae) from Iran; essential oil composition of *acorus calamus* L. (acoraceae) from north of Iran; chemical variability in the essential oil composition of five *thymus* L. species in north of Iran; analysis of essential oils from *inflorescens* and seeds of *peucedanum ruthenicum* M.B., a plant endemic to Iran; evaluation on performance of *mentha piperita* by application of organic and biological inputs under organihume planting bed; in vitro shoot proliferation of *myrtus communis* L. from field-grown plants; the first report on observation of indole 3-butyric acid in Iranian isolates of cyanobacteria; chemical composition of the essential oil of three *tanacetum* species from north-west of Iran; chemical composition of the essential oil of *tanacetum polycephalum schultz-bip. subsp polycephalum* from different location of azarbaijan province in Iran; isolation of two abietane diterpenoids from the root extract of *salvia leriifolia*; morphological diversity among wild populations of *salvia mirzayanii* (lamiaceae) in Iran; simultaneous determination and quantification of flavonoids in 8 Iranian species of *dracocephalum* by HPLC method; two sesterterpenoids from *salvia lachnocalyx*; extraction of cyclotide from *viola ignobilis* by the use microwave assisted extraction method; identification of volatile organic compounds in *bacillus thuringiensis* before and after silver nanoparticles treatments and its influence on the nature of the peppermint essential oils; a new monoterpene ester derivative from aerial parts of *ferula ovina* boiss; chemical composition of plant extracts from *ferula hirtella* and *prangos acaulis*; the effect of microencapsulation on the antioxidative capacity of color compounds of berberies (*berberis vulgaris*); HPLC determination of phenolic acids in four *salvia* species with their antioxidant activities; measurement of water requirement and crop coefficient of basil in ardabil; an overveiw on phytoremediation of hydrocarbon pollutions in soil; acaricidal effects of some formulated compositions based on peppermint and rosemary essential oils against the two-spotted spider mite (*tetranychus urticae* koch); in vitro antifungal activity of various methanolic plant extracts against *alternaria solani*; early season weed control in fennel (*foeniculum vulgare* mill.) with reduced rate of pendimethalin; isolation and identification of the main constituents of *anthemis hussknechtii*; antibacterial effects of solvent extracted materials of *prosopis juliflora* aerial parts; phytochemical analysis and antibacterial effect of *achillea tenuifolia* lam; evaluation the yield and yield components of cumin landraces (*cuminum cyminum* L.) as affected by the bio--fertilizer under drought stress; comparison of different extraction methods in the extraction of essential oils from *dracocephalum kotschyi*; evaluation of total phenolic contents and antioxidant activities of three apple (*malus domestica* L) cultivars grown in west Azerbaijan; study the ethnobotany of medicinal plants in darab, fars province; effects of different concentrations of zinc element on morpho-physiological traits of fenugreek (*trigonella foenum- graecum*) in hydroponic conditions; chromatographic purification of lycopene and beta--carotene isolated from two Iranian species of cyanobacteria; inhibitory effects of vitexin on scopolamine-induced memory impairment in rats; quality and quantity assay of tannins in fruit bark of three cultivars of Iranian pomegranate; the effect of PH on stability of the anthocyanin--copigment complex in azarshahr red onion (*allium cepa*); effect of salysilic acid application and water stresses on yeild and quility of german chamomle (*matricaria chamomilla* L.); methanolic date seed extract effect on programmed cell death in human colorectal adenocarcinoma cell line (HT29); chemical constitutes of the essential oil of *artemisia chamaemelifolia* vill; stimulation of yield and physiological factors of mint (*mentha piperita* L.) with foliar application of biostimulators; finding high- quality method for DNA extraction from *zizophora clinopodioides*; the reaction of balm (*melissa officinalis* L.) to drought stress; studying of seed yield and yield components of different ecotype of *coriandrum sativum* in climate of ardabil; effect of polyvinylpyrrolidone (PVP) on induction and multiplication of callus on Iranian *hypericum perforatum* L.; the combination of hydrophobic absorbent and hydrophilic interaction liquid chromatography for separation and purification of 10-deacetyl baccatin III and taxol separately; evaluation of seasonal effects on transplanting of *ferula gummosa* from wild to green hose; the

rooting of ziziphora tenuir L. stem cuttings without using of chemical hormones; metabolomics-based approaches and its applications in medicinal plants studies; case study on thymus vulgaris; anti-diabetic, antimicrobial and antioxidant activities of various solvent extracts from eleven medicinal plants and essential oil composition of convolvulus persicus L.

Conference Information: 2nd National Congress on Medicinal Plants (2nd)Iran, Islamic Republic of. Conference Start: 20130515 Conference End: 20130516

Publisher: School of Pharmacy, Shaheed Beheshti University of Medical Sciences

Publication Type: Journal: Conference Review

Subject Headings: *medicinal plant
germination
Thymus (plant)
concentration (parameters)
Iran
plant seed
rat
plant leaf
callus (plant)
species
plant
antioxidant activity
basil
drought stress
gall (plant)
thymus
plant growth
fennel
parameters
Salvia
in vitro study
thyme
date (fruit)
chemical composition
cock (bird)
morphological trait
male
Artemisia
savory
fenugreek
salt stress
Satureja hortensis
garlic
population
flower
black cumin
human
antimicrobial activity
cumin
extraction
cow (mammal)
cultivar
salinity
Achillea
female
mouse
broiler
irrigation (agriculture)
diabetes mellitus
Melissa officinalis

fruit (structure)
antibacterial activity
myrtle
ecotype
Calendula officinalis
Aloe vera
safflower
plant density
manure
explant
Tuber (genus)
Crocus sativus
rosemary
alcoholism
artichoke
chicken
marigold
fruit
Echinacea purpurea
pomegranate
Silybum marianum
Zataria multiflora
Portulacaceae
intercropping
toxicity
vermicompost
Artemisia dracunculus
climate
morphology
seedling
coriander
weed
microwave radiation
Staphylococcus aureus
genotype
anise
genetic variability
grain (structure)
Ocimum
herb
Mentha piperita
serum
squash
Mentha
colocynth
sowing date
parsley
Tanacetum
tissue culture
Ferula
flowering
Urtica dioica
germander
mycorrhiza
dill
Portulaca oleracea
high performance liquid chromatography
lemon
Berberis
chlorophyll content

Nepeta
cytotoxicity
alfalfa
Cucurbita pepo
planting time
Matricaria recutita
harvesting
hydrodistillation
Foeniculum
Ammi
seed yield
storage
Allium
Borago
suspension cell culture
Plantago
Stachys
fungus
shallot
Chrysoperla carnea
Pelargonium
Rubia
weight
antifungal activity
rainbow trout
ultrasound
lavender
mucilage
laboratory
harvest period
pollen
growth curve
Eucalyptus
Lavandula angustifolia
oak
cell line
temperature
summer
bacterium
soil
Pistacia
alga
embryo (anatomy)
metabolite
density
rooting
olive
Hibiscus sabdariffa
city
galbanum
drought
bile
phylogeny
cell suspension
growth regulation
biomass
rabbit
oregano
blood
arbuscular mycorrhiza

Agastache
Rosa damascena
gas
model
water stress
salt tolerance
Anthemis
adult
rangeland
Trigonella
Lamiaceae
weed control
cancer cell culture
Matricaria chamomilla
Hyoscyamus
heat stress
micropropagation
leaf area
lipid peroxidation
onion
Salvia officinalis
stem cutting
Artemisia vulgaris
Citrullus
flour
dormancy
compost
liver
Scrophulariaceae
Matricaria
Glycyrrhiza glabra
Hypericum perforatum
callus culture
hairy root culture
Avicennia
Vitex
Escherichia coli
harvest
Bacillus cereus
bark
Chrysopidae
color
carp
Rumex
tea
moisture
supplementation
inoculation
Lippia
purification
Calendula
linseed
moth
Lycium
comparative study
cut flower
Euphorbia
screening
chicory
Glycyrrhiza

Sophora
celery
Sargassum
hen
Herpes simplex virus 1
mortality
tissues
herbal medicine
callus
Salmonella typhimurium
Laurus nobilis
disk diffusion
sea
medicinal species
Mentha spicata
watercress
culture medium
fertilizer application
Ruta graveolens
antineoplastic activity
Cinnamomum zeylanicum
phytochemistry
Taxus baccata
case study
planting density
Curcuma longa
Phlomis
season
liver toxicity
DNA extraction
clove
vegetable
pH
Echinacea
powder
Pseudomonas aeruginosa
Viola tricolor
microalga
Gracilaria
Tanacetum parthenium
postharvest period
inflorescence
biological activity
tomato
developmental stage
Carum
embryo
Securidaca
motoneuron
magnetic field
Myricaceae
Sambucus
Azerbaijan
forest
newborn
grain yield
synthesis
mangrove
caraway
grain

genus
symbiosis
wound
food
engineering
solvent extraction
healing
meat
Fritillaria
Coturnix japonica
environmental factor
biosynthesis
Malva
coastal waters
water deficit
regeneration
sweet potato whitefly
gene expression
photosynthesis
antiinflammatory activity
diet
chick
Campylobacter jejuni
Aspergillus flavus
sour orange
Oman
abiotic stress
Mentha longifolia
enzyme activity
breast cancer
Azadirachta indica
sperm
bean
petal
flora
brown alga
radiation
Chenopodium album
Juniperus
Ajuga
tree
Wistar rat
Rheum
Asteraceae
ploidy
Bacillus thuringiensis
milk
Laurus
Crataegus
fiber
Linum
fermentation
Ricinus communis
Silene
Verbenaceae
flax
Klebsiella pneumoniae
Fumaria
pepper
dermatitis

cinnamon
path analysis
fingerling
grape
Atropa
anatomical concepts
wound healing
oral drug administration
aging
antidiabetic activity
prostate cancer
sweet orange
subspecies
puberty
cardamom
lymphocyte
pistachio
sciatic nerve
Thiobacillus
immune response
immune system
Marrubium
scar formation
sprout
willow
Aegle marmelos
Cirsium
dry weight
nonalcoholic fatty liver
apricot
patient
Salmonella enteritidis
cell strain MCF 7
tail suspension test
vapor
ginger
Valeriana officinalis
aroma
plant disease
examination
solid phase microextraction
plant regeneration
diseases
bioassay
nutrition
essential oil
antioxidant
fertilizer
flavonoid
salicylic acid
antiinfective agent
acid
iron
plant medicinal product
water
methanol
peppermint
alcohol
plant extract
heavy metal

enzyme
phenol
phenol derivative
anthocyanin
chamomile
phytohormone
nitrogen fertilizer
nitrogen
peroxidase
free radical
carvacrol
rosmarinic acid
proline
zinc
marker
phosphorus
antibiotic agent
silver nanoparticle
ispagula
solvent
jasmonic acid methyl ester
cadmium
fatty acid
organic fertilizer
cannabis
thymol
ascorbic acid
sodium chloride
chlorophyll
humic acid
fumigant
carbohydrate
streptozocin
hormone
curcumin
polyphenol
protein
antifungal agent
polymer
ion
pigment
mannan
sulfur
vegetable oil
carbon tetrachloride
trace element
carotenoid
atropine
putrescine
natural product
liver enzyme
amino acid
oxidizing agent
eugenol
antidepressant agent
metal
alkaloid
magnetic nanoparticle
rutoside
silver

[titanium dioxide](#)
[coumarin](#)
[silicon](#)
[terpene](#)
[volatile agent](#)
[nitric oxide](#)
[iron chelate](#)
[Ruta graveolens extract](#)
[chlormequat](#)
[mineral](#)
[DNA](#)
[colchicine](#)
[paclitaxel](#)
[absorbent](#)
[potassium nitrate](#)
[arsenic](#)
[corn oil](#)
[glycoside](#)
[flavonol](#)
[kinetin](#)
[imidacloprid](#)
[fennel oil](#)
[gum tragacanth](#)
[vitamin](#)
[pectin](#)
[sedative agent](#)
[chamazulene](#)
[parthenolide](#)
[lavender oil](#)
[synthetase](#)

Source: EMBASE

Full Text: Available from *National Library of Medicine* in *Iranian Journal of Pharmaceutical Research : IJPR*

85. *Candida* vaginitis during contraceptive use: the influence of methods, antifungal susceptibility and virulence patterns.

Citation: Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology, Nov 2013, vol. 33, no. 8, p. 850-856, 1364-6893 (November 2013)

Author(s): Güzel, A B; Küçükgöz-Güleç, U; Aydın, M; Gümral, R; Kalkanci, A; Ilkit, M

Abstract: No consensus exists about whether contraceptives cause an increased risk of vaginitis, including vulvovaginal candidosis (VVC). We investigated 495 women (252 who used contraceptives; 243 who did not) for the presence of VVC. Antifungal susceptibility testing was performed for five antifungal agents and for boric acid, and three virulence factors were also examined. We recovered 129 (26.1%) monofungal populations from vaginal samples of women with acute VVC (AVVC, n = 18), symptomatic recurrent VVC (RVVC, n = 22) and asymptomatic RVVC (n = 28), as well as of other contraceptive users who carried *Candida* in their vaginas (n = 61). It is important to note that the women who had VVC used the same contraceptive methods ($p > 0.05$). *Candida albicans* was the most common species isolated (45%), followed by *C. glabrata* (40.3%). Most of the vaginal yeast isolates exhibited low minimum inhibitory concentration levels for the five antifungals tested. However, this was not the case for boric acid. In addition, the yeast fungi that was derived from the AVVC and RVVC patients showed higher amounts of haemolytic activity than the yeast fungi found among the controls ($p < 0.05$). The use of contraception does not predispose women to VVC ($p > 0.05$). Also, both host- and organism-related factors were required to achieve optimal clinical treatment for VVC.

Subject Headings: [Turkey](#)
[Contraceptive Devices](#)

[Prevalence](#)
[Adolescent](#)
[Contraception](#)
[Candida albicans](#)
[Middle Aged](#)
[Candidiasis Vulvovaginal](#)
[Humans](#)
[Index Medicus](#)
[Contraception Behavior](#)
[Young Adult](#)
[Adult](#)
[Female](#)
[Contraceptive Agents](#)
[Candida glabrata](#)
[Drug Resistance Fungal](#)

Source: Medline

Full Text: Available from *EBSCOhost* in *Journal of Obstetrics & Gynaecology*

86. Candida vaginitis during contraceptive use: The influence of methods, antifungal susceptibility and virulence patterns

Citation: Journal of Obstetrics and Gynaecology, November 2013, vol./is. 33/8(850-856), 0144-3615;1364-6893 (November 2013)

Author(s): Guzel A.B.; Kucukgoz-Gulec U.; Aydin M.; Gumral R.; Kalkanci A.; Ilkit M.

Institution: (Guzel, Kucukgoz-Gulec) Department of Obstetrics and Gynaecology Microbiology, Faculty of Medicine, University of Cukurova, Adana, 01330, Turkey; (Aydin, Kalkanci) Division of Mycology, Department of Microbiology, University of Cukurova, Adana, Turkey; (Aydin) Department of Microbiology, Faculty of Medicine, University of Gazi, Ankara, Turkey; (Gumral) Department of Microbiology, Faculty of Medicine, Erzincan University, Erzincan, France; (Ilkit) Department of Microbiology, Gulhane Military Medical Academy, Ankara, Turkey

Language: English

Abstract: No consensus exists about whether contraceptives cause an increased risk of vaginitis, including vulvovaginal candidosis (VVC). We investigated 495 women (252 who used contraceptives; 243 who did not) for the presence of VVC. Antifungal susceptibility testing was performed for five antifungal agents and for boric acid, and three virulence factors were also examined. We recovered 129 (26.1%) monofungal populations from vaginal samples of women with acute VVC (AVVC, n = 18), symptomatic recurrent VVC (RVVC, n = 22) and asymptomatic RVVC (n = 28), as well as of other contraceptive users who carried *Candida* in their vaginas (n = 61). It is important to note that the women who had VVC used the same contraceptive methods ($p > 0.05$). *Candida albicans* was the most common species isolated (45%), followed by *C. glabrata* (40.3%). Most of the vaginal yeast isolates exhibited low minimum inhibitory concentration levels for the five antifungals tested. However, this was not the case for boric acid. In addition, the yeast fungi that was derived from the AVVC and RVVC patients showed higher amounts of haemolytic activity than the yeast fungi found among the controls ($p < 0.05$). The use of contraception does not predispose women to VVC ($p > 0.05$). Also, both host- and organism-related factors were required to achieve optimal clinical treatment for VVC. © 2013 Informa UK, Ltd.

Country of Publication: United Kingdom

Publisher: Informa Healthcare (69-77 Paul Street, London EC2A 4LQ, United Kingdom)

CAS Registry Number: 10043-35-3 (boric acid); 11113-50-1 (boric acid); 11129-12-7 (boric acid); 14213-97-9 (boric acid); 23593-75-1 (clotrimazole); 86386-73-4 (fluconazole); 84625-61-6 (itraconazole); 65277-42-1 (ketoconazole); 22916-47-8 (miconazole)

Publication Type: Journal: Article

Subject Headings: [acute disease](#)

adult
 *antifungal susceptibility
 article
 asymptomatic infection
 *Candida
 Candida albicans
 Candida glabrata
 Candida kefyr
 Candida krusei
 Candida tropicalis
 Clavispora lusitaniae
 coitus interruptus
 condom
 *contraception
 controlled study
 female
 *fungal virulence
 fungus isolation
 hemolysis
 human
 intrauterine contraceptive device
 Kluyveromyces marxianus
 lifestyle
 major clinical study
 minimum inhibitory concentration
 prevalence
 priority journal
 recurrent infection
 Saccharomyces
 Saccharomyces kudriavzevii
 vagina
 *vagina candidiasis
 *vulvovaginal candidosis
 boric acid
 clotrimazole
 fluconazole
 itraconazole
 ketoconazole
 miconazole
 oral contraceptive agent
 "virulence factor/ec [Endogenous Compound]"

Source: EMBASE

Full Text: Available from *EBSCOhost* in *Journal of Obstetrics & Gynaecology*

87. The antimicrobial effect of boric acid on trichomonas vaginalis

Citation: Sexually Transmitted Diseases, 2014, vol./is. 41/12(718-722), 0148-5717;1537-4521 (2014)

Author(s): Brittingham A.; Wilson W.A.

Institution: (Brittingham) Department of Microbiology and Immunology, Des Moines University, 3200 Grand Ave, Des Moines, IA 50312, United States; (Wilson) Department of Biochemistry and Nutrition, Des Moines University, Des Moines, IA, United States

Language: English

Abstract: Background: The treatment options for trichomoniasis are largely limited to nitroimidazole compounds (metronidazole and tinidazole). Few alternatives exist in cases of recalcitrant infections or in cases of nitroimidazole hypersensitivity. Recently, the intravaginal administration of boric acid has been advocated as an alternative treatment of trichomoniasis. However, no in vitro studies are available that directly assess the

sensitivity of *Trichomonas vaginalis* to boric acid. Methods: We examined the sensitivity of common laboratory strains and recent clinical isolates of *T. vaginalis* to boric acid. The effect of increasing concentrations of boric acid on parasite growth and viability was determined, and a minimal lethal concentration was reported. The effect of pH on boric acid toxicity was assessed and compared with that of lactic and acetic acid. Results: Boric acid is microbicidal to *T. vaginalis*, and its antitrichomonal activity is independent of environmental acidification. Unlike acetic acid and lactic acid, boric acid exposure results in growth suppression and lethality over a wide range of pH (5-7) and under conditions that are normally permissible for growth in vitro. Conclusions: The microbicidal effect of boric acid on *T. vaginalis*, coupled with its previous clinical use in treating vaginal candidiasis, supports the continued inclusion of boric acid in the therapeutic arsenal for treating trichomoniasis.

Country of Publication: United States

Publisher: Lippincott Williams and Wilkins

CAS Registry Number: 127-08-2 (acetic acid); 127-09-3 (acetic acid); 64-19-7 (acetic acid); 71-50-1 (acetic acid); 10043-35-3 (boric acid); 11113-50-1 (boric acid); 11129-12-7 (boric acid); 14213-97-9 (boric acid); 113-21-3 (lactic acid); 50-21-5 (lactic acid)

Publication Type: Journal: Article

Subject Headings: acidification
 *antibacterial activity
 antibiotic sensitivity
 article
 clinical assessment
 clinical effectiveness
 concentration response
 *drug effect
 growth inhibition
 human
 in vitro study
 laboratory test
 lethal dose
 lethality
 nonhuman
 parasite isolation
 pH
 sensitivity analysis
Trichomonas vaginalis
 *trichomoniasis
 "acetic acid/cm [Drug Comparison]"
 "*antibiotic agent/cm [Drug Comparison]"
 "*antibiotic agent/an [Drug Analysis]"
 "*antibiotic agent/dv [Drug Development]"
 "*antibiotic agent/pd [Pharmacology]"
 "*boric acid/cm [Drug Comparison]"
 "*boric acid/an [Drug Analysis]"
 "*boric acid/dv [Drug Development]"
 "*boric acid/pd [Pharmacology]"
 "lactic acid/cm [Drug Comparison]"
 "microbicide/an [Drug Analysis]"
 "microbicide/dv [Drug Development]"
 "microbicide/pd [Pharmacology]"

Source: EMBASE

88. Recurrent vulvo-vaginal candida infection

Citation: European Journal of Contraception and Reproductive Health Care, May 2014, vol./is. 19/(S21-S22), 1362-5187 (May 2014)

Author(s): Horner P.

Institution: (Horner) University of Bristol, Bristol, United Kingdom

Language: English

Abstract: Recurrent vulvo-vaginal candidiasis (VVC) occurs in ~ 5% of women with VVC. It is defined as at least 4 episodes annually and is usually caused by *Candida albicans* but may be due to non *Candida albicans* spp. such as *C. glabrata* or less commonly *C. krusei*. Poorly controlled diabetes mellitus and antimicrobial therapy are predisposing factors as is pregnancy and high dose oestrogen combined oral contraception. Premenstrual exacerbation of vulvovaginal symptoms attributed to *Candida* spp. may be due to an increase in microorganism load during the luteal phase. While there is evidence that the sexual partner is at increased risk of being colonised with the same strain the contribution of sexual transmission to the pathogenesis remains unclear. There is limited evidence to support reinfection from an intestinal reservoir. The role of tight fitting underwear is unclear and there is no evidence that iron deficiency anaemia predisposes women to recurrent VVC. Unfortunately candidiasis or "thrush" is often the lay persons term to describe any vaginal discharge with or without irritation and many women with recurrent VVC do not indeed have VVC. There is a wide differential diagnosis ranging from non-infectious aetiologies such as allergic or hypersensitivity vulvitis to other infectious causes such as bacterial vaginosis. It is therefore important that confirmation of the diagnosis is established by culture and/or microscopy. Following diagnosis, advice on avoiding possible predisposing factors is often of limited value. Initial antimycotic therapy requires an induction course with either an oral and/or vaginal antimycotic agent until the patient is asymptomatic and culture negative. Failure to continue with a maintenance regimen will result in relapse of VVC in 50% at 3 months. Fluconazole 150mgs or a clotrimazole 500mgs pessary weekly can be used for six months. There is no evidence that this can result in antimicrobial resistance. Unfortunately on stopping therapy about 40-50% relapse and the reason for this is unclear. Antimicrobial resistant recurrent VVC is rare unless the patient is immunocompromised. However some women will be colonised by non- *albicans* species, the majority of which show reduced susceptibility to azoles. Typing and antimicrobial resistance testing should be undertaken on women who do not respond to induction therapy, the results of which can inform future therapy. Nystatin pessaries, Boric acid 600mgs as a gelatin capsule or amphotericin B 50mg suppositories administered vaginally, daily for 14-21 days have been shown to be moderately effective in clinically resistant infection.

Conference Information: 13th Congress of the European Society of Contraception and Reproductive Health Lisbon Portugal. Conference Start: 20140528 Conference End: 20140531

Publisher: Informa Healthcare

Publication Type: Journal: Conference Abstract

Subject Headings: [*society](#)
[*contraception](#)
[*reproductive health](#)
[*candidiasis](#)
[female](#)
[human](#)
[therapy](#)
[antibiotic resistance](#)
[patient](#)
[vagina pessary](#)
[relapse](#)
[Candida albicans](#)
[disease predisposition](#)
[diagnosis](#)
[drug megadose](#)
[reinfection](#)
[pathogenesis](#)
[iron deficiency anemia](#)
[vagina discharge](#)

sexual transmission
 risk
 sexuality
 pregnancy
 vagina candidiasis
 luteal phase
 microorganism
 antimicrobial therapy
 vaginitis
 Candida
 suppository
 microscopy
 oral contraception
 diabetes mellitus
 vulvitis
 hypersensitivity
 etiology
 differential diagnosis
 species
 infection
 antifungal agent
 fluconazole
 clotrimazole
 nystatin
 estrogen
 antiinfective agent
 pyrrole derivative
 boric acid
 gelatin
 amphotericin B

Source: EMBASE

Full Text: Available from *EBSCOhost* in *European Journal of Contraception & Reproductive Health Care*

89. Management of persistent vaginitis.

Citation: Obstetrics and gynecology, Dec 2014, vol. 124, no. 6, p. 1135-1146, 1873-233X (December 2014)

Author(s): Nyirjesy, Paul

Abstract: With vaginitis remaining a common condition that leads women to seek care, it is not surprising that some women develop chronic vulvovaginal problems that are difficult to diagnose and treat. With a differential diagnosis that encompasses vulvar disorders and infectious and noninfectious causes of vaginitis, accurate diagnosis is the cornerstone of choosing effective therapy. Evaluation should include a symptom-specific history, careful vulvar and vaginal examination, and office-based tests (vaginal pH, amine test, saline and 10% potassium hydroxide microscopy). Ancillary tests, especially yeast culture with speciation, are frequently crucial to obtaining a correct diagnosis. A heavy but normal physiologic discharge can be determined by excluding other causes. With vulvovaginal candidiasis, differentiating between *Candida albicans* and non-*albicans* *Candida* infection has important treatment ramifications. Most patients with *C. albicans* infections can be successfully treated with maintenance antifungal therapy, usually with fluconazole. Although many non-*albicans* *Candida*, particularly *Candida glabrata*, may at times be innocent bystanders, vaginal boric acid therapy is an effective first choice for many true non-*albicans* *Candida* infections. Recurrent bacterial vaginosis, a difficult therapeutic challenge, can often be controlled with maintenance therapy. Multiple options, especially high-dose tinidazole, have been used for metronidazole-resistant trichomoniasis. With the aging of the U.S. population, atrophic vaginitis and desquamative inflammatory vaginitis, both associated with hypoestrogenism, are encountered frequently in women with persistent vaginitis.

Subject Headings: [Vaginitis](#)
[Humans](#)
[Index Medicus](#)
[Vagina](#)
[Female](#)
[Abridged Index Medicus](#)
[Chronic Disease](#)

Source: Medline

90. The antimicrobial effect of boric acid on *Trichomonas vaginalis*.

Citation: Sexually transmitted diseases, Dec 2014, vol. 41, no. 12, p. 718-722, 1537-4521 (December 2014)

Author(s): Brittingham, Andrew; Wilson, Wayne A

Abstract: The treatment options for trichomoniasis are largely limited to nitroimidazole compounds (metronidazole and tinidazole). Few alternatives exist in cases of recalcitrant infections or in cases of nitroimidazole hypersensitivity. Recently, the intravaginal administration of boric acid has been advocated as an alternative treatment of trichomoniasis. However, no in vitro studies are available that directly assess the sensitivity of *Trichomonas vaginalis* to boric acid. We examined the sensitivity of common laboratory strains and recent clinical isolates of *T. vaginalis* to boric acid. The effect of increasing concentrations of boric acid on parasite growth and viability was determined, and a minimal lethal concentration was reported. The effect of pH on boric acid toxicity was assessed and compared with that of lactic and acetic acid. Boric acid is microbicidal to *T. vaginalis*, and its antitrichomonal activity is independent of environmental acidification. Unlike acetic acid and lactic acid, boric acid exposure results in growth suppression and lethality over a wide range of pH (5-7) and under conditions that are normally permissible for growth in vitro. The microbicidal effect of boric acid on *T. vaginalis*, coupled with its previous clinical use in treating vaginal candidiasis, supports the continued inclusion of boric acid in the therapeutic arsenal for treating trichomoniasis.

Subject Headings: [Administration Intravaginal](#)
[Trichomonas vaginalis](#)
[Humans](#)
[Index Medicus](#)
[Female](#)
[Boric Acids](#)
[Treatment Outcome](#)
[Anti-Infective Agents](#)
[Trichomonas Vaginitis](#)

Source: Medline

91. Management of persistent vaginitis

Citation: Obstetrics and Gynecology, December 2014, vol./is. 124/6(1135-1146), 0029-7844;1873-233X (11 Dec 2014)

Author(s): Nyirjesy P.

Institution: (Nyirjesy) Department of Obstetrics and Gynecology, Drexel University School of Medicine, New College Building, 245 North 15th Street, Philadelphia, PA 19102, United States

Language: English

Abstract: With vaginitis remaining a common condition that leads women to seek care, it is not surprising that some women develop chronic vulvovaginal problems that are difficult to diagnose and treat. With a differential diagnosis that encompasses vulvar disorders and infectious and noninfectious causes of vaginitis, accurate diagnosis is the cornerstone of choosing effective therapy. Evaluation should include a symptom-specific history, careful vulvar and vaginal examination, and office-based tests (vaginal pH, amine test, saline and

10% potassium hydroxide microscopy). Ancillary tests, especially yeast culture with speciation, are frequently crucial to obtaining a correct diagnosis. A heavy but normal physiologic discharge can be determined by excluding other causes. With vulvovaginal candidiasis, differentiating between *Candida albicans* and non-*albicans* *Candida* infection has important treatment ramifications. Most patients with *C. albicans* infections can be successfully treated with maintenance antifungal therapy, usually with fluconazole. Although many non-*albicans* *Candida*, particularly *Candida glabrata*, may at times be innocent bystanders, vaginal boric acid therapy is an effective first choice for many true non-*albicans* *Candida* infections. Recurrent bacterial vaginosis, a difficult therapeutic challenge, can often be controlled with maintenance therapy. Multiple options, especially high-dose tinidazole, have been used for metronidazole-resistant trichomoniasis. With the aging of the U.S. population, atrophic vaginitis and desquamative inflammatory vaginitis, both associated with hypoestrogenism, are encountered frequently in women with persistent vaginitis.

Country of Publication: United Kingdom
Publisher: Lippincott Williams and Wilkins
CAS Registry Number: 18323-44-9 (clindamycin); 86386-73-4 (fluconazole); 31799-91-4 (hyaluronic acid); 9004-61-9 (hyaluronic acid); 9067-32-7 (hyaluronic acid); 50-23-7 (hydrocortisone); 65277-42-1 (ketoconazole); 39322-38-8 (metronidazole); 443-48-1 (metronidazole); 128607-22-7 (ospemifene); 11035-13-5 (paromomycin); 1263-89-4 (paromomycin); 1390-73-4 (paromomycin); 51795-47-2 (paromomycin); 54597-56-7 (paromomycin); 7542-37-2 (paromomycin); 84420-34-8 (paromomycin); 53-43-0 (prasterone); 19387-91-8 (tinidazole)

Publication Type: Journal: Article

Subject Headings: [antibiotic therapy](#)
[article](#)
[candidiasis](#)
[desquamative inflammatory vaginitis](#)
["desquamative inflammatory vaginitis/dt \[Drug Therapy\]"](#)
[evaluation study](#)
[female](#)
[human](#)
["trichomoniasis/dt \[Drug Therapy\]"](#)
[United States](#)
["vagina atrophy/dt \[Drug Therapy\]"](#)
["vagina candidiasis/dt \[Drug Therapy\]"](#)
[vagina discharge](#)
["*vaginitis/dt \[Drug Therapy\]"](#)
["clindamycin/dt \[Drug Therapy\]"](#)
["estrogen/dt \[Drug Therapy\]"](#)
["fluconazole/dt \[Drug Therapy\]"](#)
["hyaluronic acid/dt \[Drug Therapy\]"](#)
["hydrocortisone/dt \[Drug Therapy\]"](#)
["ketoconazole/dt \[Drug Therapy\]"](#)
["metronidazole/dt \[Drug Therapy\]"](#)
["nitroimidazole derivative/dt \[Drug Therapy\]"](#)
["ospemifene/dt \[Drug Therapy\]"](#)
["paromomycin/dt \[Drug Therapy\]"](#)
["prasterone/dt \[Drug Therapy\]"](#)
["tinidazole/dt \[Drug Therapy\]"](#)

Source: EMBASE

92. BASIC study: is intravaginal boric acid non-inferior to metronidazole in symptomatic bacterial vaginosis? Study protocol for a randomized controlled trial.

Citation: Trials, Jan 2015, vol. 16, p. 315., 1745-6215 (2015)

Author(s): Zeron Mullins, Melinda; Trouton, Konia M

Abstract: Bacterial vaginosis is associated with increased transmission of sexually transmitted infections, preterm labor, post-surgical infections, and endometritis. Current treatment for symptomatic bacterial vaginosis includes antibiotics, such as metronidazole, which are 70-80 % effective at one month after treatment and result in high recurrence rates and secondary candida infections. Intravaginal boric acid has been used for over a hundred years to treat vaginal infections, such as bacterial vaginosis. Boric acid is inexpensive, accessible, and has shown to be an effective treatment for other infections, such as vaginal candidiasis. To date, there has been no clinical trial evaluation of boric acid effectiveness to treat bacterial vaginosis. The BASIC (Boric Acid, Alternate Solution for Intravaginal Colonization) trial is a randomized, double-blinded, multicenter study. The study will enroll a minimum of 240 women of 16-50 years of age who are symptomatic with bacterial vaginosis. Eligible participants will have Amsel and Nugent scores confirming bacterial vaginosis. Women who are pregnant or menopausal or have other active co-infections will be excluded. Consenting participants who meet exclusion and inclusion criteria will be randomly assigned to one of three treatment groups: boric acid, metronidazole, or an inert placebo. Self-administration of treatment intravaginally for 10 days will be followed by clinical assessment at 7 and 30 days (days 17 and 40, respectively) after the end of the treatment phase. Primary outcome is a non-inferiority, per-protocol comparison of the effectiveness of boric acid with that of metronidazole at day 17, as measured by the Nugent score in 16-50 year olds. Secondary outcomes include: non-inferiority, intention-to-treat comparison of effectiveness of boric acid with that of metronidazole at day 17, analysis for both per-protocol and intention-to-treat at day 40, and safety considerations, including adverse effects requiring patient discontinuation of treatment. This study will be the first to determine whether intravaginal boric acid is non-inferior to metronidazole in the treatment of bacterial vaginosis in symptomatic women. ClinicalTrials.gov NCT00799214, registered online Nov 10, 2008.

Subject Headings: [Intention to Treat Analysis](#)
[Research Design](#)
[British Columbia](#)
[Administration Intravaginal](#)
[Adolescent](#)
[Middle Aged](#)
[Time Factors](#)
[Humans](#)
[Index Medicus](#)
[Metronidazole](#)
[Treatment Outcome](#)
[Young Adult](#)
[Adult](#)
[Female](#)
[Anti-Bacterial Agents](#)
[Boric Acids](#)
[Remission Induction](#)
[Clinical Protocols](#)
[Double-Blind Method](#)
[Vaginosis Bacterial](#)

Source: Medline

Full Text: Available from *BioMed Central* in [Trials](#)
 Available from *National Library of Medicine* in [Trials](#)

93. Glucose tetrasaccharide (Glc4) instability in urine, resolved by use of a special collection tube

Citation: Molecular Genetics and Metabolism, February 2015, vol./is. 114/2(S96-S97), 1096-7192 (February 2015)

Author(s): Prunty H.; Lock P.; Harvey K.; Burke D.; Heales S.

Institution: (Prunty, Lock, Harvey, Burke, Heales) Great Ormond Street Hospital NHS Foundation Trust, London, United Kingdom

- Language:** English
- Abstract:** Urinary glucose tetrasaccharide (Glc4) is a useful biomarker in Pompe disease, being thought to reflect the degree of glycogen storage. However, we have occasionally observed unexpectedly low results in some patients which cannot be readily explained by the clinical picture despite our initial stability studies indicating that urinary Glc4 should be stable for at least 7 days at room temperature. Bacterial contamination was thought to be a possible explanation, particularly as samples are often collected into nappies or urine bags and transported at room temperature. As it is not practical for samples to be transported frozen, and use of an established preservative such as boric acid would potentially interfere with the analytical method, we investigated whether the addition of an ion exchange resin (Duolite MB-6113 resin, activated in 2 N acetic acid), used in the sample preparation step for the HPLC method employed in our laboratory, might have a secondary role as a urine preservative. To investigate this hypothesis, urine samples from Pompe patients (n =16) and infected urine samples obtained from the microbiology department (n= 5) were spiked with Glc4 and a portion analysed at baseline and again after 5 days incubation at room temperature; with and without addition of resin. Without resin, 7 of the Pompe urines showed complete degradation of Glc4, 3 showed partial (15%, 20%, 40%) degradation, and 10 showed no degradation. The degradation did not correlate with apparent evidence of bacterial contamination on pH or Multistix analysis. These urines will be sent for microbial culture to investigate further. Of the known infected urines, those infected with *Escherichia coli* (n= 4) showed no degradation of Glc4, whereas a urine with mixed growth of coliform, *Streptococcus B*, and *Candida albicans* (n =1) showed complete degradation of Glc4. However, the addition of the ion exchange resin prior to incubation stabilised the urinary Glc4, preventing degradation in all samples. In summary, urinary Glc4 may be subject to degradation in some cases. This is most likely due to the presence of bacteria or other microorganisms, but is dependent upon the type of organisms present. Stability is variable and suitability of urine samples cannot be predicted by pH or Multistix results. Most importantly, regardless of the cause, the addition of an ion exchange resin at baseline stabilised urinary Glc4 for at least 5 days at room temperature in all of the cases studied so far. We therefore propose the use of a special urine collection tube pre-loaded with ion exchange resin to prevent Glc4 degradation and to ensure more meaningful and reliable results.
- Conference Information:** 11th Annual Research Meeting of the Lysosomal Disease Network, WORLD Symposium, 2015 Orlando, FL United States. Conference Start: 20150209 Conference End: 20150213
- Publisher:** Academic Press Inc.
- Publication Type:** Journal: Conference Abstract
- Subject Headings:** [*urine](#)
[*tube](#)
[room temperature](#)
[urinalysis](#)
[human](#)
[patient](#)
[bacterium contamination](#)
[pH](#)
[storage](#)
[analytic method](#)
[glycogen storage disease type 2](#)
[glucose urine level](#)
[Candida albicans](#)
[Streptococcus agalactiae](#)
[Escherichia coli](#)
[microbiology](#)
[hypothesis](#)
[laboratory](#)
[Bacteria](#)
[microorganism](#)
[high performance liquid chromatography](#)
[*glucose](#)

*tetrasaccharide
ion exchange resin
resin
preservative
glycogen
biological marker
boric acid
acetic acid

Source: EMBASE

94. Guideline: vulvovaginal candidosis (AWMF 015/072), S2k (excluding chronic mucocutaneous candidosis).

Citation: Mycoses, Mar 2015, vol. 58 Suppl 1, p. 1-15, 1439-0507 (March 2015)

Author(s): Mendling, Werner; Brasch, J; Cornely, O A; Effendy, I; Friese, K; Ginter-Hanselmayer, G; Hof, H; Mayser, P; Mylonas, I; Ruhnke, M; Schaller, M; Weissenbacher, E-R

Abstract: The oestrogenised vagina is colonised by *Candida* species in at least 20% of women; in late pregnancy and in immunosuppressed patients, this increases to at least 30%. In most cases, *Candida albicans* is involved. Host factors, particularly local defence mechanisms, gene polymorphisms, allergies, serum glucose levels, antibiotics, psycho-social stress and oestrogens influence the risk of candidal vulvovaginitis. Non-*albicans* species, particularly *Candida glabrata*, and in rare cases also *Saccharomyces cerevisiae*, cause less than 10% of all cases of vulvovaginitis with some regional variation; these are generally associated with milder signs and symptoms than normally seen with a *C. albicans*-associated vaginitis. Typical symptoms include premenstrual itching, burning, redness and odourless discharge. Although itching and redness of the introitus and vagina are typical symptoms, only 35-40% of women reporting genital itching in fact suffer from vulvovaginal candidosis. Medical history, clinical examination and microscopic examination of vaginal content using 400× optical magnification, or preferably phase contrast microscopy, are essential for diagnosis. In clinically and microscopically unclear cases and in chronically recurring cases, a fungal culture for pathogen determination should be performed. In the event of non-*C. albicans* species, the minimum inhibitory concentration (MIC) should also be determined. Chronic mucocutaneous candidosis, a rarer disorder which can occur in both sexes, has other causes and requires different diagnostic and treatment measures. Treatment with all antimycotic agents on the market (polyenes such as nystatin; imidazoles such as clotrimazole; and many others including ciclopirox olamine) is easy to administer in acute cases and is successful in more than 80% of cases. All vaginal preparations of polyenes, imidazoles and ciclopirox olamine and oral triazoles (fluconazole, itraconazole) are equally effective (Table); however, oral triazoles should not be administered during pregnancy according to the manufacturers. *C. glabrata* is not sufficiently sensitive to the usual dosages of antimycotic agents approved for gynaecological use. In other countries, vaginal suppositories of boric acid (600 mg, 1-2 times daily for 14 days) or flucytosine are recommended. Boric acid treatment is not allowed in Germany and flucytosine is not available. Eight hundred-milligram oral fluconazole per day for 2-3 weeks is therefore recommended in Germany. Due to the clinical persistence of *C. glabrata* despite treatment with high-dose fluconazole, oral posaconazole and, more recently, echinocandins such as micafungin are under discussion; echinocandins are very expensive, are not approved for this indication and are not supported by clinical evidence of their efficacy. In cases of vulvovaginal candidosis, resistance to *C. albicans* does not play a significant role in the use of polyenes or azoles. *Candida krusei* is resistant to the triazoles, fluconazole and itraconazole. For this reason, local imidazole, ciclopirox olamine or nystatin should be used. There are no studies to support this recommendation, however. Side effects, toxicity, embryotoxicity and allergies are not clinically significant. Vaginal treatment with clotrimazole in the first trimester of a pregnancy reduces the rate of premature births. Although it is not necessary to treat a vaginal colonisation of *Candida* in healthy women, vaginal administration of antimycotics is often recommended in the third trimester of pregnancy in Germany to reduce the rate of oral thrush and napkin dermatitis in healthy full-term newborns. Chronic recurrent vulvovaginal candidosis continues to be treated in intervals using suppressive therapy as long as immunological treatments are not available. The relapse rate associated with

weekly or monthly oral fluconazole treatment over 6 months is approximately 50% after the conclusion of suppressive therapy according to current studies. Good results have been achieved with a fluconazole regimen using an initial 200 mg fluconazole per day on 3 days in the first week and a dosage-reduced maintenance therapy with 200 mg once a month for 1 year when the patient is free of symptoms and fungal infection (Table). Future studies should include Candida autovaccination, antibodies to Candida virulence factors and other immunological experiments. Probiotics with appropriate lactobacillus strains should also be examined in future studies on the basis of encouraging initial results. Because of the high rate of false indications, OTC treatment (self-treatment by the patient) should be discouraged. © 2015 Blackwell Verlag GmbH.

Subject Headings: [Candida albicans](#)
[Humans](#)
[Candidiasis Vulvovaginal](#)
[Antifungal Agents](#)
[Microscopy Phase-Contrast](#)
[Vaginal Discharge](#)
[Pregnancy Complications Infectious](#)
[Pregnancy](#)
[Germany](#)
[Female](#)
[Infant Newborn](#)
[Index Medicus](#)
[Candida glabrata](#)
[Microbial Sensitivity Tests](#)

Source: Medline

Full Text: Available from *EBSCOhost* in [Mycoses](#)

95. Guideline: vulvovaginal candidosis (AWMF 015/072), S2k (excluding chronic mucocutaneous candidosis)

Citation: Mycoses, March 2015, vol./is. 58/(1-15), 1439-0507 (01 Mar 2015)

Author(s): Mendling W.

Institution: (Mendling) Deutsches Zentrum für Infektionen in Gynäkologie und Geburtshilfe, Vogelsangstrasse 106, 42109 Wuppertal, Germany

Language: English

Abstract: The oestrogenised vagina is colonised by Candida species in at least 20% of women; in late pregnancy and in immunosuppressed patients, this increases to at least 30%. In most cases, Candida albicans is involved. Host factors, particularly local defence mechanisms, gene polymorphisms, allergies, serum glucose levels, antibiotics, psycho-social stress and oestrogens influence the risk of candidal vulvovaginitis. Non-albicans species, particularly Candida glabrata, and in rare cases also Saccharomyces cerevisiae, cause less than 10% of all cases of vulvovaginitis with some regional variation; these are generally associated with milder signs and symptoms than normally seen with a C. albicans-associated vaginitis. Typical symptoms include premenstrual itching, burning, redness and odourless discharge. Although itching and redness of the introitus and vagina are typical symptoms, only 35-40% of women reporting genital itching in fact suffer from vulvovaginal candidosis. Medical history, clinical examination and microscopic examination of vaginal content using 400x optical magnification, or preferably phase contrast microscopy, are essential for diagnosis. In clinically and microscopically unclear cases and in chronically recurring cases, a fungal culture for pathogen determination should be performed. In the event of non-C. albicans species, the minimum inhibitory concentration (MIC) should also be determined. Chronic mucocutaneous candidosis, a rarer disorder which can occur in both sexes, has other causes and requires different diagnostic and treatment measures. Treatment with all antimycotic agents on the market (polyenes such as nystatin; imidazoles such as clotrimazole; and many others including ciclopirox olamine) is easy to administer in acute cases and is successful in more than 80% of cases. All vaginal preparations of polyenes, imidazoles and ciclopirox olamine and oral triazoles (fluconazole, itraconazole) are equally effective (Table); however, oral

triazoles should not be administered during pregnancy according to the manufacturers. *C. glabrata* is not sufficiently sensitive to the usual dosages of antimycotic agents approved for gynaecological use. In other countries, vaginal suppositories of boric acid (600 mg, 1-2 times daily for 14 days) or flucytosine are recommended. Boric acid treatment is not allowed in Germany and flucytosine is not available. Eight hundred-milligram oral fluconazole per day for 2-3 weeks is therefore recommended in Germany. Due to the clinical persistence of *C. glabrata* despite treatment with high-dose fluconazole, oral posaconazole and, more recently, echinocandins such as micafungin are under discussion; echinocandins are very expensive, are not approved for this indication and are not supported by clinical evidence of their efficacy. In cases of vulvovaginal candidosis, resistance to *C. albicans* does not play a significant role in the use of polyenes or azoles. *Candida krusei* is resistant to the triazoles, fluconazole and itraconazole. For this reason, local imidazole, ciclopirox olamine or nystatin should be used. There are no studies to support this recommendation, however. Side effects, toxicity, embryotoxicity and allergies are not clinically significant. Vaginal treatment with clotrimazole in the first trimester of a pregnancy reduces the rate of premature births. Although it is not necessary to treat a vaginal colonisation of *Candida* in healthy women, vaginal administration of antimycotics is often recommended in the third trimester of pregnancy in Germany to reduce the rate of oral thrush and napkin dermatitis in healthy full-term newborns. Chronic recurrent vulvovaginal candidosis continues to be treated in intervals using suppressive therapy as long as immunological treatments are not available. The relapse rate associated with weekly or monthly oral fluconazole treatment over 6 months is approximately 50% after the conclusion of suppressive therapy according to current studies. Good results have been achieved with a fluconazole regimen using an initial 200 mg fluconazole per day on 3 days in the first week and a dosage-reduced maintenance therapy with 200 mg once a month for 1 year when the patient is free of symptoms and fungal infection (Table). Future studies should include *Candida* autovaccination, antibodies to *Candida* virulence factors and other immunological experiments. Probiotics with appropriate lactobacillus strains should also be examined in future studies on the basis of encouraging initial results. Because of the high rate of false indications, OTC treatment (self-treatment by the patient) should be discouraged.

Country of Publication: Germany

Publication Type: Journal: Article

Subject Headings: [Candida albicans](#)
[Candida glabrata](#)
["Candidiasis Vulvovaginal/di \[Diagnosis\]"](#)
["Candidiasis Vulvovaginal/dt \[Drug Therapy\]"](#)
[*drug effects](#)
[female](#)
[Germany](#)
[human](#)
[microbial sensitivity test](#)
[microbiology](#)
[newborn](#)
[phase contrast microscopy](#)
[pregnancy](#)
["Pregnancy Complications Infectious/di \[Diagnosis\]"](#)
["Pregnancy Complications Infectious/dt \[Drug Therapy\]"](#)
[vagina discharge](#)
["antifungal agent/ad \[Drug Administration\]"](#)
["antifungal agent/dt \[Drug Therapy\]"](#)

Source: EMBASE

Full Text: Available from *EBSCOhost* in *Mycoses*

96. Guideline: Vulvovaginal candidosis (AWMF 015/072), S2k (excluding chronic mucocutaneous candidosis)

Citation: Mycoses, March 2015, vol./is. 58/S1(1-15), 0933-7407;1439-0507 (01 Mar 2015)

Author(s): Mendling W.

Institution:	(Mendling) Deutsches Zentrum für Infektionen in Gynäkologie und Geburtshilfe, Vogelsangstrasse 106, Wuppertal 42109, Germany
Language:	English
Abstract:	<p>The oestrogenised vagina is colonised by <i>Candida</i> species in at least 20% of women; in late pregnancy and in immunosuppressed patients, this increases to at least 30%. In most cases, <i>Candida albicans</i> is involved. Host factors, particularly local defence mechanisms, gene polymorphisms, allergies, serum glucose levels, antibiotics, psycho-social stress and oestrogens influence the risk of candidal vulvovaginitis. Non-<i>albicans</i> species, particularly <i>Candida glabrata</i>, and in rare cases also <i>Saccharomyces cerevisiae</i>, cause less than 10% of all cases of vulvovaginitis with some regional variation; these are generally associated with milder signs and symptoms than normally seen with a <i>C. albicans</i>-associated vaginitis. Typical symptoms include premenstrual itching, burning, redness and odourless discharge. Although itching and redness of the introitus and vagina are typical symptoms, only 35-40% of women reporting genital itching in fact suffer from vulvovaginal candidosis. Medical history, clinical examination and microscopic examination of vaginal content using 400x optical magnification, or preferably phase contrast microscopy, are essential for diagnosis. In clinically and microscopically unclear cases and in chronically recurring cases, a fungal culture for pathogen determination should be performed. In the event of non-<i>C. albicans</i> species, the minimum inhibitory concentration (MIC) should also be determined. Chronic mucocutaneous candidosis, a rarer disorder which can occur in both sexes, has other causes and requires different diagnostic and treatment measures. Treatment with all antimycotic agents on the market (polyenes such as nystatin; imidazoles such as clotrimazole; and many others including ciclopirox olamine) is easy to administer in acute cases and is successful in more than 80% of cases. All vaginal preparations of polyenes, imidazoles and ciclopirox olamine and oral triazoles (fluconazole, itraconazole) are equally effective (Table); however, oral triazoles should not be administered during pregnancy according to the manufacturers. <i>C. glabrata</i> is not sufficiently sensitive to the usual dosages of antimycotic agents approved for gynaecological use. In other countries, vaginal suppositories of boric acid (600 mg, 1-2 times daily for 14 days) or flucytosine are recommended. Boric acid treatment is not allowed in Germany and flucytosine is not available. Eight hundred-milligram oral fluconazole per day for 2-3 weeks is therefore recommended in Germany. Due to the clinical persistence of <i>C. glabrata</i> despite treatment with high-dose fluconazole, oral posaconazole and, more recently, echinocandins such as micafungin are under discussion; echinocandins are very expensive, are not approved for this indication and are not supported by clinical evidence of their efficacy. In cases of vulvovaginal candidosis, resistance to <i>C. albicans</i> does not play a significant role in the use of polyenes or azoles. <i>Candida krusei</i> is resistant to the triazoles, fluconazole and itraconazole. For this reason, local imidazole, ciclopirox olamine or nystatin should be used. There are no studies to support this recommendation, however. Side effects, toxicity, embryotoxicity and allergies are not clinically significant. Vaginal treatment with clotrimazole in the first trimester of a pregnancy reduces the rate of premature births. Although it is not necessary to treat a vaginal colonisation of <i>Candida</i> in healthy women, vaginal administration of antimycotics is often recommended in the third trimester of pregnancy in Germany to reduce the rate of oral thrush and napkin dermatitis in healthy full-term newborns. Chronic recurrent vulvovaginal candidosis continues to be treated in intervals using suppressive therapy as long as immunological treatments are not available. The relapse rate associated with weekly or monthly oral fluconazole treatment over 6 months is approximately 50% after the conclusion of suppressive therapy according to current studies. Good results have been achieved with a fluconazole regimen using an initial 200 mg fluconazole per day on 3 days in the first week and a dosage-reduced maintenance therapy with 200 mg once a month for 1 year when the patient is free of symptoms and fungal infection (Table). Future studies should include <i>Candida</i> autovaccination, antibodies to <i>Candida</i> virulence factors and other immunological experiments. Probiotics with appropriate lactobacillus strains should also be examined in future studies on the basis of encouraging initial results. Because of the high rate of false indications, OTC treatment (self-treatment by the patient) should be discouraged.</p>
Country of Publication:	United Kingdom

Publisher: Blackwell Publishing Ltd

CAS Registry Number: 1397-89-3 (amphotericin B); 30652-87-0 (amphotericin B); 41621-49-2 (ciclopiroxolamine); 23593-75-1 (clotrimazole); 24169-02-6 (econazole); 27220-47-9 (econazole); 73151-29-8 (fenticonazole nitrate); 86386-73-4 (fluconazole); 84625-61-6 (itraconazole); 208538-73-2 (micafungin); 22832-87-7 (miconazole nitrate); 1400-61-9 (nystatin); 34786-70-4 (nystatin); 62997-67-5 (nystatin); 171228-49-2 (posaconazole)

Publication Type: Journal: Article

Subject Headings: antifungal resistance
 article
 Candida albicans
 Candida glabrata
 Candida parapsilosis
 Candida tropicalis
 dyspareunia
 dysuria
 estrogen blood level
 fungal colonization
 fungal virulence
 genetic polymorphism
 gynecological examination
 human
 immunotherapy
 intravaginal drug administration
 Lactobacillus
 Meyerozyma guilliermondii
 microscopy
 nonhuman
 pH measurement
 phase contrast microscopy
 Pichia kudriavzevii
 practice guideline
 pregnancy
 priority journal
 prophylaxis
 recurrent infection
 risk factor
 self care
 serology
 systematic review
 "*vagina candidiasis/di [Diagnosis]"
 "*vagina candidiasis/dr [Drug Resistance]"
 "*vagina candidiasis/et [Etiology]"
 "*vagina candidiasis/dt [Drug Therapy]"
 vagina discharge
 vagina pain
 vaginal burning sensation
 vaginal pruritus
 amphotericin B
 "ciclopiroxolamine/dt [Drug Therapy]"
 "clotrimazole/dt [Drug Therapy]"
 "econazole/dt [Drug Therapy]"
 "estrogen/ec [Endogenous Compound]"
 "fenticonazole nitrate/dt [Drug Therapy]"
 "fluconazole/dt [Drug Therapy]"
 imidazole derivative
 itraconazole
 mannoprotein
 micafungin
 "miconazole nitrate/dt [Drug Therapy]"

nystatin
 oral contraceptive agent
 "polyene/dt [Drug Therapy]"
 posaconazole
 "pyrrole derivative/dt [Drug Therapy]"
 siderophore
 "skin cream/dt [Drug Therapy]"
 "triazole derivative/dt [Drug Therapy]"
 virulence factor

Source: EMBASE
Full Text: Available from *EBSCOhost* in *Mycoses*

97. Boric acid destabilizes the hyphal cytoskeleton and inhibits invasive growth of *Candida albicans*

Citation: Yeast, April 2015, vol./is. 32/4(389-398), 0749-503X;1097-0061 (01 Apr 2015)
Author(s): Pointer B.R.; Boyer M.P.; Schmidt M.
Institution: (Pointer, Boyer, Schmidt) Department of Biochemistry and Nutrition, Des Moines University, United States
Language: English
Abstract: Exposure of *Candida albicans* to sub-lethal concentrations of boric acid (BA) restricts the dimorphic fungus to its yeast morphology and prevents the formation of invasive hyphae on solid substrates. Exposure to BA causes a rapid and reversible disappearance of polarisome and Spitzenkorper in growing hyphae. In BA-treated hyphae of *C. albicans*, actin quickly reorganizes from cytoplasmic cables to cortical patches and cell wall growth switches from an apical to an isotropic pattern. As a result of the cytoskeletal changes, the hyphal tips broaden and directional growth of hyphae ceases in the presence of BA. An analysis of homozygous deletion strains showed that mutants with constitutive or enhanced hyphal growth (*tup1*, *nrg1*, *ssn6*, *rbf1*) are BA-sensitive, demonstrating that cellular morphology is a major determinant of BA tolerance. The screening of deletion mutants also showed that deficiencies of the main activator of hyphal gene expression, Efg1, and the Rim101-signalling cascade, leading to Efg1 activation, cause BA resistance. Taken together, the data presented show that the selective inhibitory effect on BA on *C. albicans* hyphae is rooted in a disruption of apical cytoskeletal elements of growing hyphae.
Country of Publication: United Kingdom
Publisher: John Wiley and Sons Ltd (Southern Gate, Chichester, West Sussex PO19 8SQ, United Kingdom)
CAS Registry Number: 10043-35-3 (boric acid); 11113-50-1 (boric acid); 11129-12-7 (boric acid); 14213-97-9 (boric acid)
Publication Type: Journal: Article
Subject Headings: acid tolerance
 *actin filament
 article
 **Candida albicans*
 cell structure
 deletion mutant
 EFG1 gene
 fluorescence microscopy
 *fungus growth
 *fungus hyphae
 gene
 gene activation
 gene disruption
 gene expression
 nonhuman
 priority journal

signal transduction
*boric acid

Source: EMBASE

98. BASIC study: Is intravaginal boric acid non-inferior to metronidazole in symptomatic bacterial vaginosis? Study protocol for a randomized controlled trial

Citation: Trials, July 2015, vol./is. 16/1(no pagination), 1745-6215 (July 26, 2015)

Author(s): Zeron Mullins M.; Trouton K.M.

Institution: (Zeron Mullins, Trouton) University of British Columbia, Department of Family Practice, 3rd Floor David Strangway Building, 5950 Uni. Boulevard, Vancouver, BC V6T 1Z3, Canada

Language: English

Abstract: Background: Bacterial vaginosis is associated with increased transmission of sexually transmitted infections, preterm labor, post-surgical infections, and endometritis. Current treatment for symptomatic bacterial vaginosis includes antibiotics, such as metronidazole, which are 70-80 % effective at one month after treatment and result in high recurrence rates and secondary candida infections. Intravaginal boric acid has been used for over a hundred years to treat vaginal infections, such as bacterial vaginosis. Boric acid is inexpensive, accessible, and has shown to be an effective treatment for other infections, such as vaginal candidiasis. To date, there has been no clinical trial evaluation of boric acid effectiveness to treat bacterial vaginosis. Methods/Design: The BASIC (Boric Acid, Alternate Solution for Intravaginal Colonization) trial is a randomized, double-blinded, multicenter study. The study will enroll a minimum of 240 women of 16-50 years of age who are symptomatic with bacterial vaginosis. Eligible participants will have Amsel and Nugent scores confirming bacterial vaginosis. Women who are pregnant or menopausal or have other active co-infections will be excluded. Consenting participants who meet exclusion and inclusion criteria will be randomly assigned to one of three treatment groups: boric acid, metronidazole, or an inert placebo. Self-administration of treatment intravaginally for 10 days will be followed by clinical assessment at 7 and 30 days (days 17 and 40, respectively) after the end of the treatment phase. Primary outcome is a non-inferiority, per-protocol comparison of the effectiveness of boric acid with that of metronidazole at day 17, as measured by the Nugent score in 16-50 year olds. Secondary outcomes include: non-inferiority, intention-to-treat comparison of effectiveness of boric acid with that of metronidazole at day 17, analysis for both per-protocol and intention-to-treat at day 40, and safety considerations, including adverse effects requiring patient discontinuation of treatment. Discussion: This study will be the first to determine whether intravaginal boric acid is non-inferior to metronidazole in the treatment of bacterial vaginosis in symptomatic women. Trial registration: ClinicalTrials.gov NCT00799214 , registered online Nov 10, 2008.

Country of Publication: United Kingdom

Publisher: BioMed Central Ltd.

CAS Registry Number: 10043-35-3 (boric acid); 11113-50-1 (boric acid); 11129-12-7 (boric acid); 14213-97-9 (boric acid); 39322-38-8 (metronidazole); 443-48-1 (metronidazole)

Publication Type: Journal: Article

Subject Headings: adolescent
adult
age distribution
Amsel score
article
clinical assessment
controlled study
double blind procedure
drug safety
drug self administration
drug withdrawal

female
 follow up
 human
 informed consent
 intention to treat analysis
 major clinical study
 menopause
 mixed infection
 multicenter study
 Nugent Score
 pregnant woman
 randomized controlled trial
 scoring system
 symptomatology
 treatment outcome
 "unspecified side effect/si [Side Effect]"
 "*vaginitis/di [Diagnosis]"
 "*vaginitis/dt [Drug Therapy]"
 "*boric acid/ct [Clinical Trial]"
 "*boric acid/ae [Adverse Drug Reaction]"
 "*boric acid/cm [Drug Comparison]"
 "*boric acid/va [Intravaginal Drug Administration]"
 "*boric acid/dt [Drug Therapy]"
 "*metronidazole/va [Intravaginal Drug Administration]"
 "*metronidazole/cm [Drug Comparison]"
 "*metronidazole/dt [Drug Therapy]"
 placebo

Source: EMBASE

Full Text: Available from *BioMed Central* in [Trials](#)
 Available from *National Library of Medicine* in [Trials](#)

99. An Alternative Approach to Assess the Habitat Selection of *Folsomia candida* in Contaminated Soils

Citation: Bulletin of environmental contamination and toxicology, November 2015, vol./is. 95/5(670-674), 1432-0800 (01 Nov 2015)

Author(s): Bori J.; Riva M.C.

Institution: (Bori) Center for Research and Innovation in Toxicology (CRIT-Innotex Center), Technical University of Catalonia (UPC), Ctra. Nac. 150 km 15, 08227, Terrassa, Barcelona, Spain.; (Riva) Center for Research and Innovation in Toxicology (CRIT-Innotex Center), Technical University of Catalonia (UPC), Ctra. Nac. 150 km 15, 08227, Terrassa, Barcelona, Spain

Language: English

Abstract: Avoidance tests with collembolans provide a quick assessment of soil quality. However, some parameters of the procedure can be modified in order to increase its performance. In this study we assessed the tendency of *Folsomia candida* to avoid soils contaminated with boric acid [350-700-1400-2800-5600 mg/kg soil dry weight (dw)], phenmedipham (35-70-140-280 mg/kg dw) or petroleum hydrocarbons (1312-1838-2625-3675-5250 mg/kg dw) by preferring an untreated soil. Two separate methodologies were applied, the one presented in the ISO standard 17512:2 and a modified version of the Petri dish method that allowed data acquisition after 2, 24 and 48 h of exposure. After combining data from three separate trials, effective median concentration values (EC50) from the presented method were lower and showed similar or less variability than those from the ISO procedure, suggesting the modified protocol as a suitable alternative screening tool.

Country of Publication: United States

CAS Registry Number: 10043-35-3 (boric acid); 11113-50-1 (boric acid); 11129-12-7 (boric acid); 14213-97-9 (boric acid); 8002-05-9 (petroleum); 13684-63-4 (phenmedipham)

Publication Type: Journal: Article

Subject Headings: analysis
 animal
 arthropod
 *chemistry
 *drug effects
 *ecosystem
 environmental monitoring
 *growth development and aging
 oil spill
 *procedures
 soil
 soil pollutant
 Spain
 standards
 "boric acid/an [Drug Analysis]"
 "carbamic acid derivative/an [Drug Analysis]"
 "petroleum/an [Drug Analysis]"
 phenmedipham

Source: EMBASE

100. Non-albicans Candida Vulvovaginitis: Treatment Experience at a Tertiary Care Vaginitis Center

Citation: Journal of Lower Genital Tract Disease, January 2016, vol./is. 20/1(85-89), 1089-2591;1526-0976 (01 Jan 2016)

Author(s): Powell A.M.; Gracely E.; Nyirjesy P.

Institution: (Powell, Nyirjesy) Drexel University College of Medicine, Department of Obstetrics and Gynecology, 245 N 15th St MS 495, Philadelphia, PA 19102, United States; (Gracely) Drexel University College of Medicine, Department of Family, Community and Preventive Medicine, United States; (Gracely) Department of Epidemiology and Biostatistics, Drexel School of Public Health, Philadelphia, PA, United States

Language: English

Abstract: Objectives The aims of this study are to analyze a cohort of women with vulvovaginal symptoms and positive cultures for non-albicans Candida (NAC) to determine whether yeast was responsible for their symptoms and to evaluate the mycological effectiveness of various regimens. Methods This observational study was performed from retrospective chart review of patients with positive NAC cultures between April 1, 2008, and January 31, 2011, at a tertiary care vaginitis center. Patient intake demographics were entered into a database. Follow-up visits were analyzed for data about patient treatments and outcomes. Patients were considered a clinical cure if their symptoms were significantly improved and mycologic cure (MC) if later yeast cultures were negative. If clinical symptoms improved at the same time as MC, the isolate was considered the proximate cause for the symptoms. Results One hundred eight patients meeting entry criteria were analyzed. Boric acid was effective at obtaining MC in 32 (78%) of 41 patients with *C. glabrata*, 3 of 3 patients with *C. tropicalis*, and 3 of 3 patients with *C. lusitaniae*. Fluconazole was effective as initial treatment for 3 (60%) of 5 patients with *C. glabrata* and 13 (81%) of 16 patients with *C. parapsilosis*. In 52.7% of *C. glabrata*, 66.7% of *C. parapsilosis*, and 57.1% of *C. tropicalis* cases, effective antifungal therapy led to symptom improvement. Conclusions In a tertiary care vaginitis center, NAC, when isolated on culture, caused clinically significant infections in approximately half of symptomatic patients. A majority of infections can be effectively treated with boric acid or fluconazole regardless of the non-albicans Candida species.

Country of Publication: United States

Publisher: Lippincott Williams and Wilkins

CAS Registry Number: 1397-89-3 (amphotericin B); 30652-87-0 (amphotericin B); 10043-35-3 (boric acid); 11113-50-1 (boric acid); 11129-12-7 (boric acid); 14213-97-9 (boric acid); 189768-38-5 (caspofungin); 86386-73-4 (fluconazole); 1400-61-9 (nystatin); 34786-70-4 (nystatin); 62997-67-5 (nystatin)

Publication Type: Journal: Article

Subject Headings: adult
 article
 "atrophic vaginitis/dt [Drug Therapy]"
 *Candida glabrata
 *Candida parapsilosis
 *Candida tropicalis
 *Clavispora lusitaniae
 drug efficacy
 drug treatment failure
 female
 human
 maintenance therapy
 major clinical study
 microbiological examination
 middle aged
 observational study
 retrospective study
 tertiary health care
 "vulvodynia/dt [Drug Therapy]"
 "*vulvovaginitis/dt [Drug Therapy]"
 "amphotericin B/va [Intravaginal Drug Administration]"
 "*boric acid/dt [Drug Therapy]"
 "*boric acid/po [Oral Drug Administration]"
 "*boric acid/pd [Pharmacology]"
 caspofungin
 "*fluconazole/dt [Drug Therapy]"
 "*fluconazole/pd [Pharmacology]"
 nystatin

Source: EMBASE

101. Influence of boric acid on strains of the genus Candida [Polyglot] Vliv kyseliny borite na druhy rodu Candida

Original Title: Vliv kyseliny borite na druhy rodu Candida

Citation: Ceskoslovenska gynekologie, 1949, vol./is. 14/2(97-100), 0374-6852 (1949)

Author(s): KOCKOVA-KRATOCHVILOVA A.

Language: Polyglot

Publication Type: Journal: Article

Subject Headings: article
 *candidiasis
 *boron derivative

Source: EMBASE

102. Diaper dermatitis: Current concepts

Citation: Pediatrics, 1980, vol./is. 66/4(532-536), 0031-4005 (1980)

Author(s): Weston W.L.; Lane A.T.; Weston J.A.

Institution: (Weston, Lane, Weston) Dept. Dermatol., Univ. Colorado Hlth Sci. Cent., Denver, Colo. 80262 United States

Language: English

Abstract: Diaper dermatitis may result from prolonged skin contact with wetness and bacteria. Ammonia plays no apparent role in the generation of diaper dermatitis. Candida albicans frequently contaminates a diaper dermatitis and should be considered present in any diaper dermatitis known to be present for longer than three days. Topical fluorinated

glucocorticosteroids, boric acid, and mercury-containing preparations should be avoided in the diaper area because of their toxicity.

Country of Publication: United States
Publication Type: Journal: Article
Subject Headings: article
 *Candida albicans
 *dermatitis
 *diaper
 drug therapy
 therapy
 topical drug administration
 *methylbenzethonium
 unclassified drug
Source: EMBASE

103. The boric acid powder treatment of vulvovaginal candidiasis

Citation: Journal of the American College Health Association, 1981, vol./is. 30/3(107-109) (1981)
Author(s): Keller van Slyke K.; Pender Michel V.; Rein M.F.
Institution: (Keller van Slyke, Pender Michel, Rein) Dept. Gynecol., Student Hlth Serv., Univ. Virginia, Charlottesville, VA 22908 United States
Language: English
Country of Publication: United States
CAS Registry Number: 10043-35-3 (boric acid); 11113-50-1 (boric acid); 11129-12-7 (boric acid); 14213-97-9 (boric acid)
Publication Type: Journal: Article
Subject Headings: *Candida albicans
 female genital system
 fungus
 therapy
 topical drug administration
 *vagina
 *vulva
 *boric acid
Source: EMBASE

104. Treatment of vulvovaginal candidiasis with boric acid powder

Citation: American Journal of Obstetrics and Gynecology, 1981, vol./is. 141/2(145-148), 0002-9378 (1981)
Author(s): Van Slyke K.K.; Michel V.P.; Rein M.F.
Institution: (Van Slyke, Michel, Rein) Div. Infect. Dis., Univ. Virginia Sch. Med., Charlottesville, VA 22908 United States
Language: English
Abstract: A double-blind comparison was made of the use of 14 daily intravaginal gelatin capsules containing 600 mg of boric acid powder versus the use of identical capsules containing 100,000 U nystatin diluted to volume with cornstarch for the treatment of vulvovaginal candidiasis albicans. Cure rates for boric acid were 92% at 7 to 10 days after treatment and 72% at 30 days, whereas the nystatin cure rates were 64% at 7 to 10 days and 50% at 30 days. The speed of alleviation of signs and symptoms was similar for the two drugs. There were no untoward side effects, and cervical cytologic features were not affected. In vitro studies found boric acid to be fungistatic and its effectiveness to be unrelated to pH. Blood boron analyses indicated little absorption from the vagina and a half-life of less than 12 hours. Acceptance by the patients was better than for 'messy' vaginal creams, and

self-made capsules containing boric acid powder are inexpensive (31 cents for 14) compared with the costly medication commonly prescribed.

Country of Publication: United States

CAS Registry Number: 10043-35-3 (boric acid); 11113-50-1 (boric acid); 11129-12-7 (boric acid); 14213-97-9 (boric acid); 1400-61-9 (nystatin); 34786-70-4 (nystatin); 62997-67-5 (nystatin)

Publication Type: Journal: Article

Subject Headings: [*Candida albicans](#)
[*candidiasis](#)
[controlled study](#)
[double blind procedure](#)
[female genital system](#)
[fungus](#)
[*Gardnerella vaginalis](#)
[intratumoral drug administration](#)
[intravaginal drug administration](#)
[major clinical study](#)
[powder](#)
[therapy](#)
[*Trichomonas vaginalis](#)
[*vulvovaginitis](#)
[*boric acid](#)
[borofax](#)
[*nystatin](#)
[unclassified drug](#)

Source: EMBASE

105. Current therapy of vulvovaginitis

Citation: Sexually transmitted diseases, October 1981, vol./is. 8/4 suppl(316-320), 0148-5717 (1981 Oct-Dec)

Author(s): Rein M.F.

Language: English

Abstract: Trichomoniasis is reliably treated with a single 2-g dose of metronidazole; however, with this regimen simultaneous treatment of sexual partners is particularly important. Trichomoniasis in pregnant women, who should not receive metronidazole, might be treated initially with clotrimazole vaginal suppositories, which appear to cure about 50% of cases. Topical antifungal agents of the imidazole class are superior to polyenes in treating vulvovaginal candidiasis. Boric acid powder applied intravaginally in gelatin capsules for 14 days appears as effective as imidazoles. Nonspecific vaginitis is now recognized as involving infection with anaerobic bacteria of the vaginal flora as well as Gardnerella vaginalis. The condition is most successfully treated with a seven-day course of metronidazole, which probably acts by eradicating the anaerobes. In addition, metabolites of metronidazole may act directly on G. vaginalis. Sulfanilamide-aminacrine-allantoin preparations are much less effective than specific therapies and have no role in the treatment of vulvovaginitis.

Country of Publication: United States

CAS Registry Number: 10043-35-3 (boric acid); 11113-50-1 (boric acid); 11129-12-7 (boric acid); 14213-97-9 (boric acid); 23593-75-1 (clotrimazole); 39322-38-8 (metronidazole); 443-48-1 (metronidazole)

Publication Type: Journal: Article

Subject Headings: [article](#)
["bacterial infection/dt \[Drug Therapy\]"](#)
["*candidiasis/dt \[Drug Therapy\]"](#)
[female](#)
[human](#)

male
 pregnancy
 "*Trichomonas vaginalis/dt [Drug Therapy]"
 "vaginitis/dt [Drug Therapy]"
 "*vulvovaginitis/dt [Drug Therapy]"
 "*antifungal agent/dt [Drug Therapy]"
 "boric acid/dt [Drug Therapy]"
 "clotrimazole/dt [Drug Therapy]"
 "imidazole derivative/dt [Drug Therapy]"
 "*metronidazole/dt [Drug Therapy]"

Source: EMBASE

106. The boric acid powder treatment of vulvovaginal candidiasis.

Citation: Journal of the American College Health Association, Dec 1981, vol. 30, no. 3, p. 107-109, 0002-7944 (December 1981)

Author(s): Van Slyke, K K; Michel, V P; Rein, M F

Subject Headings: Capsules
 Humans
 Candidiasis
 Vulvovaginitis
 Index Medicus
 Nystatin
 Female
 Boric Acids
 Double-Blind Method

Source: Medline

107. Enhanced differentiation of isolates of candida albicans using a modified resistogram method

Citation: Mykosen, 1982, vol./is. 25/11(589-598), 0027-5557 (1982)

Author(s): McCreight M.C.; Warnock D.W.

Institution: (McCreight, Warnock) Dep. Microbiol., Bristol R. Infirm., Bristol BS2 8HW United Kingdom

Language: English

Abstract: The method described is based on differences in the resistance of *C. albicans* isolates to five chemicals (sodium selenite, boric acid, cetrinide, sodium periodate, silver nitrate) used at critical concentrations. Of 66 isolates tested on two occasions, 61 were assigned to the same strain on re-testing. Five isolates differed in their resistance to one chemical. Of the 32 potential strains that can be distinguished, 16 were found among 198 oral isolates from 22 normal subjects sampled at 1 month intervals for 12 months. Particular strains were found to persist in individual subjects and strains with identical resistograms were found in related subjects.

Country of Publication: Germany

Publication Type: Journal: Article

Subject Headings: *Candida albicans
 diagnosis
 differentiation
 epidemiology
 fungus

Source: EMBASE

108. Nystatin versus boric acid powder in vulvovaginal candidiasis

Citation: American journal of obstetrics and gynecology, December 1982, vol./is. 144/8(992-993), 0002-9378 (15 Dec 1982)

Author(s): Orley J.
Language: English
Country of Publication: United States
CAS Registry Number: 10043-35-3 (boric acid); 11113-50-1 (boric acid); 11129-12-7 (boric acid); 14213-97-9 (boric acid); 1400-61-9 (nystatin); 34786-70-4 (nystatin); 62997-67-5 (nystatin)
Publication Type: Journal: Letter
Subject Headings: female
human
letter
powder
"*vagina candidiasis/dt [Drug Therapy]"
"*boric acid/dt [Drug Therapy]"
"*nystatin/ad [Drug Administration]"
"*nystatin/dt [Drug Therapy]"
Source: EMBASE

109. Nystatin versus boric acid powder in vulvovaginal candidiasis.

Citation: American journal of obstetrics and gynecology, Dec 1982, vol. 144, no. 8, p. 992-993, 0002-9378 (December 15, 1982)
Author(s): Orley, J
Subject Headings: Candidiasis Vulvovaginal
Humans
Powders
Index Medicus
Nystatin
Female
Boric Acids
Abridged Index Medicus
Source: Medline

110. Bacterial and chemical analysis of otitis externa during immersion in saturated solutions. Double blind test on the usefulness of prophylactic and therapeutic preparations [Italian] RILIEVI BATTERIOLOGICI E CLINICI SULL'OTITE ESTERNA IN SATURAZIONE. STUDIO A DOPPIO CIECO SULL'EFFICACIA DI PREPARATI PROFILATTICI E TERAPEUTICI

Original Title: RILIEVI BATTERIOLOGICI E CLINICI SULL'OTITE ESTERNA IN SATURAZIONE. STUDIO A DOPPIO CIECO SULL'EFFICACIA DI PREPARATI PROFILATTICI E TERAPEUTICI
Citation: Minerva Medica, 1983, vol./is. 74/35(2029-2032), 0026-4806 (1983)
Author(s): Marroni A.; Arduini R.; Conti S.
Language: Italian
Abstract: Microbiological analysis of the variation in the bacterial flora of the external auditory canal was carried out during 39 immersions in saturated solutions. A double blind test on the usefulness of prophylactic and therapeutic preparations was also carried out. Prophylactics. - 5% Al acetate in H₂O (P1), Boric alcohol (P2), lactic acid in H₂O (P3, Domeboro (P4), no prophylactic (P0). After the immersions, a significant increase in Pseudomonas Aeruginosa and Candida Albicans (p < 0,01) was noted in the auricular bacterial flora. Gram positive bacteria in general were considerably reduced (p < 0,01). Gram negative bacteria other than pseudomonas A (p < 0,3) and coagulase negative staphylococci (p < 0,03) did not vary significantly. Prophylactic preparations P1 and P2 were shown to be significantly more effective than P3, P4 and P0 in preventing the symptomatology (p < 0,01). The most effective therapeutic preparation was found to be a locally applied gentamycin-polymixin association.

Country of Publication: Italy

CAS Registry Number: 64-17-5 (alcohol); 139-12-8 (aluminum acetate); 7360-44-3 (aluminum acetate); 8006-13-1 (aluminum acetate solution); 8001-54-5 (benzalkonium); 10043-35-3 (boric acid); 11113-50-1 (boric acid); 11129-12-7 (boric acid); 14213-97-9 (boric acid); 1392-48-9 (gentamicin); 1403-66-3 (gentamicin); 1405-41-0 (gentamicin); 50-23-7 (hydrocortisone); 113-21-3 (lactic acid); 50-21-5 (lactic acid); 11004-65-2 (neomycin); 1404-04-2 (neomycin); 1405-10-3 (neomycin); 8026-22-0 (neomycin); 11081-39-3 (polymyxin); 1406-11-7 (polymyxin); 52580-78-6 (polymyxin); 1404-26-8 (polymyxin B); 1405-20-5 (polymyxin B); 8012-89-3 (propolis)

Publication Type: Journal: Article

Subject Headings: auditory system
*Candida
Candida albicans
clinical article
*drug efficacy
*drug sensitivity
*external otitis
fungus
human
prevention
*prophylaxis
*Pseudomonas
Pseudomonas aeruginosa
*Staphylococcus
*therapy
*alcohol
*aluminum acetate
*aluminum acetate solution
*benzalkonium
*boric acid
*gentamicin
*hydrocortisone
*lactic acid
*neomycin
polymyxin
*polymyxin B
*propolis

Source: EMBASE

111. [Bacteriological and clinical notes on otitis externa in saturation. Double-blind study on the efficacy of prophylactic and therapeutic preparations].

Citation: Minerva medica, Sep 1983, vol. 74, no. 35, p. 2029-2032, 0026-4806 (September 15, 1983)

Author(s): Marroni, A; Arduini, R; Conti, S

Abstract: Microbiological analysis of the variation in the bacterial flora of the external auditory canal was carried out during 39 immersion in saturated solutions. A double blind test on the usefulness of prophylactic and therapeutic preparations was also carried out. Prophylactics. - 5% Al acetate in H₂O (P1), Boric alcohol (P2), lactic acid in H₂O (P3, Domeboro (P4), no prophylactic (P0). After the immersions, a significant increase in Pseudomonas Aeruginosa and Candida Albicans (p less than 0,01) was noted in the auricular bacterial flora. Gram positive bacteria in general were considerably reduced (p less than 0,01). Gram negative bacteria other than pseudomonas. A (p less than 0,3) and coagulase negative straphylococci (p less than 0,03) did not vary significantly. Prophylactic preparations P1 and P2 were shown to be significantly more effective than P3, P4 and P0 in preventing the symptomatology (p less than 0,01). The most effective

therapeutic preparation was found to be a locally applied gentamycinpolymixin association.

Subject Headings: [Neomycin](#)
[Gentamicins](#)
[Candida albicans](#)
[Propolis](#)
[Benzalkonium Compounds](#)
[Humans](#)
[Otitis Externa](#)
[Clinical Trials as Topic](#)
[Hydrocortisone](#)
[Adult](#)
[Index Medicus](#)
[Pseudomonas aeruginosa](#)
[Double-Blind Method](#)
[Polymyxin B](#)
[Imidazoles](#)
[Glycerol](#)

Source: Medline

112. A new simple method for biotyping *Candida albicans*

Citation: Microbios, 1987, vol./is. 51/208-209(159-167), 0026-2633 (1987)

Author(s): Williamson M.I.; Samaranayake L.P.; MacFarlane T.W.

Institution: (Williamson, Samaranayake, MacFarlane) Department of Oral Medicine and Pathology, Glasgow Dental Hospital and School, Scotland, Great Britain.

Language: English

Abstract: A simple method which allows rapid, reproducible biotyping of *Candida albicans* isolates, and is suitable for use in any diagnostic medical microbiology laboratory is described. This system comprises three tests, the API ZYM system, the API 20C system, and a plate test for resistance to boric acid. The system differentiated a possible 234 biotypes, of which 33 were found amongst the 130 isolates of *C. albicans* taken from oral, genital and skin sites. Major biotypes found amongst oral and non-oral isolates were similar, although differences were found amongst minor biotypes. The new system was found to be reproducible, discriminatory, reasonably fast (48 h), easy to perform, and had no requirement for specialised equipment. Hence this biotyping system is suitable for use in diagnostic microbiology laboratories for epidemiological investigations of *C. albicans* infections.

Country of Publication: United Kingdom

CAS Registry Number: 10043-35-3 (boric acid); 11113-50-1 (boric acid); 11129-12-7 (boric acid); 14213-97-9 (boric acid)

Publication Type: Journal: Article

Subject Headings: [antibiotic resistance](#)
[article](#)
[*Candida albicans](#)
[classification](#)
[drug effect](#)
[enzymology](#)
[human](#)
[metabolism](#)
[methodology](#)
[mycology](#)
["boric acid/pd \[Pharmacology\]"](#)

Source: EMBASE

113. A new simple method for biotyping *Candida albicans*.

Citation: Microbios, Jan 1987, vol. 51, no. 208-209, p. 159-167, 0026-2633 (1987)

Author(s): Williamson, M I; Samaranayake, L P; MacFarlane, T W

Abstract: A simple method which allows rapid, reproducible biotyping of *Candida albicans* isolates, and is suitable for use in any diagnostic medical microbiology laboratory is described. This system comprises three tests, the API ZYM system, the API 20C system, and a plate test for resistance to boric acid. The system differentiated a possible 234 biotypes, of which 33 were found amongst the 130 isolates of *C. albicans* taken from oral, genital and skin sites. Major biotypes found amongst oral and non-oral isolates were similar, although differences were found amongst minor biotypes. The new system was found to be reproducible, discriminatory, reasonably fast (48 h), easy to perform, and had no requirement for specialised equipment. Hence this biotyping system is suitable for use in diagnostic microbiology laboratories for epidemiological investigations of *C. albicans* infections.

Subject Headings: [Candida albicans](#)
[Humans](#)
[Index Medicus](#)
[Boric Acids](#)
[Drug Resistance Microbial](#)
[Mycology](#)

Source: Medline

114. Clinical evaluation of a salicylic acid/boric acid/ammonium alum combination as coadjuvants in the treatment of *Trichomonas vaginalis* and *Candida albicans* vulvovaginitis [Portuguese] AVALIACAO CLINICA DE UMA ASSOCIACAO ACIDO SALICILICO/ACIDO BORICO/ALUMEN AMONIAL COMO COADJUVANTE NO TRATAMENTO DE VULVOVAGINITES POR TRICHOMONAS VAGINALIS E CANDIDA ALBICANS

Original Title: AVALIACAO CLINICA DE UMA ASSOCIACAO ACIDO SALICILICO/ACIDO BORICO/ALUMEN AMONIAL COMO COADJUVANTE NO TRATAMENTO DE VULVOVAGINITES POR TRICHOMONAS VAGINALIS E CANDIDA ALBICANS

Citation: Jornal Brasileiro de Ginecologia, 1987, vol./is. 97/7(359-362), 0368-1416 (1987)

Author(s): Cabral Goncalves N.M.C.

Institution: (Cabral Goncalves) Ginecologista e Obstetra, Medica do Servico de Medicina Ocupacional da Santa Casa de Misericordia de Porto Alegre, Porto Alegre, RS Brazil

Language: Portuguese

Country of Publication: Brazil

CAS Registry Number: 493-53-8 (acetylsalicylic acid); 50-78-2 (acetylsalicylic acid); 53663-74-4 (acetylsalicylic acid); 53664-49-6 (acetylsalicylic acid); 63781-77-1 (acetylsalicylic acid); 7784-25-0 (aluminum ammonium sulfate); 7784-26-1 (aluminum ammonium sulfate); 10043-35-3 (boric acid); 11113-50-1 (boric acid); 11129-12-7 (boric acid); 14213-97-9 (boric acid); 23593-75-1 (clotrimazole); 9001-63-2 (lysozyme); 8028-52-2 (vinegar)

Publication Type: Journal

Subject Headings: [clinical article](#)
[controlled study](#)
[drug comparison](#)
[drug efficacy](#)
[drug mixture](#)
[female genital system](#)
[human](#)
[therapy](#)
[*vulvovaginitis](#)
[**acetylsalicylic acid/cm \[Drug Comparison\]"](#)
[**aluminum ammonium sulfate/cm \[Drug Comparison\]"](#)
[**boric acid/cm \[Drug Comparison\]"](#)

*clotrimazole
 *lysozyme
 *mimorazol
 unclassified drug
 "*vinegar/cm [Drug Comparison]"

Source: EMBASE

115. Growth inhibition of *Candida albicans* and other medically important yeasts by vaginal contraceptive products.

Citation: Gynecologic and obstetric investigation, Jan 1990, vol. 29, no. 1, p. 67-70, 0378-7346 (1990)

Author(s): Shubair, M; Larsen, B

Abstract: The antifungal effects of two commercially available spermicidal gels (Conceptrol, produced by Ortho Pharmaceutical, Raritan, N.J., and Koromex, produced by Schmid Laboratories, Little Falls, N.J.) as well as pure nonoxynol-9 and boric acid (both components of vaginal contraceptive products) were tested against 50 clinical yeast isolates by the agar dilution method. The formulated products exerted comparable dose-dependent inhibitory effects against all yeasts tested. A 3-fold dilution of the formulated spermicidal products inhibited 90% of the yeast strains tested. To determine if the antifungal effect was due to the spermicidal detergent nonoxynol-9, this compound was tested for antifungal activity but was completely ineffective against *Candida albicans* in concentrations up to 10%. Boric acid, present in at least one of the products (Koromex), inhibited representative yeasts at a concentration of 0.4%. The relationship of pH and oxygen tension to inhibition by the commercial spermicides was also investigated. The pH values tested ranged from 4 to 7 and had little effect on inhibition; anaerobiosis at pH 7 slightly reduced the inhibitory activity of Conceptrol gel.

Subject Headings: Polyethylene Glycols
 Cryptococcus
 Candida albicans
 Humans
 Spermaticidal Agents
 Antifungal Agents
 Index Medicus
 Yeasts
 Female
 Nonoxynol
 Boric Acids
 Candida
 Population

Source: Medline

116. *Torulopsis glabrata* vaginitis: Clinical aspects and susceptibility to antifungal agents

Citation: Obstetrics and Gynecology, 1990, vol./is. 76/4(651-655), 0029-7844 (1990)

Author(s): Redondo-Lopez V.; Lynch M.; Schmitt C.; Cook R.; Sobel J.D.

Institution: (Redondo-Lopez, Lynch, Schmitt, Cook, Sobel) Division of Infectious Diseases, Department of Medicine, Wayne State University School of Medicine, Detroit, MI United States

Language: English

Abstract: *Torulopsis glabrata* is second only to *Candida albicans* in frequency of isolation from the vagina in both asymptomatic women and patients with yeast vaginitis. We retrospectively studied 33 patients from whom vaginal isolates of *T. glabrata* were obtained. *Torulopsis glabrata* caused symptomatic vaginitis in 42% of the patients but was unassociated with symptoms in 30%; in 27% of patients, its importance was uncertain because of concomitant pathology. Antifungal susceptibility testing was performed on 39 *T. glabrata* strains isolated from 39 patients. The minimal inhibitory concentrations (MICs) of the majority of *T. glabrata* isolates fell within the sensitive range of the antimycotic drugs

tested; however, no correlation was found between in vitro antifungal MICs and the response to azole drug therapy. Clinical success was achieved in 67% of the patients although mycologic cure occurred in only 33%. A small number of patients developed recurrent and often chronic *Torulopsis vaginitis* unresponsive to conventional therapy. Limited experience suggests that vaginal boric acid therapy may be of value in these recalcitrant cases.

Country of Publication: United States

CAS Registry Number: 1397-89-3 (amphotericin B); 30652-87-0 (amphotericin B); 10043-35-3 (boric acid); 11113-50-1 (boric acid); 11129-12-7 (boric acid); 14213-97-9 (boric acid); 23593-75-1 (clotrimazole); 86386-73-4 (fluconazole); 2022-85-7 (flucytosine); 84625-61-6 (itraconazole); 65277-42-1 (ketoconazole); 22916-47-8 (miconazole); 67915-31-5 (terconazole)

Publication Type: Journal: Article

Subject Headings: [article](#)
[clinical article](#)
[controlled study](#)
[female](#)
[fungus](#)
[human](#)
[methodology](#)
[priority journal](#)
[torulopsis glabrata](#)
["*vaginitis/dt \[Drug Therapy\]"](#)
["*amphotericin B/cm \[Drug Comparison\]"](#)
["*amphotericin B/do \[Drug Dose\]"](#)
["*amphotericin B/dt \[Drug Therapy\]"](#)
["*amphotericin B/pd \[Pharmacology\]"](#)
["*boric acid/cm \[Drug Comparison\]"](#)
["*boric acid/do \[Drug Dose\]"](#)
["*boric acid/dt \[Drug Therapy\]"](#)
["*boric acid/pd \[Pharmacology\]"](#)
["*clotrimazole/cm \[Drug Comparison\]"](#)
["*clotrimazole/do \[Drug Dose\]"](#)
["*clotrimazole/dt \[Drug Therapy\]"](#)
["*clotrimazole/pd \[Pharmacology\]"](#)
["*fluconazole/cm \[Drug Comparison\]"](#)
["*fluconazole/do \[Drug Dose\]"](#)
["*fluconazole/dt \[Drug Therapy\]"](#)
["*fluconazole/pd \[Pharmacology\]"](#)
["*flucytosine/cm \[Drug Comparison\]"](#)
["*flucytosine/do \[Drug Dose\]"](#)
["*flucytosine/dt \[Drug Therapy\]"](#)
["*flucytosine/pd \[Pharmacology\]"](#)
["*itraconazole/cm \[Drug Comparison\]"](#)
["*itraconazole/do \[Drug Dose\]"](#)
["*itraconazole/dt \[Drug Therapy\]"](#)
["*itraconazole/pd \[Pharmacology\]"](#)
["*ketoconazole/cm \[Drug Comparison\]"](#)
["*ketoconazole/do \[Drug Dose\]"](#)
["*ketoconazole/dt \[Drug Therapy\]"](#)
["*ketoconazole/pd \[Pharmacology\]"](#)
["*miconazole/cm \[Drug Comparison\]"](#)
["*miconazole/do \[Drug Dose\]"](#)
["*miconazole/dt \[Drug Therapy\]"](#)
["*miconazole/pd \[Pharmacology\]"](#)
["*terconazole/cm \[Drug Comparison\]"](#)
["*terconazole/do \[Drug Dose\]"](#)
["*terconazole/dt \[Drug Therapy\]"](#)
["*terconazole/pd \[Pharmacology\]"](#)

Source: EMBASE

117. Growth inhibition of *Candida albicans* and other medically important yeasts by vaginal contraceptive products

Citation: Gynecologic and Obstetric Investigation, 1990, vol./is. 29/1(67-70), 0378-7346 (1990)

Author(s): Shubair M.; Larsen B.

Institution: (Shubair, Larsen) Department of Microbiology, Marshall University School of Medicine, Huntington, WV 25701 United States

Language: English

Abstract: The antifungal effects of two commercially available spermicidal gels (Conceptrol, produced by Ortho Pharmaceutical, Raritan, N.J., and Koromex, produced by Schmid Laboratories, Little Falls, N.J.) as well as pure nonoxynol-9 and boric acid (both components of vaginal contraceptive products) were tested against 50 clinical yeast isolates by the agar dilution method. The formulated products exerted comparable dose-dependent inhibitory effects against all yeasts tested. A 3-fold dilution of the formulated spermicidal products inhibited 90% of the yeast strains tested. To determine if the antifungal effect was due to the spermicidal detergent nonoxynol-9, this compound was tested for antifungal activity but was completely ineffective against *Candida albicans* in concentrations up to 10%. Boric acid, present in at least one of the products (Koromex), inhibited representative yeasts at a concentration of 0.4%. The relationship of pH and oxygen tension to inhibition by the commercial spermicides was also investigated. The pH values tested ranged from 4 to 7 and had little effect on inhibition; anaerobiosis at pH 7 slightly reduced the inhibitory activity of Conceptrol gel.

Country of Publication: Switzerland

CAS Registry Number: 10043-35-3 (boric acid); 11113-50-1 (boric acid); 11129-12-7 (boric acid); 14213-97-9 (boric acid); 96827-50-8 (nonoxinol 9)

Publication Type: Journal: Article

Subject Headings: [article](#)
[*Candida albicans](#)
[*drug screening](#)
[female](#)
[fungus](#)
[human](#)
[priority journal](#)
["*boric acid/do \[Drug Dose\]"](#)
["*boric acid/pd \[Pharmacology\]"](#)
["*nonoxinol 9/do \[Drug Dose\]"](#)
["*nonoxinol 9/pd \[Pharmacology\]"](#)

Source: EMBASE

118. Antifungal agents vs. boric acid for treating chronic mycotic vulvovaginitis

Citation: Journal of Reproductive Medicine for the Obstetrician and Gynecologist, 1991, vol./is. 36/8(593-597), 0024-7758 (1991)

Author(s): Jovanovic R.; Congema E.; Nguyen H.T.

Institution: (Jovanovic, Congema, Nguyen) 895 Park Avenue, New York, NY 10021, United States

Language: English

Abstract: Ninety-two women with chronic mycotic vaginal infections were followed with microscopic examination of the vaginal discharge during prolonged therapy with anti-fungal agents and boric acid. A microscopic picture unique to chronic mycotic vaginitis was observed, representing the cytologic reaction of the mucous membrane to chronic yeast infection. This diagnostic tool proved extremely effective in detecting both symptomatic and residual, subclinical mycotic infection and provided a highly predictive measure of the probability of relapse. The ineffectiveness of conventional antifungal

agents appeared to be the main reason for chronic mycotic infections. In contrast, boric acid was effective in curing 98% of the patients who had previously failed to respond to the most commonly used antifungal agents and was clearly indicated as the treatment of choice for prophylaxis.

Country of Publication: United States

CAS Registry Number: 10043-35-3 (boric acid); 11113-50-1 (boric acid); 11129-12-7 (boric acid); 14213-97-9 (boric acid); 64872-76-0 (butoconazole); 64872-77-1 (butoconazole); 23593-75-1 (clotrimazole); 467-63-0 (crystal violet); 548-62-9 (crystal violet); 1400-61-9 (nystatin); 34786-70-4 (nystatin); 62997-67-5 (nystatin)

Publication Type: Journal: Article

Subject Headings: [article](#)
[*candidiasis](#)
[female](#)
[human](#)
[major clinical study](#)
[oral drug administration](#)
[priority journal](#)
[topical drug administration](#)
[*vulvovaginitis](#)
[*antifungal agent](#)
["*boric acid/cm \[Drug Comparison\]"](#)
["*boric acid/dt \[Drug Therapy\]"](#)
["*butoconazole/cm \[Drug Comparison\]"](#)
["*butoconazole/dt \[Drug Therapy\]"](#)
["*clotrimazole/cm \[Drug Comparison\]"](#)
["*clotrimazole/dt \[Drug Therapy\]"](#)
["*crystal violet/dt \[Drug Therapy\]"](#)
["*nystatin/cm \[Drug Comparison\]"](#)
["*nystatin/dt \[Drug Therapy\]"](#)

Source: EMBASE

119. Antifungal agents vs. boric acid for treating chronic mycotic vulvovaginitis.

Citation: The Journal of reproductive medicine, Aug 1991, vol. 36, no. 8, p. 593-597, 0024-7758 (August 1991)

Author(s): Jovanovic, R; Congema, E; Nguyen, H T

Abstract: Ninety-two women with chronic mycotic vaginal infections were followed with microscopic examination of the vaginal discharge during prolonged therapy with antifungal agents and boric acid. A microscopic picture unique to chronic mycotic vaginitis was observed, representing the cytologic reaction of the mucous membrane to chronic yeast infection. This diagnostic tool proved extremely effective in detecting both symptomatic and residual, subclinical mycotic infection and provided a highly predictive measure of the probability of relapse. The ineffectiveness of conventional antifungal agents appeared to be the main reason for chronic mycotic infections. In contrast, boric acid was effective in curing 98% of the patients who had previously failed to respond to the most commonly used antifungal agents and was clearly indicated as the treatment of choice for prophylaxis.

Subject Headings: [Administration Intravaginal](#)
[Humans](#)
[Candidiasis Vulvovaginal](#)
[Antifungal Agents](#)
[Predictive Value of Tests](#)
[Index Medicus](#)
[Recurrence](#)
[Adult](#)
[Female](#)
[Vaginal Smears](#)

Boric Acids
Chronic Disease

Source: Medline

120. Boric acid vaginal suppositories

Citation: Annals of Pharmacotherapy, 1993, vol./is. 27/11(1355-1357), 1060-0280 (1993)

Author(s): Thai L.; Hart L.L.

Institution: (Thai, Hart) Division of Clinical Pharmacy, School of Pharmacy, University of California, San Francisco, CA 94143, United States

Language: English

Country of Publication: United States

CAS Registry Number: 10043-35-3 (boric acid); 11113-50-1 (boric acid); 11129-12-7 (boric acid); 14213-97-9 (boric acid); 64872-76-0 (butoconazole); 64872-77-1 (butoconazole); 23593-75-1 (clotrimazole); 467-63-0 (crystal violet); 548-62-9 (crystal violet); 22832-87-7 (miconazole nitrate); 1400-61-9 (nystatin); 34786-70-4 (nystatin); 62997-67-5 (nystatin)

Publication Type: Journal: Note

Subject Headings: antifungal activity
Candida albicans
drug efficacy
drug safety
female
human
intravaginal drug administration
note
oral drug administration
pharmaceutics
priority journal
"rash/dt [Drug Therapy]"
*suppository
symptomatology
teratogenesis
topical drug administration
"*vagina candidiasis/dt [Drug Therapy]"
"*vagina candidiasis/pc [Prevention]"
"vagina discharge/si [Side Effect]"
"*boric acid/ae [Adverse Drug Reaction]"
"*boric acid/ad [Drug Administration]"
"*boric acid/cm [Drug Comparison]"
"*boric acid/dt [Drug Therapy]"
"*boric acid/pr [Pharmaceutics]"
"butoconazole/cm [Drug Comparison]"
"butoconazole/dt [Drug Therapy]"
"clotrimazole/cm [Drug Comparison]"
"clotrimazole/dt [Drug Therapy]"
"crystal violet/cm [Drug Comparison]"
"crystal violet/dt [Drug Therapy]"
"miconazole nitrate/cm [Drug Comparison]"
"miconazole nitrate/dt [Drug Therapy]"
"nystatin/cm [Drug Comparison]"
"nystatin/dt [Drug Therapy]"

Source: EMBASE

121. Management of persistent vulvo vaginal candidosis due to azole-resistant *Candida glabrata*

Citation: Genitourinary Medicine, 1993, vol./is. 69/2(112-114), 0266-4348 (1993)

Author(s): White D.J.; Johnson E.M.; Warnock D.W.

Institution: (White, Johnson, Warnock) Department of Genitourinary Medicine, The General Hospital, Steelhouse Lane, Birmingham B4 6NH, United Kingdom

Language: English

Abstract: Subjects - Three cases are described of long-standing vaginal candidosis due to *Candida glabrata*. These had failed to respond to local and systemic antifungals. In each case the infecting strain appeared resistant to a range of azole drugs in vitro. Clinical course: Case one - This patient recovered following prolonged treatment with oral itraconazole in combination with oral and vaginal nystatin. Case two - Yeasts were eradicated from this patient following cyclical treatment with oral dydrogesterone; prolonged vaginal treatment with nystatin may have helped. Case three - This patient did not respond to prolonged course of oral itraconazole in combination with vaginal and oral nystatin, oral medroxyprogesterone or intravaginal boric acid. Eradication of *C. glabrata* was finally achieved by local application of 1% gentian violet. Shortly after eradication of the *C. glabrata* infection, both Case two and Case three developed infections with other *Candida* species responsive to azole antifungals.

Country of Publication: United Kingdom

CAS Registry Number: 10043-35-3 (boric acid); 11113-50-1 (boric acid); 11129-12-7 (boric acid); 14213-97-9 (boric acid); 467-63-0 (crystal violet); 548-62-9 (crystal violet); 152-62-5 (dydrogesterone); 24169-02-6 (econazole); 27220-47-9 (econazole); 86386-73-4 (fluconazole); 2022-85-7 (flucytosine); 84625-61-6 (itraconazole); 65277-42-1 (ketoconazole); 520-85-4 (medroxyprogesterone); 1400-61-9 (nystatin); 34786-70-4 (nystatin); 62997-67-5 (nystatin)

Publication Type: Journal: Article

Subject Headings: adult
 article
Candida glabrata
 case report
 controlled study
 drug sensitivity
 female
 human
 "infection/di [Diagnosis]"
 "infection/dt [Drug Therapy]"
 intravaginal drug administration
 oral drug administration
 priority journal
 "*vagina disease/di [Diagnosis]"
 "*vagina disease/dt [Drug Therapy]"
 "*boric acid/dt [Drug Therapy]"
 *crystal violet
 "*dydrogesterone/dt [Drug Therapy]"
 "econazole/dt [Drug Therapy]"
 "fluconazole/dt [Drug Therapy]"
 "flucytosine/dt [Drug Therapy]"
 "*itraconazole/cb [Drug Combination]"
 "*itraconazole/do [Drug Dose]"
 "*itraconazole/dt [Drug Therapy]"
 "ketoconazole/dt [Drug Therapy]"
 "*medroxyprogesterone/dt [Drug Therapy]"
 "*nystatin/cb [Drug Combination]"
 "*nystatin/do [Drug Dose]"
 "*nystatin/dt [Drug Therapy]"

Source: EMBASE

Full Text: Available from *National Library of Medicine* in *Genitourinary Medicine*

122. Current treatment of vulvovaginal candidosis [Serbian] DANASNJE LIJECENJE VULVOVAGINALNE KANDIDOZE

Original Title:	DANASNJE LIJECENJE VULVOVAGINALNE KANDIDOZE
Citation:	Gynaecologia et Perinatologia, 1994, vol./is. 3/4(153-155), 1330-0091 (1994)
Author(s):	Tomljanovic M.
Institution:	(Tomljanovic) Tomislavova 1, 44000 Sisak, Croatia
Language:	Serbian
Abstract:	Vulvovaginal candidiasis (WC) is considered to be a 'Crux medici et patientorum' for the following reasons: its great dissemination, frequent recurrences and great number of predisposing factors. Prerequisite for the effective therapy is a proper diagnosis, which includes obvious clinical picture and the evidence of yeasts in the native preparation and/or cultivation of vaginal secretion. The treatment of WC can include: 1. Polyene macrolides, 2. Imidazoles, 3. Triazoles, 4. Pyrimidines, 5. Boric acid, 6. Water-solution of Gentian violet, 7. Immunocorrectors (antihistamines, H ₂ -receptor antagonists, prostaglandin synthesis inhibitors and chromolyn), 8. Adherence inhibitors (pepstatin A), 9. Hygienic and dietary measures. Among women with first or rare episode of WC, as in those with fastly repeated VVC, therapy is curative, that is, clinical and microbiological cure. Among women with chronic WC, therapy is suppressive, i.e. only the relief of subjective troubles. During treatment of VVC mistakes are rather frequent in routine gynaecologic practice.
Country of Publication:	Croatia
CAS Registry Number:	10043-35-3 (boric acid); 11113-50-1 (boric acid); 11129-12-7 (boric acid); 14213-97-9 (boric acid); 23593-75-1 (clotrimazole); 15826-37-6 (cromoglycate disodium); 16110-51-3 (cromoglycate disodium); 93356-79-7 (cromoglycate disodium); 93356-84-4 (cromoglycate disodium); 467-63-0 (crystal violet); 548-62-9 (crystal violet); 24169-02-6 (econazole); 27220-47-9 (econazole); 86386-73-4 (fluconazole); 2022-85-7 (flucytosine); 84625-61-6 (itraconazole); 65277-42-1 (ketoconazole); 22916-47-8 (miconazole); 1400-61-9 (nystatin); 34786-70-4 (nystatin); 62997-67-5 (nystatin); 26305-03-3 (pepstatin); 39324-30-6 (pepstatin); 67915-31-5 (terconazole)
Publication Type:	Journal: Short Survey
Subject Headings:	"*candidiasis/dt [Drug Therapy]" female human hygiene short survey "*vulvovaginitis/dt [Drug Therapy]" yeast "*antifungal agent/dt [Drug Therapy]" "antihistaminic agent/dt [Drug Therapy]" "boric acid/dt [Drug Therapy]" "clotrimazole/dt [Drug Therapy]" "cromoglycate disodium/dt [Drug Therapy]" "crystal violet/dt [Drug Therapy]" "econazole/dt [Drug Therapy]" "fluconazole/dt [Drug Therapy]" "flucytosine/dt [Drug Therapy]" "imidazole derivative/dt [Drug Therapy]" "immunomodulating agent/dt [Drug Therapy]" "itraconazole/dt [Drug Therapy]" "ketoconazole/dt [Drug Therapy]" "miconazole/dt [Drug Therapy]" "nystatin/dt [Drug Therapy]" "pepstatin/dt [Drug Therapy]" "polyene/dt [Drug Therapy]" "prostaglandin synthesis inhibitor/dt [Drug Therapy]"

"terconazole/dt [Drug Therapy]"
 "triazole derivative/dt [Drug Therapy]"
 unclassified drug

Source: EMBASE

123. Current treatment of vulvovaginal candidosis [Serbian] DANASNJE LIJECENJE VULVOVAGINALNE KANDIDOZE

Original Title: DANASNJE LIJECENJE VULVOVAGINALNE KANDIDOZE

Citation: Gynaecologia et Perinatologia, 1994, vol./is. 3/3(153-155), 1330-0091 (1994)

Author(s): Tomljanovic M.

Institution: (Tomljanovic) Tomislavova 1, 44000 Sisak, Croatia

Language: Serbian

Abstract: Vulvovaginal candidiasis (VVC) is considered to be a 'Crux medici et patientorum' for the following reasons: its great dissemination, frequent recurrences and great number of predisposing factors. Prerequisite for the effective therapy is a proper diagnosis, which includes obvious clinical picture and the evidence of yeasts in the native preparation and/or cultivation of vaginal secretion. The treatment of VVC can include: 1. Polyene macrolides, 2. Imidazoles, 3. Triazoles, 4. Pyrimidines, 5. Boric acid, 6. Water-solution of Gentian violet, 7. Immunocorrectors (antihistamines, H₂-receptor antagonists, prostaglandin synthesis inhibitors and chromolyn), 8. Adherence inhibitors (pepstatin A), 9. Hygienic and dietary measures. Among women with first or rare episode of VVC, as in those with fastly repeated VVC, therapy is curative, that is, clinical and microbiological cure. Among women with chronic VVC, therapy is suppressive, i.e. only the relief of subjective troubles. During treatment of VVC mistakes are rather frequent in routine gynaecologic practice.

Country of Publication: Croatia

CAS Registry Number: 1397-89-3 (amphotericin B); 30652-87-0 (amphotericin B); 10043-35-3 (boric acid); 11113-50-1 (boric acid); 11129-12-7 (boric acid); 14213-97-9 (boric acid); 23593-75-1 (clotrimazole); 15826-37-6 (cromoglycate disodium); 16110-51-3 (cromoglycate disodium); 93356-79-7 (cromoglycate disodium); 93356-84-4 (cromoglycate disodium); 467-63-0 (crystal violet); 548-62-9 (crystal violet); 86386-73-4 (fluconazole); 2022-85-7 (flucytosine); 84625-61-6 (itraconazole); 65277-42-1 (ketoconazole); 22916-47-8 (miconazole); 52882-37-8 (natamycin); 7681-93-8 (natamycin); 1400-61-9 (nystatin); 34786-70-4 (nystatin); 62997-67-5 (nystatin); 67915-31-5 (terconazole)

Publication Type: Journal: Short Survey

Subject Headings: clinical feature
 female
 human
 oral drug administration
 short survey
 topical drug administration
 "*vagina candidiasis/di [Diagnosis]"
 "*vagina candidiasis/dt [Drug Therapy]"
 "*vulvovaginitis/di [Diagnosis]"
 "*vulvovaginitis/dt [Drug Therapy]"
 "amphotericin B/dt [Drug Therapy]"
 "*antifungal agent/dt [Drug Therapy]"
 "antihistaminic agent/dt [Drug Therapy]"
 "*boric acid/dt [Drug Therapy]"
 "clotrimazole/dt [Drug Therapy]"
 "cromoglycate disodium/dt [Drug Therapy]"
 "crystal violet/dt [Drug Therapy]"
 "fluconazole/dt [Drug Therapy]"
 "flucytosine/dt [Drug Therapy]"
 "imidazole derivative/dt [Drug Therapy]"

"*immunomodulating agent/dt [Drug Therapy]"
 "itraconazole/dt [Drug Therapy]"
 "ketoconazole/dt [Drug Therapy]"
 "miconazole/dt [Drug Therapy]"
 "natamycin/dt [Drug Therapy]"
 "nystatin/dt [Drug Therapy]"
 "prostaglandin synthesis inhibitor/dt [Drug Therapy]"
 "pyrimidine derivative/dt [Drug Therapy]"
 "terconazole/dt [Drug Therapy]"
 "triazole derivative/dt [Drug Therapy]"
 unclassified drug

Source: EMBASE

124. Physiological traits associated with success of *Candida albicans* strains as commensal colonizers and pathogens

Citation: Journal of Clinical Microbiology, 1995, vol./is. 33/11(2920-2926), 0095-1137 (1995)

Author(s): Schmid J.; Hunter P.R.; White G.C.; Nand A.K.; Cannon R.D.

Institution: (Schmid, Hunter, White, Nand, Cannon) Department of Microbiology/Genetics, School of Biological Sciences, Massey University, Palmerston North, New Zealand

Language: English

Abstract: DNA fingerprinting with the moderately repetitive sequence Ca3 has repeatedly identified groups of genetically similar strains of *Candida albicans* that are more frequently isolated than other groups of strains from human hosts in a geographical locale. Members of these groups are found in approximately 30% of healthy individuals and in up to 70% of patients suffering from candidiasis. The high prevalence of these strains implies that they are more successful in colonizing human hosts and in causing disease than other strains (J. Schmid, Clin. Adv. Treatment Fungal Infect. 4(6):12- 16, 1993). In the present study, we have compared one such group of highly prevalent strains with other strains from the same locale to identify physiological traits associated with its success. We found that members of the group of highly prevalent strains were resistant to a larger number of chemicals than other strains in a resistogram assay. When resistance to individual chemicals used in the resistogram assay was analyzed, strains from the group of highly prevalent strains were significantly more often resistant to boric acid, cetrimide, chlorhexidine, 5-fluorocytosine, and high sodium chloride concentrations than other strains. Strains from the group of highly prevalent strains also adhered significantly (1.5 times) better to saliva- coated surfaces than did other strains. Because members of highly prevalent groups of strains are the most common infectious agents in candidiasis, these physiological traits may be involved in determining not only the success of *C. albicans* in colonizing human hosts in general but also its ability to cause disease. Sodium chloride resistance and increased adherence were also associated with infectious isolates outside the group of highly prevalent strains, indicating that they may be of particular importance in pathogenesis.

Country of Publication: United States

CAS Registry Number: 10043-35-3 (boric acid); 11113-50-1 (boric acid); 11129-12-7 (boric acid); 14213-97-9 (boric acid); 57-09-0 (cetrimide); 6899-10-1 (cetrimide); 8044-71-1 (cetrimide); 3697-42-5 (chlorhexidine); 55-56-1 (chlorhexidine); 2022-85-7 (flucytosine); 7647-14-5 (sodium chloride)

Publication Type: Journal: Article

Subject Headings: article
 bacterial colonization
 bacterium adherence
 **Candida albicans*
 "*candidiasis/di [Diagnosis]"
 "*candidiasis/ep [Epidemiology]"
 "*candidiasis/et [Etiology]"
 DNA fingerprinting
 fungal genetics

*host parasite interaction
 nonhuman
 pathogenesis
 prevalence
 priority journal
 boric acid
 cetrimide
 chlorhexidine
 flucytosine
 *fungal DNA
 sodium chloride

Source: EMBASE

Full Text: Available from *National Library of Medicine* in *Journal of Clinical Microbiology*

125. Discrimination of strains of *Candida albicans* isolated from deep and superficial sites by resistotyping.

Citation: Mycoses, Jan 1995, vol. 38, no. 1-2, p. 37-40, 0933-7407 (1995 Jan-Feb)

Author(s): Hunter, P R

Abstract: Resistotyping was used to characterise 106 strains of *Candida albicans* classified as to whether they came from deep or superficial infections. The data were analysed by logistic regression analysis. There was a statistically significant difference between the two groups of strains. After removal of variables by the log-likelihood method four resistotyping agents were found to predict source of strain: boric acid, benzalkonium chloride, malachite green and mercurochrome. Whilst there were phenotypic differences between strains isolated from deep and superficial sites it is not clear whether this strain represents different strain types or strain histories.

Subject Headings: [Drug Resistance Microbial](#)
[Mycological Typing Techniques](#)
[Index Medicus](#)
[Candida albicans](#)

Source: Medline

126. Discrimination of strains of *Candida albicans* isolated from deep and superficial sites by resistotyping

Citation: Mycoses, 1995, vol./is. 38/1-2(37-40), 0933-7407 (1995)

Author(s): Hunter P.R.

Institution: (Hunter) Public Health Laboratory, Countess of Chester Health Park, Liverpool Road, Chester CH2 1UL, United Kingdom

Language: English

Abstract: Resistotyping was used to characterise 106 strains of *Candida albicans* classified as to whether they came from deep or superficial infections. The data were analysed by logistic regression analysis. There was a statistically significant difference between the two groups of strains. After removal of variables by the log-likelihood method four resistotyping agents were found to predict source of strain: boric acid, benzalkonium chloride, malachite green and mercurochrome. Whilst there were phenotypic differences between strains isolated from deep and superficial sites it is not clear whether this strain represents different strain types or strain histories.

Country of Publication: Germany

Publication Type: Journal: Article

Subject Headings: [article](#)
[Candida albicans](#)
 "*candidiasis/di [Diagnosis]"
[clinical feature](#)
[fungus culture](#)
[human](#)

nonhuman
phenotype
priority journal
*strain difference
virulence

Source: EMBASE

127. Chronic fungal vaginitis: The value of cultures

Citation: American Journal of Obstetrics and Gynecology, 1995, vol./is. 173/3 I(820-823), 0002-9378 (1995)

Author(s): Nyirjesy P.; Seeney S.M.; Grody M.H.T.; Jordan C.A.; Buckley H.R.

Institution: (Nyirjesy, Seeney, Grody, Jordan, Buckley) Department of Obstetrics/Gynecology, Temple University School of Medicine, 3401 N. Broad St., Philadelphia, PA 19140, United States

Language: English

Abstract: OBJECTIVE: Our purpose was to examine the importance of fungal cultures in evaluating patients with symptoms of chronic vaginitis by assessing the relative contribution of various yeast species and by comparing infections caused by *Candida albicans* with those caused by other species. STUDY DESIGN: A prospective observational study of patients referred with chronic vaginal symptoms was undertaken. In addition to a standard evaluation of symptoms, cultures for yeast were performed on modified Sabouraud agar plates. RESULTS: Seventy-seven isolates were obtained from 74 patients. A total of 68% were *Candida albicans*; 32% were other species. The clinical syndromes caused by non-*Candida albicans* isolates were indistinguishable from *Candida albicans* infections. Fluconazole gave a short term mycologic cure in all *Candida albicans* but only 25% of non-*Candida albicans* cases ($p < 0.001$). In non-*Candida albicans* infections, boric acid suppositories achieved the best mycologic cure rate (85%). CONCLUSION: Because non-*Candida albicans* species are responsible for a significant number of chronic fungal vaginal infections and are more resistant to therapy with fluconazole, fungal cultures are a valuable aid in confirming the diagnosis and selecting appropriate therapy.

Country of Publication: United States

CAS Registry Number: 10043-35-3 (boric acid); 11113-50-1 (boric acid); 11129-12-7 (boric acid); 14213-97-9 (boric acid); 23593-75-1 (clotrimazole); 86386-73-4 (fluconazole); 84625-61-6 (itraconazole); 1310-58-3 (potassium hydroxide)

Publication Type: Journal: Article

Subject Headings: adult
article
Candida albicans
Candida glabrata
Candida parapsilosis
clinical trial
controlled clinical trial
controlled study
female
*fungus culture
human
intravaginal drug administration
major clinical study
"mycosis/di [Diagnosis]"
"mycosis/dt [Drug Therapy]"
"mycosis/et [Etiology]"
oral drug administration
priority journal
prospective study
Saccharomyces cerevisiae

sexual behavior
 suppository
 topical drug administration
 treatment outcome
 "*vagina candidiasis/di [Diagnosis]"
 "*vagina candidiasis/dt [Drug Therapy]"
 "*vagina candidiasis/et [Etiology]"
 "*vaginits/di [Diagnosis]"
 "*vaginits/dt [Drug Therapy]"
 "*vaginits/et [Etiology]"
 "*boric acid/dt [Drug Therapy]"
 "clotrimazole/dt [Drug Therapy]"
 "fluconazole/dt [Drug Therapy]"
 "itraconazole/dt [Drug Therapy]"
 potassium hydroxide

Source: EMBASE

128. Physiological traits associated with success of *Candida albicans* strains as commensal colonizers and pathogens.

Citation: Journal of clinical microbiology, Nov 1995, vol. 33, no. 11, p. 2920-2926, 0095-1137 (November 1995)

Author(s): Schmid, J; Hunter, P R; White, G C; Nand, A K; Cannon, R D

Abstract: DNA fingerprinting with the moderately repetitive sequence Ca3 has repeatedly identified groups of genetically similar strains of *Candida albicans* that are more frequently isolated than other groups of strains from human hosts in a geographical locale. Members of these groups are found in approximately 30% of healthy individuals and in up to 70% of patients suffering from candidiasis. The high prevalence of these strains implies that they are more successful in colonizing human hosts and in causing disease than other strains (J. Schmid, Clin. Adv. Treatment Fungal Infect. 4(6):12-16, 1993). In the present study, we have compared one such group of highly prevalent strains with other strains from the same locale to identify physiological traits a larger number of chemicals than other strains in a resistogram assay. When resistance to individual chemicals used in the resistogram assay was analyzed, strains from the group of highly prevalent strains were significantly more often resistant to boric acid, cetrimide, chlorhexidine, 5-fluorocytosine, and high sodium chloride concentrations than other strains. Strains from the group of highly prevalent strains also adhered significantly (1.5 times) better to saliva-coated surfaces than did other strains. Because members of highly prevalent groups of strains are the most common infectious agents in candidiasis, these physiological traits may be involved in determining not only the success of *C. albicans* in colonizing human hosts in general but also its ability to cause disease. Sodium chloride resistance and increased adherence were also associated with infectious isolates outside the group of highly prevalent strains, indicating that they may be of particular importance in pathogenesis.

Subject Headings: [Candida albicans](#)
[Host-Parasite Interactions](#)
[Antifungal Agents](#)
[Candidiasis](#)
[Index Medicus](#)
[Saliva](#)
[Humans](#)
[Virulence](#)
[Cell Adhesion](#)
[Drug Resistance Microbial](#)
[Anti-Infective Agents](#)
[DNA Fingerprinting](#)

Source: Medline

Full Text: Available from *National Library of Medicine* in *Journal of Clinical Microbiology*

129. Biotypes of oral *Candida albicans* isolates in a Tanzanian child population

- Citation:** APMIS, 1996, vol./is. 104/9(623-628), 0903-4641 (1996)
- Author(s):** Matee M.I.; Samaranayake L.P.; Scheutz F.; Simon E.; Lyamuya E.F.; Mwinula J.
- Institution:** (Matee, Lyamuya) Dept. of Microbiology and Immunology, Muhimbili University, College of Health Sciences, Dar-es-Salaam, Tanzania; (Samaranayake) Oral Biology Unit, Faculty of Dentistry, University of Hong Kong, Hong Kong; (Scheutz) Dept. Oral Epidemiol. and Pub. Hlth., Royal Dental College, Aarhus University, Aarhus, Denmark; (Simon) Dept. of Oral Surg. and Oral Pathol., Muhimbili University, College of Health Sciences, Dar-es-Salaam, Tanzania; (Mwinula) Dept. Paediatr. Child Dent. Hlth., Muhimbili University, College of Health Sciences, Dar-es-Salaam, Tanzania; (Samaranayake) Oral Biology Unit, Faculty of Dentistry, University of Hong Kong, 34, Hospital Road, Hong Kong
- Language:** English
- Abstract:** Although biotypes of *Candida albicans* from adult populations, especially in the West, have been described, there are no data either from a child population, or from the African continent. Hence a total of 200 oral *C. albicans* isolates from Tanzanian children aged 6-24 months were biotyped using two commercially available API micromethod kit systems and a boric acid resistance test. The predominant biotypes, which comprised two thirds of the organisms isolated, were J1S (19.5%), A1S (16.0%), J1R (14.5%), A1R (9.5%) and P1R (7.5%). In total, 16 new biotypes comprising 44 (22%) isolates which have not hitherto been described were found in this Tanzanian population and, of these, the P1R biotype predominated with 15 (7.5%) isolates. There was no significant association between predominant biotypes (with clusters <15 isolates) and age, gender, breast feeding and malnutrition. These data indicate that the biotype profile of *C. albicans* isolates may differ in paediatric and adult populations, and/or global distribution of various subtypes of this common opportunistic pathogen.
- Country of Publication:** Denmark
- Publication Type:** Journal: Article
- Subject Headings:** [article](#)
[*Candida albicans](#)
[child](#)
[fungus culture](#)
[human](#)
[infant](#)
[*mouth flora](#)
[normal human](#)
[priority journal](#)
[Tanzania](#)
- Source:** EMBASE

130. Biotypes of oral *Candida albicans* isolates in a Tanzanian child population.

- Citation:** APMIS : acta pathologica, microbiologica, et immunologica Scandinavica, Sep 1996, vol. 104, no. 9, p. 623-628, 0903-4641 (September 1996)
- Author(s):** Matee, M I; Samaranayake, L P; Scheutz, F; Simon, E; Lyamuya, E F; Mwinula, J
- Abstract:** Although biotypes of *Candida albicans* from adult populations, especially in the West, have been described, there are no data either from a child population, or from the African continent. Hence a total of 200 oral *C. albicans* isolates from Tanzanian children aged 6-24 months were biotyped using two commercially available API micromethod kit systems and a boric acid resistance test. The predominant biotypes, which comprised two thirds of the organisms isolated, were J1S (19.5%), A1S (16.0%), J1R (14.5%), A1R (9.5%) and P1R (7.5%). In total, 16 new biotypes comprising 44 (22%) isolates which have not hitherto been described were found in this Tanzanian population and, of these, the P1R biotype predominated with 15 (7.5%) isolates. There was no significant association between predominant biotypes (with clusters > or = 15 isolates) and age, gender, breast feeding and malnutrition. These data indicate that the biotype profile of *C.*

albicans isolates may differ in paediatric and adult populations, and/or global distribution of various subtypes of this common opportunistic pathogen.

Subject Headings: Infant
Candida albicans
Tongue
Tanzania
Humans
Reproducibility of Results
Mycological Typing Techniques
Index Medicus
Child Preschool
Mouth Mucosa

Source: Medline

131. Successful use of boric acid to control azole-refractory *Candida* vaginitis in a woman with AIDS

Citation: Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology, 1997, vol./is. 16/3(219-220), 1077-9450 (1997)

Author(s): Shinohara Y.T.; Tasker S.A.

Institution: (Shinohara, Tasker) Department of Pharmacy, Naval Medical Center, San Diego, CA, United States

Language: English

Country of Publication: United States

CAS Registry Number: 10043-35-3 (boric acid); 11113-50-1 (boric acid); 11129-12-7 (boric acid); 14213-97-9 (boric acid); 467-63-0 (crystal violet); 548-62-9 (crystal violet); 86386-73-4 (fluconazole); 84625-61-6 (itraconazole)

Publication Type: Journal: Article

Subject Headings: acquired immune deficiency syndrome
adult
article
"*candidiasis/dr [Drug Resistance]"
"*candidiasis/dt [Drug Therapy]"
case report
drug efficacy
female
human
*Human immunodeficiency virus infection
infection control
intravaginal drug administration
priority journal
suppository
"*vaginitis/dr [Drug Resistance]"
"*vaginitis/dt [Drug Therapy]"
"*boric acid/dt [Drug Therapy]"
crystal violet
fluconazole
itraconazole
pyrrole derivative

Source: EMBASE

132. Treatment of *Torulopsis glabrata* vaginitis: Retrospective review of boric acid therapy

Citation: Clinical Infectious Diseases, 1997, vol./is. 24/4(649-652), 1058-4838 (1997)

Author(s): Sobel J.D.; Chaim W.

Institution: (Sobel, Chaim) Division of Infections Diseases, Detroit Medical Center, Wayne State Univ. School of Medicine, Detroit, MI, United States; (Sobel) Division of Infectious Diseases, Harper Professional Building, 4160 John R Street, Detroit, MI 48201, United States

Language: English

Abstract: The charts of all patients who were seen at a vaginitis clinic between January 1989 and December 1994 were retrospectively reviewed; 80 patients whose vaginal cultures yielded *Torulopsis glabrata* were identified. Sixty of these patients experienced 75 symptomatic episodes of vaginitis attributed to *T. glabrata*, and these patients are the subject of this review. Of the 60 symptomatic patients, 40 had uncomplicated *T. glabrata* infection, and 20 had mixed infection, most commonly in association with bacterial vaginosis. Evaluation of treatment of *T. glabrata* vaginitis with vaginal boric acid (600 mg/d for 14 days) revealed clinical improvement or cure in 21 (81%) of 26 episodes and mycological eradication in 20 (77%) of 26 episodes. One-third of the patients received maintenance therapy with boric acid. The clinical response and mycological eradication rates associated with therapy with topical and systemic azoles were < 50%. The rate of therapeutic response to boric acid administered to patients with mixed *T. glabrata* infection remained high. In conclusion, in this series of patients with *T. glabrata* vaginitis, for whom repeated courses of antimycotic therapy with azoles had previously failed, boric acid emerged as a promising modality of therapy.

Country of Publication: United States

CAS Registry Number: 10043-35-3 (boric acid); 11113-50-1 (boric acid); 11129-12-7 (boric acid); 14213-97-9 (boric acid)

Publication Type: Journal: Review

Subject Headings: bacterium culture
female
human
"infection/dt [Drug Therapy]"
"infection/et [Etiology]"
major clinical study
priority journal
review
**Torulopsis glabrata*
"*vaginitis/dt [Drug Therapy]"
"*boric acid/dv [Drug Development]"
"*boric acid/dt [Drug Therapy]"

Source: EMBASE

Full Text: Available from *UHB Online* in *Clinical Infectious Diseases*; Note: ; Notes: Click on 'Sign in via OpenAthens' and enter login credentials

133. Over-the-counter and alternative medicines in the treatment of chronic vaginal symptoms

Citation: Obstetrics and Gynecology, July 1997, vol./is. 90/1(50-53), 0029-7844 (July 1997)

Author(s): Nyirjesy P.; Weitz M.V.; Grody M.H.T.; Lorber B.

Institution: (Nyirjesy, Weitz, Grody, Lorber) Dept. Obstet., Gynecol./Repro. Sci., Section of Infectious Diseases, Temple University School of Medicine, Philadelphia, PA, United States; (Nyirjesy) Dept. Obstet., Gynecol./Repro. Sci., Temple University School of Medicine, 3401 North Broad Street, Philadelphia, PA 19140, United States

Language: English

Abstract: Objective: To investigate the use of over-the-counter and alternative medicines in women with chronic vaginal symptoms. Methods: One hundred five patients, referred by their gynecologists for evaluation of chronic vaginal symptoms, were interviewed about their use of over-the-counter and alternative medicines during the preceding year, the amount of money spent on each, and whether or not their physicians had been informed of these treatments. Results: The mean age was 36 years, and one-half had finished college. The

median symptom duration was 2 years. Seventy-seven (73.3%) patients had self-treated with over-the-counter medications such as miconazole (74% of over-the-counter users), clotrimazole (38.2%), or povidone-iodine (13.2%). The median expenditure for over-the-counter use was \$50 (range \$2-1000). Forty-four (41.9%) had used alternative medicines, most frequently acidophilus pills orally (50%) or vaginally (11.4%), yogurt orally (20.5%) or vaginally (18.2%), vinegar douches (13.6%), and boric acid (13.6%). The median expenditure for alternative medicines was \$35 (range \$0- 1200). Fewer physicians were aware of the use of alternative (70.5%) than of over-the-counter medicines (88.3%). Although most patients thought that vulvovaginal candidiasis was the cause of their symptoms, the most common diagnoses at initial presentation were candidiasis in 29 (27.6%), vulvar vestibulitis in 18 (17.1%), irritant dermatitis in 16 (15.2%), and bacterial vaginosis in 11 (10.5%). Women who actually had candidiasis were more likely to have used alternative medicines (odds ratio 2.31, 95% confidence interval 1.00, 5.42) than other patients. Conclusion: Women with chronic vaginal symptoms often use over-the-counter and alternative medicines that add to health care costs and are unlikely to be of benefit.

Country of Publication: United States

CAS Registry Number: 10043-35-3 (boric acid); 11113-50-1 (boric acid); 11129-12-7 (boric acid); 14213-97-9 (boric acid); 8028-52-2 (vinegar)

Publication Type: Journal: Article

Subject Headings: [acupuncture](#)
[article](#)
[garlic](#)
[priority journal](#)
[tea](#)
["*vagina disease/dt \[Drug Therapy\]"](#)
[*boric acid](#)
["*non prescription drug/dt \[Drug Therapy\]"](#)
[*vinegar](#)
[yoghurt](#)

Source: EMBASE

134. Over-the-counter and alternative medicines in the treatment of chronic vaginal symptoms.

Citation: Obstetrics and gynecology, Jul 1997, vol. 90, no. 1, p. 50-53, 0029-7844 (July 1997)

Author(s): Nyirjesy, P; Weitz, M V; Grody, M H; Lorber, B

Abstract: To investigate the use of over-the-counter and alternative medicines in women with chronic vaginal symptoms. One hundred five patients, referred by their gynecologists for evaluation of chronic vaginal symptoms, were interviewed about their use of over-the-counter and alternative medicines during the preceding year, the amount of money spent on each, and whether or not their physicians had been informed of these treatments. The mean age was 36 years, and one-half had finished college. The median symptom duration was 2 years. Seventy-seven (73.3%) patients had self-treated with over-the-counter medications such as miconazole (74% of over-the-counter users), clotrimazole (38.2%), or povidone-iodine (13.2%). The median expenditure for over-the-counter use was %0 (range \$2-1000). Forty-four (41.9%) had used alternative medicines, most frequently acidophilus pills orally (50%) vaginally (11.4%), yogurt orally (20.5%) or vaginally (18.2%), vinegar douches (13.6%), and boric acid (13.6%). The median expenditure for alternative medicines was \$35 (range \$0-1200). Fewer physicians were aware of the use of alternative (70.5%) that of over-the-counter medicines (88.3%). Although most patients thought that vulvovaginal candidiasis was the cause of their symptoms, the most common diagnoses at initial presentation were candidiasis in 29 (27.6%), vulvar vestibulitis in 18 (17.1%), irritant dermatitis in 16 (15.2%), and bacterial vaginosis in 11 (10.5%). Women who actually had candidiasis were more likely to have used alternative medicines (odds ration 2.31, 95% confidence interval 1.00, 5.42) than other patients. Women with chronic vaginal symptoms often use

over-the-counter and alternative medicines that add to health care costs and are unlikely to be of benefit.

Subject Headings: [Vaginitis](#)
[Drug Utilization](#)
[Middle Aged](#)
[Humans](#)
[Index Medicus](#)
[Adult](#)
[Female](#)
[Abridged Index Medicus](#)
[Nonprescription Drugs](#)
[Complementary Therapies](#)
[Chronic Disease](#)

Source: Medline

135. Boric acid vaginal suppositories: A brief review

Citation: Infectious Diseases in Obstetrics and Gynecology, 1998, vol./is. 6/4(191-194), 1064-7449 (1998)

Author(s): Prutting S.M.; Cervený J.D.

Institution: (Prutting, Cervený) Ambulatory Care, Medical College of South Carolina, Charleston, SC, United States; (Cervený) Ambulatory Care, Medical College of South Carolina, 590 MUSC, Charleston, SC 29425, United States

Language: English

Country of Publication: United Kingdom

Publisher: Parthenon Publishing Group Ltd

CAS Registry Number: 1397-89-3 (amphotericin B); 30652-87-0 (amphotericin B); 10043-35-3 (boric acid); 11113-50-1 (boric acid); 11129-12-7 (boric acid); 14213-97-9 (boric acid); 23593-75-1 (clotrimazole); 86386-73-4 (fluconazole); 2022-85-7 (flucytosine); 84625-61-6 (itraconazole); 65277-42-1 (ketoconazole); 22916-47-8 (miconazole); 67915-31-5 (terconazole)

Publication Type: Journal: Review

Subject Headings: [*bacteriostasis](#)
[drug formulation](#)
[drug mechanism](#)
[drug tolerability](#)
["erythema/si \[Side Effect\]"](#)
[female](#)
[human](#)
[human cell](#)
[human tissue](#)
[intravaginal drug administration](#)
[priority journal](#)
[review](#)
[Saccharomyces cerevisiae](#)
[suppository](#)
["vagina discharge/si \[Side Effect\]"](#)
["*vaginitis/dt \[Drug Therapy\]"](#)
["amphotericin B/ad \[Drug Administration\]"](#)
["amphotericin B/dt \[Drug Therapy\]"](#)
["*boric acid/ae \[Adverse Drug Reaction\]"](#)
["*boric acid/ad \[Drug Administration\]"](#)
["*boric acid/dt \[Drug Therapy\]"](#)
["*boric acid/pr \[Pharmaceutics\]"](#)
["*boric acid/pk \[Pharmacokinetics\]"](#)
["*boric acid/pd \[Pharmacology\]"](#)

"clotrimazole/ad [Drug Administration]"
 "clotrimazole/dt [Drug Therapy]"
 "*fluconazole/ad [Drug Administration]"
 "*fluconazole/dt [Drug Therapy]"
 "*flucytosine/ad [Drug Administration]"
 "*flucytosine/dt [Drug Therapy]"
 "*itraconazole/ad [Drug Administration]"
 "*itraconazole/dt [Drug Therapy]"
 "*ketoconazole/ad [Drug Administration]"
 "*ketoconazole/dt [Drug Therapy]"
 "*miconazole/ad [Drug Administration]"
 "*miconazole/dt [Drug Therapy]"
 "suppository base/ae [Adverse Drug Reaction]"
 "suppository base/ad [Drug Administration]"
 "suppository base/dt [Drug Therapy]"
 "suppository base/pr [Pharmaceutics]"
 "suppository base/pk [Pharmacokinetics]"
 "suppository base/pd [Pharmacology]"
 "terconazole/ad [Drug Administration]"
 "terconazole/dt [Drug Therapy]"

Source: EMBASE

Full Text: Available from *National Library of Medicine* in *Infectious Diseases in Obstetrics and Gynecology*

136. Boric acid vaginal suppositories: a brief review.

Citation: Infectious diseases in obstetrics and gynecology, Jan 1998, vol. 6, no. 4, p. 191-194, 1064-7449 (1998)

Author(s): Prutting, S M; Cerveny, J D

Subject Headings: Administration Intravaginal
 Hydrogen-Ion Concentration
 Antifungal Agents
 Humans
 Index Medicus
 Female
 Boric Acids
 Suppositories
 Anti-Infective Agents

Source: Medline

Full Text: Available from *National Library of Medicine* in *Infectious Diseases in Obstetrics and Gynecology*

137. Resistogram typing of oral *Candida albicans* isolates from normal subjects in three successive trials.

Citation: Revista iberoamericana de micología, Mar 1998, vol. 15, no. 1, p. 19-21, 1130-1406 (March 1998)

Author(s): Nakamura, K; Ito-Kuwa, S; Nakamura, Y; Aoki, S; Vidotto, V; Sinicco, A

Abstract: Sixty-six oral strains of *Candida albicans*, which had been consecutively isolated from 22 normal, young females in three isolation trials at intervals of one to three weeks, were biotyped by their susceptibility to boric acid, cetrinide, silver nitrate, sodium periodate and sodium selenite. The 66 isolates were grouped into 13 resistogram types. An identical biotype strain was found three times and twice in seven and six each of the 22 subjects in the three isolation trials, respectively. In the remaining nine subjects, different strains were found at the three trials. These results suggested that certain strains tended to persist in the oral cavity of the normal subjects although changes in the biotype of oral *C. albicans* strains occurred to a certain extent.

Subject Headings:

Source: Medline

138. Susceptibility of Candida species isolated from female prostitutes with vulvovaginitis to antifungal agents and boric acid

Citation: European Journal of Clinical Microbiology and Infectious Diseases, 1999, vol./is. 18/1(59-61), 0934-9723 (1999)

Author(s): Otero L.; Fleites A.; Mendez F.J.; Palacio V.; Vazquez F.

Institution: (Otero) Servicio de Microbiología, Hospital de Cabuenes, Gijón, Spain; (Fleites) Serv. de Microbiol. y Enferm. Infec., Hospital Central de Asturias, Oviedo, Spain; (Mendez) Servicio de Microbiología, Hospital Central de Asturias, Oviedo, Spain; (Palacio) Unidad de Enferm. de Transmis. Sex., Hospital Monte Naranco, Oviedo, Spain; (Vazquez) Servicio de Microbiología, Hospital Monte Naranco, Depto. de Biología Funcional, C/ Julian Claveria s/n, E-33006 Oviedo, Spain

Language: English

Abstract: The aim of this study was to determine the antifungal susceptibility of 108 *Candida albicans* and 23 *Candida glabrata* isolates obtained from female prostitutes with vulvovaginitis, a population for which available data is limited. Amphotericin B, flucytosine, and fluconazole were tested by broth microdilution, and boric acid was tested by the agar dilution method. The susceptibility patterns found in this population were the same as those in the general population. *Candida glabrata* required greater concentrations of boric acid for inhibition in vitro than did *Candida albicans*.

Country of Publication: Germany

Publisher: Springer Verlag

CAS Registry Number: 1397-89-3 (amphotericin B); 30652-87-0 (amphotericin B); 10043-35-3 (boric acid); 11113-50-1 (boric acid); 11129-12-7 (boric acid); 14213-97-9 (boric acid); 86386-73-4 (fluconazole); 2022-85-7 (flucytosine)

Publication Type: Journal: Article

Subject Headings: [article](#)
[Candida](#)
[Candida albicans](#)
[Candida glabrata](#)
[concentration response](#)
[controlled study](#)
[drug efficacy](#)
[female](#)
[human](#)
[major clinical study](#)
[priority journal](#)
[prostitution](#)
["*vulvovaginitis/dt \[Drug Therapy\]"](#)
["*vulvovaginitis/et \[Etiology\]"](#)
["amphotericin B/cm \[Drug Comparison\]"](#)
["amphotericin B/dt \[Drug Therapy\]"](#)
["*antifungal agent/cm \[Drug Comparison\]"](#)
["*antifungal agent/dt \[Drug Therapy\]"](#)
["*boric acid/cm \[Drug Comparison\]"](#)
["*boric acid/dt \[Drug Therapy\]"](#)
["fluconazole/cm \[Drug Comparison\]"](#)
["fluconazole/dt \[Drug Therapy\]"](#)
["flucytosine/cm \[Drug Comparison\]"](#)
["flucytosine/dt \[Drug Therapy\]"](#)

Source: EMBASE

Full Text: Available from *UHB Online* in *European Journal of Clinical Microbiology and Infectious Diseases*

Available from ProQuest in *European Journal of Clinical Microbiology and Infectious Diseases*

Available from Springer NHS Pilot 2014 (NESLi2) in *European Journal of Clinical Microbiology & Infectious Diseases*; Note: ; Collection notes: Academic-License. Please when asked to pick an institution please pick NHS. Please also note access is from 1997 to date only.

139. Terconazole cream for non-Candida albicans fungal vaginitis: Results of a retrospective analysis

Citation:	Infectious Diseases in Obstetrics and Gynecology, 2000, vol./is. 8/5-6(240-243), 1064-7449 (2000)
Author(s):	Sood G.; Nyirjesy P.; Weitz M.V.; Chatwani A.
Institution:	(Sood, Nyirjesy, Weitz, Chatwani) Department of Ob/Gyn/RS, Temple University School of Medicine, 3401 N. Broad Street, Philadelphia, PA 19140, United States
Language:	English
Abstract:	Objective: Although it is FDA-approved for use in vulvovaginal candidiasis caused by non-Candida albicans species, terconazole cream has not been studied in patients with these infections. We sought to assess the clinical and mycological efficacy of terconazole cream in women with non-C. albicans vaginitis. Methods: The records of patients who had received a 7-day course of terconazole cream for culture-proved non-C. albicans vaginitis were reviewed. Data with regard to patient demographics, clinical and mycologic response to therapy within 1 month of treatment, and outcome with other antifungal therapies were analyzed. Results: Twenty-eight patients received terconazole cream for non-C. albicans infections. Three patients did not return for follow-up. The median age was 45 years. Seven (28%) patients were nulliparous. The median duration of symptoms was 3 years. Nine patients (36%) had received terconazole within the 6 months prior to referral. Overall, there were 20 C. glabrata cases, 3 C. parapsilosis, and 2 C. lusitaniae. Fourteen (56%) patients achieved a mycologic cure; 11 (44%) noted a resolution of their symptoms. Prior terconazole use was not associated with treatment failure (P = 0.09). Ten failures received boric acid suppositories as subsequent treatment; a cure was effected in 4 (40%). Two of three patients (67%) were eventually cured with flucytosine cream. Five (20%) patients remained uncured. Conclusions: Terconazole cream may be an appropriate first-line treatment for non C. albicans vaginitis, even in patients who have previously received the drug. © 2000 Wiley-Liss, Inc.
Country of Publication:	United Kingdom
Publisher:	Parthenon Publishing Group Ltd
CAS Registry Number:	10043-35-3 (boric acid); 11113-50-1 (boric acid); 11129-12-7 (boric acid); 14213-97-9 (boric acid); 2022-85-7 (flucytosine); 67915-31-5 (terconazole)
Publication Type:	Journal: Article
Subject Headings:	<p>article</p> <p>Candida glabrata</p> <p>candida lusitaniae</p> <p>candidiasis</p> <p>clinical article</p> <p>drug efficacy</p> <p>female</p> <p>fungus</p> <p>human</p> <p>priority journal</p> <p>treatment outcome</p> <p>"*vaginitis/dt [Drug Therapy]"</p> <p>"boric acid/dt [Drug Therapy]"</p> <p>"boric acid/va [Intravaginal Drug Administration]"</p> <p>"flucytosine/dt [Drug Therapy]"</p> <p>"flucytosine/tp [Topical Drug Administration]"</p> <p>"*terconazole/dt [Drug Therapy]"</p> <p>"*terconazole/tp [Topical Drug Administration]"</p>

Source: EMBASE
Full Text: Available from *National Library of Medicine* in *Infectious Diseases in Obstetrics and Gynecology*

140. Boric acid pessaries: Efficacy and toxicity in treatment of chronic vulvo vaginal candidiasis

Citation: CME Bulletin Sexually Transmitted Infections and HIV, 2000, vol./is. 4/2(27-28), 1367-014X (2000)

Author(s): Carne C.

Institution: (Carne) Department of GU Medicine, Addenbrooke's Hospital, Hills Road, Cambridge CB2 2QQ, United Kingdom

Language: English

Abstract: Boric acid treatment is one of a limited number of useful options in cases of vulvo-vaginal candidiasis that fail to respond to topical or oral azoles. The usual dose is one 600 mg pessary nocte for two weeks. If maintenance therapy is being considered an appreciation of the potential dangers from boric acid toxicity is necessary. Traumatized vaginal mucosa might absorb appreciable quantities of boric acid. Prolonged absorption causes anorexia, weight loss, vomiting, mild diarrhoea, skin rash, alopecia, convulsions and anaemia. Serum total boron is worth measuring in someone who is exhibiting symptoms of boric acid toxicity. Patients embarking on long term treatment should be warned about the possibility of toxicity.

Country of Publication: United Kingdom

Publisher: Rila Publications Ltd

CAS Registry Number: 10043-35-3 (boric acid); 11113-50-1 (boric acid); 11129-12-7 (boric acid); 14213-97-9 (boric acid)

Publication Type: Journal: Review

Subject Headings: alopecia
 anemia
 anorexia
 chronic disease
 convulsion
 diarrhea
 dose calculation
 drug absorption
 drug blood level
 drug efficacy
 "drug intoxication/di [Diagnosis]"
 human
 lethal dose
 rash
 review
 "*vagina candidiasis/dt [Drug Therapy]"
 vagina pessary
 vomiting
 weight reduction
 "*boric acid/dt [Drug Therapy]"
 "*boric acid/to [Drug Toxicity]"
 "*boric acid/va [Intravaginal Drug Administration]"
 "*boric acid/pr [Pharmaceutics]"
 "*boric acid/pk [Pharmacokinetics]"
 "*boric acid/pd [Pharmacology]"

Source: EMBASE

141. Phenotypic characterisation of *Candida albicans* isolated from chronic hyperplastic candidosis

Citation: Journal of Medical Microbiology, 2000, vol./is. 49/2(199-202), 0022-2615 (2000)

Author(s): Williams D.W.; Wilson M.J.; Potts A.J.C.; Lewis M.A.O.

Institution: (Williams, Wilson, Potts, Lewis) Department of Oral Surgery, Medicine and Pathology, Dental School, Heath Park, Cardiff, CF4 4XY, United Kingdom

Language: English

Abstract: The phenotypes of 35 *Candida albicans* isolates from 19 patients with chronic hyperplastic candidosis (CHC) and 35 isolates from 30 patients with non-CHC infections were compared. Typing was based on carbohydrate assimilation, chemical sensitivity and serology. Eight carbohydrate assimilation profiles were evident with the API-20C system and a single profile predominated for isolates from CHC (17 of 19 patients; 89%) and non-CHC (18 of 30 patients; 63%). Chemical sensitivity tests revealed four profiles with no significant difference between CHC and non-CHC isolates. Serotype A predominated for isolates from both CHC (15 of 19 patients; 79%) and non-CHC (25 of 30 patients; 83%) infections. Boric acid resistance was more prevalent in CHC isolates, although a significant difference was not apparent. In summary, there was no overall difference in the phenotypes of isolates from CHC and non-CHC patients, and clonal restriction of CHC isolates was not demonstrated.

Country of Publication: United Kingdom

Publisher: Lippincott Williams and Wilkins

Publication Type: Journal: Article

Subject Headings: [article](#)
[*Candida albicans](#)
[*candidiasis](#)
[nonhuman](#)
[phenotype](#)
[priority journal](#)
[serotype](#)
[carbohydrate](#)

Source: EMBASE

142. Biotypes of oral *Candida albicans* isolated from AIDS patients and HIV-free subjects in Thailand

Citation: Journal of Oral Pathology and Medicine, May 2000, vol./is. 29/5(193-199), 0904-2512 (May 2000)

Author(s): Teanpaisan R.; Nittayananta W.; Chongsuvivatwong V.

Institution: (Teanpaisan, Nittayananta) Department of Stomatology, Faculty of Dentistry, Hat-Yai, Songkhla, Thailand; (Chongsuvivatwong) Epidemiology Unit, Faculty of Medicine, Prince of Songkla University, Hat-Yai, Songkhla, Thailand; (Teanpaisan) Department of Stomatology, Faculty of Dentistry, Prnc. of Songkla University, Hat-Yai, P.O. Box 17, Khor Hong, Songkhla 90112, Thailand

Language: English

Abstract: This study was conducted to examine biotypes and antifungal susceptibility patterns of oral *Candida albicans* isolated from HIV-infected patients, HIV-free patients with candidiasis and healthy subjects. All isolates were biotyped using a typing system based on enzyme profiles, carbohydrate assimilation patterns and boric acid resistance. Thirty-eight biotypes were found amongst 218 oral *C. albicans* isolates. The major biotype found was A1S, which accounted for 32.6% of all isolates, and this biotype was the most common in all groups. There was a greater variety of biotypes of *C. albicans* in the HIV-infected group than in the other groups; however, there was no statistically significant difference between the groups. The minimum inhibitory concentrations (MICs) of a total of 118 isolates were determined for amphotericin B and for ketoconazole using the National Committee for Clinical Laboratory Standards (NCCLS) broth macrodilution method and the E-test. When the antifungal susceptibility patterns among the groups were compared, a statistically significant difference was found only

with amphotericin B. The median MIC of amphotericin B in the HIV-infected group was higher than in the healthy group (P = 0.013, NCCLS method; P = 0.002, E-test). However, this difference in sensitivity was not restricted to any sub-type investigated. Our results showed that the biotype patterns of *C. albicans* isolates that colonize HIV-infected patients are similar to those of HIV-free subjects, and there is no relationship between antifungal susceptibility patterns and the biotypes.

Country of Publication: Denmark
Publisher: Blackwell Munksgaard
CAS Registry Number: 1397-89-3 (amphotericin B); 30652-87-0 (amphotericin B); 65277-42-1 (ketoconazole)
Publication Type: Journal: Article
Subject Headings: ["*AIDS related complex/dt \[Drug Therapy\]"](#)
[article](#)
[*Candida albicans](#)
[classification](#)
[dose response](#)
[drug effect](#)
[human](#)
[microbiological examination](#)
[microbiology](#)
[saliva](#)
[*serodiagnosis](#)
["*thrush/dt \[Drug Therapy\]"](#)
["amphotericin B/ad \[Drug Administration\]"](#)
["ketoconazole/ad \[Drug Administration\]"](#)

Source: EMBASE

143. *Candida albicans* strain differentiation in complete denture wearers

Citation: The new microbiologica : official journal of the Italian Society for Medical, Odontoiatric, and Clinical Microbiology (SIMMOC), July 2000, vol./is. 23/3(329-337), 1121-7138 (Jul 2000)

Author(s): Abu-Elteen K.H.

Institution: (Abu-Elteen) Department of Biological Sciences, Faculty of Science, Hashemite University, Zarqa, Jordan.

Language: English

Abstract: Strain differentiation of 66 clinical isolates of *Candida albicans* obtained from healthy dentate and complete denture wearers was performed. Resistogram method based on differences in the resistance of *C. albicans* isolates to sodium selenite, boric acid, cetrimide, sodium periodate and silver nitrate was used for strain differentiation. Of the 32 potential strains that can be distinguished, 14 different resistogram strains of *C. albicans* were found among the 66 isolates tested. Strain-C--was the most predominant (24.3% of total isolates), while strain A-CDE was the least predominant (1.5%). The results showed no particular association of certain strains with *Candida* infections in complete denture wearers. Sensitivity to antifungal agents showed that isolates from different strains were most sensitive to amphotericin B and nystatin and least sensitive to miconazole.

Country of Publication: Italy

CAS Registry Number: 1397-89-3 (amphotericin B); 30652-87-0 (amphotericin B); 10043-35-3 (boric acid); 11113-50-1 (boric acid); 11129-12-7 (boric acid); 14213-97-9 (boric acid); 57-09-0 (cetrimide); 6899-10-1 (cetrimide); 8044-71-1 (cetrimide); 22916-47-8 (miconazole); 1400-61-9 (nystatin); 34786-70-4 (nystatin); 62997-67-5 (nystatin); 15056-35-6 (periodate); 10450-60-9 (periodic acid); 13444-71-8 (periodic acid); 7761-88-8 (silver nitrate); 10102-18-8 (sodium selenite)

Publication Type: Journal: Article

Subject Headings: antibiotic resistance
 article
 *Candida albicans
 classification
 "*denture/ae [Adverse Drug Reaction]"
 drug effect
 human
 microbiological examination
 microbiology
 physiology
 *stomatitis
 *thrush
 "amphotericin B/pd [Pharmacology]"
 "antifungal agent/pd [Pharmacology]"
 "boric acid/pd [Pharmacology]"
 "cetrimide/pd [Pharmacology]"
 "miconazole/pd [Pharmacology]"
 "nystatin/pd [Pharmacology]"
 periodate
 "periodic acid/pd [Pharmacology]"
 "silver nitrate/pd [Pharmacology]"
 "sodium selenite/pd [Pharmacology]"

Source: EMBASE

144. Phenotypes and randomly amplified polymorphic DNA profiles of *Candida albicans* isolates from root canal infections in a Finnish population

Citation: Oral Microbiology and Immunology, 2001, vol./is. 16/2(106-112), 0902-0055 (2001)

Author(s): Waltimo T.M.T.; Dassanayake R.S.; Orstavik D.; Haapasalo M.P.P.; Samaranayake L.P.

Institution: (Waltimo, Orstavik) NIOM, Scandinavian Institute of Dental Materials, Haslum, Norway; (Waltimo) Institute of Dentistry, University of Helsinki, Helsinki, Finland; (Dassanayake, Samaranayake) Faculty of Dentistry, University of Hong Kong, Hong Kong, Hong Kong; (Haapasalo) Division of Endodontics, Institute of Dentistry, University of Oslo, Oslo, Norway; (Waltimo) Institute of Dentistry, PL 41, FIN-00014 Helsinki, Finland

Language: English

Abstract: A total of thirty-seven *Candida albicans* isolates from root canal infections in a Finnish population were subtyped using phenotypic and genotypic methods. A previously described biotyping method based on the presence of five different enzymes, assimilation of eleven different carbohydrates and boric acid sensitivity of the yeasts was used to determine the phenotype. Commercially available API ZYM and API 20 C test kits were used to determine the presence of enzymes and assimilation of carbohydrates. The sensitivity of the isolates to boric acid was tested by their ability to grow on yeast-nitrogen-agar with incorporated boric acid (1.8 mg . ml⁻¹). Combination of the tests revealed a total of 14 different phenotypes. The majority of the isolates, 26 strains, were classifiable into three major phenotypes: 16 isolates (43.2%) belonged to phenotype A1R, six (16.2%) to A1S and four (10.8%) to B1S. The remaining 11 phenotypes represented only a single isolate each. The randomly amplified polymorphic DNA profiles were used to determine the genotypes. For this purpose two different primers, RSD6 and RSD12 were used to develop a combination randomly amplified polymorphic DNA profile for each isolate. Altogether 31 genotypes were noted among the 37 isolates, of which only three pairs of isolates presented with congruent phenotypic and genotypic profiles. The heterogeneity of both the phenotypic and randomly amplified polymorphic DNA profiles of *C. albicans* isolates from root canal infections is akin to previous reports from other oral and non-oral sources in different geographic locales.

Country of Publication: Denmark

Publisher: Blackwell Munksgaard

Publication Type: Journal: Article

Subject Headings:

Source: EMBASE

145. Candida lusitaniae as an unusual cause of recurrent vaginitis and its successful treatment with intravaginal boric acid

Citation: Infectious Diseases in Obstetrics and Gynecology, 2001, vol./is. 9/4(245-247), 1064-7449 (2001)

Author(s): Silverman N.S.; Morgan M.; Nichols W.S.

Institution: (Silverman) Department of Obstetrics and Gynecology, Burns and Allen Research Institute, UCLA School of Medicine, Los Angeles, CA 90048, United States; (Morgan, Nichols) Department of Pathology and Laboratory Medicine, Burns and Allen Research Institute, UCLA School of Medicine, Los Angeles, CA, United States

Language: English

Abstract: Increasing use of short-course antifungal therapies in patients with recurrent vulvovaginitis may enable the emergence of less-common, more resistant yeast strains as vaginal pathogens. We report the case of a patient with chronically symptomatic and repeatedly treated vaginal candidiasis whose infection was attributable to *Candida lusitaniae*, a previously unreported cause of candidal vaginitis.

Country of Publication: United Kingdom

Publisher: Parthenon Publishing Group Ltd

CAS Registry Number: 10043-35-3 (boric acid); 11113-50-1 (boric acid); 11129-12-7 (boric acid); 14213-97-9 (boric acid); 18323-44-9 (clindamycin); 86386-73-4 (fluconazole); 65277-42-1 (ketoconazole)

Publication Type: Journal: Article

Subject Headings: adult
antibiotic resistance
article
*candida lusitaniae
case report
clinical feature
diagnostic procedure
disease course
female
follow up
human
priority journal
"recurrent infection/di [Diagnosis]"
"recurrent infection/dr [Drug Resistance]"
"recurrent infection/dt [Drug Therapy]"
"recurrent infection/et [Etiology]"
suppository
symptomatology
treatment outcome
"vagina candidiasis/di [Diagnosis]"
"vagina candidiasis/dr [Drug Resistance]"
"vagina candidiasis/dt [Drug Therapy]"
"vagina candidiasis/et [Etiology]"
"*vulvovaginitis/di [Diagnosis]"
"*vulvovaginitis/dr [Drug Resistance]"
"*vulvovaginitis/dt [Drug Therapy]"
"*vulvovaginitis/et [Etiology]"
"antifungal agent/dt [Drug Therapy]"
"antifungal agent/tp [Topical Drug Administration]"

"antiinfective agent/dt [Drug Therapy]"
 "antiinfective agent/tp [Topical Drug Administration]"
 "*boric acid/do [Drug Dose]"
 "*boric acid/dt [Drug Therapy]"
 "*boric acid/va [Intravaginal Drug Administration]"
 "clindamycin/dt [Drug Therapy]"
 "clindamycin/va [Intravaginal Drug Administration]"
 "fluconazole/do [Drug Dose]"
 "fluconazole/dt [Drug Therapy]"
 "fluconazole/po [Oral Drug Administration]"
 "ketoconazole/do [Drug Dose]"
 "ketoconazole/dt [Drug Therapy]"
 "ketoconazole/po [Oral Drug Administration]"

Source: EMBASE

Full Text: Available from *National Library of Medicine* in *Infectious Diseases in Obstetrics and Gynecology*

146. Efficacy of maintenance therapy with topical boric acid in comparison with oral itraconazole in the treatment of recurrent vulvovaginal candidiasis

Citation: American Journal of Obstetrics and Gynecology, 2001, vol./is. 184/4(598-602), 0002-9378 (2001)

Author(s): Guaschino S.; De Seta F.; Sartore A.; Ricci G.; De Santo D.; Piccoli M.; Alberico S.

Institution: (Guaschino, De Seta, Sartore, Ricci, De Santo, Piccoli, Alberico) Department of Obstetrics and Gynecology, University of Trieste, Istituto Di Ricovero E Cura A Carattere Scientifico Burlo Garofolo

Language: English

Abstract: OBJECTIVE: Our purpose was to examine the efficacy of a topical long-term treatment with boric acid versus an oral long-term treatment (itraconazole) in the cure and prevention of recurrent vulvovaginal candidiasis. STUDY DESIGN: A prospective, nonrandomized study of patients affected by recurrent vulvovaginal candidiasis was undertaken. In 3 years we recruited 22 consecutive patients who underwent therapy with itraconazole (group 1) or boric acid (group 2). Women were followed up for 1 year, with clinic and microbiologic controls after 1, 3, 6, and 12 months after the first visit. RESULTS: During the treatment, the positive culture results (15.1% vs 12.1%) and the signs and symptoms (33.3% vs 24.2%) were similar within the 2 groups, with no significant statistical difference. With the withdrawal, after 6 months relapses were common in the 2 groups (54.5%). CONCLUSIONS: Boric acid seems to be a valid and promising therapy both in the cure of the vaginal infection and in the prevention of relapses of recurrent vulvovaginal candidiasis, but its efficacy ends with the suspension of the therapy.

Country of Publication: United States

Publisher: Mosby Inc.

CAS Registry Number: 10043-35-3 (boric acid); 11113-50-1 (boric acid); 11129-12-7 (boric acid); 14213-97-9 (boric acid); 84625-61-6 (itraconazole)

Publication Type: Journal: Article

Subject Headings: [adult](#)
[article](#)
[clinical article](#)
[controlled study](#)
[drug efficacy](#)
[female](#)
[fungus culture](#)
[human](#)
[infection prevention](#)
[maintenance therapy](#)

priority journal
 recurrent disease
 relapse
 symptomatology
 "*vagina candidiasis/dt [Drug Therapy]"
 "*vagina candidiasis/pc [Prevention]"
 "*boric acid/cm [Drug Comparison]"
 "*boric acid/dt [Drug Therapy]"
 "*boric acid/tp [Topical Drug Administration]"
 "*itraconazole/cm [Drug Comparison]"
 "*itraconazole/dt [Drug Therapy]"
 "*itraconazole/po [Oral Drug Administration]"

Source: EMBASE

147. Efficacy of maintenance therapy with topical boric acid in comparison with oral itraconazole in the treatment of recurrent vulvovaginal candidiasis.

Citation: American journal of obstetrics and gynecology, Mar 2001, vol. 184, no. 4, p. 598-602, 0002-9378 (March 2001)

Author(s): Guaschino, S; De Seta, F; Sartore, A; Ricci, G; De Santo, D; Piccoli, M; Alberico, S

Abstract: Our purpose was to examine the efficacy of a topical long-term treatment with boric acid versus an oral long-term treatment (itraconazole) in the cure and prevention of recurrent vulvovaginal candidiasis. A prospective, nonrandomized study of patients affected by recurrent vulvovaginal candidiasis was undertaken. In 3 years we recruited 22 consecutive patients who underwent therapy with itraconazole (group 1) or boric acid (group 2). Women were followed up for 1 year, with clinic and microbiologic controls after 1, 3, 6, and 12 months after the first visit. During the treatment, the positive culture results (15.1% vs 12.1%) and the signs and symptoms (33.3% vs. 24.2%) were similar within the 2 groups, with no significant statistical difference. With the withdrawal, after 6 months relapses were common in the 2 groups (54.5%). Boric acid seems to be a valid and promising therapy both in the cure of the vaginal infection and in the prevention of relapses of recurrent vulvovaginal candidiasis, but its efficacy ends with the suspension of the therapy.

Subject Headings: Vulvar Diseases
 Prospective Studies
 Antifungal Agents
 Humans
 Candidiasis
 Vaginal Diseases
 Recurrence
 Adult
 Female
 Boric Acids
 Itraconazole
 Abridged Index Medicus
 Index Medicus

Source: Medline

148. Phenotypes and randomly amplified polymorphic DNA profiles of Candida albicans isolates from root canal infections in a Finnish population.

Citation: Oral microbiology and immunology, Apr 2001, vol. 16, no. 2, p. 106-112, 0902-0055 (April 2001)

Author(s): Waltimo, T M; Dassanayake, R S; Ørstavik, D; Haapasalo, M P; Samaranayake, L P

Abstract: A total of thirty-seven Candida albicans isolates from root canal infections in a Finnish population were subtyped using phenotypic and genotypic methods. A previously described biotyping method based on the presence of five different enzymes, assimilation of eleven different carbohydrates and boric acid sensitivity of the yeasts was used to

determine the phenotype. Commercially available API ZYM and API 20 C test kits were used to determine the presence of enzymes and assimilation of carbohydrates. The sensitivity of the isolates to boric acid was tested by their ability to grow on yeast-nitrogen-agar with incorporated boric acid (1.8 mg. ml(-1)). Combination of the tests revealed a total of 14 different phenotypes. The majority of the isolates, 26 strains, were classifiable into three major phenotypes: 16 isolates (43.2%) belonged to phenotype A1R, six (16.2%) to A1S and four (10.8%) to B1S. The remaining 11 phenotypes represented only a single isolate each. The randomly amplified polymorphic DNA profiles were used to determine the genotypes. For this purpose two different primers, RSD6 and RSD12 were used to develop a combination randomly amplified polymorphic DNA profile for each isolate. Altogether 31 genotypes were noted among the 37 isolates, of which only three pairs of isolates presented with congruent phenotypic and genotypic profiles. The heterogeneity of both the phenotypic and randomly amplified polymorphic DNA profiles of *C. albicans* isolates from root canal infections is akin to previous reports from other oral and non-oral sources in different geographic locales.

Subject Headings: [Genotype](#)
[Candida albicans](#)
[Periapical Periodontitis](#)
[Finland](#)
[Humans](#)
[Phenotype](#)
[Dentistry](#)
[Random Amplified Polymorphic DNA Technique](#)
[Bacterial Typing Techniques](#)
[DNA Fingerprinting](#)

Source: Medline

149. Treatment of chronic recurrent vulvovaginal candidiasis by oral fluconazole and prophylactic local boric acid [Hungarian] Chronicus recidivalo vulvovaginalis candidosis kezelese per os fluconazolal es prophylaxisa lokalis borsavval

Original Title: Chronicus recidivalo vulvovaginalis candidosis kezelese per os fluconazolal es prophylaxisa lokalis borsavval

Citation: Magyar Noorvosok Lapja, 2002, vol./is. 65/6(437-441), 0025-021X (2002)

Author(s): Andras U.; Istvan S.; Zoltan P.

Language: Hungarian

Abstract: The treatment of recurrent vulvovaginal candidiasis includes an initial regimen of oral antimycotic drug to ensure clinical remission continued with maintenance therapy to prevent recurrent infection. This maintenance therapy should last at least 6 month. At the I. Department of Obstetrics and Gynecology of Semmelweis University we performed follow up of 24 nonpregnant patients with recurrent vulvovaginal candidiasis who had four or more previous episodes of proved infection during a 12-month period. After treating the acute fungal vaginitis with 1 x 150 mg (rarely 2 x 150 mg) oral fluconazole we started the maintenance therapy with topical boric acid. The efficacy of this topical maintenance therapy was measured with the occurrence of symptomatic recurrences during the period of prophylaxis and 6 months after. We also studied the side effects of oral fluconazole and topical boric acid treatment. 3 patients of the 24 (12,5%) were excluded from the study because interruption of the maintenance therapy. During the period of the maintenance therapy recurrent infection was not occurred among 18 patients of the remaining 21 (86%), although 3 patients (14%) experienced symptomatic fungal vaginitis. 7 patients fulfilled the 6 months after completing the period of topical boric acid prophylaxis. During this 6 months 2 patients of this 7 (29%) had acute episode, the remaining 5 (71%) did not experienced symptomatic infection. Side effects were not mentioned during the study. Topical boric acid seems to be an effective maintenance therapy in the prevention of relapses of recurrent vulvovaginal candidiasis.

Country of Publication: Hungary

Publisher: Magyar Noovos Tarsasag

CAS Registry Number: 10043-35-3 (boric acid); 11113-50-1 (boric acid); 11129-12-7 (boric acid); 14213-97-9 (boric acid); 86386-73-4 (fluconazole)

Publication Type: Journal: Article

Subject Headings: [article](#)
[clinical article](#)
[drug efficacy](#)
[female](#)
[human](#)
[maintenance therapy](#)
[prophylaxis](#)
["recurrent infection/dt \[Drug Therapy\]"](#)
[relapse](#)
["side effect/si \[Side Effect\]"](#)
["*vagina candidiasis/dt \[Drug Therapy\]"](#)
[vaginitis](#)
["antifungal agent/dt \[Drug Therapy\]"](#)
["antifungal agent/po \[Oral Drug Administration\]"](#)
["*boric acid/ae \[Adverse Drug Reaction\]"](#)
["*boric acid/dt \[Drug Therapy\]"](#)
["*boric acid/tp \[Topical Drug Administration\]"](#)
["*fluconazole/ae \[Adverse Drug Reaction\]"](#)
["*fluconazole/dt \[Drug Therapy\]"](#)
["*fluconazole/po \[Oral Drug Administration\]"](#)

Source: EMBASE

150. Boric acid susceptibility testing of non-*C. albicans* Candida and *Saccharomyces cerevisiae*: Comparison of three methods

Citation: Medical Mycology, 2002, vol./is. 40/3(319-322), 1369-3786 (2002)

Author(s): Otero L.; Palacio V.; Mendez F.J.; Vazquez F.

Institution: (Otero, Palacio, Mendez, Vazquez) Departamento de Biología Funcional, Area de Microbiología, Facultad de Medicina, C/ Julian Claveria s/n, 33006 Oviedo, Spain

Language: English

Abstract: To establish the best method for boric acid susceptibility testing, we compared two agar dilution methods (high and low inoculum) and a standard broth microdilution method (from the National Committee for Clinical Laboratory Standards document NCCLS M-27A). *Saccharomyces cerevisiae* (37) and non-*C. albicans* Candida (39) isolates, as well as one isolate of *Trichosporon* sp., were included. All were isolated from female workers with vulvovaginitis. Good agreement within a fourfold dilution range was found between the three methods, and only the broth microdilution method versus the agar dilution method with high inoculum showed significant discrepancies. Reading results was easier with the broth microdilution method than with the agar dilution methods because of partial growth inhibition in the latter. In conclusion, broth microdilution is a suitable method for testing yeast susceptibility to boric acid.

Country of Publication: United Kingdom

Publisher: BIOS Scientific Publishers Ltd.

CAS Registry Number: 10043-35-3 (boric acid); 11113-50-1 (boric acid); 11129-12-7 (boric acid); 14213-97-9 (boric acid)

Publication Type: Journal: Article

Subject Headings: [agar dilution](#)
[agar medium](#)
[article](#)
[broth microdilution](#)
[*Candida](#)
[Candida glabrata](#)

[Candida parapsilosis](#)
[comparative study](#)
[data analysis](#)
[dilution](#)
[drug sensitivity](#)
[female](#)
[female worker](#)
[fungus growth](#)
[fungus isolation](#)
[growth inhibition](#)
[human](#)
[in vitro study](#)
[inoculation](#)
[intermethod comparison](#)
[minimum inhibitory concentration](#)
[nonhuman](#)
[*Saccharomyces cerevisiae](#)
[standard](#)
[Trichosporon](#)
[vulvovaginitis](#)
["*boric acid/dv \[Drug Development\]"](#)

Source: EMBASE

151. Vaginitis due to *Candida krusei*: epidemiology, clinical aspects, and therapy.

Citation: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, Nov 2002, vol. 35, no. 9, p. 1066-1070, 1537-6591 (November 1, 2002)

Author(s): Singh, Shivani; Sobel, Jack D; Bhargava, Pallavi; Boikov, Dina; Vazquez, Jose A

Abstract: Twelve women with vaginal *Candida krusei* infection were evaluated. In vitro antifungal susceptibility testing and molecular typing were performed. Patients infected with *C. krusei* frequently had refractory vulvovaginal signs and symptoms that were otherwise indistinguishable from vaginitis due to other yeasts. Patients were 32-63 years old and had previously received multiple courses of antimycotic agents, including fluconazole and miconazole. The most active azole in vitro was clotrimazole, with a 90% minimum inhibitory concentration of 0.25 microg/mL. Four of 6 patients treated with boric acid had clinical and mycological cure. Two dominant genotypes of *C. krusei* were identified via contour-clamped homogenous electrical field analysis. No major genotypic change was observed in successive isolates from the same patient in most cases, suggesting that these refractory cases were relapses. *C. krusei* is a rare but important cause of refractory vaginitis and is unique because of its intrinsic resistance to fluconazole.

Subject Headings: [Vaginitis](#)
[Treatment Outcome](#)
[Genotype](#)
[Antifungal Agents](#)
[Humans](#)
[Index Medicus](#)
[Karyotyping](#)
[Adult](#)
[Female](#)
[Middle Aged](#)
[Candida](#)
[Microbial Sensitivity Tests](#)

Source: Medline

Full Text: Available from *EBSCOhost* in [Clinical Infectious Diseases](#)
 Available from *UHB Online* in [Clinical Infectious Diseases](#); Note: ; Notes: Click on 'Sign in via OpenAthens' and enter login credentials

152. Vaginitis due to *Candida krusei*: Epidemiology, clinical aspects, and therapy

Citation: Clinical Infectious Diseases, November 2002, vol./is. 35/9(1066-1070), 1058-4838 (01 Nov 2002)

Author(s): Singh S.; Sobel J.D.; Bhargava P.; Boikov D.; Vazquez J.A.

Institution: (Singh, Sobel, Bhargava, Boikov, Vazquez) Div. of Infectious Diseases, Harper University Hospital, 4 Brush Ctr., 3390 John R. Rd, Detroit, MI 48201, United States

Language: English

Abstract: Twelve women with vaginal *Candida krusei* infection were evaluated. In vitro antifungal susceptibility testing and molecular typing were performed. Patients infected with *C. krusei* frequently had refractory vulvovaginal signs and symptoms that were otherwise indistinguishable from vaginitis due to other yeasts. Patients were 32-63 years old and had previously received multiple courses of antimycotic agents, including fluconazole and miconazole. The most active azole in vitro was clotrimazole, with a 90% minimum inhibitory concentration of 0.25 µg/mL. Four of 6 patients treated with boric acid had clinical and mycological cure. Two dominant genotypes of *C. krusei* were identified via contour-clamped homogenous electrical field analysis. No major genotypic change was observed in successive isolates from the same patient in most cases, suggesting that these refractory cases were relapses. *C. krusei* is a rare but important cause of refractory vaginitis and is unique because of its intrinsic resistance to fluconazole.

Country of Publication: United States

Publisher: University of Chicago Press

CAS Registry Number: 1397-89-3 (amphotericin B); 30652-87-0 (amphotericin B); 10043-35-3 (boric acid); 11113-50-1 (boric acid); 11129-12-7 (boric acid); 14213-97-9 (boric acid); 189768-38-5 (casposfungin); 23593-75-1 (clotrimazole); 86386-73-4 (fluconazole); 2022-85-7 (flucytosine); 84625-61-6 (itraconazole); 65277-42-1 (ketoconazole); 22916-47-8 (miconazole); 1400-61-9 (nystatin); 34786-70-4 (nystatin); 62997-67-5 (nystatin); 137234-62-9 (voriconazole)

Publication Type: Journal: Article

Subject Headings: adult
 article
 candida krusei
 clinical article
 drug sensitivity
 electric field
 female
 fungus isolation
 genotype
 human
 minimum inhibitory concentration
 molecular typing
 priority journal
 relapse
 symptomatology
 "*vagina candidiasis/di [Diagnosis]"
 "*vagina candidiasis/dt [Drug Therapy]"
 "*vagina candidiasis/ep [Epidemiology]"
 "amphotericin B/cm [Drug Comparison]"
 "amphotericin B/dt [Drug Therapy]"
 "amphotericin B/tp [Topical Drug Administration]"
 "*antifungal agent/cm [Drug Comparison]"
 "*antifungal agent/dt [Drug Therapy]"
 "boric acid/dt [Drug Therapy]"
 "casposfungin/cm [Drug Comparison]"
 "clotrimazole/cm [Drug Comparison]"
 "clotrimazole/tp [Topical Drug Administration]"
 "fluconazole/cm [Drug Comparison]"
 "fluconazole/dt [Drug Therapy]"

"flucytosine/dt [Drug Therapy]"
 "flucytosine/tp [Topical Drug Administration]"
 "itraconazole/cm [Drug Comparison]"
 "itraconazole/dt [Drug Therapy]"
 "ketoconazole/dt [Drug Therapy]"
 "miconazole/cm [Drug Comparison]"
 "miconazole/dt [Drug Therapy]"
 "nystatin/dt [Drug Therapy]"
 "nystatin/tp [Topical Drug Administration]"
 "pyrrole derivative/cm [Drug Comparison]"
 "voriconazole/cm [Drug Comparison]"

Source: EMBASE

Full Text: Available from *EBSCOhost* in *Clinical Infectious Diseases*
 Available from *UHB Online* in *Clinical Infectious Diseases*; Note: ; Notes: Click on 'Sign in via OpenAthens' and enter login credentials

153. Otomycosis in Turkey: predisposing factors, aetiology and therapy.

Citation: The Journal of laryngology and otology, Jan 2003, vol. 117, no. 1, p. 39-42, 0022-2151 (January 2003)

Author(s): Ozcan, K Murat; Ozcan, Muge; Karaarslan, Aydin; Karaarslan, Filiz

Abstract: Otomycosis usually requires long-term treatment and tends to recur. This study was performed on 87 patients with the clinical diagnosis of otomycosis and 20 controls in order to determine the pathogenic agents, predisposing factors and a cost-effective treatment. The predisposing factors included wearing head clothes (74.7 per cent), presence of dermatomycoses (34.5 per cent) and swimming (27.6 per cent). The most common pathogenic fungus was *Aspergillus niger* (44.8 per cent) in the otomycosis group. The only isolate was *Candida albicans* in the control group (2.5 per cent). We concluded that administration of four per cent boric acid solution in alcohol and frequent suction cleaning of the ear canal might be a cost-effective treatment for otomycosis since 77 per cent of the patients were treated effectively this way. Eighty per cent of the resistant cases had mixed fungal-bacterial infections, and 50 per cent of them had dermatomycoses. These resistant cases were treated by administration of tioconazole ointment.

Subject Headings: [Turkey](#)
[Male](#)
[Adolescent](#)
[Ear Diseases](#)
[Bacterial Infections](#)
[Index Medicus](#)
[Antifungal Agents](#)
[Risk Factors](#)
[Humans](#)
[Aged 80 and over](#)
[Adult](#)
[Female](#)
[Middle Aged](#)
[Boric Acids](#)
[Abridged Index Medicus](#)
[Aged](#)
[Mycoses](#)
[Age Distribution](#)

Source: Medline

Full Text: Available from *ProQuest* in *Journal of Laryngology and Otology, The*

154. Vulvovaginal trichosporonosis

- Citation:** Infectious Diseases in Obstetrics and Gynecology, 2003, vol./is. 11/2(131-133), 1064-7449 (2003)
- Author(s):** Makela P.; Leaman D.; Sobel J.D.
- Institution:** (Makela) Department of Obstetrics, Wayne Stt. Univ. School of Medicine, Detroit, MI, United States; (Leaman, Sobel) Division of Infectious Disease, Wayne Stt. Univ. School of Medicine, Detroit, MI, United States; (Makela) 4707 St Antoine, Detroit, MI 48201, United States
- Language:** English
- Abstract:** Objective: Isolation of Trichosporon species from vaginal secretions is a rare event, and no data are available on its pathogenic role. A case series is presented to determine the pathogenic role of Trichosporon species in vulvovaginal infections. Methods: We performed a retrospective chart review of patients seen in the W.S.U. Vaginitis Clinic in order to identify patients from whom Trichosporon species were isolated. Results: Between 1986 and 2001, a total of 13 patients had a total of 18 positive vaginal cultures for Trichosporon species. All 18 vaginal isolates were T. inkin. In general, positive vaginal cultures were accompanied by low yeast colony counts. Four out of 18 positive T. inkin cultures were obtained from visits by asymptomatic patients. Of the remaining 14 positive T. inkin cultures from patients with symptoms, nine out of 14 cultures had other diagnoses (Candida albicans, six cases; bacterial vaginosis, two cases; Trichomonas, one case). Five positive T. inkin cultures were obtained from visits at which patients had symptoms and no associated diagnosis. In only one of the five episodes could we establish a clear pathogenic role for Trichosporon. In this case the patient was treated with boric acid and had resolution of symptoms and a negative culture at follow-up. In-vitro susceptibility tests revealed that T. inkin was resistant to flucytosine and susceptible to all topical and oral azoles. Conclusions: T. inkin is occasionally found in vulvovaginal cultures and is usually a non-pathogen. Transient colonization tended to occur in women, usually of African-American origin, with major perturbations in vaginal flora (bacterial vaginosis and trichomoniasis) and increased pH. Pathogenic consequences of Trichosporon colonization appear to be rare.
- Country of Publication:** United Kingdom
- Publisher:** Taylor and Francis Ltd.
- CAS Registry Number:** 10043-35-3 (boric acid); 11113-50-1 (boric acid); 11129-12-7 (boric acid); 14213-97-9 (boric acid); 23593-75-1 (clotrimazole); 86386-73-4 (fluconazole); 2022-85-7 (flucytosine); 84625-61-6 (itraconazole); 65277-42-1 (ketoconazole); 22916-47-8 (miconazole); 137234-62-9 (voriconazole)
- Publication Type:** Journal: Review
- Subject Headings:** [adult](#)
[alkalinity](#)
[antibiotic resistance](#)
[Candida albicans](#)
[clinical article](#)
[female](#)
[follow up](#)
[fungus culture](#)
[fungus isolation](#)
[human](#)
[medical record](#)
["*mycosis/di \[Diagnosis\]"](#)
["*mycosis/dt \[Drug Therapy\]"](#)
["*mycosis/et \[Etiology\]"](#)
[negro](#)
[nonhuman](#)
[priority journal](#)
[retrospective study](#)
[review](#)
[risk factor](#)

symptom
 Trichomonas
 *Trichosporon
 *trichosporon inkin
 United States
 vagina flora
 "*vaginitis/di [Diagnosis]"
 "*vaginitis/dt [Drug Therapy]"
 "*vaginitis/et [Etiology]"
 "*boric acid/dt [Drug Therapy]"
 clotrimazole
 fluconazole
 flucytosine
 itraconazole
 ketoconazole
 miconazole
 "pyrrole derivative/po [Oral Drug Administration]"
 "pyrrole derivative/tp [Topical Drug Administration]"
 voriconazole

Source: EMBASE

Full Text: Available from *EBSCOhost* in *Infectious Diseases in Obstetrics & Gynecology*
 Available from *ProQuest* in *Infectious Diseases in Obstetrics and Gynecology*
 Available from *National Library of Medicine* in *Infectious Diseases in Obstetrics and Gynecology*

155. Otomycosis in Turkey: Predisposing factors, aetiology and therapy

Citation: Journal of Laryngology and Otology, January 2003, vol./is. 117/1(39-42), 0022-2151 (01 Jan 2003)

Author(s): Ozcan K.M.; Ozcan M.; Karaarslan A.; Karaarslan F.

Institution: (Karaarslan) Dept. of Otolaryngology/Dermatol., Ankara Numune Educ. and Res. Hosp., Ankara, Turkey; (Karaarslan) Department of Microbiology, Ankara Univ. Faculty of Medicine, Ankara, Turkey; (Ozcan) Yucetepe sit. A blok. 59/6, 06580 Anitpepe, Ankara, Turkey

Language: English

Abstract: Otomycosis usually requires long-term treatment and tends to recur. This study was performed on 87 patients with the clinical diagnosis of otomycosis and 20 controls in order to determine the pathogenic agents, predisposing factors and a cost-effective treatment. The predisposing factors included wearing head clothes (74.7 per cent), presence of dermatomycoses (34.5 per cent) and swimming (27.6 per cent). The most common pathogenic fungus was *Aspergillus niger* (44.8 per cent) in the otomycosis group. The only isolate was *Candida albicans* in the control group (2.5 per cent). We concluded that administration of four per cent boric acid solution in alcohol and frequent suction cleaning of the ear canal might be a cost-effective treatment for otomycosis since 77 per cent of the patients were treated effectively this way. Eighty per cent of the resistant cases had mixed fungal-bacterial infections, and 50 per cent of them had dermatomycoses. These resistant cases were treated by administration of tioconazole ointment.

Country of Publication: United Kingdom

Publisher: Royal Society of Medicine Press Ltd

CAS Registry Number: 64-17-5 (alcohol); 10043-35-3 (boric acid); 11113-50-1 (boric acid); 11129-12-7 (boric acid); 14213-97-9 (boric acid); 61675-64-7 (tioconazole); 65899-73-2 (tioconazole)

Publication Type: Journal: Article

Subject Headings: adolescent
 adult
 aged

[article](#)
[Aspergillus niger](#)
[Candida albicans](#)
[clothing](#)
[controlled study](#)
[cost effectiveness analysis](#)
[dermatomycosis](#)
[disease predisposition](#)
[female](#)
[human](#)
[major clinical study](#)
[male](#)
["*mycosis/dt \[Drug Therapy\]"](#)
["*mycosis/et \[Etiology\]"](#)
["*mycosis/th \[Therapy\]"](#)
["*otomycosis/dt \[Drug Therapy\]"](#)
["*otomycosis/et \[Etiology\]"](#)
["*otomycosis/th \[Therapy\]"](#)
[swimming](#)
[Turkey \(republic\)](#)
[*alcohol](#)
[*boric acid](#)
["*tioconazole/dt \[Drug Therapy\]"](#)

Source: EMBASE

Full Text: Available from *ProQuest* in *Journal of Laryngology and Otology, The*

156. Phenotypic diversity of oral *C. albicans* isolated on single and sequential visits in an HIV-infected Chinese cohort

Citation: APMIS, February 2003, vol./is. 111/2(329-337), 0903-4641 (01 Feb 2003)

Author(s): Samaranayake Y.H.; Samaranayake L.P.; Yau J.Y.Y.; Dassanayake R.S.; Li T.K.L.; Anil S.

Institution: (Samaranayake, Samaranayake, Yau, Dassanayake, Anil) Oral Bio-sciences, University of Hong Kong, Hong Kong, Hong Kong; (Li) Oral Diagnosis, Faculty of Dentistry, University of Hong Kong, Hong Kong, Hong Kong; (Samaranayake) Oral Bio-sciences, Faculty of Dentistry, University of Hong Kong, Hong Kong, Hong Kong

Language: English

Abstract: HIV-infected individuals maintain multiple oral *C. albicans* strains over time that are thought to undergo microevolution in terms of both phenotypic and genotypic features. To study this phenomenon, a 12-month prospective study was conducted in a cohort of 16 HIV-infected ethnic Chinese individuals with (A) and without (B) symptoms of oropharyngeal candidiasis to evaluate the phenotype distribution among oral *C. albicans* isolates during disease progression. Oral rinse samples were obtained and up to five *C. albicans* colony-forming units were selected per each visit, during the one year period of multiple visits. The isolates were phenotyped using two commercially available biotyping kits, the API 20C system, API ZYM system, and a plate test for resistance to boric acid. A total of 261 *C. albicans* strains in group A were differentiated into 67 biotypes, while 42 biotypes were seen amongst the 182 isolates from group B. The major biotypes in the two groups were similar and were in decreasing order of prevalence J1R, J1S, J6S, J6R, J2S, K1S, J10R, K1R, and K6R; 48 different biotypes were seen in group A and 24 in group B, with some uniquely represented in each group, leading to a significant association between the prevalence of the biotypes J1S and J2S and symptomatic candidiasis ($p < 0.05$). Taken together this study illustrates the wide phenotypic spectrum of oral *C. albicans* associated with HIV-infection.

Country of Publication: Denmark

Publisher: Blackwell Munksgaard

Publication Type: Journal: Article

Subject Headings: [adult](#)

article
 biotype
 Candida albicans
 "*candidiasis/et [Etiology]"
 China
 clinical article
 clinical feature
 cohort analysis
 colony forming unit
 controlled study
 disease course
 ethnology
 female
 fungal genetics
 fungus isolation
 genotype
 human
 *Human immunodeficiency virus infection
 male
 *microbial diversity
 *mouth flora
 oropharynx
 *phenotype
 prevalence
 priority journal

Source: EMBASE

Full Text: Available from *EBSCOhost* in *APMIS*

157. Common complementary and alternative therapies for yeast vaginitis and bacterial vaginosis: A systematic review

Citation: Obstetrical and Gynecological Survey, May 2003, vol./is. 58/5(351-358), 0029-7828 (01 May 2003)

Author(s): Van Kessel K.; Assefi N.; Marrazzo J.; Eckert L.

Institution: (Van Kessel, Eckert) Department of Obstetrics, University of Washington, Harborview Medical Center, 325 9th Avenue, Seattle, WA 98104, United States; (Assefi) Dept. of General Internal Medicine, University of Washington, Harborview Medical Center, Seattle, WA, United States; (Marrazzo) Department of Medicine, University of Washington, Harborview Medical Center, Seattle, WA, United States

Language: English

Abstract: This article is a systematic review of the literature regarding the most commonly used complementary and alternative medicine (CAM) therapies for yeast vaginitis and bacterial vaginosis. A search was conducted of all published literature on conventional search engines (PubMed, EMBASE, the Cochrane Registry, CINAHL, LILACS) and alternative medicine databases (Natural Medicines Comprehensive Database, Longwood Herbal Taskforce, and Alternative Medicine Alert), for all studies of the five most commonly used CAM treatments of vaginitis. Inconsistencies in definition of vaginitis, type of intervention, control groups, and outcomes prevented performance of a meta-analysis, and paucity of high-quality studies made ranking by evidence-based scales unsuitable. Lactobacillus recolonization (via yogurt or capsules) shows promise for the treatment of both yeast vaginitis and bacterial vaginosis with little potential for harm. Boric acid can be recommended to women with recurrent vulvovaginal Candidal infections who are resistant to conventional therapies, but can occasionally cause vaginal burning. Because of associated risks in the absence of well-documented clinical benefits, douching remains a practice that should not be recommended for the treatment of vaginitis. Finally, tea tree oil and garlic show some in vitro potential for the treatment of vaginitis, but the lack of in vivo studies preclude their recommendation to patients for the time-being. The available evidence for CAM treatments of vaginitis is of poor quality

despite the prevalent use of these therapies. Well-designed randomized, controlled trials investigating the efficacy and safety of these therapies for vaginitis are needed before any reliable clinical recommendations can be made.

Country of Publication: United States

Publisher: Lippincott Williams and Wilkins

CAS Registry Number: 539-86-6 (allicin); 10043-35-3 (boric acid); 11113-50-1 (boric acid); 11129-12-7 (boric acid); 14213-97-9 (boric acid); 1400-61-9 (nystatin); 34786-70-4 (nystatin); 62997-67-5 (nystatin)

Publication Type: Journal: Review

Subject Headings: [*alternative medicine](#)
[bibliographic database](#)
[Cinahl](#)
[clinical trial](#)
[Cochrane Library](#)
["diarrhea/si \[Side Effect\]"](#)
[Embase](#)
[evidence based medicine](#)
["flatulence/si \[Side Effect\]"](#)
["gastrointestinal symptom/si \[Side Effect\]"](#)
["heartburn/si \[Side Effect\]"](#)
[herbal medicine](#)
[human](#)
[Lactobacillus acidophilus](#)
[lilacs database](#)
[Medline](#)
["nausea/si \[Side Effect\]"](#)
[review](#)
["skin allergy/si \[Side Effect\]"](#)
["skin irritation/si \[Side Effect\]"](#)
["vagina candidiasis/dt \[Drug Therapy\]"](#)
["vagina candidiasis/et \[Etiology\]"](#)
["*vaginitis/dt \[Drug Therapy\]"](#)
["*vaginitis/et \[Etiology\]"](#)
["vulvovaginitis/dt \[Drug Therapy\]"](#)
["vulvovaginitis/et \[Etiology\]"](#)
[allicin](#)
["*boric acid/ct \[Clinical Trial\]"](#)
["*boric acid/dt \[Drug Therapy\]"](#)
["*boric acid/va \[Intravaginal Drug Administration\]"](#)
["*garlic extract/ae \[Adverse Drug Reaction\]"](#)
["*garlic extract/dt \[Drug Therapy\]"](#)
["nystatin/dt \[Drug Therapy\]"](#)
[placebo](#)
["*tea tree oil/ae \[Adverse Drug Reaction\]"](#)
["*tea tree oil/dt \[Drug Therapy\]"](#)
["*yoghurt/ae \[Adverse Drug Reaction\]"](#)
["*yoghurt/ct \[Clinical Trial\]"](#)
["*yoghurt/dt \[Drug Therapy\]"](#)
["*yoghurt/va \[Intravaginal Drug Administration\]"](#)
["*yoghurt/po \[Oral Drug Administration\]"](#)
["*yoghurt/tp \[Topical Drug Administration\]"](#)

Source: EMBASE

158. Treatment of vaginitis caused by *Candida glabrata*: Use of topical boric acid and flucytosine

Citation: American Journal of Obstetrics and Gynecology, November 2003, vol./is. 189/5(1297-1300), 0002-9378 (November 2003)

Author(s): Sobel J.D.; Chaim W.; Nagappan V.; Leaman D.

Institution: (Sobel, Nagappan, Leaman) Division of Infectious Diseases, Wayne State Univ. School of Medicine, Detroit, MI, United States; (Chaim) Dept. of Obstetrics and Gynecology, Ben Gurion University, Beer Sheva, Israel; (Sobel) Division of Infectious Diseases, Harper Hospital, 3990 John R, Detroit, MI 48201, United States

Language: English

Abstract: OBJECTIVE: The purpose of this study was to review the treatment outcome and safety of topical therapy with boric acid and flucytosine in women with *Candida glabrata* vaginitis. STUDY DESIGN: This was a retrospective review of case records of 141 women with positive vaginal cultures of *C glabrata* at two sites, Wayne State University School of Medicine and Ben Gurion University. RESULTS: The boric acid regimen, 600 mg daily for 2 to 3 weeks, achieved clinical and mycologic success in 47 of 73 symptomatic women (64%) in Detroit and 27 of 38 symptomatic women (71%) in Beer Sheba. No advantage was observed in extending therapy for 14 to 21 days. Topical flucytosine cream administered nightly for 14 days was associated with a successful outcome in 27 of 30 of women (90%) whose condition had failed to respond to boric acid and azole therapy. Local side effects were uncommon with both regimens. CONCLUSIONS: Topical boric acid and flucytosine are useful additions to therapy for women with azolerefractory *C glabrata* vaginitis.

Country of Publication: United States

Publisher: Mosby Inc.

CAS Registry Number: 10043-35-3 (boric acid); 11113-50-1 (boric acid); 11129-12-7 (boric acid); 14213-97-9 (boric acid); 2022-85-7 (flucytosine)

Publication Type: Journal: Review

Subject Headings: adolescent
adult
aged
**Candida glabrata*
drug safety
female
fungus culture
human
major clinical study
nonhuman
priority journal
retrospective study
review
"side effect/si [Side Effect]"
symptomatology
treatment outcome
"*vaginitis/dt [Drug Therapy]"
"*vaginitis/et [Etiology]"
"*boric acid/ae [Adverse Drug Reaction]"
"*boric acid/dt [Drug Therapy]"
"*boric acid/tp [Topical Drug Administration]"
"*flucytosine/ae [Adverse Drug Reaction]"
"*flucytosine/dt [Drug Therapy]"
"*flucytosine/tp [Topical Drug Administration]"

Source: EMBASE

159. [Up to date in sexually transmitted infections: epidemiology, diagnostic approaches and treatments].

Citation: Enfermedades infecciosas y microbiología clínica, Aug 2004, vol. 22, no. 7, p. 392-411, 0213-005X (2004 Aug-Sep)

Author(s): Vázquez, Fernando; Otero, Luis; Ordás, José; Junquera, María Luisa; Varela, José Antonio

Abstract: In the last years, there have been important advances in sexually transmitted infections such as genome sequencing of *Treponema pallidum*, *Chlamydia trachomatis* or *Mycoplasma genitalium*; the new taxonomic position of *Calymmatobacterium granulomatis*; commercial diagnostic systems based on nucleic acid amplification; the emergence of quinolone resistance in *Neisseria gonorrhoeae*; new therapeutic approaches in vulvovaginal candidiasis that include boric acid; the demonstration that valacyclovir reduces the risk of transmission of genital herpes or the availability of immune-response modifier in the treatment of genital warts, and that are questions in the goal of this review. Viral hepatitis and HIV were no reviewed by space reasons.

Subject Headings: [Sexually Transmitted Diseases](#)
[Humans](#)
[Index Medicus](#)

Source: Medline

160. Up to date in sexually transmitted infections: Epidemiology, diagnostic approaches and treatments [Spanish]
Actualizacion en infecciones de transmision sexual: Epidemiologia, diagnostico y tratamiento

Original Title: Actualizacion en infecciones de transmision sexual: Epidemiologia, diagnostico y tratamiento

Citation: Enfermedades Infecciosas y Microbiologia Clinica, August 2004, vol./is. 22/7(392-411), 0213-005X (August/September 2004)

Author(s): Vazquez F.; Otero L.; Ordas J.; Junquera M.L.; Varela J.A.

Institution: (Vazquez) Hospital Monte Naranco, Departamento de Biologia Funcional, Facultad de Medicina, Oviedo, Spain; (Otero) Servicio de Microbiologia, Hospital de Cabuenes, Gijon, Spain; (Ordas) Servicio de Microbiologia, Hospital Central de Asturias, Oviedo, Spain; (Junquera) Serv. de Dermatologia y Venereologia, Unidad de ITS, Hospital Monte Naranco, Oviedo, Spain; (Varela) Serv. de Dermatologia y Venereologia, Unidad de ITS, Ambulatorio de Pumarín, Gijon, Spain; (Vazquez) Departamento de Biologia Funcional, Area de Microbiologia, Facultad de Medicina, Julian Claveria, s/n, 33006 Oviedo, Spain

Language: Spanish

Abstract: In the last years, there have been important advances in sexually transmitted infections such as genome sequencing of *Treponema pallidum*, *Chlamydia trachomatis* or *Mycoplasma genitalium*; the new taxonomic position of *Calymmatobacterium granulomatis*, commercial diagnostic systems based on nucleic acid amplification; the emergence of quinolone resistance in *Neisseria gonorrhoeae*; new therapeutic approaches in vulvovaginal candidiasis that include boric acid; the demonstration that valacyclovir reduces the risk of transmission of genital herpes or the availability of immune-response modifier in the treatment of genital warts, and that are questions in the goal of this review. Viral hepatitis and HIV were no reviewed by space reasons.

Country of Publication: Spain

Publisher: Ediciones Doyma, S.L.

CAS Registry Number: 59277-89-3 (aciclovir); 26787-78-0 (amoxicillin); 34642-77-8 (amoxicillin); 61336-70-7 (amoxicillin); 83905-01-5 (azithromycin); 10043-35-3 (boric acid); 11113-50-1 (boric acid); 11129-12-7 (boric acid); 14213-97-9 (boric acid); 79350-37-1 (cefixime); 73384-59-5 (ceftriaxone); 74578-69-1 (ceftriaxone); 11111-12-9 (cephalosporin); 134-90-7 (chloramphenicol); 2787-09-9 (chloramphenicol); 56-75-7 (chloramphenicol); 113852-37-2 (cidofovir); 85721-33-1 (ciprofloxacin); 10592-13-9 (doxycycline); 17086-28-1 (doxycycline); 564-25-0 (doxycycline); 114-07-8 (erythromycin); 70536-18-4 (erythromycin); 109545-84-8 (evernimicin); 104227-87-4 (famciclovir); 112811-59-3 (gatifloxacin); 180200-66-2 (gatifloxacin); 556-50-3 (glycylglycine); 100986-85-4 (levofloxacin); 138199-71-0 (levofloxacin); 165800-03-3 (linezolid); 82419-36-1 (ofloxacin); 146836-84-2 (trovafloxacin); 124832-26-4 (valaciclovir)

Publication Type: Journal: Review

Subject Headings: [antibiotic resistance](#)
[antibiotic sensitivity](#)

bacterial genome
 bacterium culture
 calymmatobacterium granulomatis
 Chlamydia trachomatis
 "condyloma/dt [Drug Therapy]"
 female
 gene sequence
 "genital herpes/et [Etiology]"
 "gonorrhea/dr [Drug Resistance]"
 "gonorrhea/et [Etiology]"
 "herpes/di [Diagnosis]"
 "herpes/dt [Drug Therapy]"
 "herpes/et [Etiology]"
 human
 Mycoplasma genitalium
 Neisseria gonorrhoeae
 nucleic acid amplification
 review
 "*sexually transmitted disease/di [Diagnosis]"
 "*sexually transmitted disease/dr [Drug Resistance]"
 "*sexually transmitted disease/dt [Drug Therapy]"
 "*sexually transmitted disease/ep [Epidemiology]"
 "*sexually transmitted disease/et [Etiology]"
 "syphilis/di [Diagnosis]"
 "syphilis/dt [Drug Therapy]"
 "syphilis/et [Etiology]"
 Treponema pallidum
 "vagina candidiasis/dt [Drug Therapy]"
 virus transmission
 "aciclovir/dt [Drug Therapy]"
 "aminoglycoside antibiotic agent/dt [Drug Therapy]"
 "amoxicillin/do [Drug Dose]"
 "amoxicillin/dt [Drug Therapy]"
 "amoxicillin/po [Oral Drug Administration]"
 "*antibiotic agent/do [Drug Dose]"
 "*antibiotic agent/dt [Drug Therapy]"
 "*antibiotic agent/po [Oral Drug Administration]"
 "*antivirus agent/dt [Drug Therapy]"
 "azithromycin/do [Drug Dose]"
 "azithromycin/dt [Drug Therapy]"
 "azithromycin/po [Oral Drug Administration]"
 "boric acid/dt [Drug Therapy]"
 "cefixime/dt [Drug Therapy]"
 "ceftriaxone/do [Drug Dose]"
 "ceftriaxone/dt [Drug Therapy]"
 "ceftriaxone/iv [Intravenous Drug Administration]"
 "ceftriaxone/cj [Subconjunctival Drug Administration]"
 "cephalosporin/dt [Drug Therapy]"
 "chloramphenicol/dt [Drug Therapy]"
 "cidofovir/dt [Drug Therapy]"
 "ciprofloxacin/dt [Drug Therapy]"
 "doxycycline/do [Drug Dose]"
 "doxycycline/dt [Drug Therapy]"
 "doxycycline/po [Oral Drug Administration]"
 "erythromycin/do [Drug Dose]"
 "erythromycin/dt [Drug Therapy]"
 "erythromycin/po [Oral Drug Administration]"
 "evernimicin/dt [Drug Therapy]"
 "famciclovir/dt [Drug Therapy]"
 "gatifloxacin/dt [Drug Therapy]"

"glycylglycine/dt [Drug Therapy]"
 "interferon/dt [Drug Therapy]"
 "levofloxacin/dt [Drug Therapy]"
 "linezolid/dt [Drug Therapy]"
 "ofloxacin/dt [Drug Therapy]"
 "penicillin derivative/dt [Drug Therapy]"
 quinoline derived antiinfective agent
 "sulfonamide/dt [Drug Therapy]"
 "tetracycline derivative/dt [Drug Therapy]"
 "trovafloxacin/dt [Drug Therapy]"
 unindexed drug
 "valaciclovir/dt [Drug Therapy]"

Source: EMBASE

161. Phospholipase, proteinase and haemolytic activities of *Candida albicans* isolated from oral cavities of patients with type 2 diabetes mellitus.

Citation: Journal of medical microbiology, Oct 2007, vol. 56, p. 1393-1398, 0022-2615 (October 2007)

Author(s): Tsang, C S P; Chu, F C S; Leung, W K; Jin, L J; Samaranayake, L P; Siu, S C

Abstract: The aim of this study was to biotype and characterize phospholipase, proteinase and haemolytic activities of oral *Candida albicans* isolates from 210 Chinese patients with type 2 diabetes mellitus (DM) and 210 age- and sex-matched healthy controls. Seventy-six and 50 *C. albicans* isolates were obtained from type 2 DM patients and controls, respectively, using the oral rinse technique. The isolates were characterized with a biotyping system based on enzyme profiles, carbohydrate assimilation patterns and boric acid resistance of the yeasts, and the isolates were further tested for in vitro phospholipase, proteinase and haemolytic activities. The major biotypes of *C. albicans* isolates from the type 2 DM and control groups were A1R (42.1 %) and J1R (36.0 %), respectively. Significantly higher proteinase and haemolytic activities were found in the isolates from the type 2 DM group ($P < 0.05$). Proteinase activity was higher in isolates from patients with ≥ 10 years of DM history than those with < 10 years ($P < 0.05$). Haemolytic activity was significantly higher in isolates from female DM patients than in those from male counterparts ($P < 0.05$). These data provide evidence of increased extracellular enzyme activity in *Candida* isolates taken from DM patients.

Subject Headings: Case-Control Studies
 Candida albicans
 Hemolysin Proteins
 Middle Aged
 Humans
 Candidiasis
 Index Medicus
 Phospholipases
 China
 Adult
 Female
 Mouth
 Mycological Typing Techniques
 Aged
 Peptide Hydrolases
 Male
 Diabetes Mellitus Type 2

Source: Medline

162. Local treatment of vulvovaginal candidosis : general and practical considerations.

Citation: Drugs, Jan 2008, vol. 68, no. 13, p. 1787-1802, 0012-6667 (2008)

- Author(s):** das Neves, José; Pinto, Eugénia; Teixeira, Branca; Dias, Gustavo; Rocha, Patrocínia; Cunha, Teresa; Santos, Bárbara; Amaral, Maria H; Bahia, Maria F
- Abstract:** Vulvovaginal candidosis is a common worldwide female medical problem, occurring mostly in women of childbearing age. Currently available options for the treatment of this condition include local and oral (systemic) therapy. Both alternatives have been considered equally effective in the treatment of uncomplicated vulvovaginal candidosis, although oral regimens are often preferred by physicians and women. However, local treatment presents several advantageous and unique features that may favour this therapeutic approach. The availability of numerous antifungal drugs and products for topical administration makes the selection quite challenging as this task is mostly based on personal experience or anecdotal data. Also, recent advances have been made in topical antifungal formulations and there is an increasing availability of over-the-counter products. Therefore, a review of both general and practical considerations related to the local treatment of vulvovaginal candidosis is timely. In summary, azoles and short-term regimens are usually recommended for the local treatment of vulvovaginal candidosis, with nystatin and boric acid considered as second-line alternatives. Unconventional approaches may also be regarded as suitable in patients refractory to usual treatments. In addition to the susceptibility of implicated *Candida* spp. to the antifungal agents, this choice should take into consideration other important issues such as particular situations (e.g. pregnancy, menopause, drug hypersensitivity), women's preferences, and the availability, particularities and cost of antifungal formulations.
- Subject Headings:** [Antifungal Agents](#)
[Candidiasis Vulvovaginal](#)
[Humans](#)
[Administration Topical](#)
[Female](#)
[Candida](#)
[Index Medicus](#)
[Nonprescription Drugs](#)
- Source:** Medline
- Full Text:** Available from *EBSCOhost* in [Drugs](#)
Available from *Springer NHS Pilot 2014 (NESLi2)* in [Drugs](#); Note: ; Collection notes: Academic-License. Please when asked to pick an institution please pick NHS. Please also note access is from 1997 to date only.
Available from *ProQuest* in [Drugs](#)
Available from *EBSCOhost* in [Drugs](#)

163. Biotypes, genotypes and ketoconazole susceptibility of *Candida albicans* isolates from a group of Thai AIDS patients.

- Citation:** The new microbiologica, Jul 2008, vol. 31, no. 3, p. 409-416, 1121-7138 (July 2008)
- Author(s):** Teanpaisan, Rawee; Niyombandith, Mali; Pripatnanant, Prisana; Sattayasanskul, Wilad
- Abstract:** A total of eighty-seven *Candida albicans* isolates from a group of Thai AIDS patients were characterized for phenotypic and genotypic profiles and antifungal susceptibility to ketoconazole. Phenotyping of the isolates was carried out by a biotyping method based on the enzyme profiles, carbohydrate assimilation patterns and boric acid resistance of the yeasts. Genotyping was performed through randomly amplified polymorphic DNA (RAPD) analysis. Antifungal susceptibility of ketoconazole was performed using the NCCLS broth microdilution method. Combination of the biotypic tests revealed a total of 49 different biotypes. The most predominant was A1S (31%), the remaining biotypes represented only few isolates in each. RAPD profiles identified 14 clusters of genotype among the 87 isolates. Almost every individual harboured his/her own specific isolate and in 25 of 26 (96.2%) harboured more than one clonal type. The heterogeneity of both phenotypic and genotypic profiles of *C. albicans* isolates in this study was similar to previous reports from other oral sources in different geographic areas. All isolates were susceptible to ketoconazole. The findings may be useful as baseline information of oral *C. albicans* colonization in Thai population living in the south of Thailand.

Subject Headings: [Genotype](#)
[Candida albicans](#)
[Antifungal Agents](#)
[Humans](#)
[Microbial Sensitivity Tests](#)
[Ketoconazole](#)
[Polymerase Chain Reaction](#)
[Thailand](#)
[Mycological Typing Techniques](#)
[Index Medicus](#)
[Acquired Immunodeficiency Syndrome](#)

Source: Medline

164. [Evaluation of biotyping of medically important Candida spp].

Citation: Klinická mikrobiologie a infekční lékařství, Aug 2009, vol. 15, no. 4, p. 116-124, 1211-264X (August 2009)

Author(s): Hamal, Petr; Koukalová, Dagmar

Abstract: The biotyping system according to Odds and Abbott belongs to the most frequently used phenotypic methods. The aim of the study was to evaluate its discriminatory power in our laboratory. In addition, biotypes of isolates obtained from various body locations, present in defined age groups of patients and in males and females were also compared. A total of 343 clinical isolates were typed belonging to six most frequent *Candida* spp. Nine types of tests for biotyping were prepared: sorbose, citrate and urea assimilation, tolerance to pH 1.4, pH 1.55 and higher concentration of NaCl, resistance to sodium periodate and boric acid and the ability to grow on MacConkey agar. Forty-one biotypes were found among 230 *C. albicans* isolates, nine among 21 *C. glabrata*, 13 among 25 *C. parapsilosis*, 12 among 25 *C. krusei* and five biotypes among 18 *C. lusitaniae* isolates. Contrary to other species, all of 18 *C. tropicalis* isolates belonged to the same biotype. In accordance with previously published reports, high discriminatory power of the method was found with Simpson's diversity index for *C. albicans* reaching 0.92. On the other hand, reproducibility was relatively low; from 12 randomly chosen *C. albicans* isolates tested repeatedly, only two showed identical results, five differed in one test and the others in several tests. Analysis of the occurrence of individual biotypes related to different anatomical locations, age groups and sexes of patients revealed neither statistically significant variations in distribution nor predilection of any single biotype. These findings suggest that the source of infection was endogenous in most cases. In comparison with results of similar studies, marked discrepancies in profiles of predominant biotypes were found, probably due to slight differences in composition of the test media or distinctive evaluation of results; however, it may reflect also geographical specificity of isolates. It can be concluded that the main advantages of the Odds biotyping system are high discriminatory power and cost-effectiveness. On the other hand, discrepancies in reproducibility of results as well as relatively long period for preparation of test media and for achieving of results decline its usefulness for epidemiological studies.

Subject Headings: [Infant](#)
[Male](#)
[Adolescent](#)
[Middle Aged](#)
[Humans](#)
[Index Medicus](#)
[Young Adult](#)
[Adult](#)
[Female](#)
[Child](#)
[Candida](#)
[Mycological Typing Techniques](#)
[Aged](#)
[Child Preschool](#)

Source: Medline

165. Impact of platinum on the soil invertebrate *Folsomia candida*.

Citation: Neuro endocrinology letters, Jan 2012, vol. 33 Suppl 3, p. 173-178, 0172-780X (2012)

Author(s): Nemcova, Barbora; Bednarova, Ivana; Mikulaskova, Hana; Beklova, Miroslava

Abstract: Regarding the environmental pollution, platinum group elements (PGE) are in the centre of interest of current research. These rare elements are used as effective substances in automotive catalysts to reduce pollution by emissions originating from fuel combustion. Due to their harmful potential, it is necessary to monitor their content and behaviour in different samples. Comprehensive studies on PGE behaviour and effects are still lacking. Their distribution in the food chain and data on bioaccumulation has not been described so far. We focused on reproductive effects of platinum (PtCl₄), in particular. Our study is based on a collembolan laboratory breed, test optimization and validation according to the OECD 232 standards [CSN ISO 11267 - Soil quality - Inhibition of reproduction of *Collembola* (*Folsomia candida*) by soil pollutants]. The concentrations of PtCl₄ tested were as follows: 5, 10, 25, 50 and 100 µM. The EC₅₀ was determined after 28 days of testing. The results were evaluated using the inhibition of reproduction compared with controls. The EC₅₀ was determined after the 28-day test. The value of 28dEC₅₀ of the boric acid test was estimated at 120 mg/kg and the measured 28dEC₅₀ of PtCl₄ was 200.4 µM. The presented data can be considered as a step forward in the assessment of the potential risk of platinum in the terrestrial environment. However, more toxicity data for various species are needed to evaluate the environmental risk of platinum in soils.

Subject Headings: [Platinum](#)
[Age Factors](#)
[Animals](#)
[Female](#)
[Toxicity Tests](#)
[Soil Pollutants](#)
[Index Medicus](#)
[Arthropods](#)
[Reproduction](#)
[Behavior Animal](#)
[Platinum Compounds](#)
[Male](#)

Source: Medline

166. Boric acid as reference substance: pros, cons and standardization.

Citation: Ecotoxicology (London, England), Apr 2012, vol. 21, no. 3, p. 919-924, 1573-3017 (April 2012)

Author(s): Amorim, M J B; Natal-da-Luz, T; Sousa, J P; Loureiro, S; Becker, L; Römbke, J; Soares, A M V M

Abstract: Boric acid (BA) has been successfully used as reference substance in some standard test guidelines. Due to the fact that previously selected reference substances present a significant risk to human health and/or are banned for environmental reasons, BA is being discussed for broader adoption in OECD or ISO guidelines. To provide input on BA data and contribute to the discussion on its suitability as a reference substance, in the present study BA was tested with two standard soil organisms, *Enchytraeus albidus* and *Folsomia candida*, in terms of survival, reproduction and avoidance. Additionally, published data on other organisms was analysed to derive the most sensitive soil dwelling invertebrate (hazard concentration-HC₅). Results showed that BA affected the tested organisms, being two times more toxic for collembolans (LC₅₀ = 96; EC₅₀ = 54 mg/kg) than for enchytraeids (LC₅₀ = 325; EC₅₀ = 104 mg/kg). No avoidance behaviour occurred despite the fact that BA affects earthworms. Actually, it is the recommended reference substance for the earthworm avoidance test. Clearly, the suitable performance of BA in one species should not be generalized to other species. Absolute toxicity is not an important criterion for the selection of a reference substance, but it has been proposed that effects should

occur within a reasonable range, i.e. <1,000 mg/kg. We could confirm, compiling previous data that for most soil invertebrates, the EC50 is expected to be below 1,000 mg/kg. From these data it could be derived that the most sensitive soil dwelling invertebrate (HC5, 50%) is likely to be affected (EC10) at 28 (8-53) mg H(3)BO(3)/Kg, equivalent to 4.6 (1.4-8.7) mg boron/kg.

Subject Headings:

[Reference Standards](#)
[Oligochaeta](#)
[Animals](#)
[Escape Reaction](#)
[Insects](#)
[Toxicity Tests](#)
[Avoidance Learning](#)
[Index Medicus](#)
[Environmental Monitoring](#)
[Soil Pollutants](#)
[Behavior Animal](#)
[Boric Acids](#)
[Guidelines as Topic](#)

Source:

Medline

Full Text:

Available from *Springer NHS Pilot 2014 (NESLi2)* in *Ecotoxicology*; Note: ; Collection notes: Academic-License. Please when asked to pick an institution please pick NHS. Please also note access is from 1997 to date only.
 Available from *ProQuest* in *Ecotoxicology*

167. Rapid separations of Nile blue stained microorganisms as cationic charged species by chip-CE with LIF.**Citation:**

Electrophoresis, May 2012, vol. 33, no. 9-10, p. 1421-1426, 1522-2683 (May 2012)

Author(s):

Nuchtavorn, Nantana; Bek, Fritz; Macka, Mirek; Suntornasuk, Worapot; Suntornasuk, Leena

Abstract:

Rapid detection of microorganisms by alternative methods is desirable. Electromigration separation methods have the capability to separate microorganisms according to their charge and size and laser-induced fluorescence (LIF) detection have single-cell detection capability. In this work, a new combined separation and detection scheme was introduced using chip-based capillary electrophoresis (chip-CE) platform with LIF detection. Three microorganisms *Escherichia coli*, *Staphylococcus aureus*, and *Candida albicans* were selected as representatives of Gram-positive bacteria, Gram-negative bacteria, and fungi. While their cells carry an overall negative charge in neutral to alkaline pH, staining them with Nile blue (NB) provided highly sensitive LIF detection with excitation and emission wavelengths at 635 nm and 685 nm, respectively, and at the same time, the overall charge was converted to positive. Electrolyte pH and concentration of polyethylene oxide (PEO) significantly affected the resolution of the microorganisms. Their optimal separation in the 14 mm separation channel was achieved in less than 30 s ($R(s) > 5.3$) in an electrolyte consisting of 3.94 mM Tris, 0.56 mM boric acid, 0.013 mM ethylenediaminetetraacetic acid disodium salt dihydrate (pH 10.5), and 0.025% PEO, with injection/separation voltages of +1000/+1000 V. The separation mechanism is likely employing contributions to the overall cationic charge from both the prevalently anionic membrane proteins and the cationic NB. Importantly, the resulting cationic NB-stained cells exhibited excellent separation selectivity and efficiency of ≈ 38000 theoretical plates for rapid separations within 30-40 s. The results indicate the potential of chip-CE for microbial analysis, which offers separations of a wide range of species with high efficiency, sensitivity, and throughput. © 2012 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Subject Headings:

[Polyethylene Glycols](#)
[Flow Cytometry](#)
[Candida albicans](#)
[Hydrogen-Ion Concentration](#)
[Bacteriological Techniques](#)
[Staphylococcus aureus](#)
[Fluorescent Dyes](#)

Oxazines
 Cations
 Electrophoresis Capillary
 Index Medicus
 Escherichia coli

Source: Medline

168. Symptomatic *Trichomonas vaginalis* infection in the setting of severe nitroimidazole allergy: successful treatment with boric acid.

Citation: Sexual health, Sep 2012, vol. 9, no. 4, p. 389-391, 1448-5028 (September 2012)

Author(s): Muzny, Christina; Barnes, Arti; Mena, Leandro

Abstract: This report describes a patient with symptomatic *Trichomonas vaginalis* infection who was unable to tolerate nitroimidazole drugs because of severe hypersensitivity, for which desensitisation was not possible. Use of intravaginal clotrimazole, intravaginal paromomycin, intravaginal furazolidone, povidone-iodine douches, and oral nitazoxanide were unsuccessful in eradicating the patient's *T. vaginalis* infection. A 2-month course of intravaginal topical boric acid subsequently achieved a complete symptomatic cure and the patient remained *T. vaginalis* wet prep- and culture-negative 60 days after treatment.

Subject Headings: Drug Hypersensitivity
 Administration Intravaginal
Trichomonas vaginalis
 Humans
 Index Medicus
 Adult
 Female
 Boric Acids
Trichomonas Vaginitis
 Nitroimidazoles

Source: Medline

169. [Genotyping of Vaginal *Candida glabrata* Isolates Using Microsatellite Marker Analysis and DNA Sequencing to Identify Mutations Associated with Antifungal Resistance].

Citation: Mikrobiyoloji bülteni, Jan 2013, vol. 47, no. 1, p. 109-121, 0374-9096 (January 2013)

Author(s): Döğen, Aylin; Durukan, Hüseyin; Güzel, Ahmet Barış; Oksüz, Zehra; Kaplan, Engin; Serin, Mehmet Sami; Serin, Ayşe; Emekdaş, Gürol; Aslan, Gönül; Tezcan, Seda; Kalkancı, Ayşe; Ilkit, Macit

Abstract: Vulvovaginal candidosis is the second most common cause of vaginitis (17-39%) after bacterial vaginosis (22-50%). Since the diagnosis of vulvovaginal candidosis mainly depends on clinical findings without mycologic confirmatory tests and treated empirically, the actual incidence rate of vulvovaginal candidosis is unknown. Approximately 70-90% of vulvovaginal candidosis cases are caused by *Candida albicans*, however the increasing incidence of *C. glabrata* infections and its reduced susceptibility to azole drug therapy have generated increasing attention. The epidemiology and population structure of vulvovaginal candidosis due to *C. glabrata* are poorly characterized. This study was aimed to genotype the *C. glabrata* strains isolated from vaginal samples in Cukurova region, Turkey by microsatellite markers, to investigate the antifungal susceptibility profiles of the strains and to determine the molecular mechanisms leading to phenotypical azole resistance. A total of 34 unrelated vaginal *C. glabrata* strains isolated from patients with acute (n= 11) and recurrent (n= 14) vulvovaginal candidosis, control group (n= 9) without vaginitis symptoms, and a reference strain of *C. glabrata* CBS 138 (ATCC 2001) were included in the study. These isolates were genotyped using multiple-locus variable number tandem repeat analysis of three microsatellite markers (RPM2, MTI, and Cg6). Analysis of microsatellite markers was performed by fragment size determination of RPM2, MTI, and Cg6 PCR products through capillary electrophoresis. For each of the evaluated strains, DNA sequence analysis was performed for one gene (CgERG11) and four loci (CgPDR1, NTM1, TRP1, and URA3) to detect

mutations possibly associated with antifungal resistance in each strain. In vitro susceptibility profiles of the strains to 13 antifungals and boric acid were determined according to CLSI document M27-A3 to investigate possible relationships between detected mutations and phenotypic resistance. *C.glabrata* CBS 138 strain was found to be susceptible to all the antifungals tested, while one of (%2.9) 34 vaginal *C.glabrata* isolates was found to be dose-dependent susceptible to fluconazole, 13 (38.2%) to itraconazole and 3 (8.8%) to voriconazole. No resistant strain were detected in the study population. Only three isolates were found to be resistant to clotrimazole (8.8%), however no relationship was identified between the genotypes and phenotypic resistance ($p > 0.05$). Thirteen genotypes were detected by microsatellite marker analysis, with high discrimination power (DP= 0.877). As a result, microsatellite marker analysis was validated as a rapid, reliable method for genotyping *C.glabrata* strains with good, but not optimal discriminatory power. Further studies examining larger numbers of isolates are needed to verify possible relationships between mutations and phenotypic resistance.

Subject Headings: [Genotype](#)
[Sequence Analysis DNA](#)
[Humans](#)
[Index Medicus](#)
[Antifungal Agents](#)
[Microsatellite Repeats](#)
[Mutation](#)
[Female](#)
[Candida](#)
[Drug Resistance Fungal](#)
[Candida glabrata](#)
[Microbial Sensitivity Tests](#)

Source: Medline

170. Boric acid destabilizes the hyphal cytoskeleton and inhibits invasive growth of *Candida albicans*.

Citation: Yeast (Chichester, England), Apr 2015, vol. 32, no. 4, p. 389-398, 1097-0061 (April 2015)

Author(s): Pointer, Benjamin R; Boyer, Michael P; Schmidt, Martin

Abstract: Exposure of *Candida albicans* to sub-lethal concentrations of boric acid (BA) restricts the dimorphic fungus to its yeast morphology and prevents the formation of invasive hyphae on solid substrates. Exposure to BA causes a rapid and reversible disappearance of polarisome and Spitzenkörper in growing hyphae. In BA-treated hyphae of *C. albicans*, actin quickly reorganizes from cytoplasmic cables to cortical patches and cell wall growth switches from an apical to an isotropic pattern. As a result of the cytoskeletal changes, the hyphal tips broaden and directional growth of hyphae ceases in the presence of BA. An analysis of homozygous deletion strains showed that mutants with constitutive or enhanced hyphal growth (*tup1*, *nrg1*, *ssn6*, *rbf1*) are BA-sensitive, demonstrating that cellular morphology is a major determinant of BA tolerance. The screening of deletion mutants also showed that deficiencies of the main activator of hyphal gene expression, Efg1, and the Rim101-signalling cascade, leading to Efg1 activation, cause BA resistance. Taken together, the data presented show that the selective inhibitory effect on BA on *C. albicans* hyphae is rooted in a disruption of apical cytoskeletal elements of growing hyphae. Copyright © 2015 John Wiley & Sons, Ltd.

Subject Headings: [Fungal Proteins](#)
[Candida albicans](#)
[Gene Expression Regulation Fungal](#)
[Antifungal Agents](#)
[Index Medicus](#)
[Hyphae](#)
[Boric Acids](#)
[Cytoskeleton](#)

Source: Medline

171. An Alternative Approach to Assess the Habitat Selection of *Folsomia candida* in Contaminated Soils.

- Citation:** Bulletin of environmental contamination and toxicology, Nov 2015, vol. 95, no. 5, p. 670-674, 1432-0800 (November 2015)
- Author(s):** Bori, Jaume; Riva, Maria Carme
- Abstract:** Avoidance tests with collembolans provide a quick assessment of soil quality. However, some parameters of the procedure can be modified in order to increase its performance. In this study we assessed the tendency of *Folsomia candida* to avoid soils contaminated with boric acid [350-700-1400-2800-5600 mg/kg soil dry weight (dw)], phenmedipham (35-70-140-280 mg/kg dw) or petroleum hydrocarbons (1312-1838-2625-3675-5250 mg/kg dw) by preferring an untreated soil. Two separate methodologies were applied, the one presented in the ISO standard 17512:2 and a modified version of the Petri dish method that allowed data acquisition after 2, 24 and 48 h of exposure. After combining data from three separate trials, effective median concentration values (EC50) from the presented method were lower and showed similar or less variability than those from the ISO procedure, suggesting the modified protocol as a suitable alternative screening tool.
- Subject Headings:** [Animals](#)
[Ecosystem](#)
[Petroleum](#)
[Environmental Monitoring](#)
[Soil Pollutants](#)
[Index Medicus](#)
[Petroleum Pollution](#)
[Arthropods](#)
[Soil](#)
[Boric Acids](#)
[Carbamates](#)
[Spain](#)
- Source:** Medline

172. Non-albicans *Candida* Vulvovaginitis: Treatment Experience at a Tertiary Care Vaginitis Center.

- Citation:** Journal of lower genital tract disease, Jan 2016, vol. 20, no. 1, p. 85-89, 1526-0976 (January 2016)
- Author(s):** Powell, Anna M; Gracely, Edward; Nyirjesy, Paul
- Abstract:** The aims of this study are to analyze a cohort of women with vulvovaginal symptoms and positive cultures for non-albicans *Candida* (NAC) to determine whether yeast was responsible for their symptoms and to evaluate the mycological effectiveness of various regimens. This observational study was performed from retrospective chart review of patients with positive NAC cultures between April 1, 2008, and January 31, 2011, at a tertiary care vaginitis center. Patient intake demographics were entered into a database. Follow-up visits were analyzed for data about patient treatments and outcomes. Patients were considered a clinical cure if their symptoms were significantly improved and mycologic cure (MC) if later yeast cultures were negative. If clinical symptoms improved at the same time as MC, the isolate was considered the proximate cause for the symptoms. One hundred eight patients meeting entry criteria were analyzed. Boric acid was effective at obtaining MC in 32 (78%) of 41 patients with *C. glabrata*, 3 of 3 patients with *C. tropicalis*, and 3 of 3 patients with *C. lusitaniae*. Fluconazole was effective as initial treatment for 3 (60%) of 5 patients with *C. glabrata* and 13 (81%) of 16 patients with *C. parapsilosis*. In 52.7% of *C. glabrata*, 66.7% of *C. parapsilosis*, and 57.1% of *C. tropicalis* cases, effective antifungal therapy led to symptom improvement. In a tertiary care vaginitis center, NAC, when isolated on culture, caused clinically significant infections in approximately half of symptomatic patients. A majority of infections can be effectively treated with boric acid or fluconazole regardless of the non-albicans *Candida* species.
- Subject Headings:** [Index Medicus](#)
- Source:** Medline

173. Boric acid-dependent decrease in regulatory histone H3 acetylation is not mutagenic in yeast.

Citation: FEMS microbiology letters, Jul 2016, vol. 363, no. 13, 1574-6968 (July 2016)

Author(s): Pointer, Benjamin R; Schmidt, Martin

Abstract: *Candida albicans* is a dimorphic yeast commonly found on human mucosal membranes that switches from yeast to hyphal morphology in response to environmental factors. The change to hyphal growth requires histone H3 modifications by the yeast-specific histone acetyltransferase Rtt109. In addition to its role in morphogenesis, Rtt109-dependent acetylation of histone H3 lysine residues 9 and 56 has regulatory functions during DNA replication and repair. Boric acid (BA) is a broad-spectrum agent that specifically inhibits *C. albicans* hyphal growth, locking the fungus in its harmless commensal yeast state. The present study characterizes the effect of BA on *C. albicans* histone acetylation in respect to specificity, time-course and significance. We demonstrate that sublethal concentrations of BA reduce H3K9/H3K56 acetylation, both on a basal level and in response to genotoxic stress. Acetylation at other selected histone sites were not affected by BA. qRT-PCR expression analysis of the DNA repair gene Rad51 indicated no elevated level of genotoxic stress during BA exposure. A forward-mutation analysis demonstrated the BA does not increase spontaneous or induced mutations. The findings suggest that DNA repair remains effective even when histone H3 acetylation decreases and dispels the notion that BA treatment impairs genome integrity in yeast. © FEMS 2016. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Subject Headings: [Index Medicus](#)

Source: Medline